<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child - Bromley, R - 2023 | Cochrane Library</title> <meta content="Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child - Bromley, R - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010224.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child - Bromley, R - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010224.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010224.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child" name="citation_title"/> <meta content="Rebecca Bromley" name="citation_author"/> <meta content="rebecca.bromley@manchester.ac.uk" name="citation_author_email"/> <meta content="Naghme Adab" name="citation_author"/> <meta content="Walsgrave Hospital, University Hospitals Coventry and Warwickshire NHS Trust" name="citation_author_institution"/> <meta content="Matt Bluett-Duncan" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="Jill Clayton-Smith" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="Jakob Christensen" name="citation_author"/> <meta content="Aarhus University Hospital" name="citation_author_institution"/> <meta content="Katherine Edwards" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Janette Greenhalgh" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Ruaraidh A Hill" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Cerian F Jackson" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Sonia Khanom" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="Ronan N McGinty" name="citation_author"/> <meta content="John Radcliffe Hospital" name="citation_author_institution"/> <meta content="Catrin Tudur Smith" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Jennifer Pulman" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Institute of Systems, Molecular and Integrative Biology, University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010224.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/08/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010224.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010224.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010224.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cohort Studies; *Epilepsy [drug therapy, epidemiology]; Lamotrigine; Phenytoin; *Prenatal Exposure Delayed Effects; Prospective Studies; Topiramate" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010224.pub3&amp;doi=10.1002/14651858.CD010224.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010224\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010224\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","ja","fa","id","fr","hu"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD010224.pub3",title:"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child",firstPublishedDate:"Aug 29, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010224.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010224.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010224.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010224.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010224.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010224.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010224.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010224.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010224.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010224.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4772 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010224.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-sec-1542"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-sec-1523"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/appendices#CD010224-sec-1548"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/supinfo/CD010224-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/supinfo/CD010224-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Bromley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0005">Naghme Adab</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0006">Matt Bluett-Duncan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0007">Jill Clayton-Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0008">Jakob Christensen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0009">Katherine Edwards</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0010">Janette Greenhalgh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0011">Ruaraidh A Hill</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0012">Cerian F Jackson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0013">Sonia Khanom</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0014">Ronan N McGinty</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0015">Catrin Tudur Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0016">Jennifer Pulman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information#CD010224-cr-0017">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information/en#CD010224-sec-1558">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 August 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010224.pub3">https://doi.org/10.1002/14651858.CD010224.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010224-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010224-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010224-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010224-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010224-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010224-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD010224-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010224-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010224-abs-0001" lang="en"> <section id="CD010224-sec-0001"> <h3 class="title" id="CD010224-sec-0001">Background</h3> <p>Prenatal exposure to certain anti‐seizure medications (ASMs) is associated with an increased risk of major congenital malformations (MCM). The majority of women with epilepsy continue taking ASMs throughout pregnancy and, therefore, information on the potential risks associated with ASM treatment is required. </p> </section> <section id="CD010224-sec-0002"> <h3 class="title" id="CD010224-sec-0002">Objectives</h3> <p>To assess the effects of prenatal exposure to ASMs on the prevalence of MCM in the child. </p> </section> <section id="CD010224-sec-0003"> <h3 class="title" id="CD010224-sec-0003">Search methods</h3> <p>For the latest update of this review, we searched the following databases on 17 February 2022: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to February 16, 2022), SCOPUS (1823 onwards), and <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, <a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform</a> (ICTRP). No language restrictions were imposed. </p> </section> <section id="CD010224-sec-0004"> <h3 class="title" id="CD010224-sec-0004">Selection criteria</h3> <p>We included prospective cohort controlled studies, cohort studies set within pregnancy registries, randomised controlled trials and epidemiological studies using routine health record data. Participants were women with epilepsy taking ASMs; the two control groups were women without epilepsy and untreated women with epilepsy. </p> </section> <section id="CD010224-sec-0005"> <h3 class="title" id="CD010224-sec-0005">Data collection and analysis</h3> <p>Five authors independently selected studies for inclusion. Eight authors completed data extraction and/or risk of bias assessments. The primary outcome was the presence of an MCM. Secondary outcomes included specific types of MCM. Where meta‐analysis was not possible, we reviewed included studies narratively. </p> </section> <section id="CD010224-sec-0006"> <h3 class="title" id="CD010224-sec-0006">Main results</h3> <p>From 12,296 abstracts, we reviewed 283 full‐text publications which identified 49 studies with 128 publications between them. Data from ASM‐exposed pregnancies were more numerous for prospective cohort studies (n = 17,963), than data currently available for epidemiological health record studies (n = 7913). The MCM risk for children of women without epilepsy was 2.1% (95% CI 1.5 to 3.0) in cohort studies and 3.3% (95% CI 1.5 to 7.1) in health record studies. </p> <p>The known risk associated with sodium valproate exposure was clear across comparisons with a pooled prevalence of 9.8% (95% CI 8.1 to 11.9) from cohort data and 9.7% (95% CI 7.1 to 13.4) from routine health record studies. This was elevated across almost all comparisons to other monotherapy ASMs, with the absolute risk differences ranging from 5% to 9%. Multiple studies found that the MCM risk is dose‐dependent. Children exposed to carbamazepine had an increased MCM prevalence in both cohort studies (4.7%, 95% CI 3.7 to 5.9) and routine health record studies (4.0%, 95% CI 2.9 to 5.4) which was significantly higher than that for the children born to women without epilepsy for both cohort (RR 2.30, 95% CI 1.47 to 3.59) and routine health record studies (RR 1.14, 95% CI 0.80 to 1.64); with similar significant results in comparison to the children of women with untreated epilepsy for both cohort studies (RR 1.44, 95% CI 1.05 to 1.96) and routine health record studies (RR 1.42, 95% CI 1.10 to 1.83). </p> <p>For phenobarbital exposure, the prevalence was 6.3% (95% CI 4.8 to 8.3) and 8.8% (95% CI 0.0 to 9277.0) from cohort and routine health record data, respectively. This increased risk was significant in comparison to the children of women without epilepsy (RR 3.22, 95% CI 1.84 to 5.65) and those born to women with untreated epilepsy (RR 1.64, 95% CI 0.94 to 2.83) in cohort studies; data from routine health record studies was limited. For phenytoin exposure, the prevalence of MCM was elevated for cohort study data (5.4%, 95% CI 3.6 to 8.1) and routine health record data (6.8%, 95% CI 0.1 to 701.2). The prevalence of MCM was higher for phenytoin‐exposed children in comparison to children of women without epilepsy (RR 3.81, 95% CI 1.91 to 7.57) and the children of women with untreated epilepsy (RR 2.01. 95% CI 1.29 to 3.12); there were no data from routine health record studies. </p> <p>Pooled data from cohort studies indicated a significantly increased MCM risk for children exposed to lamotrigine in comparison to children born to women without epilepsy (RR 1.99, 95% CI 1.16 to 3.39); with a risk difference (RD) indicating a 1% increased risk of MCM (RD 0.01. 95% CI 0.00 to 0.03). This was not replicated in the comparison to the children of women with untreated epilepsy (RR 1.04, 95% CI 0.66 to 1.63), which contained the largest group of lamotrigine‐exposed children (&gt; 2700). Further, a non‐significant difference was also found both in comparison to the children of women without epilepsy (RR 1.19, 95% CI 0.86 to 1.64) and children born to women with untreated epilepsy (RR 1.00, 95% CI 0.79 to 1.28) from routine data studies. For levetiracetam exposure, pooled data provided similar risk ratios to women without epilepsy in cohort (RR 2.20, 95% CI 0.98 to 4.93) and routine health record studies (RR 0.67, 95% CI 0.17 to 2.66). This was supported by the pooled results from both cohort (RR 0.71, 95% CI 0.39 to 1.28) and routine health record studies (RR 0.82, 95% CI 0.39 to 1.71) when comparisons were made to the offspring of women with untreated epilepsy. For topiramate, the prevalence of MCM was 3.9% (95% CI 2.3 to 6.5) from cohort study data and 4.1% (0.0 to 27,050.1) from routine health record studies. Risk ratios were significantly higher for children exposed to topiramate in comparison to the children of women without epilepsy in cohort studies (RR 4.07, 95% CI 1.64 to 10.14) but not in a smaller comparison to the children of women with untreated epilepsy (RR 1.37, 95% CI 0.57 to 3.27); few data are currently available from routine health record studies. Exposure in utero to topiramate was also associated with significantly higher RRs in comparison to other ASMs for oro‐facial clefts. Data for all other ASMs were extremely limited. </p> <p>Given the observational designs, all studies were at high risk of certain biases, but the biases observed across primary data collection studies and secondary use of routine health records were different and were, in part, complementary. Biases were balanced across the ASMs investigated, and it is unlikely that the differential results observed across the ASMs are solely explained by these biases. </p> </section> <section id="CD010224-sec-0007"> <h3 class="title" id="CD010224-sec-0007">Authors' conclusions</h3> <p>Exposure in the womb to certain ASMs was associated with an increased risk of certain MCMs which, for many, is dose‐dependent. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010224-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010224-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010224-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010224-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010224-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD010224-abs-0017">Magyar</a> </li> <li class="section-language"> <a class="" href="full/id#CD010224-abs-0014">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010224-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010224-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010224-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD010224-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010224-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010224-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010224-abs-0002" lang="en"> <h3>Treatment for epilepsy in pregnant women and the physical health of the child</h3> <p><b>Background</b> </p> <p>For most women who have epilepsy, continuing their medication during pregnancy is important for their health. Over the last 40 years, research has shown that children exposed to anti‐seizure medications in the womb can be at a higher risk of having a malformation or birth defect. </p> <p><b>Research question</b> </p> <p>This review aimed to understand whether exposure to anti‐seizure medication during pregnancy is linked to an increased risk of having a child with a major structural congenital malformation (also known as a birth defect). </p> <p><b>Characteristics of the studies</b> </p> <p>The review included 49 published studies which included over 25,000 pregnancies where ASMs were used. We compared the children of women with epilepsy who were taking a single anti‐seizure medication to the children of women without epilepsy or women who had epilepsy but who were not being treated with anti‐seizure medications. We also made comparisons between children exposed to different anti‐seizure medications in the womb. The evidence presented in this review is up‐to‐date as of February 2022. </p> <p><b>Results</b> </p> <p>The amount of data available from the studies reviewed varied greatly depending on the type of anti‐seizure medication used, and this could account for some findings. </p> <p>The rate of malformations in children born to women without epilepsy was between 2.1% and 3.3% and, for children born to women with an untreated epilepsy, this rate was between 3.0% and 3.2%. Therefore, we consider that the background risk of being born with a malformation is between 2% and 3%. Overall, the data did not show a higher rate of malformation in infants exposed to either lamotrigine (2.7% to 3.5%) or levetiracetam (2.6% to 2.8%). However, in one well‐designed study, higher doses of lamotrigine were linked to a higher risk of malformations. There were fewer data regarding oxcarbazepine exposure but, based on current experience, there is not a significant increase of malformations in exposed infants (2.8% to 4.8%). </p> <p>Children exposed to sodium valproate were at the highest risk of having a malformation with 9.7% to 9.8% of exposed children having one or more malformation(s). Specifically, risks were higher for spinal, skeletal, cardiac and facial malformations. The level of the risk was associated with the dose of the valproate taken; higher doses of valproate were linked to higher rates of malformation. The risk associated with valproate exposure was higher than that seen for other ASM exposures, including those with a higher risk themselves (for example, topiramate or phenobarbital). </p> <p>Children exposed to phenobarbital had a higher rate of malformation with 6.3% to 8.8% of children being born with a malformation. This was higher than certain groups not exposed to anti‐seizure medications and children born exposed to other anti‐seizure medications. However, the risk was lower than that associated with valproate. Children exposed to phenobarbital were specially at risk of cardiac malformations. </p> <p>Children exposed to phenytoin had a higher rate of malformation with 5.4% to 6.8% of children being born with a malformation. This risk was higher than unexposed children and children exposed to certain other anti‐seizure medications. Data were too few to understand which specific types of malformation were most likely to occur following exposure in the womb to phenytoin. </p> <p>Children exposed to carbamazepine had a higher rate of malformation with 4.0% to 4.7% of children being born with a malformation. This was higher than unexposed children and children exposed to other anti‐seizure medications. The risk of malformation was found to increase at higher doses of carbamazepine. </p> <p>There were fewer pregnancies in women exposed to topiramate, but a higher rate of malformation was noted with 3.9% to 4.1% of exposed children having a malformation. This was higher than in children born to women without epilepsy. The data demonstrated that children exposed to topiramate were at particular risk of facial malformations. </p> <p>The data were too limited for other anti‐seizure medications to be certain about their results at this time. </p> <p><b>Quality of the studies</b> </p> <p>The quality of included studies varied, but we do not consider that this accounts for the results of the review where we see different levels of risk associated with different anti‐seizure medications. </p> <p><b>Conclusions</b> </p> <p>This review found that children exposed to certain anti‐seizure medications in the womb were at an increased risk of having a major malformation at birth and that the level of risk is determined, in most cases, by the dose of the medication child is exposed to. Levetiracetam and lamotrigine appear to be the anti‐seizure medications associated with the lowest level of risk, but more data are needed, particularly concerning individual types of malformation and higher doses. For many of the antiseizure medications considered in this review, there were too little data to reach conclusions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010224-sec-1542" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010224-sec-1542"></div> <h3 class="title" id="CD010224-sec-1543">Implications for practice</h3> <section id="CD010224-sec-1543"> <p>There is consistent evidence, across different study designs, that prenatal exposure to VPA increases the risk of having a child with a major malformation with the risk including neural tube, cardiac, skeletal, limb, oro‐facial cleft and craniofacial malformations. Whilst the prevalence of major malformation is 9.8%, this outcome is only one of a constellation of symptoms associated with VPA exposure in utero (<a href="./references#CD010224-bbs2-0108" title="Clayton-SmithJ , BromleyR , DeanJ , JournelH , OdentS , WoodA , et al. Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet Journal of Rare Diseases2019;14(1):180. [PMID: 31324220]">Clayton‐Smith 2019</a>; <a href="./references#CD010224-bbs2-0109" title="DeanJC , MooreSJ , TurnpennyPD . Developing diagnostic criteria for the fetal anticonvulsant syndromes. Seizure2000;9(3):233–4. [PMID: 10775521]">Dean 2000</a>; <a href="./references#CD010224-bbs2-0091" title="YerbyMS , LeavittA , EricksonDM , McCormickKB , LoewensonRB , SellsCJ , et al. Antiepileptics and the development of congenital anomalies. Neurology1992;42(4 Suppl 5):132-40. [PMID: 1574169]">Yerby 1992</a>) and which constitute the condition, foetal valproate spectrum disorder (ICD 11 LD2F.03) (<a href="./references#CD010224-bbs2-0108" title="Clayton-SmithJ , BromleyR , DeanJ , JournelH , OdentS , WoodA , et al. Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet Journal of Rare Diseases2019;14(1):180. [PMID: 31324220]">Clayton‐Smith 2019</a>). The impact of VPA on the developing foetus is clearly dose‐related (<a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>) and this should be considered when counselling regarding the risks associated with in utero exposure to VPA. The evidence reported here therefore supports regulatory limitations on VPA’s use, unless clinically necessary, to treat maternal epilepsy (<a href="./references#CD010224-bbs2-0124" title="National Institute for Clinical Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. www.nice.org.uk/guidance/ng217 (accessed prior to 4 Feb 2023).">NICE 2022</a>) and where clear counselling has been given to the patient. There are other ASMs, however, which also require careful patient counselling and these include CBZ, PB, TPM and PHT. </p> <p>The increased data included in this review update did not alter the previous findings which suggested no increased risk of major malformation for children exposed to either LTG or LEV in utero compared with either control group across the different study types. There is more limited information on LEV exposure and specific malformation outcomes, however. For all other ASMs, the data are limited, and more data are required before conclusions can be drawn for either an overall major malformation risk or for specific malformation types. Further, it is now clear that the dose of ASM is a key component to major malformation risk for non‐VPA ASMS also. CBZ, PB and even LTG have demonstrated such an association when cohorts are adequately powered. For other ASMs, including LEV, the data are limited at present to inform reliably on malformation risks at higher doses. The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration has the largest dataset stratified by dose of ASM currently. This lack of limited data for specific doses should be openly discussed with women planning a pregnancy or who are in the childbearing years and an absence of data should not imply a lack of risk. </p> <p>Given the variance in major malformation risk associated with individual ASM treatments and at different doses, preconceptual counselling should be tailored to the individual patient. Although traditional counselling has been that 90% of children born to women with epilepsy have healthy children, this oversimplifies a complex set of data. The ASM type, but also dose and considerations regarding specific malformation types, should also be central to counselling. It is also important to note that major malformation risk is just one aspect and that minor malformations and longer‐term child health and neurodevelopmental outcome risks should also feature in counselling. </p> <p>Finally, every effort should be made by clinicians to inform women about local initiatives collecting data on ASM use in pregnancy and child malformation outcomes to improve the availability of evidence on which to base treatment decisions. Epilepsy and pregnancy registers have made a large contribution to the available dataset, but this is only possible with the support of referring clinicians and the women who participate. </p> </section> <h3 class="title" id="CD010224-sec-1544">Implications for research</h3> <section id="CD010224-sec-1544"> <section id="CD010224-sec-1545"> <h5 class="title">Implications for research and pharmacovigilance</h5> <p>There is an obvious delay between the approval of a medication for use and obtaining comprehensive evidence regarding the potential major malformation risk. Some delay is inevitable, however, a longer delay than necessary will limit evidence‐based decision‐making regarding optimising the treatment of maternal epilepsy whilst limiting potential foetal risk. A failure to document the first few years’ worth of pregnancies to women on newer medications delays knowledge acquisition and new ASMs use in women of childbearing age may be unnecessarily avoided for longer than required. There are numerous medications approved for the treatment of epilepsy around the world, yet we see many without data at this time. The emergence of population level datasets using routine health record databases will likely have a positive impact on this latency, due to their automatic inclusion of large populations (<a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>). Whilst low in participation selection bias, utilising routine healthcare data has reduced measurement sensitivity though, and disease pregnancy and epilepsy registers or clinical studies which employ blinded, standardised review of the malformation outcome offer a more sensitive approach to outcome measurement. The pharmacovigilance strategy for the ASMs, therefore, should actively include different study designs which balance each other's methodological areas of strength and weakness to form a reliable and comprehensive evidence base. </p> <p>The RoB ratings highlight the issue that within‐study methodological improvements are required. Few studies, for example, report on how the major malformation was assessed and determined to be major or minor and whether this was done blinded to the ASM history, despite this being the primary study outcome. Therefore, an easily adopted improvement for research is to encourage the use of blinded, standardised assessments of the physical outcomes and use standardised classification approaches, such as those used by clinical geneticists, including the Human Phenotype Ontology (HPO) (http:// human‐phenotype‐ontology.github.io/about.html) to allow for more accurate comparison across studies. </p> <p>Whilst research methodologies have become more refined over the years, for example, by reporting individual ASM types, rather than a single monotherapy group or recognising the importance of ASM dose, there are still several limitations in the approach to data reporting. The provision of an overall major malformation risk figure, for example, is unlikely to be reliable, as demonstrated for PB and TPM, and future data collection and analysis should implement automatic reporting at the specific malformation level, including this as supplementary information. To improve the data at this finer level, initiatives will require large cohorts and, therefore, there should be a movement towards standardised protocols and procedural alignment across research initiatives to allow for large enough datasets regarding specific malformation types for specific ASMs and specific doses. </p> <p>Further investigations are also required into the factors which may modify the major malformation risk. This includes further consideration regarding folate supplementation and regarding the optimal dose for women with epilepsy. As cohorts increase in size, more nuanced investigations into dose associations are required by specific malformation types and future work should also consider any family risk factors. Observations have shown that some women who take ASMs, even at a very low dose, appear to be at higher risk of having a child with an ASM‐associated malformation. Further research focusing on identification of genomic variants which might modify how different women metabolise ASMs is crucial so that those who may be at higher risk of having a child with a major malformation, even when taking a lower dose of a specific ASM, can be identified and ASM treatment selected accordingly. Whilst this has proven difficult in the past, whole exome/genome sequencing, with careful selection of individuals for testing, is likely to make this more achievable (<a href="./references#CD010224-bbs2-0117" title="KuCS , NaidooN , WuM , SoongR . Studying the epigenome using next generation sequencing. Journal of Medical Genetics2011;48(11):721-30. [PMID: 21825079]">Ku 2011</a>). </p> <p>Finally, longitudinal work which also investigates the longer‐term health outcomes of children with ASM exposures should be undertaken to understand the true impact. Where possible, research initiatives which recruit pregnant women with epilepsy for the purpose of investigating major malformation outcomes should also seek to, where possible, utilise these populations to understand child health and neurodevelopmental outcomes. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010224-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010224-sec-0008"></div> <div class="table" id="CD010224-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ Lamotrigine</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Lamotrigine in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in the exposed children</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence LTG</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lamotrigine vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.99 (1.16, 3.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4862 (7)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 3.3% (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19 (0.86, 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,288 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lamotrigine vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0% (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.66, 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3918 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2% (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.79, 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,445 (3)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58, 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5612 (10)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.37, 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2316 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3113</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (1.06, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8568 (13)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.88, 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4503 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4471</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.36, 0.96)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4780 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 270.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2666</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50 (2.76, 4.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6896 (12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.49 (1.86, 3.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3590 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3895</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33, 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2541 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.67, 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2535 (3)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2847</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.26, 1.65)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3922 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> RD was non‐significant; <sup>b</sup> Random‐effects RR was calculated due to heterogeneity. </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>MED: Medication<br/>N/A: not available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010224-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Levetiracetam</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Levetiracetam in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in the exposed children</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Prevalence LEV (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Prevalence</b> </p> <p><b>comparator (95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Levetiracetam vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.98, 4.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1596 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.3% (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0,17, 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369,385 (1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Levetiracetam vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.0% (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.39, 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1825 (6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.2% (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.39, 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,625 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58‐ 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5612 (10)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.37, 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2316 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3113</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 (1.01, 2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5056 (11)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.78, 3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1248 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2556</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32, 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1629 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.06, 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.77 (2.48, 5.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3485 (10)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.26 (1.51, 7.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>911 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51, 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1166 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (0.45, 3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>932</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.25, 1.71)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>995 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> RD was non‐significant; <sup>b</sup> Random‐effects RR was calculated due to heterogeneity. </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010224-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010224-sec-0009"></div> <p>This review is an update of the Cochrane Review first published in 2004 (<a href="./references#CD010224-bbs2-0132" title="AdabN , TudurSC , VintenJ , WilliamsonP , WinterbottomJ . Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004848. [DOI: 10.1002/14651858.CD004848]">Adab 2004</a>), and last updated in 2016 (<a href="./references#CD010224-bbs2-0134" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton-SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD010224. [DOI: 10.1002/14651858.CD010224.pub2]">Weston 2016</a>). </p> <section id="CD010224-sec-0010"> <h3 class="title" id="CD010224-sec-0010">Description of the condition</h3> <p>Epilepsy is a common neurological disorder with a lifetime prevalence of 7.60 per 1000 persons (<a href="./references#CD010224-bbs2-0112" title="FiestKM , SauroKM , WiebeS , PattenSB , KwonCS , DykemanJ , et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology2017;88(3):296-303. [PMID: 27986877]">Fiest 2017</a>). A significant number of women with epilepsy will be in their childbearing years (<a href="./references#CD010224-bbs2-0124" title="National Institute for Clinical Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. www.nice.org.uk/guidance/ng217 (accessed prior to 4 Feb 2023).">NICE 2022</a>) and, of these, approximately 0.5% to 0.6% of all annual pregnancies are reportedly exposed to an anti‐seizure medication (ASM) in utero (<a href="./references#CD010224-bbs2-0118" title="ManSL , PetersenI , ThompsonM , NazarethI . Antiepileptic drugs during pregnancy in primary care: a UK population based study. PLOS One2012;7:e52339. [PMID: 23272239]">Man 2012</a>, <a href="./references#CD010224-bbs2-0124" title="National Institute for Clinical Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. www.nice.org.uk/guidance/ng217 (accessed prior to 4 Feb 2023).">NICE 2022</a>). ASM treatment of epilepsy in the childbearing years requires careful optimisation to improve maternal outcomes whilst minimising, where possible, foetal risks. Research demonstrates an association between children born to women with epilepsy treated with ASMs and an increased risk of major congenital malformations, including cardiac, neural tube and craniofacial defects (<a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0115" title="JentinkJ , LoaneMA , DolkH , BarisicI , GarneE , MorrisJK , et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine2010;362(23):2185-93. [PMID: 20558369]">Jentink 2010a</a>; <a href="./references#CD010224-bbs2-0121" title="MeadorK , ReynoldsMW , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81(1):1-13. [PMID: 18565732]">Meador 2008</a>). </p> </section> <section id="CD010224-sec-0011"> <h3 class="title" id="CD010224-sec-0011">Description of the intervention</h3> <p>ASMs are the most common treatment for epilepsy, and most women with epilepsy require treatment continuation during pregnancy. </p> </section> <section id="CD010224-sec-0012"> <h3 class="title" id="CD010224-sec-0012">How the intervention might work</h3> <p>ASMs readily cross the placenta from the mother into the foetusus (<a href="./references#CD010224-bbs2-0102" title="BrentRL . Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics2004;113(4 Suppl):957-68. [PMID: 15060188]">Brent 2004</a>; <a href="./references#CD010224-bbs2-0127" title="TetroN , MoushaevS , ShmuelM , EyalS . Antiseizure medications and fetal nutrients: effects on choline transporters in a human placental cell line. Epilepsia2021;62(6):1451-9. [PMID: 33890297]">Tetro 2017</a>). Prospective observational studies (e.g. <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>), registry‐based studies (e.g. <a href="./references#CD010224-bbs2-0128" title="TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al, EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]">Tomson 2011</a>), case‐control studies (<a href="./references#CD010224-bbs2-0115" title="JentinkJ , LoaneMA , DolkH , BarisicI , GarneE , MorrisJK , et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine2010;362(23):2185-93. [PMID: 20558369]">Jentink 2010a</a>), and epidemiological studies using datasets of routine health records (e.g. <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>) provide evidence of an association between ASM treatment and an increased prevalence of major congential malformations. The level of risk varies for different types of ASM, with first trimester valproate (VPA) exposure associated with the largest increase in prevalence (<a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>). The mechanisms through which prenatal exposure to ASMs are associated with an increased prevalence of major malformations likely differs by treatment type and may be multifactorial. </p> <p>This review investigates the outcomes for monotherapy treatment with different ASMs to identify currently available evidence on which to base treatment decisions. </p> </section> <section id="CD010224-sec-0013"> <h3 class="title" id="CD010224-sec-0013">Why it is important to do this review</h3> <p>The decision to continue ASM treatment during pregnancy requires taking a risk‐benefit decision. On the one hand, there is the potential risk posed to the foetus when the medication is a teratogen yet on the other hand, there is the health and well‐being of the mother, who requires treatment throughout her pregnancy to minimise the risk of seizures (<a href="./references#CD010224-bbs2-0129" title="TomsonT , MarsonA , BoonP , CaneviniMP , CovanisA , GailyE , et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia2015;56(7):1006-19. [PMID: 25851171]">Tomson 2015</a>); the choice of ASM depends on the type of epilepsy and the seizures (<a href="./references#CD010224-bbs2-0120" title="MarsonAG , Al-KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al, SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1016-26. [PMID: 17382828]">Marson 2007</a>). A lack of knowledge regarding foetal safety limits treatment options for women with epilepsy in their childbearing years, as women and their doctors may avoid ASMs with limited data. Conversely, a lack of evidence may lead to an ASM with a higher foetal risk profile being used extensively, prior to a full understanding of its risks. </p> <p>While a number of studies indicate a teratogenic risk from certain ASMs, there are conflicting results regarding the degree of risk and the types of malformations associated with specific ASMs. Data are slow to accumulate and an earlier version of this review (<a href="./references#CD010224-bbs2-0134" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton-SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD010224. [DOI: 10.1002/14651858.CD010224.pub2]">Weston 2016</a>) found extremely limited data on ASMs with a decade or more of clinical use. Such a lack of evidence makes it difficult to counsel women about treatment choices before or during pregnancy. There is, therefore, a clear need for a systematic review and meta‐analysis of existing data to inform these decisions. Randomised controlled trials (RCTs) would provide the most reliable evidence about the effects of ASMs in pregnancy, but are essentially precluded by ethical considerations and logistical challenges pertaining to study design, recruitment and interpretation. </p> <p>In view of this, we performed a systematic review of all available evidence including registry‐based, prospective cohort studies, RCTs and epidemiological studies using routine health record databases. At the protocol stage, we decided not to include malformation case‐control studies (e.g. <a href="./references#CD010224-bbs2-0115" title="JentinkJ , LoaneMA , DolkH , BarisicI , GarneE , MorrisJK , et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine2010;362(23):2185-93. [PMID: 20558369]">Jentink 2010a</a>; <a href="./references#CD010224-bbs2-0116" title="JentinkJ , DolkH , LoaneMA , MorrisJK , WellesleyD , GarneE , et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ2010;341:c6581. [PMID: 21127116]">Jentink 2010b</a>) due to the substantial differences in the approach in these studies and how these methods compare to prospective observational cohort studies. This decision is discussed further in <a href="#CD010224-sec-1538">Overall completeness and applicability of evidence</a>. This review is an update of two previous reviews (<a href="./references#CD010224-bbs2-0132" title="AdabN , TudurSC , VintenJ , WilliamsonP , WinterbottomJ . Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004848. [DOI: 10.1002/14651858.CD004848]">Adab 2004</a>; <a href="./references#CD010224-bbs2-0134" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton-SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD010224. [DOI: 10.1002/14651858.CD010224.pub2]">Weston 2016</a>). Evidence from this review, along with the related review by the same Cochrane team (<a href="./references#CD010224-bbs2-0103" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010236. [DOI: 10.1002/14651858.CD010236.pub2]">Bromley 2014</a>), will aid the decisions that clinicians and women with epilepsy have to make about the treatment of epilepsy during the potential childbearing years. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010224-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010224-sec-0014"></div> <p>To assess the effects of prenatal exposure to commonly prescribed ASMs on the prevalence of major congenital malformations in the child. </p> <p>This review examines the association between specific ASM exposures and the prevalence of major congenital malformations compared to the general population or unexposed pregnancies in women with epilepsy. It also compares the prevalence of specific major congenital malformations types across the ASM treatment groups. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010224-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010224-sec-0015"></div> <section id="CD010224-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010224-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered the following types of studies.</p> <p> <ol id="CD010224-list-0001"> <li> <p>Randomised controlled trials (RCTs). These studies included women with epilepsy who were randomised to a particular ASM prior to conception. The intervention group(s) comprised women with epilepsy taking ASM monotherapy. </p> </li> <li> <p>Prospective observational cohort studies. These included consecutive participants whose clinical information was collected prior to the birth of the child. The intervention group(s) comprised women with epilepsy treated with ASM monotherapy. </p> </li> <li> <p>Registry studies. These involve the collection of data from a wide region, country or number of countries, and recruitment is often based on self‐referral or clinician‐referral, leading to non‐sequential case ascertainment. We considered both disease‐based registries (e.g. pregnancy and epilepsy registries) and industry‐sponsored product registry datasets. Pregnant women with epilepsy prescribed ASM monotherapy were recruited prospectively prior to childbirth. </p> </li> <li> <p>Population‐based routine health record datasets. These studies utilise data collected for routine health monitoring, administrative or reimbursement reasons for entire national populations or specific populations (e.g. medical insurance databases). Individual recruitment of participants is not required. The intervention group(s) comprised women with epilepsy taking ASM monotherapy. </p> </li> </ol> </p> </section> <section id="CD010224-sec-0018"> <h4 class="title">Types of participants</h4> <p>Pregnant women with epilepsy taking a single ASM of interest were eligible for the intervention group. </p> <p>Participants eligible for the comparator groups were:</p> <p> <ul id="CD010224-list-0002"> <li> <p>pregnant women with epilepsy taking an ASM;</p> </li> <li> <p>pregnant women with epilepsy taking no ASM; or</p> </li> <li> <p>pregnant women who do not have epilepsy.</p> </li> </ul> </p> <p>We excluded studies reporting ASM use solely in pregnant women with other conditions (e.g. mood disorders, pain). We included studies involving women taking ASMs for epilepsy and other conditions if the non‐epilepsy conditions accounted for 30% or less of the total treatment group. This percentage criterion was increased from the previous review to accommodate data from population healthcare datasets, which often include a wider group of participant indications. </p> </section> <section id="CD010224-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD010224-sec-0020"> <h5 class="title">Intervention group</h5> <p>Women with epilepsy who received any of the following ASMs as monotherapy: acetazolmide, brivaracetam, bromide, carbamazepine, cenobamate, clomethiazole, clonazepam, clorazepate, diazepam, dimethyloxazolidinedione, eslicarbazepine, ethosuximide, estazolam, felbamate, flunarizine, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, magnesium sulphate, medazepam, methylphenobarbital, mephenytoin, meprobamate, methazolamide, methsuximide, methyloxazepam, midazolam, nimetazepam, nitrazepam, oxcarbazepine, perampanel, phenobarbitone, phenytoin, primidone, pregabalin, remacemide, retigabine, rufinamide, sodium valproate, stiripentol, sulthiame, tiagabine, topiramate, trimethadione, trifluoromethoxy benzothiazole, valnoctamide, vigabatrin, or zonisamide. </p> </section> <section id="CD010224-sec-0021"> <h5 class="title">Comparator groups</h5> <p>We used two separate types of comparator groups in this review, as currently there is no clear evidence regarding the reliability of combining data from these two different groups. The two comparator groups are: </p> <p> <ul id="CD010224-list-0003"> <li> <p>controls: women with a diagnosis of epilepsy who were not taking ASMs and women without epilepsy. </p> </li> <li> <p>comparator treatment: women with epilepsy treated with ASM monotherapy, evaluated in subgroup analyses to enable treatment comparisons. </p> </li> </ul> </p> </section> </section> <section id="CD010224-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD010224-sec-0023"> <h5 class="title">Primary outcomes</h5> <section id="CD010224-sec-0024"> <h6 class="title">Major congenital malformations</h6> <p>The proportion of children who present with any type of major congenital malformation (as defined by study authors). Major malformations are structural abnormalities of the body or organs present from birth and which require intervention (e.g., corrective surgery) or have a significant level of impact on the child's daily functioning (<a href="./references#CD010224-bbs2-0111" title="EUROCAT European Surveillance of Congenital Anomalies. EUROCAT guide 1.3 and reference documents: instructions for the registration and surveillance of congenital anomalies. eu-rd-platform.jrc.ec.europa.eu/sites/default/files/EUROCAT-Guide-1.3.pdf (accessed August 2015).">EUROCAT</a>). </p> </section> </section> <section id="CD010224-sec-0025"> <h5 class="title">Secondary outcomes</h5> <section id="CD010224-sec-0026"> <h6 class="title">Specific major congenital malformations</h6> <p>The proportion of children who present with the following specific major congenital malformations by area of the body. </p> <p> <ul id="CD010224-list-0004"> <li> <p>Neural tube malformations.</p> </li> <li> <p>Cardiac malformations.</p> </li> <li> <p>Oro‐facial cleft/craniofacial malformation.</p> </li> <li> <p>Skeletal or limb malformations.</p> </li> </ul> </p> <p>We chose the above disorders because they are important major malformations associated with exposure to ASMs in utero, because these are the most prevalent congenital malformations in the general population (ref: https://eu‐rd‐platform.jrc.ec.europa.eu/eurocat/eurocat‐data/prevalence_en), and because of the availability of data within the included studies. When extracting data from included studies, we compiled a list of all the specified malformations. Author JCS, a clinical geneticist, then reviewed the list and classified the items into one of the four specific malformation categories. </p> </section> </section> </section> </section> <section id="CD010224-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010224-sec-0028"> <h4 class="title">Electronic searches</h4> <p>Searches for the original review were run in January 2012. Subsequent searches were run in March 2013, May 2014, and September 2015. For the latest update, we searched the following databases on 17 February 2022: </p> <p> <ol id="CD010224-list-0005"> <li> <p>Cochrane Register of Studies (CRS Web), using the search strategy set out in <a href="./appendices#CD010224-sec-1549">Appendix 1</a>; </p> </li> <li> <p>MEDLINE (Ovid, 1946 to February 16, 2022) using the search strategy set out in <a href="./appendices#CD010224-sec-1550">Appendix 2</a>; </p> </li> <li> <p>SCOPUS (1823 onwards) using the search strategy set out in <a href="./appendices#CD010224-sec-1551">Appendix 3</a>; </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> using the search strategy set out in <a href="./appendices#CD010224-sec-1552">Appendix 4</a>; </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform</a> (ICTRP) using the search strategy set out in <a href="./appendices#CD010224-sec-1553">Appendix 5</a>. </p> </li> </ol> </p> <p>CRS Web includes randomised or quasi‐randomised, controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialized Registers of Cochrane Review Groups including Epilepsy. In MEDLINE (Ovid), the coverage end date always lags a few days behind the search date. Previously we also searched Embase, Pharmline and Reprotox. </p> <p>We did not impose any language restrictions in the search and, when necessary, we obtained translations of articles written in languages other than English. </p> </section> <section id="CD010224-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We reviewed conference abstracts from neurology meetings published from 2010 to 2022, including abstracts from the International League Against Epilepsy meetings (American Epilepsy Society, International Epilepsy Congress, European Congress on Epileptology, Asian and Oceanian Epilepsy Congress and Latin American Congress on Epilepsy) and Teratology meetings (Teratology Society and European Teratology Society). Where possible, we linked abstracts to published datasets or categorised them as awaiting classification. </p> <p>We cross‐matched reference lists of original research and review articles to the studies generated from the electronic searches. We handsearched reference lists of recent review articles and contacted lead and corresponding authors in the area for any relevant unpublished material. </p> </section> </section> <section id="CD010224-sec-0030"> <h3 class="title" id="CD010224-sec-0030">Data collection and analysis</h3> <section id="CD010224-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Five authors (RB, JW, JG, KE, RMcG) reviewed the titles and abstracts of articles highlighted by the searches and removed studies that obviously did not meet the inclusion criteria. Four authors (RB, JW, KE, RMcG) used full‐text reports to determine study eligibility. We discussed disagreements and sought the opinion of a third author (JG, CJ, RB), when necessary. Multiple reports from single studies are common in this field. To ensure that each cohort was represented only once in our analysis, therefore to avoid double‐counting the population across papers of included studies, we linked studies by recruitment date and sought confirmation from authors whether reports referred to single study populations. Where this was unclear, we contacted study authors for clarification. </p> </section> <section id="CD010224-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Eight authors (RB, JW, NA, JG, AM, KE, RMcG, SK, CJ) undertook data extraction of the included studies. We used pre‐standardised electronic data extraction forms that members of the review team piloted and then amended, where necessary. We then cross‐checked data extraction. All entries into RevMan were also double‐checked. </p> </section> <section id="CD010224-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Due to the observational design of the majority of the studies, we utilised the Risk Of Bias In Non‐Randomized Studies ‐ of Interventions (ROBINS‐I) tool which the Cochrane Non‐Randomised Studies Methods Group has developed (<a href="./references#CD010224-bbs2-0126" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919. [PMID: 27733354]">Sterne 2016</a>). The ROBINS‐I tool for assessing risk of bias examines bias in the domains of confounding, selection, treatment classification, missing data, measurement and reported results. ROBINS‐I uses signalling questions on a four‐point scale to determine level of bias in specific elements of biases for each of these domains. Overall domain bias ratings are then classed as low, moderate, serious, critical or no information. </p> <p>ROBINS‐I was developed for treatment studies and not pharmacovigilance studies, where the person taking the medication (the mother) is not the same person in which the outcome can occur (the child). Therefore, ROBINS‐I needed to be adapted for use in this review. The adaption was led by author RB with input from other authors. Important confounder and mediator variables were selected based on published evidence of an association both in the general population and specifically in investigations regarding in utero ASM exposure and congential malformation outcomes. See <a href="./appendices#CD010224-sec-1554">Appendix 6</a> for further information. Eight authors completed risk of bias ratings (RB, JW, NA, JG, AM, KE, SK, MBD). Each included study was reviewed by two independent raters and the opinion of a third author (RB) was sought where there were disagreements in the domain level ratings. For RCTs, we intended to use the original Cochrane tool for assessing risk of bias (RoB1) (<a href="./references#CD010224-bbs2-0114" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p>We intended, where applicable, to create Summary of findings tables for outcomes and to grade each outcome accordingly using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (<a href="./references#CD010224-bbs2-0113" title="GuyattGH , OxmanAD , VistG , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>). However, we found GRADE to not be optimised for these types of data and using it would have led to differential ratings across comparisons, depending on whether there was a difference in MCM rate or not; thus, producing ratings of lower evidence confidence for comparisons with no difference between the ASMs. Further work is required on GRADE and ROBINS‐I to optimise them for pregnancy pharmacovigilance investigations. </p> </section> <section id="CD010224-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We considered that different study design types or comparator groups may lead to different outcome results and, therefore, we did not combine all data into a single meta‐analysis containing mixed study types, groups of different ASMs and comparator groups. Meta‐analyses were instead stratified by study type, by comparator group (e.g. women with epilepsy untreated and women without epilepsy and with no treatment), and by ASM versus ASM comparison. We computed pooled prevalences of malformations within AED (antiepileptic drug) groups (using fixed‐effect models, unless otherwise stated) and reported them at the beginning of each drug section. The primary and secondary outcomes are presented as risk ratios (RRs). We also computed risk differences (RDs) using Review Manager (RevMan) to take into account studies with no reported events. We calculated these effect estimates in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and reported them in the results section (<a href="./references#CD010224-bbs2-0114" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Where treatment effects were reported from individual studies, we used the summary effect measure that had been utilised by the study authors to report results from the study. In some cases, OR instead of RR was reported by individual study authors. </p> <p>The RR is a measure of relative effect expressed as the ratio of the risk of an event in the two groups. If the 95% confidence interval includes the value of 1.00, this implies there is no difference between the groups (i.e. a non‐significant result). If the value of 1.00 lies outside the 95% confidence interval, this implies there is a difference between the groups (i.e. a significant result). The RD is a measure of absolute effect expressed as the difference of the risk of an event in the two groups. If the 95% confidence interval contains the value of 0.00, this implies there is no difference between the groups (i.e. both groups have the same risk). If the value of 0.00 lies outside the 95% confidence interval, this implies there is a difference between the groups (i.e. a significant result). The significance of the RR and RD may be different, as the RD takes into account comparisons where there were no events in either arm, whilst the other does not. Although the RR estimates are large in many comparisons, the corresponding risk difference estimates are fairly small; but even a small increase in risk for a specific major malformation is clinically meaningful. In these cases, it would be up to the patient/clinician to interpret these risk estimates in the context of the adverse outcome and in relation to the potential benefits of treatment (e.g. seizure control). We did not account for multiple testing and the totality of the evidence for a particular exposure should be considered rather than the outcomes of a single comparison. Finally, we did not carry out any formal analysis of a dose‐response relationship. We have taken any dose‐response results reported directly from the study papers. </p> </section> <section id="CD010224-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>Data published in studies are often duplicated as they are updated, particularly in the case of the prospective pregnancy registries, which update their publications as the numbers of enrolled pregnancies increase. In such cases, we considered the latest time point as the 'primary' study for inclusion. In some cohorts, this meant that we used different publications for different ASMs. Further, there are studies that report combined data from a number of different registers (e.g. <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>) which also report independently and routine health record studies with cohort overlap (e.g. <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>). Where the combined data reported provided greater numbers for a particular ASM comparison, it was included in the meta‐analysis but, where individual initiatives had greater numbers for a specific comparison (e.g. ASM vs control group), we included the individual study data and provided a narrative report of the collaborative initiatives. We carefully examined data to ensure that we did not include them more than once in the analysis and that we did not omit any non‐duplicated data. </p> </section> <section id="CD010224-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to obtain missing statistics from included studies to input into the meta‐analysis. We also investigated study reasons for missing data to determine if they were missing at random or not. </p> </section> <section id="CD010224-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by examining the differences in study characteristics in order to inform decisions regarding the combination of study data in meta‐analysis. A priori hypotheses of sources of clinical heterogeneity included: type of population (regional, national or international, single or multicentre), loss to follow‐up, maternal factors including age, duration of ASM treatment, family history of congenital malformation, lifestyle factors, monotherapy, socioeconomic status, type of epilepsy, use of other medications and years of education. Child factors included: age of assessment, sex, seizure exposure, length of follow‐up and outcome measurement. </p> <p>Where applicable, we also assessed statistical heterogeneity by examining the I<sup>2</sup> statistic and a Chi<sup>2</sup> test, using the guidelines outlined in <a href="./references#CD010224-bbs2-0114" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a> for interpreting the results. According to these guidelines, an I<sup>2</sup> statistic of 0% to 40% may not be important, 30% to 60% may indicate moderate heterogeneity, 50% to 90% may indicate substantial heterogeneity and 75% to 100% may indicate considerable heterogeneity. Therefore, for this review, we considered an I<sup>2</sup> statistic of more than 50% to indicate significant heterogeneity. The I<sup>2</sup> statistic was not applicable in comparisons where there was only a single study or when only one study contributed data to the analysis. When interpreting the Chi<sup>2</sup> test, a P value of less than 0.01 was considered to indicate significant heterogeneity. When we found statistical heterogeneity, we presented both fixed‐effect and random‐effects analyses to enable exploration of differences. </p> </section> <section id="CD010224-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We included studies using the Outcome Reporting Bias in Trials (ORBIT) classification system if we suspected selective outcome reporting bias. We requested all protocols from included study authors to enable comparison of outcomes of interest; however, we received very few responses, complicating our performance of this comparison. </p> <p>Our comprehensive search of multiple sources and data types, together with our requests for unpublished data or clarification from authors, minimised the risk of publication bias. </p> </section> <section id="CD010224-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We employed both fixed‐effect and random‐effects meta‐analyses to synthesise the data. We presented the primary outcome (major congenital malformations) and the secondary outcome of specific malformations as a risk ratio (RR). Within certain comparisons, we have also presented the risk differences (RD) for both primary outcome (overall malformation rate). In the event that we deemed meta‐analysing inappropriate (e.g. presence of clinical heterogeneity), we applied a narrative form to the review, discussing all comparisons according to the findings presented within the studies. </p> <p>Comparisons carried out included:</p> <p> <ol id="CD010224-list-0006"> <li> <p>specific ASM monotherapy group versus controls on major congenital malformations;</p> </li> <li> <p>specific ASM monotherapy group versus controls on specific major congential malformation types; </p> </li> <li> <p>specific ASM monotherapy group versus specific ASM monotherapy group on major congential malformations; </p> </li> <li> <p>specific ASM monotherapy group versus specific ASM monotherapy group on specific major congential malformations. </p> </li> </ol> </p> <p>We stratified each comparison by control group, comparator group and study design to ensure appropriate combination of study data. For example, cases reported in a national pregnancy and epilepsy register may also be represented in epidemiological datasets of routine health data which covers the same region or a case in an administrative insurance database may also have been reported to a national epilepsy and pregnancy register and therefore data were not combined across these different data sources. </p> </section> <section id="CD010224-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was stratified by ASM and type of control or comparator group. When heterogeneity was present across outcomes, we carried out a random‐effects analysis. We examined differences between analyses and reported the appropriate analysis. </p> </section> <section id="CD010224-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We adopted a cautious approach to combining data extracted from different types of study, and also where different comparator groups were included as outlined in <a href="#CD010224-sec-0034">Measures of treatment effect</a>. Additionally, we only included studies where over 70% of the cohort were women taking ASMs for the treatment of epilepsy. This was due to the heterogeneity around doses prescribed, across women taking ASMs for different conditions. This decision is supported by the findings of Hernandez Diaz and colleagues (<a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>) who found that differences in the dose of topiramate prescribed for women with epilepsy compared to women prescribed it for other conditions altered the risk of oro‐facial anomalies. </p> </section> <section id="CD010224-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>In this review, we considered ASM use in during pregnancy in women with epilepsy and the major malformation rate in their exposed children (<a href="#CD010224-fig-0001">Figure 1</a>). Comparisons were made across the different ASM treatments and to unexposed children. The outcomes are summarised in <a href="#CD010224-tbl-0003">Table 1</a> along with <a href="./full#CD010224-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD010224-tbl-0002">summary of findings Table 2</a> for lamotrigine and levetiracetam and in <a href="#CD010224-tbl-0004">Table 2</a>, <a href="#CD010224-tbl-0005">Table 3</a>, <a href="#CD010224-tbl-0006">Table 4</a>, and <a href="#CD010224-tbl-0007">Table 5</a> for carbamazepine, oxcarbazepine, topiramate and valproate, respectively. The data for other ASMs were too limited at this time for useful tables to be compiled. Relative risks and risk differences are displayed in <a href="#CD010224-tbl-0008">Table 6</a> and <a href="#CD010224-tbl-0009">Table 7</a>. </p> <div class="figure" id="CD010224-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram*50 studies were included in the original review but, due to changes to the inclusion criteria, 16 studies were excluded.** for some studies only certain data were able to be included in the meta‐analysis." data-id="CD010224-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> <p>*50 studies were included in the original review but, due to changes to the inclusion criteria, 16 studies were excluded. </p> <p>** for some studies only certain data were able to be included in the meta‐analysis.</p> </div> </div> </div> <div class="table" id="CD010224-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prevalence of major congenital malformations for each monotherapy ASM stratified by study type</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Database</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>All</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ASM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Upper 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Upper 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Upper 95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>CZP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>321.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9722.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,060.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No med</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12,994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen POP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>376,565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Specific prevalences are weighted for cohort size.</p> <p>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>CZP: Clonazepam<br/>GBP: Gabapentin<br/>LAC: Lacosamide<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>ND: No Data<br/>OXC: Oxcarbazepine<br/>PB: Phenobarbital<br/>PHT: Phenytoin<br/>POP: Population <br/>PRM: Primidone<br/>TPM: Topiramate<br/>VPA: Sodium Valproate<br/>ZNS: Zonisamide </p> </div> </div> <div class="table" id="CD010224-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of findings table ‐ Carbamazepine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Carbamazepine in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence CBZ</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Carbamazepine vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.30 (1.47, 3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5047 (13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3% (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (0.80, 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,094 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Carbamazepine vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0% (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.44 (1.05, 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5289 (20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2% (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 (1.10, 1.83)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,334 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 (1.01, 2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5056 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.78, 3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1248 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2556</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (1.06, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8568 (13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.88, 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4503 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4471</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51, 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4156 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27,060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.17, 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1437 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2109</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (0.37, 0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8090 (29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.33, 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4157 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3338</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74, 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2877 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.44, 0.91)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3015 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2290</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.07, 10.35)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2841 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> RD was non‐significant; <sup>b</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </div> <div class="table" id="CD010224-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of findings table ‐ Oxcarbazepine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Oxcarbazepine in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC Prevalence</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.67, 7.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>951(2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 3.3 (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.10, 4.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369,324 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0 (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.40 (0.68, 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>922 (6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2 (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75 (1.22, 2.52)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,819 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51, 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1166 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (0.45, 3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>932</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine Vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33, 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2541 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.67, 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2535 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2847</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oxcarbazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>706 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.04, 4.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48 (1.42, 4.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1561 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 (1.11, 2.29)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1701 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1714</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74, 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2887 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.44, 0.91)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3015 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2290</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oxcarbazepine vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.48 (0.24, 82.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </div> <div class="table" id="CD010224-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings table ‐ Topiramate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Topiramate in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM Prevalence</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.07 (1.64, 10.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1192 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 3.3 (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.43, 6.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369,315 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0 (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.57, 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1219 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2 (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.62 (0.40, 6.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1948 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32, 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1629 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.06, 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.36, 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4780 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 0.68% (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2666</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oxcarbazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>706 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.04, 4.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.47 (1.50, 4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2723 (7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.27 (0.36, 4.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1533</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51, 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4156 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.17, 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1437 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2109</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Topiramate vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.54, 4.66)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>Gen pop: General population<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </div> <div class="table" id="CD010224-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings table ‐ Valproate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Valproate in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA Prevalence</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Valproate vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.53 (3.29, 9.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3135 (10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 3.3 (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.29 (1.71, 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,649 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Valproate vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0 (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.77 (2.03, 3.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3998 (17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2 (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.01 (2.42, 3.75)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,369 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.77 (2.48, 5.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3485(10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.26 (1.51, 7.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>911 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50 (2.76, 4.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6896 (12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 0.68% (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.49 (1.86, 3.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3590 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3894</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48 (1.42, 4.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1561 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 (1.11, 2.29)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1701 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1714</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.47 (1.50, 4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2723 (7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.27 (0.36, 4.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (0.37, 0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8090 (29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.33, 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4157 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3338</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.34 (0.95, 5.80)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1677 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>Gen pop: General population<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </div> <div class="table" id="CD010224-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Relative risks (RRs) for specific ASM comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gen Pop</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No Med</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.30 (1.47 to 3.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.44 (1.05 to 1.96)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82 (0.63 to 5.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.55 (0.57 to 4.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.51 (1.01 to 2.26)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.37 (1.06 to 1.77)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74 to 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.61 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.62 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.23 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.44 (0.37 to 0.53)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94, (0.36 to 2.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.76 (0.55 to 13.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.21 to 5.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82 (0.63 to 5.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.32 to 3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.29 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.01 to 5.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.05 to 13.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.10 to 5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.03 to 15.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.29 (0.09 to 0.90)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.78 (0.50 to 6.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.77 (0.46 to 6.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.55 (0.57 to 4.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.46 to 5.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.34 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.13 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.08 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.15 (0.69 to 6.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32 (0.09 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.27 (1.60 to 11.35)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.10 to 2.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.98 to 4.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.39 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.51 (1.01 to 2.26)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.32 to 3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.46 to 5.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.29 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.58 (0.34 to 0.97)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.02 to 3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.77 (2.48 to 5.74)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.25 to 1.71)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.99 (1.16 to 3.39)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.66 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.37 (1.06 to 1.77)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.29 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.34 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.32 (0.17 to 0.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55 (0.35 to 0.87)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.02 to 3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.59 (0.36 to 0.96)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.50 (2.76 to 4.46)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.26 to 1.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.67 to 7.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.40 (0.68 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74 to 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.01 to 5.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.13 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.83 to 3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.48 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (0.08 to 4.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.48 (1.42 to 4.31)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.48 (0.24 to 82.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.22 (1.84 to 5.65)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.64 (0.94 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.61 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.05 to 13.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.08 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.29 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.32 (0.17 to 0.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.83 to 3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.57 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.21 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38 (0.68 to 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.49 (1.08 to 2.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.46 (0.62 to 175.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.81 (1.91 to 7.57)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.01 (1.29 to 3.12)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.62 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.10 to 5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.15 (0.69 to 6.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.58 (0.34 to 0.97)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55 (0.35 to 0.87)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.48 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.57 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.39 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.48 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.92 (1.44 to 2.56)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.42 to 3.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.61 (1.41 to 9.23)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.23 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.02 to 3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.02 to 3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (0.08 to 4.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.21 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.39 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.00 (0.30 to 118.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.39 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.07 (1.64 to 10.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.57 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.03 to 15.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32 (0.09 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.59 (0.36 to 0.96)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38 (0.680 to 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.48 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.00 (0.30 to 118.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.47 (1.50 to 4.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.54 to 4.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.53 (3.29 to 9.29)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.77 (2.03 to 3.79)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.44 (0.37 to 0.53)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.29 (0.09 to 0.90)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.27 (1.60 to 11.35)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.77 (2.48 to 5.74)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.50 (2.76 to 4.46)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.48 (1.42 to 4.31)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.49 (1.08 to 2.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.92 (1.44 to 2.56)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.39 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.47 (1.50 to 4.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.34 (0.95 to 5.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.21 to 6.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.20 (1.09 to 9.43)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94, (0.36 to 2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.10 to 2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.25 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.26 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.48 (0.24 to 82.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.46 (0.62 to 175.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.42to 3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.54 to 4.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.34 (0.95 to 5.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Bold indicates statistically significant</p> <p>ASM: Anti‐Seizure Medication<br/>CBZ: Carbamazepine<br/>CZP: Clonazepam<br/>GBP: Gabapentin<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>ND: No Data<br/>NE: Not Estimable<br/>OXC: Oxcarbazepine<br/>PB: Phenobarbital<br/>PHT: Phenytoin<br/>POP: Population <br/>PRM: Primidone<br/>RR: Relative Risk <br/>TPM: Topiramate<br/>VPA: Sodium Valproate<br/>ZNS: Zonisamide </p> </div> </div> <div class="table" id="CD010224-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Risk differences (RDs) for specific ASM comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gen Pop</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No Med</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.02 (0.01 to 0.03)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04,</b> </p> <p><b>(‐0.00 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>( −0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05 (−0.06 to −0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.03 to 0.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.03 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.11 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04,</b> </p> <p><b>(‐0.00 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.14 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.05 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.18 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.08 (−0.66 to 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.13 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.09 (−0.13 to 0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (‐0.37 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.05 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.14 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.08 to 0.00)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.03 (−0.05 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.08 (0.01 to 0.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.15 to 0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.00 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.05 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.01 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.02 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.05 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to −0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.39 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.04 to 0.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.03)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.01 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.01 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.07 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.02 (−0.03 to −0.00)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (−0.37 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.03 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.16 to 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.02 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (−0.03 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>( −0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.18 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.02 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.03 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.34 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.03 to 0.09)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.01 to 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04 (0.01 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (−0.01 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.08 (−0.66 to 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.08 to 0.00)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.05 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.07 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.12 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.02 to 0.09)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03 (0.01 to 0.05)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.13 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to −0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.03 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.03 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.11 to 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.00 to 0.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.39 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (−0.37 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.34 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.12 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02</p> <p>(−0.44 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.13 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.03 (−0.05 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.03 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02</p> <p>(−0.44 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.02 to 0.11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.02 to 0.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.04 to 0.10)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.04 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05 (−0.06 to −0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.09 (−0.13 to 0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.08 (0.01 to 0.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.03 to 0.09)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.03 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.13 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.02 to 0.11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.11 to 0.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (−0.03 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.03 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.15 to 0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.04 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.16 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.01 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.02 to 0.09)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.11 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.02 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.11 to 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Bold indicates statistical significance</p> <p>ASM: Anti‐Seizure Medication<br/>CBZ: Carbamazepine<br/>CZP: Clonazepam<br/>GBP: Gabapentin<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>ND: No Data<br/>NE: Not Estimable<br/>OXC: Oxcarbazepine<br/>PB: Phenobarbital<br/>PHT: Phenytoin<br/>POP: Population <br/>PRM: Primidone<br/>TPM: Topiramate<br/>VPA: Sodium Valproate<br/>ZNS: Zonisamide </p> </div> </div> <p>The Robins‐I was adapted for use here to understand the risk of biases but is not yet optimised for pregnancy pharmacovigilance work and, therefore, caution is required in the interpretation of its ratings. It did, however, show that different methodological approaches have different patterns of biases and are therefore in part complimentary (<a href="#CD010224-fig-0002">Figure 2</a>). Cohort studies with primary data collection, for example, tend to have lower risks of misclassification of treatment and standardised review of the congenital malformation outcome in the children (leading to low risk of bias ratings), yet they are at higher risk of bias for cohort selection. The use of routine health record data at a national population level does not have these selection risks, however. Stratification of the results by study type provides an internal validation for the results (<a href="#CD010224-fig-0003">Figure 3</a>) and the evidence presented in this review should be considered more certain when the results of different comparisons are consistent across study types. </p> <div class="figure" id="CD010224-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias for included studies by individual domain" data-id="CD010224-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-02.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias for included studies by individual domain</p> </div> </div> </div> <div class="figure" id="CD010224-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Prevalence and 95% CI of major congenital malformations for each anti‐seizure medication by data source" data-id="CD010224-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prevalence and 95% CI of major congenital malformations for each anti‐seizure medication by data source </p> </div> </div> </div> <p>Malformations are rare outcomes and therefore larger groups are needed to reliably detect a higher risk of malformation in one group over another. Therefore, the certainty of the evidence is greater for medications such as VPA, carbamazepine (CBZ) and lamotrigine (LTG) where the numbers of children are higher within and across the comparisons. The available data were more moderate for levetiracetam (LEV), phenytoin (PHT) and phenobarbital (PB) in certain comparisons. Care should be taken in the interpretation of comparisons where there were fewer than 1000 pregnancies. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010224-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010224-sec-0043"></div> <section id="CD010224-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD010224-sec-0045"> <h4 class="title">Results of the search</h4> <p>In this updated review, electronic searches identified 1067 additional publications; this was in addition to the 11,695 records previously detected in searches for an earlier version of this review (<a href="./references#CD010224-bbs2-0134" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton-SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD010224. [DOI: 10.1002/14651858.CD010224.pub2]">Weston 2016</a>). We found two additional records through handsearching. Following the removal of duplicates, 12,296 abstracts were screened for inclusion in the review across the original and this update. We excluded 12,013 abstracts due to irrelevance, leaving 283 full texts (156 new for this update) to be assessed for eligibility. As the inclusion criteria had been extended to include studies using routine health records in this update, we re‐evaluated search results from the last version for such studies and identified eight additional studies (14 papers). In total, we excluded 155 full‐text papers where they did not meet the inclusion criteria. See <a href="./references#CD010224-sec-1565" title="">Characteristics of excluded studies</a> and <a href="#CD010224-fig-0001">Figure 1</a> for the study flow diagram. We ultimately included 49 studies (128 publications) in this review. Of these, 113 records and 45 studies contributed data to the meta‐analyses, two studies had certain data included in the meta‐analysis whilst other data were narratively reviewed. </p> </section> <section id="CD010224-sec-0046"> <h4 class="title">Included studies</h4> <p>A total of 128 included full‐text publications reported on the 49 independent studies included in this review, of which all but one were non‐randomised studies. The high number of publications per study were from longitudinal research initiatives such as epilepsy and pregnancy registers which update their results periodically. These full texts were related to an included study, as they presented information on the same cohort of children but either at a different time point or on a related, but not included, outcome (i.e. obstetric or neurodevelopmental outcome). Reported outcomes for each ASM were taken from the most relevant publication within a series; therefore, malformation information for specific ASMs may come from different publications within a series. </p> </section> <section id="CD010224-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded 42 studies (55 papers) from the review (<a href="#CD010224-sec-0047">Excluded studies</a>). Several of these papers were not written in the English language and, therefore, were sent for translation and data extraction in order to determine the study design and methodology used. The most frequent reasons for exclusion, however, were absence of reported ASM monotherapy‐specific malformation outcomes, retrospective study design, and case‐control study design. Studies were also excluded where the maternal indication was not epilepsy in 70% or more of participants, or if a subgroup analysis was not provided for women with epilepsy indication. These decisions were made to limit the likely heterogeneity regarding doses of ASMs used across indications, as dose is a significant driver of higher malformation risk (<a href="./references#CD010224-bbs2-0102" title="BrentRL . Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics2004;113(4 Suppl):957-68. [PMID: 15060188]">Brent 2004</a>). </p> </section> </section> <section id="CD010224-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>Robins‐I ratings are displayed in <a href="#CD010224-fig-0002">Figure 2</a>. </p> <section id="CD010224-sec-0049"> <h4 class="title">Bias in confounding</h4> <p>For bias in confounding, no studies were rated as low as no studies were comparable to a randomised controlled trial. Ten studies were rated as moderate (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a>; <a href="./references#CD010224-bbs2-0035" title="DanskyLV , AndermannE , RosenblattD , SherwinAL , AndermannF . Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Annals of Neurology1987;21(2):176-82. [PMID: 3827226]OguniM , DanskyL , AndermannE , SherwinA , AndermannF . Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain &amp; Development1992;14(6):371-80. [PMID: 1492649]">Montreal Series</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0044" title="RegestaG , TanganelliP . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana contro l'Epilessia1996;95/96:351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology1992;42(4 Suppl 5):89-93. [PMID: 1574184]">Tanganelli 1992</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>) which is the highest rating for non‐randomised studies in this domain. Twenty studies were rated as serious due to a lack of control for key confounders (<a href="./references#CD010224-bbs2-0006" title="CassinaM , DilaghiA , Di GianantonioE , CesariE , De SantisM , MannaioniG , et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology2013;39:50-7. [PMID: 23591043]">Cassina 2013</a>; <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0013" title="ArtamaM , AuvinenA , RaudaskoskiT , IsojärviI , IsojärviJ . Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology2005;64(11):1874-8. [PMID: 15955936]ArtamaM , RitvanenA , GisslerM , IsojärviJ , AuvinenA . Congenital structural anomalies in offspring of women with epilepsy - a population-based cohort study in Finland. International Journal of Epidemiology2006;35(2):280-7. [PMID: 16280367]">Finland Health Record Registers</a>; <a href="./references#CD010224-bbs2-0016" title="HosnyH , ElkattanM , ZakiMA , RamzyGM , MagdyR , Abo Al-AzayemS . Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: an Egyptian prospective study. Epilepsy &amp; Behavior2021;123:108251. [PMID: 34411949]">Hosny 2021</a>; <a href="./references#CD010224-bbs2-0018" title="PutignanoD , ClavennaA , CampiR , CaneviniMP , VignoliA , BattinoD , et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy &amp; Behavior2019;92:14-7. [PMID: 30599457]">Italian Lombardy Region Health Register</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0022" title="KaurTP , SahuL , RathoreAM , BhasinS . Obstetric outcomes in pregnant women with seizure disorder: a hospital-based, longitudinal study. Turkish Journal of Obstetrics &amp; Gynecology2020;17(3):161-9. [PMID: 33072419]">Kaur 2020</a>; <a href="./references#CD010224-bbs2-0023" title="KellyTE , EdwardsP , ReinM , MillerJQ , DreifussFE . Teratogenicity of anticonvulsant drugs II: a prospective study. American Journal of Medical Genetics1984;19(3):435-43. [PMID: 6507489]">Kelly 1984</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0025" title="Jäger-RomanE , DeichlA , JakobS , HartmannAM , KochS , RatingD , et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Journal of Pediatrics1986;108(6):997-1004. [PMID: 3086531]KochS , Gopfert-GeyerI , Jager-RomanE , JakobS , HuthH , HartmannA , et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development [Antiepileptika wahrend der schwangerschaft. Eine prospektive studie uber schwangerschaftsverlauf, fehlbildungen und kindliche entwicklung]. Deutsche Medizinische Wochenschrift1983;108(7):250-7. [PMID: 6402356]KochS , LöscheG , Jager-RomänE , JakobS , RatingD , DeichlA , et al. Major and minor birth malformations and antiepileptic drugs. Neurology1992;42(4 Suppl 5):83-8. [PMID: 1574183]KuhnzW , Jäger-RomanE , RatingD , DeichlA , KunzeJ , HelgeH , et al. Carbamazepine and carbamazepine-10, -11 epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatric Pharmacology1983;3(3-4):199-208. [PMID: 6677873]KuhnzW , KochS , JakobS , HartmannA , HelgeH , NauH . Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology1984;18(5):671-7. [PMID: 6508976]RatingD , Jager-RomanE , KochS , DeichlA , HartmannH , JakobS , et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. In: NauH , Scott WJ Jr, editors(s). Pharmacokinetics in Teratogenesis. Vol. 1. CRC Press, 1987:205-23. [ISBN: 978-0849368738]RatingD , NauH , Jäger-RomanE , Göpfert-GeyerI , KochS , Beck-MannagettaG , et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia1982;71(2):301-11. [PMID: 7136638]">Koch 1992</a>; <a href="./references#CD010224-bbs2-0026" title="LindhoutD , HöppenerRJ , MeinardiH . Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia1984;25(1):77-83. [PMID: 6692794]LindhoutD , MeinardiH , MeijerJW , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42(4 Suppl 5):94-110. [PMID: 1574185]">Lindhout 1992</a>; <a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0039" title="OmtzigtJG , LosFJ , GrobbeeDE , PijpersL , JahodaMG , BrandenburgH , et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology1992;42(4 Suppl 5):119-25. [PMID: 1574165]OmtzigtJG , LosFJ , HagenaarsAM , StewartPA , SachsES , LindhoutD . Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal Diagnosis1992;12(11):893-7. [PMID: 1283633]">Omtzigt 1992</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>; <a href="./references#CD010224-bbs2-0042" title="Steegers-TheunissenRP , RenierWO , BormGF , ThomasCM , MerkusHM , Op de CoulDA , et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Research1994;18(3):261-9. [PMID: 7805647]">Steegers‐Theunissen 1994</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>; <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>; <a href="./references#CD010224-bbs2-0049" title="WatersCH , BelaiY , GottPS , ShenP , De GiorgioCM . Outcomes of pregnancy associated with antiepileptic drugs. Archives of Neurology1994;51(3):250-3. [PMID: 8129635]">Waters 1994</a>), and nine studies were rated as critical (<a href="./references#CD010224-bbs2-0001" title="Al BunyanM , Abo-TalibZ . Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure1999;8(1):26-9. [PMID: 10091844]">Al Bunyan 1999</a>; <a href="./references#CD010224-bbs2-0002" title="AlSheikhMH . Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences2020;25(1):32-7. [PMID: 31982897]">AlSheikh 2020</a>; <a href="./references#CD010224-bbs2-0004" title="BagS , BehariM , AhujaGK , KarmarkarMG . Pregnancy and epilepsy. Journal of Neurology1989;236(5):311-3. [PMID: 2760652]">Bag 1989</a>; <a href="./references#CD010224-bbs2-0005" title="BarqawiR . Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal2005;11(4):601-5. [PMID: 16700374]">Barqawi 2005</a>; <a href="./references#CD010224-bbs2-0008" title="ĐelmišJ , DražančićA , TkalčevićT , IvaniševićM . Epilepsy in pregnancy [Epilepsija i trudnoća]. Jugoslavenska Ginekologija i Perinatologija1991;31(1-2):23-6. [PMID: 1875716]">Delmiš 1991</a>, <a href="./references#CD010224-bbs2-0007" title="D'SouzaSW , RobertsonIG , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1991;65(3):320-4. [PMID: 2025009]">D'Souza 1991</a>; <a href="./references#CD010224-bbs2-0010" title="EroğluE , GökçilZ , BekS , UlaşUH , OdabaşiZ . Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurologica Belgica2008;108(2):53-7. [PMID: 18795597]">Eroglu 2008</a>; <a href="./references#CD010224-bbs2-0012" title="FairgrieveSD , JacksonM , JonasP , WalshawD , WhiteK , MontgomeryTL , et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal2000;321(7262):674-5. [PMID: 10987772]">Fairgrieve 2000</a>; <a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a>; <a href="./references#CD010224-bbs2-0015" title="Garza-MoralesS , Ibarra-PuigJM , Poblano-LunaA , Gilda Mayén-MolinaD , Córdova-LópezS . Epilepsy and pregnancy: prospective study of 100 cases [Epilepsia y embarazo. Estudio prospectivo 100 casos]. Ginecología y Obstetricia de México1996;64:449-54. [PMID: 8974948]">Garza‐Morales 1996</a>; <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0027" title="Martinez FerriM , Pena MayorP , Perez Lopez-FraileI , Escartin SiquierA , Martin MoroM , Forcadas BerdusanM , et al. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia2018;33(2):78-84. [PMID: 27452623]Martinez FerriM , Pena MayorP , Perez Loppez-FraileI , Castro VilanovaMD , Escartin SiquierA , Martin MoroM , et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [Malformaciones y muerte fetal en el registro espanol de farmacos antiepilepticos y embarazo: resultados a los 6 anos]. Neurologia2009;24(6):360-5. [PMID: 19798601]">Martinez Ferri 2018</a>; <a href="./references#CD010224-bbs2-0030" title="MeischenguiserR , D'GianoCH , FerraroSM . Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy &amp; Behaviour2004;5(2):163-7. [PMID: 15123016]">Meischenguiser 2004</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>; <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>; <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>). </p> </section> <section id="CD010224-sec-0050"> <h4 class="title">Bias in selection</h4> <p>For bias in selection, three studies were rated as low (<a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>, <a href="./references#CD010224-bbs2-0013" title="ArtamaM , AuvinenA , RaudaskoskiT , IsojärviI , IsojärviJ . Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology2005;64(11):1874-8. [PMID: 15955936]ArtamaM , RitvanenA , GisslerM , IsojärviJ , AuvinenA . Congenital structural anomalies in offspring of women with epilepsy - a population-based cohort study in Finland. International Journal of Epidemiology2006;35(2):280-7. [PMID: 16280367]">Finland Health Record Registers</a>, <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>) as they represented national datasets and one study was rated as moderate (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). All cohort or pregnancy register studies were at risk of selection biases and therefore 37 studies were rated as serious (<a href="./references#CD010224-bbs2-0002" title="AlSheikhMH . Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences2020;25(1):32-7. [PMID: 31982897]">AlSheikh 2020</a>; <a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0005" title="BarqawiR . Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal2005;11(4):601-5. [PMID: 16700374]">Barqawi 2005</a>; <a href="./references#CD010224-bbs2-0006" title="CassinaM , DilaghiA , Di GianantonioE , CesariE , De SantisM , MannaioniG , et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology2013;39:50-7. [PMID: 23591043]">Cassina 2013</a>; <a href="./references#CD010224-bbs2-0010" title="EroğluE , GökçilZ , BekS , UlaşUH , OdabaşiZ . Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurologica Belgica2008;108(2):53-7. [PMID: 18795597]">Eroglu 2008</a>; <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0012" title="FairgrieveSD , JacksonM , JonasP , WalshawD , WhiteK , MontgomeryTL , et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal2000;321(7262):674-5. [PMID: 10987772]">Fairgrieve 2000</a>; <a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a>; <a href="./references#CD010224-bbs2-0015" title="Garza-MoralesS , Ibarra-PuigJM , Poblano-LunaA , Gilda Mayén-MolinaD , Córdova-LópezS . Epilepsy and pregnancy: prospective study of 100 cases [Epilepsia y embarazo. Estudio prospectivo 100 casos]. Ginecología y Obstetricia de México1996;64:449-54. [PMID: 8974948]">Garza‐Morales 1996</a>; <a href="./references#CD010224-bbs2-0016" title="HosnyH , ElkattanM , ZakiMA , RamzyGM , MagdyR , Abo Al-AzayemS . Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: an Egyptian prospective study. Epilepsy &amp; Behavior2021;123:108251. [PMID: 34411949]">Hosny 2021</a>; <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0018" title="PutignanoD , ClavennaA , CampiR , CaneviniMP , VignoliA , BattinoD , et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy &amp; Behavior2019;92:14-7. [PMID: 30599457]">Italian Lombardy Region Health Register</a>; <a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0022" title="KaurTP , SahuL , RathoreAM , BhasinS . Obstetric outcomes in pregnant women with seizure disorder: a hospital-based, longitudinal study. Turkish Journal of Obstetrics &amp; Gynecology2020;17(3):161-9. [PMID: 33072419]">Kaur 2020</a>; <a href="./references#CD010224-bbs2-0023" title="KellyTE , EdwardsP , ReinM , MillerJQ , DreifussFE . Teratogenicity of anticonvulsant drugs II: a prospective study. American Journal of Medical Genetics1984;19(3):435-43. [PMID: 6507489]">Kelly 1984</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0025" title="Jäger-RomanE , DeichlA , JakobS , HartmannAM , KochS , RatingD , et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Journal of Pediatrics1986;108(6):997-1004. [PMID: 3086531]KochS , Gopfert-GeyerI , Jager-RomanE , JakobS , HuthH , HartmannA , et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development [Antiepileptika wahrend der schwangerschaft. Eine prospektive studie uber schwangerschaftsverlauf, fehlbildungen und kindliche entwicklung]. Deutsche Medizinische Wochenschrift1983;108(7):250-7. [PMID: 6402356]KochS , LöscheG , Jager-RomänE , JakobS , RatingD , DeichlA , et al. Major and minor birth malformations and antiepileptic drugs. Neurology1992;42(4 Suppl 5):83-8. [PMID: 1574183]KuhnzW , Jäger-RomanE , RatingD , DeichlA , KunzeJ , HelgeH , et al. Carbamazepine and carbamazepine-10, -11 epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatric Pharmacology1983;3(3-4):199-208. [PMID: 6677873]KuhnzW , KochS , JakobS , HartmannA , HelgeH , NauH . Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology1984;18(5):671-7. [PMID: 6508976]RatingD , Jager-RomanE , KochS , DeichlA , HartmannH , JakobS , et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. In: NauH , Scott WJ Jr, editors(s). Pharmacokinetics in Teratogenesis. Vol. 1. CRC Press, 1987:205-23. [ISBN: 978-0849368738]RatingD , NauH , Jäger-RomanE , Göpfert-GeyerI , KochS , Beck-MannagettaG , et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia1982;71(2):301-11. [PMID: 7136638]">Koch 1992</a>; <a href="./references#CD010224-bbs2-0027" title="Martinez FerriM , Pena MayorP , Perez Lopez-FraileI , Escartin SiquierA , Martin MoroM , Forcadas BerdusanM , et al. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia2018;33(2):78-84. [PMID: 27452623]Martinez FerriM , Pena MayorP , Perez Loppez-FraileI , Castro VilanovaMD , Escartin SiquierA , Martin MoroM , et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [Malformaciones y muerte fetal en el registro espanol de farmacos antiepilepticos y embarazo: resultados a los 6 anos]. Neurologia2009;24(6):360-5. [PMID: 19798601]">Martinez Ferri 2018</a>; <a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>; <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0039" title="OmtzigtJG , LosFJ , GrobbeeDE , PijpersL , JahodaMG , BrandenburgH , et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology1992;42(4 Suppl 5):119-25. [PMID: 1574165]OmtzigtJG , LosFJ , HagenaarsAM , StewartPA , SachsES , LindhoutD . Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal Diagnosis1992;12(11):893-7. [PMID: 1283633]">Omtzigt 1992</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>; <a href="./references#CD010224-bbs2-0042" title="Steegers-TheunissenRP , RenierWO , BormGF , ThomasCM , MerkusHM , Op de CoulDA , et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Research1994;18(3):261-9. [PMID: 7805647]">Steegers‐Theunissen 1994</a>; <a href="./references#CD010224-bbs2-0044" title="RegestaG , TanganelliP . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana contro l'Epilessia1996;95/96:351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology1992;42(4 Suppl 5):89-93. [PMID: 1574184]">Tanganelli 1992</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>; <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>; <a href="./references#CD010224-bbs2-0049" title="WatersCH , BelaiY , GottPS , ShenP , De GiorgioCM . Outcomes of pregnancy associated with antiepileptic drugs. Archives of Neurology1994;51(3):250-3. [PMID: 8129635]">Waters 1994</a>) and three studies were rated as critical due to the risk of selection biases (<a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a>; <a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0030" title="MeischenguiserR , D'GianoCH , FerraroSM . Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy &amp; Behaviour2004;5(2):163-7. [PMID: 15123016]">Meischenguiser 2004</a>). There was not sufficient information to rate five studies (<a href="./references#CD010224-bbs2-0001" title="Al BunyanM , Abo-TalibZ . Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure1999;8(1):26-9. [PMID: 10091844]">Al Bunyan 1999</a>; <a href="./references#CD010224-bbs2-0004" title="BagS , BehariM , AhujaGK , KarmarkarMG . Pregnancy and epilepsy. Journal of Neurology1989;236(5):311-3. [PMID: 2760652]">Bag 1989</a>; <a href="./references#CD010224-bbs2-0007" title="D'SouzaSW , RobertsonIG , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1991;65(3):320-4. [PMID: 2025009]">D'Souza 1991</a>; <a href="./references#CD010224-bbs2-0008" title="ĐelmišJ , DražančićA , TkalčevićT , IvaniševićM . Epilepsy in pregnancy [Epilepsija i trudnoća]. Jugoslavenska Ginekologija i Perinatologija1991;31(1-2):23-6. [PMID: 1875716]">Delmiš 1991</a>; <a href="./references#CD010224-bbs2-0035" title="DanskyLV , AndermannE , RosenblattD , SherwinAL , AndermannF . Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Annals of Neurology1987;21(2):176-82. [PMID: 3827226]OguniM , DanskyL , AndermannE , SherwinA , AndermannF . Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain &amp; Development1992;14(6):371-80. [PMID: 1492649]">Montreal Series</a>). </p> </section> <section id="CD010224-sec-0051"> <h4 class="title">Bias in classification</h4> <p>For bias in classification, 14 studies were rated as low (<a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0026" title="LindhoutD , HöppenerRJ , MeinardiH . Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia1984;25(1):77-83. [PMID: 6692794]LindhoutD , MeinardiH , MeijerJW , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42(4 Suppl 5):94-110. [PMID: 1574185]">Lindhout 1992</a>; <a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0039" title="OmtzigtJG , LosFJ , GrobbeeDE , PijpersL , JahodaMG , BrandenburgH , et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology1992;42(4 Suppl 5):119-25. [PMID: 1574165]OmtzigtJG , LosFJ , HagenaarsAM , StewartPA , SachsES , LindhoutD . Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal Diagnosis1992;12(11):893-7. [PMID: 1283633]">Omtzigt 1992</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>; <a href="./references#CD010224-bbs2-0042" title="Steegers-TheunissenRP , RenierWO , BormGF , ThomasCM , MerkusHM , Op de CoulDA , et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Research1994;18(3):261-9. [PMID: 7805647]">Steegers‐Theunissen 1994</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>), 17 studies were rated as moderate (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0004" title="BagS , BehariM , AhujaGK , KarmarkarMG . Pregnancy and epilepsy. Journal of Neurology1989;236(5):311-3. [PMID: 2760652]">Bag 1989</a>; <a href="./references#CD010224-bbs2-0007" title="D'SouzaSW , RobertsonIG , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1991;65(3):320-4. [PMID: 2025009]">D'Souza 1991</a>; <a href="./references#CD010224-bbs2-0008" title="ĐelmišJ , DražančićA , TkalčevićT , IvaniševićM . Epilepsy in pregnancy [Epilepsija i trudnoća]. Jugoslavenska Ginekologija i Perinatologija1991;31(1-2):23-6. [PMID: 1875716]">Delmiš 1991</a>; <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0010" title="EroğluE , GökçilZ , BekS , UlaşUH , OdabaşiZ . Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurologica Belgica2008;108(2):53-7. [PMID: 18795597]">Eroglu 2008</a>; <a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a>; <a href="./references#CD010224-bbs2-0015" title="Garza-MoralesS , Ibarra-PuigJM , Poblano-LunaA , Gilda Mayén-MolinaD , Córdova-LópezS . Epilepsy and pregnancy: prospective study of 100 cases [Epilepsia y embarazo. Estudio prospectivo 100 casos]. Ginecología y Obstetricia de México1996;64:449-54. [PMID: 8974948]">Garza‐Morales 1996</a>; <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0023" title="KellyTE , EdwardsP , ReinM , MillerJQ , DreifussFE . Teratogenicity of anticonvulsant drugs II: a prospective study. American Journal of Medical Genetics1984;19(3):435-43. [PMID: 6507489]">Kelly 1984</a>; <a href="./references#CD010224-bbs2-0025" title="Jäger-RomanE , DeichlA , JakobS , HartmannAM , KochS , RatingD , et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Journal of Pediatrics1986;108(6):997-1004. [PMID: 3086531]KochS , Gopfert-GeyerI , Jager-RomanE , JakobS , HuthH , HartmannA , et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development [Antiepileptika wahrend der schwangerschaft. Eine prospektive studie uber schwangerschaftsverlauf, fehlbildungen und kindliche entwicklung]. Deutsche Medizinische Wochenschrift1983;108(7):250-7. [PMID: 6402356]KochS , LöscheG , Jager-RomänE , JakobS , RatingD , DeichlA , et al. Major and minor birth malformations and antiepileptic drugs. Neurology1992;42(4 Suppl 5):83-8. [PMID: 1574183]KuhnzW , Jäger-RomanE , RatingD , DeichlA , KunzeJ , HelgeH , et al. Carbamazepine and carbamazepine-10, -11 epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatric Pharmacology1983;3(3-4):199-208. [PMID: 6677873]KuhnzW , KochS , JakobS , HartmannA , HelgeH , NauH . Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology1984;18(5):671-7. [PMID: 6508976]RatingD , Jager-RomanE , KochS , DeichlA , HartmannH , JakobS , et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. In: NauH , Scott WJ Jr, editors(s). Pharmacokinetics in Teratogenesis. Vol. 1. CRC Press, 1987:205-23. [ISBN: 978-0849368738]RatingD , NauH , Jäger-RomanE , Göpfert-GeyerI , KochS , Beck-MannagettaG , et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia1982;71(2):301-11. [PMID: 7136638]">Koch 1992</a>; <a href="./references#CD010224-bbs2-0027" title="Martinez FerriM , Pena MayorP , Perez Lopez-FraileI , Escartin SiquierA , Martin MoroM , Forcadas BerdusanM , et al. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia2018;33(2):78-84. [PMID: 27452623]Martinez FerriM , Pena MayorP , Perez Loppez-FraileI , Castro VilanovaMD , Escartin SiquierA , Martin MoroM , et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [Malformaciones y muerte fetal en el registro espanol de farmacos antiepilepticos y embarazo: resultados a los 6 anos]. Neurologia2009;24(6):360-5. [PMID: 19798601]">Martinez Ferri 2018</a>; <a href="./references#CD010224-bbs2-0030" title="MeischenguiserR , D'GianoCH , FerraroSM . Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy &amp; Behaviour2004;5(2):163-7. [PMID: 15123016]">Meischenguiser 2004</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>), 16 studies were rated as serious (<a href="./references#CD010224-bbs2-0002" title="AlSheikhMH . Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences2020;25(1):32-7. [PMID: 31982897]">AlSheikh 2020</a>; <a href="./references#CD010224-bbs2-0005" title="BarqawiR . Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal2005;11(4):601-5. [PMID: 16700374]">Barqawi 2005</a>; <a href="./references#CD010224-bbs2-0006" title="CassinaM , DilaghiA , Di GianantonioE , CesariE , De SantisM , MannaioniG , et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology2013;39:50-7. [PMID: 23591043]">Cassina 2013</a>; <a href="./references#CD010224-bbs2-0012" title="FairgrieveSD , JacksonM , JonasP , WalshawD , WhiteK , MontgomeryTL , et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal2000;321(7262):674-5. [PMID: 10987772]">Fairgrieve 2000</a>; <a href="./references#CD010224-bbs2-0013" title="ArtamaM , AuvinenA , RaudaskoskiT , IsojärviI , IsojärviJ . Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology2005;64(11):1874-8. [PMID: 15955936]ArtamaM , RitvanenA , GisslerM , IsojärviJ , AuvinenA . Congenital structural anomalies in offspring of women with epilepsy - a population-based cohort study in Finland. International Journal of Epidemiology2006;35(2):280-7. [PMID: 16280367]">Finland Health Record Registers</a>; <a href="./references#CD010224-bbs2-0016" title="HosnyH , ElkattanM , ZakiMA , RamzyGM , MagdyR , Abo Al-AzayemS . Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: an Egyptian prospective study. Epilepsy &amp; Behavior2021;123:108251. [PMID: 34411949]">Hosny 2021</a>; <a href="./references#CD010224-bbs2-0018" title="PutignanoD , ClavennaA , CampiR , CaneviniMP , VignoliA , BattinoD , et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy &amp; Behavior2019;92:14-7. [PMID: 30599457]">Italian Lombardy Region Health Register</a>; <a href="./references#CD010224-bbs2-0022" title="KaurTP , SahuL , RathoreAM , BhasinS . Obstetric outcomes in pregnant women with seizure disorder: a hospital-based, longitudinal study. Turkish Journal of Obstetrics &amp; Gynecology2020;17(3):161-9. [PMID: 33072419]">Kaur 2020</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>; <a href="./references#CD010224-bbs2-0035" title="DanskyLV , AndermannE , RosenblattD , SherwinAL , AndermannF . Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Annals of Neurology1987;21(2):176-82. [PMID: 3827226]OguniM , DanskyL , AndermannE , SherwinA , AndermannF . Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain &amp; Development1992;14(6):371-80. [PMID: 1492649]">Montreal Series</a>; <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>; <a href="./references#CD010224-bbs2-0044" title="RegestaG , TanganelliP . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana contro l'Epilessia1996;95/96:351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology1992;42(4 Suppl 5):89-93. [PMID: 1574184]">Tanganelli 1992</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>;<a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>; <a href="./references#CD010224-bbs2-0049" title="WatersCH , BelaiY , GottPS , ShenP , De GiorgioCM . Outcomes of pregnancy associated with antiepileptic drugs. Archives of Neurology1994;51(3):250-3. [PMID: 8129635]">Waters 1994</a>), one study was rated as critical (<a href="./references#CD010224-bbs2-0001" title="Al BunyanM , Abo-TalibZ . Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure1999;8(1):26-9. [PMID: 10091844]">Al Bunyan 1999</a>) and the other had limited information (<a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>). </p> </section> <section id="CD010224-sec-0052"> <h4 class="title">Bias in missing data</h4> <p>For bias in missing data, 17 studies were rated as low (<a href="./references#CD010224-bbs2-0005" title="BarqawiR . Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal2005;11(4):601-5. [PMID: 16700374]">Barqawi 2005</a>; <a href="./references#CD010224-bbs2-0007" title="D'SouzaSW , RobertsonIG , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1991;65(3):320-4. [PMID: 2025009]">D'Souza 1991</a>; <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0010" title="EroğluE , GökçilZ , BekS , UlaşUH , OdabaşiZ . Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurologica Belgica2008;108(2):53-7. [PMID: 18795597]">Eroglu 2008</a>; <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0013" title="ArtamaM , AuvinenA , RaudaskoskiT , IsojärviI , IsojärviJ . Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology2005;64(11):1874-8. [PMID: 15955936]ArtamaM , RitvanenA , GisslerM , IsojärviJ , AuvinenA . Congenital structural anomalies in offspring of women with epilepsy - a population-based cohort study in Finland. International Journal of Epidemiology2006;35(2):280-7. [PMID: 16280367]">Finland Health Record Registers</a>; <a href="./references#CD010224-bbs2-0015" title="Garza-MoralesS , Ibarra-PuigJM , Poblano-LunaA , Gilda Mayén-MolinaD , Córdova-LópezS . Epilepsy and pregnancy: prospective study of 100 cases [Epilepsia y embarazo. Estudio prospectivo 100 casos]. Ginecología y Obstetricia de México1996;64:449-54. [PMID: 8974948]">Garza‐Morales 1996</a>; <a href="./references#CD010224-bbs2-0018" title="PutignanoD , ClavennaA , CampiR , CaneviniMP , VignoliA , BattinoD , et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy &amp; Behavior2019;92:14-7. [PMID: 30599457]">Italian Lombardy Region Health Register</a>; <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0030" title="MeischenguiserR , D'GianoCH , FerraroSM . Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy &amp; Behaviour2004;5(2):163-7. [PMID: 15123016]">Meischenguiser 2004</a>; <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>; <a href="./references#CD010224-bbs2-0039" title="OmtzigtJG , LosFJ , GrobbeeDE , PijpersL , JahodaMG , BrandenburgH , et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology1992;42(4 Suppl 5):119-25. [PMID: 1574165]OmtzigtJG , LosFJ , HagenaarsAM , StewartPA , SachsES , LindhoutD . Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal Diagnosis1992;12(11):893-7. [PMID: 1283633]">Omtzigt 1992</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>), nine studies were rated as moderate (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0012" title="FairgrieveSD , JacksonM , JonasP , WalshawD , WhiteK , MontgomeryTL , et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal2000;321(7262):674-5. [PMID: 10987772]">Fairgrieve 2000</a>; <a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0022" title="KaurTP , SahuL , RathoreAM , BhasinS . Obstetric outcomes in pregnant women with seizure disorder: a hospital-based, longitudinal study. Turkish Journal of Obstetrics &amp; Gynecology2020;17(3):161-9. [PMID: 33072419]">Kaur 2020</a>; <a href="./references#CD010224-bbs2-0023" title="KellyTE , EdwardsP , ReinM , MillerJQ , DreifussFE . Teratogenicity of anticonvulsant drugs II: a prospective study. American Journal of Medical Genetics1984;19(3):435-43. [PMID: 6507489]">Kelly 1984</a>; <a href="./references#CD010224-bbs2-0026" title="LindhoutD , HöppenerRJ , MeinardiH . Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia1984;25(1):77-83. [PMID: 6692794]LindhoutD , MeinardiH , MeijerJW , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42(4 Suppl 5):94-110. [PMID: 1574185]">Lindhout 1992</a>; <a href="./references#CD010224-bbs2-0044" title="RegestaG , TanganelliP . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana contro l'Epilessia1996;95/96:351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology1992;42(4 Suppl 5):89-93. [PMID: 1574184]">Tanganelli 1992</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>; <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>), ten studies were rated as serious (<a href="./references#CD010224-bbs2-0006" title="CassinaM , DilaghiA , Di GianantonioE , CesariE , De SantisM , MannaioniG , et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology2013;39:50-7. [PMID: 23591043]">Cassina 2013</a>; <a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a>; <a href="./references#CD010224-bbs2-0016" title="HosnyH , ElkattanM , ZakiMA , RamzyGM , MagdyR , Abo Al-AzayemS . Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: an Egyptian prospective study. Epilepsy &amp; Behavior2021;123:108251. [PMID: 34411949]">Hosny 2021</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0035" title="DanskyLV , AndermannE , RosenblattD , SherwinAL , AndermannF . Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Annals of Neurology1987;21(2):176-82. [PMID: 3827226]OguniM , DanskyL , AndermannE , SherwinA , AndermannF . Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain &amp; Development1992;14(6):371-80. [PMID: 1492649]">Montreal Series</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>; <a href="./references#CD010224-bbs2-0049" title="WatersCH , BelaiY , GottPS , ShenP , De GiorgioCM . Outcomes of pregnancy associated with antiepileptic drugs. Archives of Neurology1994;51(3):250-3. [PMID: 8129635]">Waters 1994</a>), and no studies were rated as critical. There was not sufficient information to rate levels of missing data in 13 studies, however (<a href="./references#CD010224-bbs2-0001" title="Al BunyanM , Abo-TalibZ . Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure1999;8(1):26-9. [PMID: 10091844]">Al Bunyan 1999</a>, <a href="./references#CD010224-bbs2-0002" title="AlSheikhMH . Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences2020;25(1):32-7. [PMID: 31982897]">AlSheikh 2020</a>; <a href="./references#CD010224-bbs2-0004" title="BagS , BehariM , AhujaGK , KarmarkarMG . Pregnancy and epilepsy. Journal of Neurology1989;236(5):311-3. [PMID: 2760652]">Bag 1989</a>; <a href="./references#CD010224-bbs2-0008" title="ĐelmišJ , DražančićA , TkalčevićT , IvaniševićM . Epilepsy in pregnancy [Epilepsija i trudnoća]. Jugoslavenska Ginekologija i Perinatologija1991;31(1-2):23-6. [PMID: 1875716]">Delmiš 1991</a>; <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0025" title="Jäger-RomanE , DeichlA , JakobS , HartmannAM , KochS , RatingD , et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Journal of Pediatrics1986;108(6):997-1004. [PMID: 3086531]KochS , Gopfert-GeyerI , Jager-RomanE , JakobS , HuthH , HartmannA , et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development [Antiepileptika wahrend der schwangerschaft. Eine prospektive studie uber schwangerschaftsverlauf, fehlbildungen und kindliche entwicklung]. Deutsche Medizinische Wochenschrift1983;108(7):250-7. [PMID: 6402356]KochS , LöscheG , Jager-RomänE , JakobS , RatingD , DeichlA , et al. Major and minor birth malformations and antiepileptic drugs. Neurology1992;42(4 Suppl 5):83-8. [PMID: 1574183]KuhnzW , Jäger-RomanE , RatingD , DeichlA , KunzeJ , HelgeH , et al. Carbamazepine and carbamazepine-10, -11 epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatric Pharmacology1983;3(3-4):199-208. [PMID: 6677873]KuhnzW , KochS , JakobS , HartmannA , HelgeH , NauH . Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology1984;18(5):671-7. [PMID: 6508976]RatingD , Jager-RomanE , KochS , DeichlA , HartmannH , JakobS , et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. In: NauH , Scott WJ Jr, editors(s). Pharmacokinetics in Teratogenesis. Vol. 1. CRC Press, 1987:205-23. [ISBN: 978-0849368738]RatingD , NauH , Jäger-RomanE , Göpfert-GeyerI , KochS , Beck-MannagettaG , et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia1982;71(2):301-11. [PMID: 7136638]">Koch 1992</a>; <a href="./references#CD010224-bbs2-0027" title="Martinez FerriM , Pena MayorP , Perez Lopez-FraileI , Escartin SiquierA , Martin MoroM , Forcadas BerdusanM , et al. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia2018;33(2):78-84. [PMID: 27452623]Martinez FerriM , Pena MayorP , Perez Loppez-FraileI , Castro VilanovaMD , Escartin SiquierA , Martin MoroM , et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [Malformaciones y muerte fetal en el registro espanol de farmacos antiepilepticos y embarazo: resultados a los 6 anos]. Neurologia2009;24(6):360-5. [PMID: 19798601]">Martinez Ferri 2018</a>; <a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>; <a href="./references#CD010224-bbs2-0042" title="Steegers-TheunissenRP , RenierWO , BormGF , ThomasCM , MerkusHM , Op de CoulDA , et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Research1994;18(3):261-9. [PMID: 7805647]">Steegers‐Theunissen 1994</a>). </p> </section> <section id="CD010224-sec-0053"> <h4 class="title">Bias in measurement</h4> <p>For bias in measurement, 11 studies were rated as low (<a href="./references#CD010224-bbs2-0007" title="D'SouzaSW , RobertsonIG , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1991;65(3):320-4. [PMID: 2025009]">D'Souza 1991</a>; <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a>; <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0026" title="LindhoutD , HöppenerRJ , MeinardiH . Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia1984;25(1):77-83. [PMID: 6692794]LindhoutD , MeinardiH , MeijerJW , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42(4 Suppl 5):94-110. [PMID: 1574185]">Lindhout 1992</a>; <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0039" title="OmtzigtJG , LosFJ , GrobbeeDE , PijpersL , JahodaMG , BrandenburgH , et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology1992;42(4 Suppl 5):119-25. [PMID: 1574165]OmtzigtJG , LosFJ , HagenaarsAM , StewartPA , SachsES , LindhoutD . Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal Diagnosis1992;12(11):893-7. [PMID: 1283633]">Omtzigt 1992</a>; <a href="./references#CD010224-bbs2-0042" title="Steegers-TheunissenRP , RenierWO , BormGF , ThomasCM , MerkusHM , Op de CoulDA , et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Research1994;18(3):261-9. [PMID: 7805647]">Steegers‐Theunissen 1994</a>) due to undertaking standardised reviews of the outcomes blinded to ASM exposure history. Two studies were rated as moderate (<a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>) and 27 studies were rated as serious (<a href="./references#CD010224-bbs2-0002" title="AlSheikhMH . Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences2020;25(1):32-7. [PMID: 31982897]">AlSheikh 2020</a>; <a href="./references#CD010224-bbs2-0004" title="BagS , BehariM , AhujaGK , KarmarkarMG . Pregnancy and epilepsy. Journal of Neurology1989;236(5):311-3. [PMID: 2760652]">Bag 1989</a>; <a href="./references#CD010224-bbs2-0006" title="CassinaM , DilaghiA , Di GianantonioE , CesariE , De SantisM , MannaioniG , et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology2013;39:50-7. [PMID: 23591043]">Cassina 2013</a>; <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0010" title="EroğluE , GökçilZ , BekS , UlaşUH , OdabaşiZ . Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurologica Belgica2008;108(2):53-7. [PMID: 18795597]">Eroglu 2008</a>; <a href="./references#CD010224-bbs2-0012" title="FairgrieveSD , JacksonM , JonasP , WalshawD , WhiteK , MontgomeryTL , et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal2000;321(7262):674-5. [PMID: 10987772]">Fairgrieve 2000</a>; <a href="./references#CD010224-bbs2-0013" title="ArtamaM , AuvinenA , RaudaskoskiT , IsojärviI , IsojärviJ . Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology2005;64(11):1874-8. [PMID: 15955936]ArtamaM , RitvanenA , GisslerM , IsojärviJ , AuvinenA . Congenital structural anomalies in offspring of women with epilepsy - a population-based cohort study in Finland. International Journal of Epidemiology2006;35(2):280-7. [PMID: 16280367]">Finland Health Record Registers</a>; <a href="./references#CD010224-bbs2-0015" title="Garza-MoralesS , Ibarra-PuigJM , Poblano-LunaA , Gilda Mayén-MolinaD , Córdova-LópezS . Epilepsy and pregnancy: prospective study of 100 cases [Epilepsia y embarazo. Estudio prospectivo 100 casos]. Ginecología y Obstetricia de México1996;64:449-54. [PMID: 8974948]">Garza‐Morales 1996</a>; <a href="./references#CD010224-bbs2-0016" title="HosnyH , ElkattanM , ZakiMA , RamzyGM , MagdyR , Abo Al-AzayemS . Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: an Egyptian prospective study. Epilepsy &amp; Behavior2021;123:108251. [PMID: 34411949]">Hosny 2021</a>; <a href="./references#CD010224-bbs2-0018" title="PutignanoD , ClavennaA , CampiR , CaneviniMP , VignoliA , BattinoD , et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy &amp; Behavior2019;92:14-7. [PMID: 30599457]">Italian Lombardy Region Health Register</a>; <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0022" title="KaurTP , SahuL , RathoreAM , BhasinS . Obstetric outcomes in pregnant women with seizure disorder: a hospital-based, longitudinal study. Turkish Journal of Obstetrics &amp; Gynecology2020;17(3):161-9. [PMID: 33072419]">Kaur 2020</a>; <a href="./references#CD010224-bbs2-0023" title="KellyTE , EdwardsP , ReinM , MillerJQ , DreifussFE . Teratogenicity of anticonvulsant drugs II: a prospective study. American Journal of Medical Genetics1984;19(3):435-43. [PMID: 6507489]">Kelly 1984</a>; <a href="./references#CD010224-bbs2-0025" title="Jäger-RomanE , DeichlA , JakobS , HartmannAM , KochS , RatingD , et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Journal of Pediatrics1986;108(6):997-1004. [PMID: 3086531]KochS , Gopfert-GeyerI , Jager-RomanE , JakobS , HuthH , HartmannA , et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development [Antiepileptika wahrend der schwangerschaft. Eine prospektive studie uber schwangerschaftsverlauf, fehlbildungen und kindliche entwicklung]. Deutsche Medizinische Wochenschrift1983;108(7):250-7. [PMID: 6402356]KochS , LöscheG , Jager-RomänE , JakobS , RatingD , DeichlA , et al. Major and minor birth malformations and antiepileptic drugs. Neurology1992;42(4 Suppl 5):83-8. [PMID: 1574183]KuhnzW , Jäger-RomanE , RatingD , DeichlA , KunzeJ , HelgeH , et al. Carbamazepine and carbamazepine-10, -11 epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatric Pharmacology1983;3(3-4):199-208. [PMID: 6677873]KuhnzW , KochS , JakobS , HartmannA , HelgeH , NauH . Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology1984;18(5):671-7. [PMID: 6508976]RatingD , Jager-RomanE , KochS , DeichlA , HartmannH , JakobS , et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. In: NauH , Scott WJ Jr, editors(s). Pharmacokinetics in Teratogenesis. Vol. 1. CRC Press, 1987:205-23. [ISBN: 978-0849368738]RatingD , NauH , Jäger-RomanE , Göpfert-GeyerI , KochS , Beck-MannagettaG , et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia1982;71(2):301-11. [PMID: 7136638]">Koch 1992</a>; <a href="./references#CD010224-bbs2-0030" title="MeischenguiserR , D'GianoCH , FerraroSM . Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy &amp; Behaviour2004;5(2):163-7. [PMID: 15123016]">Meischenguiser 2004</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0035" title="DanskyLV , AndermannE , RosenblattD , SherwinAL , AndermannF . Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Annals of Neurology1987;21(2):176-82. [PMID: 3827226]OguniM , DanskyL , AndermannE , SherwinA , AndermannF . Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain &amp; Development1992;14(6):371-80. [PMID: 1492649]">Montreal Series</a>; <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>; <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>; <a href="./references#CD010224-bbs2-0049" title="WatersCH , BelaiY , GottPS , ShenP , De GiorgioCM . Outcomes of pregnancy associated with antiepileptic drugs. Archives of Neurology1994;51(3):250-3. [PMID: 8129635]">Waters 1994</a>) due to their use of routine clinical data which did not have standardised assessment and were not blinded to ASM exposure history. No studies were rated as critical, but there was insufficient information to rate the likelihood of measurement biases in nine studies (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0005" title="BarqawiR . Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal2005;11(4):601-5. [PMID: 16700374]">Barqawi 2005</a>; <a href="./references#CD010224-bbs2-0008" title="ĐelmišJ , DražančićA , TkalčevićT , IvaniševićM . Epilepsy in pregnancy [Epilepsija i trudnoća]. Jugoslavenska Ginekologija i Perinatologija1991;31(1-2):23-6. [PMID: 1875716]">Delmiš 1991</a>; <a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a><a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0027" title="Martinez FerriM , Pena MayorP , Perez Lopez-FraileI , Escartin SiquierA , Martin MoroM , Forcadas BerdusanM , et al. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia2018;33(2):78-84. [PMID: 27452623]Martinez FerriM , Pena MayorP , Perez Loppez-FraileI , Castro VilanovaMD , Escartin SiquierA , Martin MoroM , et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [Malformaciones y muerte fetal en el registro espanol de farmacos antiepilepticos y embarazo: resultados a los 6 anos]. Neurologia2009;24(6):360-5. [PMID: 19798601]">Martinez Ferri 2018</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>; <a href="./references#CD010224-bbs2-0044" title="RegestaG , TanganelliP . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana contro l'Epilessia1996;95/96:351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology1992;42(4 Suppl 5):89-93. [PMID: 1574184]">Tanganelli 1992</a>). </p> </section> <section id="CD010224-sec-0054"> <h4 class="title">Bias in reporting</h4> <p>This domain was difficult to assess as, for most of the studies, no protocol was available (particularly for older studies) or contact with the authors could not be established (<a href="./references#CD010224-bbs2-0001" title="Al BunyanM , Abo-TalibZ . Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure1999;8(1):26-9. [PMID: 10091844]">Al Bunyan 1999</a>; <a href="./references#CD010224-bbs2-0002" title="AlSheikhMH . Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences2020;25(1):32-7. [PMID: 31982897]">AlSheikh 2020</a>; <a href="./references#CD010224-bbs2-0004" title="BagS , BehariM , AhujaGK , KarmarkarMG . Pregnancy and epilepsy. Journal of Neurology1989;236(5):311-3. [PMID: 2760652]">Bag 1989</a>; <a href="./references#CD010224-bbs2-0005" title="BarqawiR . Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal2005;11(4):601-5. [PMID: 16700374]">Barqawi 2005</a>; <a href="./references#CD010224-bbs2-0007" title="D'SouzaSW , RobertsonIG , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1991;65(3):320-4. [PMID: 2025009]">D'Souza 1991</a>; <a href="./references#CD010224-bbs2-0008" title="ĐelmišJ , DražančićA , TkalčevićT , IvaniševićM . Epilepsy in pregnancy [Epilepsija i trudnoća]. Jugoslavenska Ginekologija i Perinatologija1991;31(1-2):23-6. [PMID: 1875716]">Delmiš 1991</a>; <a href="./references#CD010224-bbs2-0010" title="EroğluE , GökçilZ , BekS , UlaşUH , OdabaşiZ . Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurologica Belgica2008;108(2):53-7. [PMID: 18795597]">Eroglu 2008</a>; <a href="./references#CD010224-bbs2-0013" title="ArtamaM , AuvinenA , RaudaskoskiT , IsojärviI , IsojärviJ . Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology2005;64(11):1874-8. [PMID: 15955936]ArtamaM , RitvanenA , GisslerM , IsojärviJ , AuvinenA . Congenital structural anomalies in offspring of women with epilepsy - a population-based cohort study in Finland. International Journal of Epidemiology2006;35(2):280-7. [PMID: 16280367]">Finland Health Record Registers</a>; <a href="./references#CD010224-bbs2-0014" title="FröscherW , HerrmannR , NiesenM , BülauP , PeninH , HildenbrandG . The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zur teratogenität der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur Neurologie und Psychiatrie1991;142(5):389-407. [PMID: 1721236]">Fröscher 1991</a>; <a href="./references#CD010224-bbs2-0015" title="Garza-MoralesS , Ibarra-PuigJM , Poblano-LunaA , Gilda Mayén-MolinaD , Córdova-LópezS . Epilepsy and pregnancy: prospective study of 100 cases [Epilepsia y embarazo. Estudio prospectivo 100 casos]. Ginecología y Obstetricia de México1996;64:449-54. [PMID: 8974948]">Garza‐Morales 1996</a>; <a href="./references#CD010224-bbs2-0016" title="HosnyH , ElkattanM , ZakiMA , RamzyGM , MagdyR , Abo Al-AzayemS . Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: an Egyptian prospective study. Epilepsy &amp; Behavior2021;123:108251. [PMID: 34411949]">Hosny 2021</a>; <a href="./references#CD010224-bbs2-0018" title="PutignanoD , ClavennaA , CampiR , CaneviniMP , VignoliA , BattinoD , et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy &amp; Behavior2019;92:14-7. [PMID: 30599457]">Italian Lombardy Region Health Register</a>; <a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0022" title="KaurTP , SahuL , RathoreAM , BhasinS . Obstetric outcomes in pregnant women with seizure disorder: a hospital-based, longitudinal study. Turkish Journal of Obstetrics &amp; Gynecology2020;17(3):161-9. [PMID: 33072419]">Kaur 2020</a>; <a href="./references#CD010224-bbs2-0023" title="KellyTE , EdwardsP , ReinM , MillerJQ , DreifussFE . Teratogenicity of anticonvulsant drugs II: a prospective study. American Journal of Medical Genetics1984;19(3):435-43. [PMID: 6507489]">Kelly 1984</a>; <a href="./references#CD010224-bbs2-0025" title="Jäger-RomanE , DeichlA , JakobS , HartmannAM , KochS , RatingD , et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Journal of Pediatrics1986;108(6):997-1004. [PMID: 3086531]KochS , Gopfert-GeyerI , Jager-RomanE , JakobS , HuthH , HartmannA , et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development [Antiepileptika wahrend der schwangerschaft. Eine prospektive studie uber schwangerschaftsverlauf, fehlbildungen und kindliche entwicklung]. Deutsche Medizinische Wochenschrift1983;108(7):250-7. [PMID: 6402356]KochS , LöscheG , Jager-RomänE , JakobS , RatingD , DeichlA , et al. Major and minor birth malformations and antiepileptic drugs. Neurology1992;42(4 Suppl 5):83-8. [PMID: 1574183]KuhnzW , Jäger-RomanE , RatingD , DeichlA , KunzeJ , HelgeH , et al. Carbamazepine and carbamazepine-10, -11 epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatric Pharmacology1983;3(3-4):199-208. [PMID: 6677873]KuhnzW , KochS , JakobS , HartmannA , HelgeH , NauH . Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology1984;18(5):671-7. [PMID: 6508976]RatingD , Jager-RomanE , KochS , DeichlA , HartmannH , JakobS , et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. In: NauH , Scott WJ Jr, editors(s). Pharmacokinetics in Teratogenesis. Vol. 1. CRC Press, 1987:205-23. [ISBN: 978-0849368738]RatingD , NauH , Jäger-RomanE , Göpfert-GeyerI , KochS , Beck-MannagettaG , et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia1982;71(2):301-11. [PMID: 7136638]">Koch 1992</a>; <a href="./references#CD010224-bbs2-0026" title="LindhoutD , HöppenerRJ , MeinardiH . Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia1984;25(1):77-83. [PMID: 6692794]LindhoutD , MeinardiH , MeijerJW , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42(4 Suppl 5):94-110. [PMID: 1574185]">Lindhout 1992</a>; <a href="./references#CD010224-bbs2-0027" title="Martinez FerriM , Pena MayorP , Perez Lopez-FraileI , Escartin SiquierA , Martin MoroM , Forcadas BerdusanM , et al. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia2018;33(2):78-84. [PMID: 27452623]Martinez FerriM , Pena MayorP , Perez Loppez-FraileI , Castro VilanovaMD , Escartin SiquierA , Martin MoroM , et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [Malformaciones y muerte fetal en el registro espanol de farmacos antiepilepticos y embarazo: resultados a los 6 anos]. Neurologia2009;24(6):360-5. [PMID: 19798601]">Martinez Ferri 2018</a>; <a href="./references#CD010224-bbs2-0030" title="MeischenguiserR , D'GianoCH , FerraroSM . Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy &amp; Behaviour2004;5(2):163-7. [PMID: 15123016]">Meischenguiser 2004</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>; <a href="./references#CD010224-bbs2-0035" title="DanskyLV , AndermannE , RosenblattD , SherwinAL , AndermannF . Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Annals of Neurology1987;21(2):176-82. [PMID: 3827226]OguniM , DanskyL , AndermannE , SherwinA , AndermannF . Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain &amp; Development1992;14(6):371-80. [PMID: 1492649]">Montreal Series</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>; <a href="./references#CD010224-bbs2-0039" title="OmtzigtJG , LosFJ , GrobbeeDE , PijpersL , JahodaMG , BrandenburgH , et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology1992;42(4 Suppl 5):119-25. [PMID: 1574165]OmtzigtJG , LosFJ , HagenaarsAM , StewartPA , SachsES , LindhoutD . Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal Diagnosis1992;12(11):893-7. [PMID: 1283633]">Omtzigt 1992</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>; <a href="./references#CD010224-bbs2-0042" title="Steegers-TheunissenRP , RenierWO , BormGF , ThomasCM , MerkusHM , Op de CoulDA , et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Research1994;18(3):261-9. [PMID: 7805647]">Steegers‐Theunissen 1994</a>; <a href="./references#CD010224-bbs2-0044" title="RegestaG , TanganelliP . The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana contro l'Epilessia1996;95/96:351-4. TanganelliP , RegestaG . Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology1992;42(4 Suppl 5):89-93. [PMID: 1574184]">Tanganelli 1992</a>; <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>; <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>). Fourteen studies were rated as having low risk for reporting bias, where the protocol could be reviewed in relation to the outcomes and comparisons investigated (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0006" title="CassinaM , DilaghiA , Di GianantonioE , CesariE , De SantisM , MannaioniG , et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology2013;39:50-7. [PMID: 23591043]">Cassina 2013</a>; <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0012" title="FairgrieveSD , JacksonM , JonasP , WalshawD , WhiteK , MontgomeryTL , et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal2000;321(7262):674-5. [PMID: 10987772]">Fairgrieve 2000</a>; <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>). </p> </section> </section> <section id="CD010224-sec-0055"> <h3 class="title" id="CD010224-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD010224-tbl-0001"><b>Summary of findings 1</b> Summary of findings ‐ Lamotrigine</a>; <a href="./full#CD010224-tbl-0002"><b>Summary of findings 2</b> Summary of findings ‐ Levetiracetam</a> </p> <p>Each included comparison is reviewed below with both the meta‐analysis results being reported alongside any studies which required narrative review only. In comparisons where there were less than 50 children in both groups, the meta‐analysis is not reported, but the data is summarised narratively. Summary tables displaying the pooled prevalences, RR and RDs for each comparison are available in <a href="#CD010224-tbl-0003">Table 1</a> along with <a href="./full#CD010224-tbl-0001">summary of findings Table 1</a> for lamotrigine; <a href="./full#CD010224-tbl-0002">summary of findings Table 2</a> for levetiracetam, <a href="#CD010224-tbl-0004">Table 2</a> for carbamazepine, <a href="#CD010224-tbl-0005">Table 3</a> for oxcarbazepine, <a href="#CD010224-tbl-0006">Table 4</a> for topiramate, and <a href="#CD010224-tbl-0007">Table 5</a> for valproate. A complete summary of all included ASM pooled prevalences, RR and RDs can be found in <a href="#CD010224-tbl-0003">Table 1</a>, <a href="#CD010224-tbl-0008">Table 6</a>, and <a href="#CD010224-tbl-0009">Table 7</a>, respectively with a visual presentation of the major malformation rates displayed in <a href="#CD010224-fig-0003">Figure 3</a>. </p> <section id="CD010224-sec-0056"> <h4 class="title">Women without epilepsy</h4> <p>The prevalence of major malformations (any type) in the cohort studies for children of women without epilepsy (N = 3537), based on data from 12 studies, was 2.1% (95% CI 1.5 to 3.0). The prevalence of major malformations in routine health record studies for children of women without epilepsy (N = 373,028), based on data from three studies, was 3.3% (95% CI 1.5 to 7.1). </p> </section> <section id="CD010224-sec-0057"> <h4 class="title">Women with epilepsy (no medication)</h4> <p>The prevalence of major malformations (any type) in the cohort studies for children of women with epilepsy (no medication) (N = 1708), based on data from 21 studies, was 3.0% (95% CI 2.1 to 4.2). The prevalence of major malformations in routine health record studies for children of women with epilepsy (no medication) (N = 11,286), based on data from three studies, was 3.2% (95% CI 1.7 to 6.1). </p> </section> <section id="CD010224-sec-0058"> <h4 class="title">Carbamazepine</h4> <p>The prevalence of major malformations (any type) in the cohort studies for children exposed to carbamazepine (CBZ) (N = 5415), based on data from 37 studies, was 4.7% (95% CI 3.7 to 5.9). The prevalence of major malformations in routine health record studies for children exposed to CBZ (N = 2806), based on data from five studies, was 4.0% (95% CI 2.9 to 5.4). </p> <section id="CD010224-sec-0059"> <h5 class="title">1 CBZ versus controls</h5> <section id="CD010224-sec-0060"> <h6 class="title">1.1 All major malformations</h6> <section id="CD010224-sec-0061"> <p><b>1.1.1 CBZ versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from 13 cohort studies suggested an increased risk with CBZ (RR 2.30, 95% CI 1.47 to 3.59; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 1448) experiencing more major malformations than control children (N = 3599) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). The RD also suggested a higher absolute risk (RD 0.02, 95% CI 0.01 to 0.03; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). </p> <p>The multicentre study, <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>, reported 22 (8%) cases of major malformations from 280 infants exposed to CBZ. However, the numbers from centres with a control group were smaller, with four cases of malformation out of just 14 exposed infants. This suggested an increased risk relative to the control children born to women without epilepsy (RR 4.9, 95% CI 1.3 to 18.0). </p> </section> <section id="CD010224-sec-0062"> <p><b>1.1.2 CBZ versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled findings from 20 cohort studies suggested an increased risk with CBZ (RR 1.44, 95% CI 1.05 to 1.96; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 3598) experiencing more major malformations than control children (N = 1691) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). The RD also suggested an increased risk with CBZ (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 1%) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD010224-sec-0063"> <p><b>1.1.3 CBZ versus no medication (in women without epilepsy): routine health record studies</b></p> <p>Results from two routine health record studies suggested no evidence of a difference in risk (RR 1.14 95% CI 0.80 to 1.64; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 983) experiencing a similar major malformation rate to control children (N = 372,111) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD010224-sec-0064"> <p><b>1.1.4 CBZ versus no medication (in women with epilepsy): routine health record studies</b></p> <p>Pooled results from four routine health record studies suggested an increased risk with CBZ (RR 1.42 95% CI 1.10 to 1.83; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 2116) experiencing more major malformations than control children (N = 12,218) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). The RD suggested an increased level of risk for CBZ (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0004" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD010224-sec-0065"> <h6 class="title">1.2 Neural tube malformations</h6> <section id="CD010224-sec-0066"> <p><b>1.2.1 CBZ versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 3.09, 95% CI 0.38 to 25.40; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 269) and compared to control children (N = 1801) (<a href="./references#CD010224-fig-0005" title="">Analysis 1.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010224-sec-0067"> <p><b>1.2.2 CBZ versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from nine cohort studies suggested a comparable level of risk (RR 2.54, 95% CI 0.63 to 10.20; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 1194) and in control children (N = 679) (<a href="./references#CD010224-fig-0005" title="">Analysis 1.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010224-sec-0068"> <p><b>1.2.3 CBZ versus no medication (in women without epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0069"> <p><b>1.2.4 CBZ versus no medication (in women with epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> <section id="CD010224-sec-0070"> <h6 class="title">1.3 Cardiac malformations</h6> <section id="CD010224-sec-0071"> <p><b>1.3.1 CBZ versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 1.46, 95% CI 0.43 to 4.99; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to CBZ (N = 269) and in control children (N = 1801) (<a href="./references#CD010224-fig-0006" title="">Analysis 1.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.02 to 0.01; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD010224-sec-0072"> <p><b>1.3.2 CBZ versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested no evidence of a difference in risk (RR 0.87, 95% CI 0.41 to 1.84; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to CBZ (N = 1212) and control children (N = 691) (<a href="./references#CD010224-fig-0006" title="">Analysis 1.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.02 to 0.01; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD010224-sec-0073"> <p><b>1.3.3 CBZ versus no medication (in women without epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0074"> <p><b>1.3.4 CBZ versus no medication (in women with epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> <section id="CD010224-sec-0075"> <h6 class="title">1.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0076"> <p><b>1.4.1 CBZ versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from seven cohort studies suggested an increased risk with CBZ (RR 9.04, 95% CI 2.16 to 37.87; I<sup>2</sup> = 10%), with children exposed to CBZ (N = 269) experiencing more oro‐facial cleft/craniofacial malformations than control children (N = 1801) (<a href="./references#CD010224-fig-0007" title="">Analysis 1.4</a>). The RD suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.01 to 0.03; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD010224-sec-0077"> <p><b>1.4.2 CBZ versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 0.99, 95% CI 0.27 to 3.62; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to CBZ (N = 709) and control children (N = 347) (<a href="./references#CD010224-fig-0007" title="">Analysis 1.4</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.02 to 0.02; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD010224-sec-0078"> <p><b>1.4.3 CBZ versus no medication (in women without epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0079"> <p><b>1.4.4 CBZ versus no medication (in women with epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> <section id="CD010224-sec-0080"> <h6 class="title">1.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0081"> <p><b>1.5.1 CBZ versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 5.13, 95% CI 0.52 to 50.67, I<sup>2</sup> = 0%), with no difference in skeletal/limb malformations in children exposed to CBZ (N = 269) and control children (N = 1801) (<a href="./references#CD010224-fig-0008" title="">Analysis 1.5</a>). The RD also suggested a comparable level of risk (RD 0.00, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD010224-sec-0082"> <p><b>1.5.2 CBZ versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 0.96, 95% CI 0.35 to 2.82; I<sup>2</sup> = 0%), with no difference in the number of skeletal and limb malformations in children exposed to CBZ (N = 1194) and control children (N = 679) (<a href="./references#CD010224-fig-0008" title="">Analysis 1.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD010224-sec-0083"> <p><b>1.5.3 CBZ versus no medication (in women without epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0084"> <p><b>1.5.4 CBZ versus no medication (in women with epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> </section> <section id="CD010224-sec-0085"> <h5 class="title">Carbamazepine dose</h5> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration has reported on the largest uniformly assessed group of children exposed to CBZ (N = 1957). They reported a higher malformation rate with higher doses of CBZ. Doses =/&lt; 700 mg/d were found to have a malformation risk of 4.5% (95% CI 3.5% to 5.8%), whilst dose &gt; 700 mg/d were associated with a prevalence of 7.2%, (95% CI 5.4 to 9.4); a difference which suggested a dose association (OR 1.56, 95% CI 1.03 to 2.37, P = 0.0352). When compared to children exposed to =/&lt; 325 mg/d of LTG, the prevalence was higher for doses =/&lt; 700 mg/d (OR 1.71 95% CI 1.12 to 2.61, P = 0.0143), and doses over 700 mg/d were also higher (OR 2.68, 95% CI 1.71 to 4.19, P = 0.0002). In contrast, however, the <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a> (N = 1033) failed to document an association between the risk of major malformation and the dose of CBZ; however, this group was smaller. The <a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>, the <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>, and a number of smaller studies also did not identify a dose effect (<a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>). </p> <p>Data regarding the impact of dose are limited from routine healthcare record‐based studies. Data analyses from <a href="./references#CD010224-bbs2-0013" title="ArtamaM , AuvinenA , RaudaskoskiT , IsojärviI , IsojärviJ . Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology2005;64(11):1874-8. [PMID: 15955936]ArtamaM , RitvanenA , GisslerM , IsojärviJ , AuvinenA . Congenital structural anomalies in offspring of women with epilepsy - a population-based cohort study in Finland. International Journal of Epidemiology2006;35(2):280-7. [PMID: 16280367]">Finland Health Record Registers</a> did not establish a dose relationship, however, the number of carbamazepine monotherapy cases was small (N = 32). Results from the <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a> and <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a> did not capture ASM doses, and researchers using the <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a> or the <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a> were not able to access dose information. Dose data have not currently been provided by the <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a> for CBZ dose. </p> </section> </section> <section id="CD010224-sec-0086"> <h4 class="title">Clonazepam</h4> <section id="CD010224-sec-0087"> <h5 class="title">2 CZP versus controls</h5> <section id="CD010224-sec-0088"> <h6 class="title">2.1 All major malformations</h6> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to clonazepam (CZP) (N = 95), based on data from four studies, was 2.1% (95% CI 0.2 to 17.3). The prevalence of major malformations in routine health record studies for children exposed to CZP (N = 161), based on data from one study, was 2.5% (95% CI 0.0 to 131.8). </p> <section id="CD010224-sec-0089"> <p><b>2.1.1 CZP versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk (RR 2.76, 95% CI 0.55 to 13.94; I<sup>2</sup> = 0%), with children exposed to CZP (N = 65) experiencing comparable rates of major malformations to control children (N = 504) (<a href="./references#CD010224-fig-0009" title="">Analysis 2.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.03 to 0.07; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0009" title="">Analysis 2.1</a>). </p> </section> <section id="CD010224-sec-0090"> <p><b>2.1.2 CZP versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled findings from three cohort studies suggested no evidence of a difference in risk (RR 1.08, 95% CI 0.21 to 5.42; I<sup>2</sup> = 0%), with children exposed to CZP (N = 31) experiencing comparable rates of major malformations to control children (N = 524) (<a href="./references#CD010224-fig-0009" title="">Analysis 2.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.03, 95% CI ‐0.11 to 0.04; I<sup>2</sup> = 0%) (<a href="./references#CD010224-fig-0009" title="">Analysis 2.1</a>). </p> </section> <section id="CD010224-sec-0091"> <p><b>2.1.3 CZP versus no medication (in women without epilepsy): routine health record studies</b></p> <p>One study suggested no evidence of a difference in risk (RR 0.70, 95% CI 0.18 to 2.77; I<sup>2</sup> = NA (not available)) with children exposed to CZP (N = 113) experiencing comparable rates of major malformations to control children (N = 369,267). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.03 to 0.02; I<sup>2</sup> = NA) (<a href="./references#CD010224-fig-0009" title="">Analysis 2.1</a>). </p> </section> <section id="CD010224-sec-0092"> <p><b>2.1.4 CZP versus no medication (in women with epilepsy): routine health record studies</b></p> <p>One study suggested no evidence of a difference in risk (RR 0.69, 95% CI 0.17 to 2.79; I<sup>2</sup> = NA) with children exposed to CZP (N = 113) experiencing comparable rates of major malformations to control children (N = 1900). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.03 to 0.02; I<sup>2</sup> = NA) (<a href="./references#CD010224-fig-0009" title="">Analysis 2.1</a>). </p> <p>Specific malformation types were not reviewed due to the small amount of data.</p> </section> </section> <section id="CD010224-sec-0093"> <h6 class="title">CZP Dose</h6> <p>There is too little experience with CZP in pregnancy to be able to report on the potential of an association between the dose of CZP and MCM risk. </p> </section> </section> </section> <section id="CD010224-sec-0094"> <h4 class="title">Gabapentin</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to gabapentin (GBP) (N = 192) based on data from four studies was 2.0% (95% CI 0.1 to 32.2). The prevalence of major malformations in routine health record studies for children exposed to GBP (N = 18), was based on data from one study and therefore could not be calculated. </p> <section id="CD010224-sec-0095"> <h5 class="title">3 GBP versus controls</h5> <section id="CD010224-sec-0096"> <h6 class="title">3.1 All major malformations</h6> <section id="CD010224-sec-0097"> <p><b>3.1.1 GBP versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk of major malformations for the children exposed to gabapentin (N = 147) in comparison to children born to women without epilepsy (N = 570) (RR 1.78, 95% CI 0.50 to ‐6.29, P = 0.37, I<sup>2</sup> = 89%), but there was heterogeneity in the results (<a href="./references#CD010224-fig-0010" title="">Analysis 3.1</a>). A random‐effects RR was calculated which also suggested a comparable level of risk (RR 8.04, 95% CI 0.03 to 1898.73, P = 0.45, I<sup>2</sup> = 89%). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.03; I<sup>2</sup> = 75%). Due to heterogeneity, a random‐effects RD was calculated which also found a comparable level of risk (RD 0.19, 95% CI ‐0.37 to 0.74, P = 0.51, I<sup>2</sup> = 75%) (<a href="./references#CD010224-fig-0010" title="">Analysis 3.1</a>). </p> </section> <section id="CD010224-sec-0098"> <p><b>3.1.2 GBP versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk of major malformation for the children exposed to gabapentin (n=47) in comparison to control children (n= 721) (RR 1.77, 95% CI 0.46 to 6.90, P = 0.41, I<sup>2</sup> = 0% (<a href="./references#CD010224-fig-0010" title="">Analysis 3.1</a>). </p> </section> <section id="CD010224-sec-0099"> <p><b>3.1.3 GBP versus no medication (in women without epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison in a format that could be combined in a meta‐analysis. However, Patorno and colleagues (<a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>) conducted a sensitivity analysis that was restricted to epilepsy indications and included 347 pregnancies exposed to gabapentin in comparison to an unexposed reference group of 11,861 pregnancies. There was no reported difference in the malformation outcome either in the epilepsy subgroup (RR 1.40, 95% CI 0.73 to 2.71, P = 0.31) or in the main analysis which included 3745 gabapentin‐exposed children (RR 1.07, 95% CI 0.94 to 1.21, P = 0.33). </p> </section> <section id="CD010224-sec-0100"> <p><b>3.1.4 GBP versus no medication (in women with epilepsy): routine health record studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> <section id="CD010224-sec-0101"> <h6 class="title">3.2 Neural tube malformations</h6> <section id="CD010224-sec-0102"> <p><b>3.2.1 GBP versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR for the included study due to there being no reported neural tube malformations in children exposed to GBP (N = 2) or control children (N = 128) (<a href="./references#CD010224-fig-0011" title="">Analysis 3.2</a>). </p> </section> <section id="CD010224-sec-0103"> <p><b>3.2.2 GBP versus no medication (in women with epilepsy): cohort studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0104"> <p><b>3.2.3 GBP versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0105"> <p><b>3.2.4 GBP versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> <section id="CD010224-sec-0106"> <h6 class="title">3.3 Cardiac malformations</h6> <section id="CD010224-sec-0107"> <p><b>3.3.1 GBP versus no medication (in women without epilepsy): cohort studies</b></p> <p>Data from one study suggested a difference in risk (RR 129.00, 95% CI 6.49 to 2562.48, I<sup>2</sup> = NA) with children exposed to GBP (N = 2) being at higher risk than control children (N = 128) (<a href="./references#CD010224-fig-0012" title="">Analysis 3.3</a>). However, the RD suggested no difference in the level of risk (RD 0.50, 95% CI ‐0.07 to 1.07; I<sup>2</sup> = NA) </p> </section> <section id="CD010224-sec-0108"> <p><b>3.3.2 GBP versus no medication (in women with epilepsy): cohort studies</b></p> <p>Included studies did not reach the threshold for reporting in the meta‐analysis (<a href="./references#CD010224-fig-0012" title="">Analysis 3.3</a>). However, available data showed that there was one case of cardiac malformation in children exposed to GBP (N = 2) in comparison to zero cases in the control children (N = 4), based on data from one study (<a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>). </p> </section> <section id="CD010224-sec-0109"> <p><b>3.3.3 GBP versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>Patorno and colleagues, using data including the <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>, found a comparable level of risk for cardiac anomalies in children exposed to gabapentin (N = 347) versus children born to women without epilepsy (N = 11,861) (RR 1.40, 95% CI 0.73 to 2.71, P = 0.31). </p> </section> <section id="CD010224-sec-0110"> <p><b>3.3.4 GBP versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> <section id="CD010224-sec-0111"> <h6 class="title">3.4 Oro‐Facial Cleft/Craniofacial malformations</h6> <section id="CD010224-sec-0112"> <p><b>3.4.1 GBP versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no oro‐facial cleft / craniofacial malformations in children exposed to GBP (n=2) in comparison to no cases in 128 control children (<a href="./references#CD010224-fig-0013" title="">Analysis 3.4</a>). </p> </section> <section id="CD010224-sec-0113"> <p><b>3.4.2 GBP versus no medication (in women with epilepsy): cohort studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0114"> <p><b>3.4.3 GBP versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0115"> <p><b>3.4.4 GBP versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> <section id="CD010224-sec-0116"> <h6 class="title">3.5 Skeletal/Limb malformations</h6> <section id="CD010224-sec-0117"> <p><b>3.5.1 GBP versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to GBP (n=2) or 128 control children, based on data from one study (<a href="./references#CD010224-fig-0014" title="">Analysis 3.5</a>). </p> </section> <section id="CD010224-sec-0118"> <p><b>3.5.2 GBP versus no medication (in women with epilepsy): cohort studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0119"> <p><b>3.5.3 GBP versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> <section id="CD010224-sec-0120"> <p><b>3.5.4 GBP versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>There were no studies that provided data for this comparison.</p> </section> </section> </section> <section id="CD010224-sec-0121"> <h5 class="title">Gabapentin dose</h5> <p>The investigation of GBP dose and its potential association with an increased rate of malformations is limited due to the relatively small number of pregnancies where data are currently available. The <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> is the most reliable data source currently available. The study authors did not find that malformation risk increased with dose according to tertiles of the first and the highest prescribed daily dose filled. Doses of 600 mg/d through to 900 mg/d (RR 1.00, 95% CI 0.80 to 1.24, P = 0.98) or doses above 900 mg/d (RR 1.17, 95% CI 0.95 to 1.44, P = 0.15) were not associated with a risk above the baseline risk. The largest cohort study of GBP‐exposed pregnancies was from the <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a> (N = 145) and no association between increasing dose and increased malformation risk was identified in this study. The participant numbers in other included studies of GBP were too small to investigate any effect of dose size and MCM risk. </p> </section> </section> <section id="CD010224-sec-0122"> <h4 class="title">Levetiracetam</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to levetiracetam (LEV) (N = 1242), based on data from 11 studies, was 2.6% (95% CI 1.6 to 4.4). The prevalence of major malformations in routine health record studies for children exposed to LEV (N = 248), based on data from two studies, was 2.8% (95% CI 0.0 to 321.9). </p> <section id="CD010224-sec-0123"> <h5 class="title">4 LEV versus controls</h5> <section id="CD010224-sec-0124"> <h6 class="title">4.1 All major malformations</h6> <section id="CD010224-sec-0125"> <p><b>4.1.1 LEV versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 2.20, 95% CI 0.98 to 4.93; I<sup>2</sup> = 0%), with children exposed to LEV (N = 574) experiencing comparable rates of major malformations to control children (N = 1022) (<a href="./references#CD010224-fig-0015" title="">Analysis 4.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.00 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0126"> <p><b>4.1.2 LEV versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.71, 95% CI 0.39 to 1.28; I<sup>2</sup> = 0%), with children exposed to LEV (N = 724) experiencing comparable rates of major malformations to control children (N = 1101) (<a href="./references#CD010224-fig-0015" title="">Analysis 4.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.03 to 0.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0127"> <p><b>4.1.3 LEV versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>One study suggested no evidence of a difference in risk (RR 0.67, 95% CI 0.17 to 2.66; I<sup>2</sup> = NA) for children exposed to LEV (N = 118) experiencing comparable rates of major malformations to control children (N = 369,267). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.03 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0128"> <p><b>4.1.4 LEV versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 0.82, 95% CI 0.39 to 1.71; I<sup>2</sup> = 0%), with children exposed to LEV (N = 248) experiencing comparable rates of major malformations to control children (N = 10,377) (<a href="./references#CD010224-fig-0015" title="">Analysis 4.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.03 to 0.01; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0129"> <h6 class="title">4.2 Neural tube malformations</h6> <section id="CD010224-sec-0130"> <p><b>4.2.1 LEV versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported cases of neural tube malformation in children exposed to LEV (N = 105) or control children (N = 383) (<a href="./references#CD010224-fig-0016" title="">Analysis 4.2</a>). </p> </section> <section id="CD010224-sec-0131"> <p><b>4.2.2 LEV versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported cases of neural tube malformations in children exposed to LEV (N = 173) or control children (N = 361) (<a href="./references#CD010224-fig-0016" title="">Analysis 4.2</a>). </p> </section> <section id="CD010224-sec-0132"> <p><b>4.2.3 LEV versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0133"> <p><b>4.2.4 LEV versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0134"> <h6 class="title">4.3 Cardiac malformations</h6> <section id="CD010224-sec-0135"> <p><b>4.3.1 LEV versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk (RR 3.92, 95% CI 0.57 to 27.07; I<sup>2</sup> = 0), with children exposed to LEV (N = 105) experiencing comparable rates of major malformations to control children (N = 383) (<a href="./references#CD010224-fig-0017" title="">Analysis 4.3</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.02 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0136"> <p><b>4.3.2 LEV versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.90, 95% CI 0.31 to 2.60; I<sup>2</sup> = 0), with children exposed to LEV (N = 281) experiencing comparable rates of major malformations to control children (N = 384) (<a href="./references#CD010224-fig-0017" title="">Analysis 4.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.03 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0137"> <p><b>4.3.3 LEV versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0138"> <p><b>4.3.4 LEV versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0139"> <h6 class="title">4.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0140"> <p><b>4.4.1 LEV versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to LEV (N = 105) or control children (N = 383) (<a href="./references#CD010224-fig-0018" title="">Analysis 4.4</a>). </p> </section> <section id="CD010224-sec-0141"> <p><b>4.4.2 LEV versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 0.14, 95% CI 0.01 to 3.18; I<sup>2</sup> = N/A), with children exposed to LEV (N=186) experiencing comparable rates of oro‐facial cleft/craniofacial malformations as control children (N=44) (<a href="./references#CD010224-fig-0018" title="">Analysis 4.4</a>). </p> </section> <section id="CD010224-sec-0142"> <p><b>4.4.3 LEV versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0143"> <p><b>4.4.4 LEV versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0144"> <h6 class="title">4.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0145"> <p><b>4.5.1 LEV versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no skeletal / limb malformations in children exposed to LEV (N = 105) or control children (N = 383) (<a href="./references#CD010224-fig-0019" title="">Analysis 4.5</a>). </p> </section> <section id="CD010224-sec-0146"> <p><b>4.5.2 LEV versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 3.21, 95% CI 0.46 to 22.50; I<sup>2</sup> = NA), with children exposed to LEV (N = 272) experiencing comparable rates of skeletal/limb malformations to control children (N = 376) (<a href="./references#CD010224-fig-0019" title="">Analysis 4.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0147"> <p><b>4.5.3 LEV versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0148"> <p><b>4.5.4 LEV versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data for this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0149"> <h5 class="title">Levetiracetam dose</h5> <p><a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> had the largest cohort of LEV‐exposed children to conduct dose investigations in 599 exposed children. Whilst they did not make comparisons between different levels of LEV dose directly, they did report that there was evidence of lower risk of any LEV dose (250‐4000 mg/d) in comparison to doses of VPA &lt;/= 650 mg/d and dose of CBZ &gt; 700 mg/d, whilst there was no evidence of difference in comparison to doses of LTG either at &lt;/= 325 mg/d or &gt; 325 mg/d, or in comparison to OXC at doses ranging from 75‐4500 mg/d. Additionally, the <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a> reporting on LEV‐exposed children (N = 450), the <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a> (N = 304), the <a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a> (N = 139), the <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a> (N = 106) and the <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a> study (N = 99) also failed to find an association between increasing doses of LEV and congenital anomaly risk; however, group sizes may still be too limited at higher dose levels to detect increased levels of MCM risk. </p> </section> </section> <section id="CD010224-sec-0150"> <h4 class="title">Lamotrigine</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to lamotrigine (LTG) (N = 4704), based on data from 15 studies, was 2.7% (95% CI 1.9 to 3.8). The prevalence of major malformations in routine health record studies for children exposed to LTG (N = 2502), based on data from four studies, was 3.5% (95% CI 2.5 to 4.9). </p> <section id="CD010224-sec-0151"> <h5 class="title">5 LTG versus controls</h5> <section id="CD010224-sec-0152"> <h6 class="title">5.1 All major malformations</h6> <section id="CD010224-sec-0153"> <p><b>5.1.1 LTG versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from seven studies suggested an increased risk with LTG (RR 1.97, 95% CI 1.16 to 3.39; I<sup>2</sup> = 0%), with children exposed to LTG (N = 1899) experiencing more major malformations to control children (N = 2693) (<a href="./references#CD010224-fig-0020" title="">Analysis 5.1</a>). The RD also suggested a higher risk (RD 0.01, 95% CI 0.00 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0154"> <p><b>5.1.2 LTG versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from eight studies suggested no evidence of a difference in risk (RR 1.04, 95% CI 0.66 to 1.63; I<sup>2</sup> = 0%), with children exposed to LTG (N = 2767) experiencing comparable rates of major malformations to control children (N = 1151) (<a href="./references#CD010224-fig-0020" title="">Analysis 5.1</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0155"> <p><b>5.1.3 LTG versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 1.19, 95% CI 0.86 to 1.64; I<sup>2</sup> = 18%), with children exposed to LTG (N = 1177) experiencing comparable rates of major malformations to control children (N = 372,111) (<a href="./references#CD010224-fig-0020" title="">Analysis 5.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.02; I<sup>2</sup> = 22%). </p> </section> <section id="CD010224-sec-0156"> <p><b>5.1.4 LTG versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 1.00, 95% CI 0.79 to 1.28; I<sup>2</sup> = 0%), with children exposed to LTG (N = 2166) experiencing comparable rates of major malformations to control children (N = 11,279) (<a href="./references#CD010224-fig-0020" title="">Analysis 5.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0157"> <h6 class="title">5.2 Neural tube malformations</h6> <section id="CD010224-sec-0158"> <p><b>5.2.1 LTG versus no medication (in women without epilepsy)</b></p> <p>Pooled results from five studies suggested an increased risk with LTG (RR 7.55, 95% CI 1.05 to 54.09; I<sup>2</sup> = 0%), with children exposed to LTG (N = 313) experiencing more major malformations to control children (N = 1654) (<a href="./references#CD010224-fig-0021" title="">Analysis 5.2</a>). However, the RD suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0159"> <p><b>5.2.2 LTG versus no medication (in women with epilepsy)</b></p> <p>We were unable to estimate a RR from five studies, as there were no reported neural tube malformations in children exposed to LTG (N = 521) or control children (N = 563) (<a href="./references#CD010224-fig-0021" title="">Analysis 5.2</a>). </p> </section> <section id="CD010224-sec-0160"> <p><b>5.2.3 LTG versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0161"> <p><b>5.2.4 LTG versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0162"> <h6 class="title">5.3 Cardiac malformations</h6> <section id="CD010224-sec-0163"> <p><b>5.3.1 LTG versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from six studies suggested an increased risk with LTG (RR 2.71, 95% CI 1.05 to 6.98; I<sup>2</sup> = 0%), with children exposed to LTG (N = 348) experiencing more major malformations to control children (N = 1658) (<a href="./references#CD010224-fig-0022" title="">Analysis 5.3</a>). However, the RD suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0164"> <p><b>5.3.2 LTG versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from six studies suggested no evidence of a difference in risk (RR 0.97, 95% CI 0.28 to 3.32; I<sup>2</sup> = 0%), with children exposed to LTG (N = 541) experiencing comparable rates of major malformations to control children (N = 571) (<a href="./references#CD010224-fig-0022" title="">Analysis 5.3</a>). However, the RD suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0165"> <p><b>5.3.3 LTG versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data for this outcome.</p> </section> <section id="CD010224-sec-0166"> <p><b>5.3.4 LTG versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data for this outcome.</p> </section> </section> <section id="CD010224-sec-0167"> <h6 class="title">5.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0168"> <p><b>5.4.1 LTG versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate RR from the four included studies due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to LTG (N = 197) or control children (N = 826) (<a href="./references#CD010224-fig-0023" title="">Analysis 5.4</a>). </p> </section> <section id="CD010224-sec-0169"> <p><b>5.4.2 LTG versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from five studies suggested no evidence of a difference in risk (RR 1.37, 95% CI 0.29 to 6.56; I<sup>2</sup> = 65%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to LTG (N = 491) and control children (N = 322) (<a href="./references#CD010224-fig-0023" title="">Analysis 5.4</a>). Due to high heterogeneity, a random‐effects RR was calculated which also found no difference (RR 0.90, 95% CI 0.03 to 32.04, P = 0.95, I<sup>2</sup> = 65%). The RD suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0170"> <p><b>5.4.3 LTG versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>In the study using the <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> by Hernandez‐Diaz and colleagues, there was no evidence of a difference in the oral cleft rates for children exposed to LTG (N = 2796) in comparison to the children born to women without epilepsy (N = 1,322,955) (RR 1.89, 95% CI 0.85 to 4.21). </p> </section> <section id="CD010224-sec-0171"> <p><b>5.4.4 LTG versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data for this outcome.</p> </section> </section> <section id="CD010224-sec-0172"> <h6 class="title">5.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0173"> <p><b>5.5.1 LTG versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from five studies suggested an increased risk with LTG (RR 11.29, 95% CI 2.37 to 53.91; I<sup>2</sup> = 0%), with children exposed to LTG (N = 311) experiencing more major malformations to control children (N = 1654) (<a href="./references#CD010224-fig-0024" title="">Analysis 5.5</a>). However, the RD suggested no difference in the level of risk (RD 0.01, 95% CI −0.00 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0174"> <p><b>5.5.2 LTG versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from five studies suggested no evidence of a difference in risk (RR 0.75, 95% CI 0.20 to 2.89; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to LTG (N = 521) and control children (N = 563) (<a href="./references#CD010224-fig-0024" title="">Analysis 5.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0175"> <p><b>5.5.3 LTG versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data for this outcome.</p> </section> <section id="CD010224-sec-0176"> <p><b>5.5.4 LTG versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data for this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0177"> <h5 class="title">Lamotrigine dose</h5> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration has reported on a large, uniformly assessed, group of children exposed to LTG (N = 2514). It reported a higher MCM rate with higher doses of LTG. Doses =/&lt; 325 mg/d were found to have an MCM risk of 2.5% (95% CI 1.8% to 3.3%), whilst doses &gt; 325 mg/d were associated with MCM in 4.3% of children (95% CI 2.9% to 6.2%); a difference which suggested a dose association (OR 1.68, 95% CI 1.01 to 2.80, P = 0.0463). </p> <p>When <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> compared lower dose LTG (=/&lt; 325 mg/d) to other monotherapy ASMs, they found evidence suggesting a lower MCM risk in comparison to CBZ at =/&lt; 700 mg/d (OR 1.71 95% CI 1.12 to 2.61, P = 0.0143) and lower risk than CBZ doses &gt; 700 mg/d (OR 2.68, 95% CI 1.71 to 4.19, P = 0.0002). In comparison to LEV, there was no evidence of a difference between lower doses of LTG (&lt;/= 325 mg/d) and LEV doses between =/&gt; 250‐4000 mg/d (OR 1.11, 95% CI 0.62 to 2.00, P = 0.7282). Comparisons to VPA demonstrated lower MCM risks for lower LTG dose (=/&lt; 325 mg/d) in comparison to VPA doses at =/&lt; 650 mg/d (OR 2.70, 95% CI 1.67 to 4.38, P = 0.0002), &gt; 650 mg/d to =/&lt; 1450 mg/d (OR 4.72, 95% CI 3.11 to 7.18, P &lt; 0.0002), or at doses of VPA &gt; 1450 mg/d (OR 13.52, 95% CI 7.73 to 23.64, P = 0.0002). Exposure to LTG at a dose =/&lt; 325 mg daily was associated with a lower MCM risk than PB exposure at doses of between &gt; 80 and =/&lt; 130 mg/d (OR 2.46, 95% CI 1.16 to 5.23, P = 0.0196) and at PB doses &gt; 130 mg/d (OR 5.81, 95% CI 2.40 to 14.08, P = 0.0002). There was, however, no evidence of a difference in comparison of LTG doses =/&lt; 325 mg/d to the lowest investigated PB dose of =/&lt; 80 mg/d (OR 1.07, 95% CI 0.25 to 4.60, P = 0.923). Rates of PHT, TPM, and OXC‐exposed pregnancies were lower in the EURAP study which should be considered with regard to findings suggesting that there is no dose association here. In comparison to lower dose LTG (=/&lt; 325 mg/d), there was no evidence of difference for PHT doses between =/30 mg/d and 730 mg/d (OR 1.93, 95% CI 0.78 to 4.75, P = 0.1554) or TPM doses =/&gt; 25 mg/d to 500 mg/d (OR 1.67, 95% CI 0.69 to 4.04, P = 0.2524) or OXC doses between =/&gt; 75 to 4500 mg/d (OR 1.13, 95% CI 0.55 to 2.31, P = 0.7358). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration also compared higher doses of LTG (&gt; 325 mg/d) and found a comparable level of risk to higher doses of CBZ (&gt; 700 mg/d, OR 0.63, 95% CI 0.38 to 1.05, P = 0.0766), to LEV doses between =/&gt; 250‐4000 mg/d (OR 1.51, 95% CI 0.79 to 2.88, P = 0.2077) and to OXC doses between 75‐4500 mg/d (OR 1.49, 95% CI 0.70 to 3.17, P = 0.3051). Higher doses of LTG (&gt; 325 mg/d) were not associated with lower rates of MCM compared to the lowest investigated dose range for VPA (=/&lt; 650 mg/d, OR 0.62, 95% CI 0.36 to 1.09, P = 0.0959) but there was evidence suggesting higher doses of LTG were associated with a lower MCM risk than VPA doses between &gt; 650 to =/&lt; 1450 mg/d (OR 2.81, 95% 1.70 to 4.65, P = 0.0002). </p> <p>In contrast to the data from EURAP, the <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a> (N = 2198) found no evidence of risk with increasing doses of LTG (0 to 200 mg/d vs 200 to 400 mg/d; 0 to 200 mg/d vs &gt; 400 mg/d). The <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a> (N = 1562), the <a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a> (N = 406), and the <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a> (N = 114) studies did not identify dose‐related risks associated with LTG. The frequency of MCM was too low in other included studies to allow reliable investigation of dose. </p> </section> </section> <section id="CD010224-sec-0178"> <h4 class="title">Oxcarbazepine</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to oxcarbazepine (OXC) (N = 378), based on data from 11 studies, was 2.8% (95% CI 1.1 to 6.6). The prevalence of major malformations in routine health record studies for children exposed to OXC (N = 507), based on data from four studies, was 4.8% (95% CI 0.7 to 31.5). </p> <section id="CD010224-sec-0179"> <h5 class="title">6 OXC versus controls</h5> <section id="CD010224-sec-0180"> <h6 class="title">6.1 All major malformations</h6> <section id="CD010224-sec-0181"> <p><b>6.1.1 OXC versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 2.20, 95% CI 0.67 to 7.27; I<sup>2</sup> = 18%), with children exposed to OXC (N = 184) experiencing comparable rates of major malformations to control children (N = 767) (<a href="./references#CD010224-fig-0025" title="">Analysis 6.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0182"> <p><b>6.1.2 OXC versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from six studies suggested no evidence of a difference in risk (RR 1.40, 95% CI 0.68 to 2.91; I<sup>2</sup> = 23%), with children exposed to OXC (N = 134) experiencing comparable rates of major malformations to control children (N = 788) (<a href="./references#CD010224-fig-0025" title="">Analysis 6.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.03 to 0.07; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0183"> <p><b>6.1.3 OXC versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>Results from one study found no evidence of a difference in risk (RR 0.70, 95% CI 0.10 to 4.86; I<sup>2</sup> = N/A), with children exposed to OXC (N = 57) experiencing comparable rates of major malformations to control children (N = 369,267) (<a href="./references#CD010224-fig-0025" title="">Analysis 6.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.04 to 0.03; I<sup>2</sup> = N/A). </p> </section> <section id="CD010224-sec-0184"> <p><b>6.1.4 OXC versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>Pooled results from three studies suggested an increased risk with OXC (RR 1.75, 95% CI 1.22 to 2.52; I<sup>2</sup> = 94%), with children exposed to OXC (N = 503) experiencing higher rates of major malformations than control children (N = 11,316) (<a href="./references#CD010224-fig-0025" title="">Analysis 6.1</a>). Due to high heterogeneity, a random‐effects RR was calculated and found no evidence of a difference in risk (RR 1.61, 95% CI 0.26 to 9.86; I<sup>2</sup> = 94%). The RD suggested a higher risk for OXC (RD 0.03, 95% CI 0.01 to 0.05; I<sup>2</sup> = 94%); however, a random‐effects RD due to heterogeneity found no difference in the level of risk (RD 0.04, 95% CI ‐0.05 to 0.12; I<sup>2</sup> = 94%). </p> </section> </section> <section id="CD010224-sec-0185"> <h6 class="title">6.2 Neural tube malformations</h6> <section id="CD010224-sec-0186"> <p><b>6.2.1 OXC versus no medication (in women without epilepsy): cohort studies</b></p> <p>No included studies reported data for this outcome.</p> </section> <section id="CD010224-sec-0187"> <p><b>6.2.2 OXC versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from the two included studies due to there being no reported neural tube malformations in children exposed to OXC (N = 102) or control children (N = 361) (<a href="./references#CD010224-fig-0026" title="">Analysis 6.2</a>). </p> </section> <section id="CD010224-sec-0188"> <p><b>6.2.3 OXC versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data for this outcome.</p> </section> <section id="CD010224-sec-0189"> <p><b>6.2.4 OXC versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0190"> <h6 class="title">6.3 Cardiac malformations</h6> <section id="CD010224-sec-0191"> <p><b>6.3.1 OXC versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR in the included study due to there being no reported cardiac malformations in children exposed to OXC (N = 1) or control children (N = 128) (<a href="./references#CD010224-fig-0027" title="">Analysis 6.3</a>). </p> </section> <section id="CD010224-sec-0192"> <p><b>6.3.2 OXC versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 1.10, 95% CI 0.36 to 3.35; I<sup>2</sup> = 22%), with children exposed to OXC (N = 106) experiencing comparable rates of major malformations to control children (N = 373) (<a href="./references#CD010224-fig-0027" title="">Analysis 6.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.04 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0193"> <p><b>6.3.3 OXC versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0194"> <p><b>6.3.4 OXC versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0195"> <h6 class="title">6.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0196"> <p><b>6.4.1 OXC versus no medication (in women without epilepsy): cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0197"> <p><b>6.4.2 OXC versus no medication (in women with epilepsy): cohort studies</b></p> <p>Included studies did not reach the threshold for reporting the meta‐analysis (<a href="./references#CD010224-fig-0028" title="">Analysis 6.4</a>). However, available data showed there were 0/34 cases of oro‐facial cleft/craniofacial malformations in children exposed to OXC and 1/29 cases in control children, based on data from two studies (<a href="./references#CD010224-bbs2-0002" title="AlSheikhMH . Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes. Neurosciences2020;25(1):32-7. [PMID: 31982897]">AlSheikh 2020</a>; <a href="./references#CD010224-bbs2-0016" title="HosnyH , ElkattanM , ZakiMA , RamzyGM , MagdyR , Abo Al-AzayemS . Risk factors of fetal deaths and major birth defects in newborns of women with epilepsy: an Egyptian prospective study. Epilepsy &amp; Behavior2021;123:108251. [PMID: 34411949]">Hosny 2021</a>). </p> </section> <section id="CD010224-sec-0198"> <p><b>6.4.3 OXC versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0199"> <p><b>6.4.4 OXC versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0200"> <h6 class="title">6.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0201"> <p><b>6.5.1 OXC versus no medication (in women without epilepsy): cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0202"> <p><b>6.5.2 OXC versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled data from two studies suggested no evidence of a difference in risk (RR 2.39, 95% CI 0.22 to 26.05; I<sup>2</sup> = NA), with children exposed to OXC (N = 102) experiencing comparable rates of major malformations to control children (N = 361) (<a href="./references#CD010224-fig-0029" title="">Analysis 6.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0203"> <p><b>6.5.3 OXC versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0204"> <p><b>6.5.4 OXC versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0205"> <h5 class="title">Oxcarbazepine dose</h5> <p>The limited published experience of OXC in pregnancy limits dose comparisons, even in the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> study for different doses of OXC (N = 333). In <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>, there was no evidence that doses of OXC between =/&gt; 75 to 4500 mg/d were different from those for lower dose LTG (=/&lt; 325 mg/d) (OR 1.13, 95% CI 0.55 to 2.31, P = 0.7282) or dose of LTG &gt; 325 mg/d (OR 1.49, 95% CI 0.70 to 3.17, P = 0.3051). Similarly, a lack of difference was also found in comparison to any dose of LEV exposure (OR 1.02, 95% CI 0.45 to 2.30, P = 0.9644). A lower prevalence of MCM was found for any dose of OXC (3.0%, 95% CI 1.4 to 5.4) in comparison to low dose VPA (=/&lt; 650 mg/d, 6.3%, 95% CI 4.5 to 8.6) (OR 2.39, 95% CI 1.13 to 5.08, P = 0.0235), but was not reported for any higher‐dose VPA. </p> <p>Other studies were limited to the number of OXC‐exposed pregnancies or had not published dose data. </p> </section> </section> <section id="CD010224-sec-0206"> <h4 class="title">Phenobarbital</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to phenobarbital (PB) (N = 840), based on data from 26 studies, was 6.3% (95% CI 4.8 to 8.3). The prevalence of major malformations in routine health record studies for children exposed to PB (N = 34), based on data from two studies, was 8.8% (95% CI 0.0 to 9722.4). </p> <section id="CD010224-sec-0207"> <h5 class="title">7 PB versus controls</h5> <section id="CD010224-sec-0208"> <h6 class="title">7.1 All major malformations</h6> <section id="CD010224-sec-0209"> <p><b>7.1.1 PB versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from eight studies suggested an increased risk with PB (RR 3.22, 95% CI 1.84 to 5.65; I<sup>2</sup> = 0%), with children exposed to PB (N = 353) experiencing more major malformations than control children (N = 2042) (<a href="./references#CD010224-fig-0030" title="">Analysis 7.1</a>). The RD also suggested a higher risk for PB (RD 0.04, 95% CI 0.01 to 0.07; I<sup>2</sup> = 0%). </p> <p><a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported five cases of major malformation out of 48 exposed infants (10%). Numbers were more limited in the comparison to control children (as not all centres in the study included control children), with just one malformation case out of six PB‐exposed children; analysis suggested no evidence of a difference between the groups (RR 2.4, 95% CI 0.3 to 23.0). </p> </section> <section id="CD010224-sec-0210"> <p><b>7.1.2 PB versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from 13 studies suggested no evidence of a difference in risk (RR 1.64, 95% CI 0.94 to 2.83; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PB (N = 438) and control children (N = 999) (<a href="./references#CD010224-fig-0030" title="">Analysis 7.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.01 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0211"> <p><b>7.1.3 PB versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>The results from one study suggested no evidence of a difference in risk (RR 2.94, 95% CI 0.77 to 11.15; I<sup>2</sup> = NA), with children exposed to PB (N = 27) experiencing comparable rates of major malformations to control children (N = 369,267) (<a href="./references#CD010224-fig-0030" title="">Analysis 7.1</a>). The RD also suggested no difference in the level of risk (RD 0.05, 95% CI −0.05 to 0.15; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0212"> <p><b>7.1.4 PB versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>The results from one study suggested no evidence of a difference in risk (RR 2.87, 95% CI 0.74 to 11.21; I<sup>2</sup> = NA), with children exposed to PB (N = 27) experiencing comparable rates of major malformations to control children (N = 1900) (<a href="./references#CD010224-fig-0030" title="">Analysis 7.1</a>). The RD also suggested no difference in the level of risk (RD 0.05, 95% CI −0.05 to 0.15; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0213"> <h6 class="title">7.2 Neural tube malformations</h6> <section id="CD010224-sec-0214"> <p><b>7.2.1 PB versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no neural tube malformations in children exposed to PB (N = 7) or control children (N = 244) (<a href="./references#CD010224-fig-0031" title="">Analysis 7.2</a>). </p> </section> <section id="CD010224-sec-0215"> <p><b>7.2.2 PB versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 3.85, 95% CI 0.47 to 31.26, I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to PB (N = 146) and control children (N = 512) (<a href="./references#CD010224-fig-0031" title="">Analysis 7.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0216"> <p><b>7.2.3 PB versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0217"> <p><b>7.2.4 PB versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0218"> <h6 class="title">7.3 Cardiac malformations</h6> <section id="CD010224-sec-0219"> <p><b>7.3.1 PB versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 7.80, 95% CI 0.36 to 168.52, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to PB (N = 7) and control children (N = 244) (<a href="./references#CD010224-fig-0032" title="">Analysis 7.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.27 to 0.26; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0220"> <p><b>7.3.2 PB versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 1.80, 95% CI 0.69 to 4.71, I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to PB (N = 149) and control children (N = 516) (<a href="./references#CD010224-fig-0032" title="">Analysis 7.3</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.02 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0221"> <p><b>7.3.3 PB versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0222"> <p><b>7.3.4 PB versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0223"> <h6 class="title">7.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0224"> <p><b>7.4.1 PB versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 3.34, 95% CI 0.20 to 56.35, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to PB (N = 7) and control children (N = 244) (<a href="./references#CD010224-fig-0033" title="">Analysis 7.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.28 to 0.25; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0225"> <p><b>7.4.2 PB versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to PB (N = 9) or control children (N = 172) (<a href="./references#CD010224-fig-0033" title="">Analysis 7.4</a>). </p> </section> <section id="CD010224-sec-0226"> <p><b>7.4.3 PB versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0227"> <p><b>7.4.4 PB versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0228"> <h6 class="title">7.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0229"> <p><b>7.5.1 PB versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 7.80, 95% CI 0.36 to 168.52, I<sup>2</sup> = NA) with no difference in the number of skeletal/limb malformations in children exposed to PB (N = 7) in comparison to control children (N=244). (<a href="./references#CD010224-fig-0034" title="">Analysis 7.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.27 to 0.26; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0230"> <p><b>7.5.2 PB versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 3.01, 95% CI 0.56 to 16.07; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to PB (N = 146) and control children (N = 512) (<a href="./references#CD010224-fig-0034" title="">Analysis 7.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0231"> <p><b>7.5.3 PB versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0232"> <p><b>7.5.4 PB versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0233"> <h5 class="title">Phenobarbital dose</h5> <p>Despite data being reported in 26 studies, most studies did not investigate dose or report the results of analyses of PB dose with regard to MCM risk or were too limited in terms of the number of included pregnancies. <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> included 294 PB monotherapy‐exposed cases which is the largest cohort. They found that increasing PB dose was associated with an increasing prevalence of MCM risk. Doses =/&lt; 80 mg/d had a prevalence of 2.7% (95% CI 0.3 to 9.5), doses &gt; 80 to =/&lt; 130 mg/d had a prevalence of 6.2% (95%CI 3.0 to 11.1), and doses &gt; 130 mg/d had the highest prevalence of 11.7% (95% CI 4.8 to 22.6); there was evidence of a dose association the for comparison of the lowest and highest PB dose levels investigated (OR 5.41, 95% CI 1.05 to 27.89, P = 0.0436). PB doses &gt; 130 mg/d were associated with a higher MCM risk than LTG at doses =/&lt; 325 mg/d (OR 5.81, 95% CI 2.40 to 14.08, P = 0.0002). There were no comparisons of the different PB dose levels to other ASM doses, however. The <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a> reported on 137 pregnancies and demonstrated an increase in MCM risk with increasing dose; PB &gt; 200 mg/d had a prevalence of 10.3% whilst PB doses &gt; 45 to 60 mg/d had a prevalence of 3.5%. However, it is possible that there was some case overlap with the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> cases as the <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a> is a EURAP collaborator. The collaboration reported by <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> and colleagues reported a likely dose association with PB. The <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a> included 199 PB‐exposed pregnancies and did not find an association with dose. <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a> did find an association between PB exposure (N = 79) and increased malformation rate. Other studies were too small or did not investigate an association between PB dose and MCM risk. </p> </section> </section> <section id="CD010224-sec-0234"> <h4 class="title">Phenytoin</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to phenytoin (PHT) (N = 1327), based on data from 26 studies, was 5.4% (95% CI 3.6 to 8.1). The prevalence of major malformations in routine health record studies for children exposed to PHT (N = 103), based on data from one study, was 6.8% (95% CI 0.1 to 91.3). </p> <section id="CD010224-sec-0235"> <h5 class="title">8 PHT versus controls</h5> <section id="CD010224-sec-0236"> <h6 class="title">8.1 All major malformations</h6> <section id="CD010224-sec-0237"> <p><b>8.1.1 PHT versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from eight studies suggested an increased risk with PHT (RR 3.81, 95% CI 1.91 to 7.57; I<sup>2</sup> = 35%), with children exposed to PHT (N = 496) experiencing more major malformations than control children (N = 1397) (<a href="./references#CD010224-fig-0035" title="">Analysis 8.1</a>). The RD also suggested a higher risk for PHT (RD 0.03, 95% CI 0.01 to 0.06; I<sup>2</sup> = 44%). </p> <p><a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported nine cases of major malformation in 141 (6%) PHT‐exposed children. Outcomes at centres with a control group in this study were limited to five cases from 33 exposed children, which gave a non‐significant difference (RR 2.2, 95% CI 0.7 to 6.7). </p> </section> <section id="CD010224-sec-0238"> <p><b>8.1.2 PHT versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from 15 studies suggested an increased risk with PHT (RR 2.01, 95% CI 1.29 to 3.12; I<sup>2</sup> = 0%), with children exposed to PHT (N = 750) experiencing more major malformations than control children (N = 1588) (<a href="./references#CD010224-fig-0035" title="">Analysis 8.1</a>). The RD also suggested a higher risk for PHT (RD 0.03, 95% CI 0.01 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0239"> <p><b>8.1.3 PHT versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0240"> <p><b>8.1.4 PHT versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0241"> <h6 class="title">8.2 Neural tube malformations</h6> <section id="CD010224-sec-0242"> <p><b>8.2.1 PHT versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 13.17, 95% CI 0.58 to 299.00, I<sup>2</sup> = NA) with no difference in the number of neural tube malformations in children exposed to PHT (N = 48) and control children (N = 590) (<a href="./references#CD010224-fig-0036" title="">Analysis 8.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.06 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0243"> <p><b>8.2.2 PHT versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from six studies suggested no evidence of a difference in risk (RR 2.56, 95% CI 0.64 to 10.17; I<sup>2</sup> = 28%), with no difference in the number of neural tube malformations in children exposed to PHT (N = 252) and control children (N = 595) (<a href="./references#CD010224-fig-0036" title="">Analysis 8.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0244"> <p><b>8.2.3 PHT versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0245"> <p><b>8.2.4 PHT versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0246"> <h6 class="title">8.3 Cardiac malformations</h6> <section id="CD010224-sec-0247"> <p><b>8.3.1 PHT versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 6.31, 95% CI 0.75 to 52.91, I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to PHT (N = 48) and control children (N = 590) (<a href="./references#CD010224-fig-0037" title="">Analysis 8.3</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.05 to 0.08; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0248"> <p><b>8.3.2 PHT versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from seven studies suggested no evidence of a difference in risk (RR 1.86, 95% CI 0.72 to 4.80; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to PHT (N = 253) and control children (N = 599) (<a href="./references#CD010224-fig-0037" title="">Analysis 8.3</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0249"> <p><b>8.3.3 PHT versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0250"> <p><b>8.3.4 PHT versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0251"> <h6 class="title">8.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0252"> <p><b>8.4.1 PHT versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 0.67, 95% CI 0.04 to 12.54, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/ craniofacial malformations in children exposed to PHT (N = 48) and control children (N = 590) (<a href="./references#CD010224-fig-0038" title="">Analysis 8.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.08 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0253"> <p><b>8.4.2 PHT versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from five studies due to no reported oro‐facial cleft/craniofacial malformations in children exposed to PHT (N = 133) and control children (N = 530) (<a href="./references#CD010224-fig-0038" title="">Analysis 8.4</a>). </p> </section> <section id="CD010224-sec-0254"> <p><b>8.4.3 PHT versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0255"> <p><b>8.4.4 PHT versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0256"> <h6 class="title">8.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0257"> <p><b>8.5.1 PHT versus no medication (in women without epilepsy)</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 1.56, 95% CI 0.07 to 37.19, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to PHT (N = 48) and control children (N = 590) (<a href="./references#CD010224-fig-0039" title="">Analysis 8.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.07 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0258"> <p><b>8.5.2 PHT versus no medication (in women with epilepsy)</b></p> <p>Pooled results from six studies suggested no evidence of a difference in risk (RR 1.57, 95% CI 0.31 to 7.95; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to PHT (N = 252) and control children (N = 595) (<a href="./references#CD010224-fig-0039" title="">Analysis 8.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0259"> <p><b>8.5.3 PHT versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0260"> <p><b>8.5.4 PHT versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0261"> <h5 class="title">Phenytoin dose</h5> <p>The majority of included studies did not investigate or formally report on the relationship between the dose of PHT and malformation outcome, with many being limited by included numbers of PHT‐exposed pregnancies. The <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>, based on 416 exposed children, did not find an increased MCM with higher doses of PHT. <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a> with 124 PHT‐exposed children also reported no association with dose. However, in contrast, <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a> reported evidence of an association between PHT dose and MCM prevalence, based on 132 children exposed to monotherapy PHT (no further details given). <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> included 125 pregnancies with PHT exposure and reported a prevalence of 6.4% (95% CI 2.8 to 12.2). They did not investigate within‐group dose associations because of group size but they did report that, in comparison to LTG at doses =/&lt; 325 mg/d, children exposed to PHT at doses between =/&gt; 30 mg/d to 730 mg/d demonstrated no evidence of a difference in risk (OR 1.93, 95% CI 0.78 to 4.75); but this should be considered with caution due to the wide range of PHT doses included. Data from other included studies were limited by group size or dose associations were not reported. </p> </section> </section> <section id="CD010224-sec-0262"> <h4 class="title">Primidone</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to primidone (PRM) (N = 112), based on data from seven studies, was 7.9% (95% CI 2.6 to 21.5). The prevalence of major malformations in routine health record studies for children exposed to PRM (N = 3), was based on data from one study and therefore was not calculated. </p> <section id="CD010224-sec-0263"> <h5 class="title">9 PRM versus controls</h5> <section id="CD010224-sec-0264"> <h6 class="title">9.1 All major malformations</h6> <section id="CD010224-sec-0265"> <p><b>9.1.1 PRM versus no medication (in women without epilepsy): cohort studies</b></p> <p>The results from one study (<a href="./references#CD010224-bbs2-0025" title="Jäger-RomanE , DeichlA , JakobS , HartmannAM , KochS , RatingD , et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Journal of Pediatrics1986;108(6):997-1004. [PMID: 3086531]KochS , Gopfert-GeyerI , Jager-RomanE , JakobS , HuthH , HartmannA , et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development [Antiepileptika wahrend der schwangerschaft. Eine prospektive studie uber schwangerschaftsverlauf, fehlbildungen und kindliche entwicklung]. Deutsche Medizinische Wochenschrift1983;108(7):250-7. [PMID: 6402356]KochS , LöscheG , Jager-RomänE , JakobS , RatingD , DeichlA , et al. Major and minor birth malformations and antiepileptic drugs. Neurology1992;42(4 Suppl 5):83-8. [PMID: 1574183]KuhnzW , Jäger-RomanE , RatingD , DeichlA , KunzeJ , HelgeH , et al. Carbamazepine and carbamazepine-10, -11 epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatric Pharmacology1983;3(3-4):199-208. [PMID: 6677873]KuhnzW , KochS , JakobS , HartmannA , HelgeH , NauH . Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology1984;18(5):671-7. [PMID: 6508976]RatingD , Jager-RomanE , KochS , DeichlA , HartmannH , JakobS , et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. In: NauH , Scott WJ Jr, editors(s). Pharmacokinetics in Teratogenesis. Vol. 1. CRC Press, 1987:205-23. [ISBN: 978-0849368738]RatingD , NauH , Jäger-RomanE , Göpfert-GeyerI , KochS , Beck-MannagettaG , et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia1982;71(2):301-11. [PMID: 7136638]">Koch 1992</a>) suggested no evidence of a difference in risk (RR 0.48, 95% CI 0.03 to 8.43, I<sup>2</sup> = NA) (<a href="./references#CD010224-fig-0040" title="">Analysis 9.1</a>) with no difference in the number of major malformations in children exposed to PRM (N = 21) and control children (N = 116). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.12 to 0.03; I<sup>2</sup> = NA). </p> <p><a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported four cases of major malformations out of 43 PRM‐exposed children (9%). When limited to centres with control children, there were three cases out of 39 exposed children, which suggested no evidence of difference from control children (RR 1.0, 95% CI 0.3 to 3.8). </p> </section> <section id="CD010224-sec-0266"> <p><b>9.1.2 PRM versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from six studies suggested an increased risk with PRM (RR 3.61, 95% CI 1.41 to 9.23; I<sup>2</sup> = 8%), with children exposed to PRM (N = 108) experiencing more major malformations than control children (N = 573) (<a href="./references#CD010224-fig-0040" title="">Analysis 9.1</a>). The RD also suggested a higher risk for PRM (RD 0.07, 95% CI 0.00 to 0.14; I<sup>2</sup> = 11%). </p> </section> <section id="CD010224-sec-0267"> <p><b>9.1.3 PRM versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0268"> <p><b>9.1.4 PRM versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Specific malformation types were not reviewed due to no reported data on these outcomes.</p> </section> </section> </section> <section id="CD010224-sec-0269"> <h5 class="title">Primidone dose</h5> <p>No included studies investigated the dose of PRM and malformation risk.</p> </section> </section> <section id="CD010224-sec-0270"> <h4 class="title">Topiramate</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to topiramate (TPM) (N = 510), based on data from eight studies, was 3.9% (95% CI 2.3 to 6.5). The prevalence of major malformations in routine health record studies for children exposed to TPM (N = 49), based on data from two studies, was 4.1% (95% CI 0.0 to 27,060). </p> <section id="CD010224-sec-0271"> <h5 class="title">10 TPM versus controls</h5> <section id="CD010224-sec-0272"> <h6 class="title">10.1 All major malformations</h6> <section id="CD010224-sec-0273"> <p><b>10.1.1 TPM versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled data from three studies suggested an increased risk with TPM (RR 4.07, 95% CI 1.64 to 10.14; I<sup>2</sup> = 0%), with children exposed to TPM (N = 367) experiencing more major malformations than control children (N = 825) (<a href="./references#CD010224-fig-0041" title="">Analysis 10.1</a>). The RD also suggested a higher risk for TPM (RD 0.03, 95% CI 0.01 to 0.06; I<sup>2</sup> = 0). </p> <p>There was just one case of MCM in 41 monotherapy cases described by the <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>, giving a prevalence of 4.9%, which suggested no difference in risk to control children (3.4%, P value not reported). </p> </section> <section id="CD010224-sec-0274"> <p><b>10.1.2 TPM versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from five studies suggested no evidence of a difference in risk (RR 1.37, 95% CI 0.57 to 3.27; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to TPM (N = 139) and control children (N = 1080) (<a href="./references#CD010224-fig-0041" title="">Analysis 10.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.03 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0275"> <p><b>10.1.3 TPM versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>The results from one study suggested no evidence of a difference in risk (RR 1.65, 95% CI 0.43 to 6.42; I<sup>2</sup> = NA), with children exposed to TPM (N = 48) experiencing comparable rates of major malformations to control children (N = 369,267) (<a href="./references#CD010224-fig-0041" title="">Analysis 10.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.04 to 0.07; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0276"> <p><b>10.1.4 TPM versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>The results from one study suggested no evidence of a difference in risk (RR 1.62, 95% CI 0.40 to 6.45; I<sup>2</sup> = NA), with children exposed to TPM (N = 48) experiencing comparable rates of major malformations to control children (N = 1900) (<a href="./references#CD010224-fig-0041" title="">Analysis 10.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.04 to 0.07; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0277"> <h6 class="title">10.2 Neural tube malformations</h6> <section id="CD010224-sec-0278"> <p><b>10.2.1 TPM versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported neural tube malformations in children exposed to TPM (N = 8) or control children (N = 383) (<a href="./references#CD010224-fig-0042" title="">Analysis 10.2</a>). </p> </section> <section id="CD010224-sec-0279"> <p><b>10.2.2 TPM versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from three studies due to there being no reported neural tube malformations in children exposed to TPM (N = 59) and control children (N = 383) (<a href="./references#CD010224-fig-0042" title="">Analysis 10.2</a>). </p> </section> <section id="CD010224-sec-0280"> <p><b>10.2.3 TPM versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0281"> <p><b>10.2.4 TPM versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0282"> <h6 class="title">10.3 Cardiac malformations</h6> <section id="CD010224-sec-0283"> <p><b>10.3.1 TPM versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled data from two included studies suggested evidence of a difference in risk (RR 20.71, 95% CI 2.64 to 162.72, I<sup>2</sup> = 0%), with children exposed to TPM (N = 8) experiencing more cardiac malformations than control children (N = 383) (<a href="./references#CD010224-fig-0043" title="">Analysis 10.3</a>). However, the RD suggested no difference in the level of risk (RD 0.12, 95% CI −0.16 to 0.39; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0284"> <p><b>10.3.2 TPM versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled data from four included studies suggested no evidence of a difference in risk (RR 2.48, 95% CI 0.49 to 12.49; I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to TPM (N = 60) and control children (N = 510) (<a href="./references#CD010224-fig-0043" title="">Analysis 10.3</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0285"> <p><b>10.3.3 TPM versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0286"> <p><b>10.3.4 TPM versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0287"> <h6 class="title">10.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0288"> <p><b>10.4.1 TPM versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported oro‐facial cleft/ craniofacial malformations in children exposed to TPM (N = 8) or control children (N = 383) (<a href="./references#CD010224-fig-0044" title="">Analysis 10.4</a>). </p> </section> <section id="CD010224-sec-0289"> <p><b>10.4.2 TPM versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled data from three included studies suggested no evidence of a difference in risk (RR 1.50, 95% CI 0.09 to 24.92; I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to TPM (N = 51) and control children (N = 170) (<a href="./references#CD010224-fig-0044" title="">Analysis 10.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.05 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0290"> <p><b>10.4.3 TPM versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome to be included in the meta‐analysis. However, the study by Hernandez‐Diaz and colleagues using <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> could not be included in the meta‐analysis due to a lack of reporting of specific numbers of oral clefts. In comparison to children born to women without epilepsy (N = 1,322,955), the children exposed to TPM (N = 2425) had higher rates of oral clefts of 4.1 per 1000 live births (RR 3.63, 95% CI 1.95 to 6.76). </p> </section> <section id="CD010224-sec-0291"> <p><b>10.4.4 TPM versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0292"> <h6 class="title">10.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0293"> <p><b>10.5.1 TPM versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported skeletal/limb malformations in children exposed to TPM (N = 8) or control children (N = 383) (<a href="./references#CD010224-fig-0045" title="">Analysis 10.5</a>). </p> </section> <section id="CD010224-sec-0294"> <p><b>10.5.2 TPM versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled data from three included studies suggested no evidence of a difference in risk (RR 2.06, 95% CI 0.24 to 17.42; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to TPM (N = 59) and control children (N = 502) (<a href="./references#CD010224-fig-0045" title="">Analysis 10.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.05 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0295"> <p><b>10.5.3 TPM versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0296"> <p><b>10.5.4 TPM versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0297"> <h5 class="title">Topiramate dose</h5> <p>The largest included cohort of TPM‐exposed pregnancies came from the study by Hernandez‐ Diaz using data from the <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> (N = 2425). This register reported the risk of oral clefts for doses ≤ 100 mg/d as 2.4 per 1000 live births, and for doses &gt; 100 mg/d, as 7.3 per 1000 live births. The adjusted values of corresponding adjusted RRs for daily doses ≤ 100 and &gt; 100 mg were 1.64 (95% CI 0.53 to 5.07) and 5.16 (95% CI 1.94 to 13.73) for lower and higher doses, respectively. The data were too limited to provide dose investigations specifically for women with epilepsy, but they did report that higher doses tended to be used for women requiring TPM for the treatment of epilepsy. </p> <p><a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a> found no evidence of a difference in the median dose between TPM‐exposed children (N = 359) who had MCM versus those who did not (P value not reported). The <a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a> (N = 53), did not find a dose association for monotherapy TPM but did see an increase in risk with polytherapy (prevalence not given). The <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a> cohort (N = 70) also failed to find an association between the dose of TPM and the risk of overall MCM. However, caution is required due to smaller numbers from the Epilepsy and Pregnancy Register cohorts currently for monotherapy TPM exposure in pregnancy. </p> </section> </section> <section id="CD010224-sec-0298"> <h4 class="title">Valproate</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to valproate (VPA) (N = 3018), based on data from 31 studies, was 9.8% (95% CI 8.1 to 11.9). The prevalence of major malformations in routine health record studies for children exposed to VPA (N = 1364), based on data from six studies, was 9.7% (95% CI 7.1 to 13.4). </p> <section id="CD010224-sec-0299"> <h5 class="title">11 VPA versus controls</h5> <section id="CD010224-sec-0300"> <h6 class="title">11.1. All major malformations</h6> <section id="CD010224-sec-0301"> <p><b>11.1.1 VPA versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from 10 studies suggested an increased risk with VPA (RR 5.53, 95% CI 3.29 to 9.29; I<sup>2</sup> = 0%), with children exposed to VPA (N = 501) experiencing more major malformations than control children (N = 2634) (<a href="./references#CD010224-fig-0046" title="">Analysis 11.1</a>). The RD also suggested a higher risk for VPA (RD 0.07, 95% CI 0.04 to 0.10; I<sup>2</sup> = 40%). </p> <p>Data from the <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a> study, including women treated with VPA for epilepsy and other indications (restricted to monotherapy), reported major congenital malformations (MCM) in 3/89 (3.4%) VPA‐treated cases compared with 31/1236 (2.5%) of control children. <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported 16 cases of major malformations out of 184 (9%) VPA‐exposed children. When limited to the two sites with control children, investigators reported six cases with malformation out of 21 children exposed to VPA, which was higher than control children (RR 4.9, 95% CI 1.6 to 15.0). </p> </section> <section id="CD010224-sec-0302"> <p><b>11.1.2 VPA versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from 17 studies suggested an increased risk with VPA (RR 2.77, 95% CI 2.03 to 3.79; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2288) experiencing more major malformations than control children (N = 1710) (<a href="./references#CD010224-fig-0046" title="">Analysis 11.1</a>). The RD also suggested a higher risk for VPA (RD 0.06, 95% CI 0.04 to 0.07; I<sup>2</sup> = 32%). </p> </section> <section id="CD010224-sec-0303"> <p><b>11.1.3 VPA versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>Pooled results from three studies suggested an increased risk with VPA (RR 2.29, 95% CI 1.71 to 3.08; I<sup>2</sup> = 0%), with children exposed to VPA (N = 621) experiencing more major malformations than control children (N = 373,028) (<a href="./references#CD010224-fig-0046" title="">Analysis 11.1</a>). The RD also suggested a higher risk for VPA (RD 0.04, 95% CI 0.02 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0304"> <p><b>11.1.4 VPA versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>Pooled results from four studies suggested an increased risk with VPA (RR 3.01, 95% CI 2.42 to 3.75; I<sup>2</sup> = 55%), with children exposed to VPA (N = 1151) experiencing more major malformations than control children (N = 12,218) (<a href="./references#CD010224-fig-0046" title="">Analysis 11.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which found a similar result (RR 2.97, 95% CI 2.08 to 4.24, I<sup>2</sup> =55%). The RD also suggested a higher risk for VPA (RD 0.06, 95% CI 0.05 to 0.08; I<sup>2</sup> = 81%). Due to high heterogeneity, a random‐effects RD was calculated which found a similar result (RD 0.06, 95% CI 0.02 to 0.10, I<sup>2</sup> =85%). </p> </section> </section> <section id="CD010224-sec-0305"> <h6 class="title">11.2 Neural tube malformations</h6> <section id="CD010224-sec-0306"> <p><b>11.2.1 VPA versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 6.05, 95% CI 0.94 to 38.81; I<sup>2</sup> = 20%), with no difference in the number of neural tube malformations in children exposed to VPA (N = 104) and control children (N = 836) (<a href="./references#CD010224-fig-0047" title="">Analysis 11.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0307"> <p><b>11.2.2 VPA versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from eight studies suggested an increased risk with VPA (RR 5.64, 95% CI 1.37 to 23.24; I<sup>2</sup> = 0%), with a higher number of neural tube malformations in children exposed to VPA (N = 814) than in control children (N = 664) (<a href="./references#CD010224-fig-0047" title="">Analysis 11.2</a>). The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.01 to 0.03; I<sup>2</sup> = 6%). </p> </section> <section id="CD010224-sec-0308"> <p><b>11.2.3 VPA versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0309"> <p><b>11.2.4 VPA versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>Data from one study suggested an increased risk with VPA (RR 8.02, 95% CI 1.48 to 43.50, I<sup>2</sup> = NA), with a higher number of neural tube malformations in children exposed to VPA (N = 225) than in control children (N = 902) (<a href="./references#CD010224-fig-0047" title="">Analysis 11.2</a>). The RD also suggested a higher risk for VPA (RD 0.02, 95% CI −0.00 to 0.03; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0310"> <h6 class="title">11.3 Cardiac malformations</h6> <section id="CD010224-sec-0311"> <p><b>11.3.1 VPA versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested an increased risk with VPA (RR 11.89 95% CI 2.88 to 49.08; I<sup>2</sup> = 0%), with children exposed to VPA (N = 104) experiencing more cardiac malformations than control children (N = 836) (<a href="./references#CD010224-fig-0048" title="">Analysis 11.3</a>). However, the RD suggested no difference in the level of risk (RD 0.04, 95% CI −0.00 to 0.09; I<sup>2</sup> = 28%). </p> </section> <section id="CD010224-sec-0312"> <p><b>11.3.2 VPA versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from 10 studies suggested an increased risk with VPA (RR 2.71, 95% CI 1.42 to 5.17; I<sup>2</sup> = 0%), with a higher number of cardiac malformations in children exposed to VPA (N = 821) than in control children (N = 676) (<a href="./references#CD010224-fig-0048" title="">Analysis 11.3</a>). The RD also suggested a higher risk for VPA (RD 0.03, 95% CI 0.01 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0313"> <p><b>11.2.3 VPA versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0314"> <p><b>11.2.4 VPA versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0315"> <h6 class="title">11.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0316"> <p><b>11.4.1 VPA versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 2.76, 95% CI 0.31 to 24.78; I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to VPA (N = 104) and control children (N = 836) (<a href="./references#CD010224-fig-0049" title="">Analysis 11.4</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0317"> <p><b>11.4.2 VPA versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from eight studies suggested an increased risk with VPA (RR 4.44, 95% CI 1.14 to 17.27; I<sup>2</sup> = 2%), with more children exposed to VPA (N = 474) experiencing oro‐facial cleft/craniofacial malformations than control children (N = 332) (<a href="./references#CD010224-fig-0049" title="">Analysis 11.4</a>). The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.00 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0318"> <p><b>11.4.3 VPA versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0319"> <p><b>11.4.4 VPA versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0320"> <h6 class="title">11.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0321"> <p><b>11.5.1 VPA versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled results from four studies suggested an increased risk with VPA (RR 16.48, 95% CI 2.46 to 110.49; I<sup>2</sup> = 0%), with children exposed to VPA (N = 104) experiencing more skeletal/limb malformations than control children (N = 836) (<a href="./references#CD010224-fig-0050" title="">Analysis 11.5</a>). However, the RD suggested no difference in the level of risk (RD 0.03, 95% CI −0.01 to 0.07; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0322"> <p><b>11.5.2 VPA versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled results from eight studies suggested no evidence of a difference in risk (RR 2.38, 95% CI 0.93 to 6.12; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to VPA (N = 814) and control children (N = 664) (<a href="./references#CD010224-fig-0050" title="">Analysis 11.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.00 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0323"> <p><b>11.5.3 VPA versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0324"> <p><b>11.5.4 VPA versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0325"> <h5 class="title">Valproate dose</h5> <p>In contrast to the results on dosage for the other AEDs, for VPA there appears to be a consistently documented and clear association between increased dose and the risk for MCM in VPA‐exposed children. <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> reported evidence that suggested a dose‐related MCM risk for VPA exposure. In 1381 exposed pregnancies, the MCM risk ranged from 6.3% (95% CI 4.5 to 8.6%) for doses =/&lt; 650 mg/d, to 11.3% for doses &gt; 650 mg/d to =/&lt; 1450 mg/day and, most concerning, 25.2% (95% CI 17.6 to 34.2) for doses &gt; 1450 mg/d. Doses of VPA =/&lt; 650 mg/d (OR 2.70, 95% CI 1.67 to 4.38, P = 0.0002), doses &gt; 650 mg/d to =/&lt; 1450 mg/day (OR 4.72, 95% CI 3.11 to 7.18, P = 0.0002) and doses &gt; 1450 mg/d (OR 13.52, 95% CI 7.73 to 23.64, P = 0.0002) were all associated with higher risk than LTG exposure at doses &lt; 325 mg/d. Similarly, doses of &gt; 650 mg/d to =/&lt; 1450 mg/day (OR 2.81, 95% CI 1.70 to 4.65, P = 0.0002) had higher risk than LTG &gt; 325 mg/d. The highest level of VPA exposure was not statistically compared to LTG doses &gt; 325 mg/d, but there was a large difference in prevalence (25.2% vs 4.3%). The lowest doses of VPA investigated (=/&lt; 650 mg/d) were not associated with a lower MCM risk than higher doses (&gt; 325 mg/d) of LTG (OR 0.62, 95% CI 0.36 to 1.09, P = 0.0959). </p> <p>In the <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a> (N = 1220), an increase in malformation from 5.0% at doses &lt; 600 mg/d to 10.4% for doses &gt; 1000 mg/d (OR 2.20 95% CI 1.26 to 3.82, P = 0.0045) was reported. The <a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a> cohort also demonstrated an association with VPA (N = 290), as did the <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a> (N = 323), where investigators reported the median daily dose in VPA‐exposed children with a malformation to be 1000 mg/d compared with children exposed to VPA without an MCM (750 mg/d). The <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a> reported a prevalence of MCM of 3.0% for doses of VPA =/&lt; 400 mg/d, 9.5% for doses between &gt; 400 to 800 mg/d, and 28.6% for doses over 800 mg/d. Smaller studies including VPA‐exposed children also reported data showing an association between VPA dose or serum levels and increased MCM rate (<a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0026" title="LindhoutD , HöppenerRJ , MeinardiH . Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia1984;25(1):77-83. [PMID: 6692794]LindhoutD , MeinardiH , MeijerJW , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42(4 Suppl 5):94-110. [PMID: 1574185]">Lindhout 1992</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>). <a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a> was the only smaller study that investigated a dose‐response association without finding a positive correlation (N = 61 VPA‐exposed pregnancies). </p> <p>Investigations from studies using population health record data are fewer, due to the lack of dose information available for the <a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>, <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>, and the absence of dose information for the <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a> or <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a> at this time. Putignano and colleagues 2019, using the <a href="./references#CD010224-bbs2-0018" title="PutignanoD , ClavennaA , CampiR , CaneviniMP , VignoliA , BattinoD , et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy &amp; Behavior2019;92:14-7. [PMID: 30599457]">Italian Lombardy Region Health Register</a>, reported that children with MCMs had a higher dose of VPA. </p> </section> </section> <section id="CD010224-sec-0326"> <h4 class="title">Zonisamide</h4> <p>The prevalence of major malformations (any type) in cohort studies for children exposed to zonisamide (ZNS) (N = 130), based on data from four studies, was 2.7% (95% CI 0.1 to 47.3). There were no children exposed to ZNS in routine health record studies, therefore, the prevalence of major malformations rated could not be calculated. </p> <section id="CD010224-sec-0327"> <h5 class="title">12 ZNS versus controls</h5> <section id="CD010224-sec-0328"> <h6 class="title">12.1. All major malformations</h6> <section id="CD010224-sec-0329"> <p><b>12.1.1 ZNS versus no medication (in women without epilepsy): cohort studies</b></p> <p>Pooled data from two studies suggested no evidence of a difference in risk (RR 1.13, 95% CI 0.21 to 6.11; I<sup>2</sup> = 36%), with no difference in the number of major malformations in children exposed to ZNS (N = 103) and control children (N = 548) (<a href="./references#CD010224-fig-0051" title="">Analysis 12.1</a>). The RD also suggested no difference in the level of risk (RD −0.00, 95% CI −0.03 to 0.02; I<sup>2</sup> = 39%). </p> </section> <section id="CD010224-sec-0330"> <p><b>12.1.2 ZNS versus no medication (in women with epilepsy): cohort studies</b></p> <p>Pooled data from two studies suggested an increased risk with ZNS (RR 3.20, 95% CI 1.09 to 9.43; I<sup>2</sup> = 0%), with a higher number of major malformations in children exposed to ZNS (N = 39) than in control children (N = 556) (<a href="./references#CD010224-fig-0051" title="">Analysis 12.1</a>). However, the RD suggested no difference in the level of risk (RD 0.07, 95% CI −0.03 to 0.18; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0331"> <p><b>12.1.3 ZNS versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0332"> <p><b>12.1.4 ZNS versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0333"> <h6 class="title">12.2. Neural tube malformations</h6> <section id="CD010224-sec-0334"> <p><b>12.2.1 ZNS versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one included study due to there being no reported neural tube malformations in children exposed to ZNS (N = 13) or control children (N = 106) (<a href="./references#CD010224-fig-0052" title="">Analysis 12.2</a>). </p> </section> <section id="CD010224-sec-0335"> <p><b>12.2.2 ZNS versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one included study due to there being no reported neural tube malformations in children exposed to ZNS (N = 13) or control children (N = 15) (<a href="./references#CD010224-fig-0052" title="">Analysis 12.2</a>). </p> </section> <section id="CD010224-sec-0336"> <p><b>12.2.3 ZNS versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0337"> <p><b>12.2.4 ZNS versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0338"> <h6 class="title">12.3 Cardiac malformations</h6> <section id="CD010224-sec-0339"> <p><b>12.3.1 ZNS versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one included study due to there being no reported cardiac malformations in children exposed to ZNS (N = 13) or control children (N = 106) (<a href="./references#CD010224-fig-0053" title="">Analysis 12.3</a>). </p> </section> <section id="CD010224-sec-0340"> <p><b>12.3.2 ZNS versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one included study due to there being no reported cardiac malformations in children exposed to ZNS (N = 13) or control children (N = 15) (<a href="./references#CD010224-fig-0053" title="">Analysis 12.3</a>). </p> </section> <section id="CD010224-sec-0341"> <p><b>12.3.3 ZNS versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0342"> <p><b>12.3.4 ZNS versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0343"> <h6 class="title">12.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0344"> <p><b>12.4.1 ZNS versus no medication (in women without epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one included study due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to ZNS (N = 13) or control children (N = 106) (<a href="./references#CD010224-fig-0054" title="">Analysis 12.4</a>). </p> </section> <section id="CD010224-sec-0345"> <p><b>12.4.2 ZNS versus no medication (in women with epilepsy): cohort studies</b></p> <p>We were unable to estimate a RR from one included study due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to ZNS (N = 13) or control children (N = 15) (<a href="./references#CD010224-fig-0054" title="">Analysis 12.4</a>). </p> </section> <section id="CD010224-sec-0346"> <p><b>12.4.3 ZNS versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0347"> <p><b>12.4.4 ZNS versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0348"> <h6 class="title">12.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0349"> <p><b>12.5.1 ZNS versus no medication (in women without epilepsy)</b></p> <p>We were unable to estimate a RR from one included study due to there being no skeletal/limb malformations in children exposed to ZNS (N = 13) or control children (N = 106) (<a href="./references#CD010224-fig-0055" title="">Analysis 12.5</a>). </p> </section> <section id="CD010224-sec-0350"> <p><b>12.5.2 ZNS versus no medication (in women with epilepsy)</b></p> <p>We were unable to estimate a RR from one included study due to there being no reported skeletal/limb malformations in children exposed to ZNS (N = 13) or control children (N = 15) (<a href="./references#CD010224-fig-0055" title="">Analysis 12.5</a>). </p> </section> <section id="CD010224-sec-0351"> <p><b>12.5.3 ZNS versus no medication (in women without epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0352"> <p><b>12.5.4 ZNS versus no medication (in women with epilepsy): routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0353"> <h5 class="title">Zonisamide dose</h5> <p>No included study investigated a potential association between ZNS and malformation risk. </p> </section> </section> <section id="CD010224-sec-0354"> <h4 class="title">ASM versus ASM comparisons</h4> <section id="CD010224-sec-0355"> <h5 class="title">13 CBZ versus CZP</h5> <section id="CD010224-sec-0356"> <h6 class="title">13.1. All major malformations</h6> <section id="CD010224-sec-0357"> <p><b>13.1.1 Cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 1.82, 95% CI 0.63 to 5.26; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CBZ (N = 1311) and children exposed to CZP (N = 95) (<a href="./references#CD010224-fig-0056" title="">Analysis 13.1</a>). However, the RD suggested a higher risk for CBZ (RD 0.04, 95% CI ‐0.00 to 0.08; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0358"> <p><b>13.1.2 Routine health record data studies</b></p> <p>Pooled data from two studies suggested no evidence of a difference in risk (RR 1.29, 95% CI 0.47 to 3.51; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CBZ (N = 1388) and children exposed to CZP (N = 161). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.00 to 0.04; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0359"> <h6 class="title">13.2 Neural tube malformations</h6> <section id="CD010224-sec-0360"> <p><b>13.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0361"> <p><b>13.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0362"> <h6 class="title">13.3 Cardiac malformations</h6> <section id="CD010224-sec-0363"> <p><b>13.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0364"> <p><b>13.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0365"> <h6 class="title">13.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0366"> <p><b>13.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0367"> <p><b>13.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0368"> <h6 class="title">13.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0369"> <p><b>13.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0370"> <p><b>13.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0371"> <h5 class="title">14 CBZ versus GBP</h5> <section id="CD010224-sec-0372"> <h6 class="title">14.1. All major malformations</h6> <section id="CD010224-sec-0373"> <p><b>14.1.1 Cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk(RR 1.55, 95% CI 0.57 to 4.26; I<sup>2</sup> = 47%), with no difference in the number of major malformations in children exposed to CBZ (N = 3112) and children exposed to GBP (N = 192) (<a href="./references#CD010224-fig-0057" title="">Analysis 14.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.00 to 0.04; I<sup>2</sup> = 42%). </p> </section> <section id="CD010224-sec-0374"> <p><b>14.1.2 Routine health record data studies</b></p> <p>Data from one study suggested no evidence of a difference in risk (RR 1.54, 95% CI 0.10 to 24.27; I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to CBZ (N = 703) and children exposed to GBP (N = 18) (<a href="./references#CD010224-fig-0057" title="">Analysis 14.1</a>). The RD also suggested no difference in the level of risk (RD 0.04, 95% CI ‐0.03 to 0.11; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0375"> <h6 class="title">14.2 Neural tube malformations</h6> <section id="CD010224-sec-0376"> <p><b>14.2.1 Cohort studies</b></p> <p>Data from one included study suggested no evidence of a difference in risk (RR 0.12, 95% CI 0.01 to 2.93, I<sup>2</sup> = NA) with no difference in the number of neural tube malformations in children exposed to CBZ (N= 361) and GBP‐exposed children (N = 14) (<a href="./references#CD010224-fig-0058" title="">Analysis 14.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.09 to 0.09; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0377"> <p><b>14.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0378"> <h6 class="title">14.3 Cardiac malformations</h6> <section id="CD010224-sec-0379"> <p><b>14.3.1 Cohort studies</b></p> <p>Pooled results from two studies suggest n increased in risk (RR 0.13, 95% CI 0.02 to 0.95, I<sup>2</sup> = 0%) with children exposed to GBP (N = 16) being at a higher risk of cardiac malformation than children exposed to CBZ (N = 374)(<a href="./references#CD010224-fig-0059" title="">Analysis 14.3</a>). However, the RD also suggested no difference in the level of risk (RD ‐0.05, 95% CI −0.18 to 0.08; I<sup>2</sup> = 74%). </p> </section> <section id="CD010224-sec-0380"> <p><b>14.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0381"> <h6 class="title">14.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0382"> <p><b>14.4.1 Cohort studies</b></p> <p>Results from one included study suggested no evidence of a difference in risk (RR 0.37, 95% CI 0.02 to 6.62, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to CBZ (N = 361) and children exposed to GBP (N = 14) (<a href="./references#CD010224-fig-0060" title="">Analysis 14.4</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.08 to 0.10; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0383"> <p><b>14.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0384"> <h6 class="title">14.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0385"> <p><b>14.5.1 Cohort studies</b></p> <p>Results from one included study suggest no evidence of a difference in risk (RR 0.21, 95% CI 0.01 to 4.13, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to CBZ (N = 361) and children exposed to GBP (N = 14) (<a href="./references#CD010224-fig-0061" title="">Analysis 14.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.09 to 0.10; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0386"> <p><b>14.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0387"> <h5 class="title">15 CBZ versus LEV</h5> <section id="CD010224-sec-0388"> <h6 class="title">15.1. All major malformations</h6> <section id="CD010224-sec-0389"> <p><b>15.1.1 Cohort studies</b></p> <p>Pooled results from 11 studies suggested an increased risk with CBZ(RR 1.51, 95% CI 1.01 to 2.26; I<sup>2</sup> = 0%), with more children exposed to CBZ (N = 3814) experiencing major malformations than children exposed to LEV (N = 1242) (<a href="./references#CD010224-fig-0062" title="">Analysis 15.1</a>). The RD also suggested a higher risk for CBZ (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 2.8% (95% CI 1.7 to 4.5) for children exposed to LEV. No direct statistical comparison was made at the group level, investigations were made across different doses of the two ASMs (see Carbamazepine dose and Levetiracetam dose sections). </p> </section> <section id="CD010224-sec-0390"> <p><b>15.1.2 Routine health record data studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 1.73, 95% CI 0.78 to 3.83; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CBZ (N = 1000) and children exposed to LEV (N = 248) (<a href="./references#CD010224-fig-0062" title="">Analysis 15.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.00 to 0.04; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0391"> <h6 class="title">15.2 Neural tube malformations</h6> <section id="CD010224-sec-0392"> <p><b>15.2.1 Cohort studies</b></p> <p>Pooled results from 10 studies suggested no evidence of a difference in risk (RR 1.57, 95% CI 0.41 to 6.08; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 3731) and children exposed to LEV (N = 1148) (<a href="./references#CD010224-fig-0063" title="">Analysis 15.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.01; I<sup>2</sup> = 0%). </p> <p><a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> reported a prevalence of 0.35% (7/1957) for cases of neural tube anomaly in children exposed to CBZ and 0% (0/599) in children exposed to LEV. </p> </section> <section id="CD010224-sec-0393"> <p><b>15.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0394"> <h6 class="title">15.3 Cardiac malformations</h6> <section id="CD010224-sec-0395"> <p><b>15.3.1 Cohort studies</b></p> <p>Pooled results from 11 studies suggested no evidence of a difference in risk (RR 1.20, 95% CI 0.57 to 2.52; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to CBZ (N = 3736) and children exposed to LEV (N = 1156) (<a href="./references#CD010224-fig-0064" title="">Analysis 15.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p><a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> reported a prevalence of 1.4% (28/1957) for cases of a cardiac anomaly in children exposed to CBZ and 0.8% (5/599) in children exposed to LEV. </p> </section> <section id="CD010224-sec-0396"> <p><b>15.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0397"> <h6 class="title">15.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0398"> <p><b>15.4.1 Cohort studies</b></p> <p>Pooled results from 10 studies suggested no evidence of a difference in risk (RR 1.79, 95% CI 0.43 to 7.41; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to CBZ (N = 3246) and children exposed to LEV (N = 1050) (<a href="./references#CD010224-fig-0065" title="">Analysis 15.4</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.01; I<sup>2</sup> = 0%). </p> <p><a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> reported two cases of cleft lip or palate anomaly out of 1957 children exposed to CBZ and one case out of 599 children exposed to LEV. </p> </section> <section id="CD010224-sec-0399"> <p><b>15.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0400"> <h6 class="title">15.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0401"> <p><b>15.5.1 Cohort studies</b></p> <p>Pooled results from 10 studies suggested no evidence of a difference in risk (RR 0.99, 95% CI 0.37 to 2.68; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to CBZ (N = 3731) and children exposed to LEV (N = 1147) (<a href="./references#CD010224-fig-0066" title="">Analysis 15.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0402"> <p><b>15.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0403"> <h5 class="title">16 CBZ versus LTG</h5> <section id="CD010224-sec-0404"> <h6 class="title">16.1. All major malformations</h6> <section id="CD010224-sec-0405"> <p><b>16.1.1: Cohort studies</b></p> <p>Pooled results from 13 cohort studies suggested an increased risk with CBZ (RR 1.37, 95% CI 1.06 to 1.77; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 4018) experiencing more major malformations than children exposed to LTG (N = 4550) (<a href="./references#CD010224-fig-0067" title="">Analysis 16.1</a>). The RD also suggested a higher risk for CBZ (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 2.9% (95% CI 2.3 to 3.7) for children exposed to LTG. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Carbamazepine dose and Lamotrigine dose sections). </p> </section> <section id="CD010224-sec-0406"> <p><b>16.1.2: Routine health record studies</b></p> <p>Pooled results from four routine health record studies suggested no evidence of a difference in risk (RR 1.21, 95% CI 0.88 to 1.67; I<sup>2</sup> = 21%), with no difference in the number of major malformations in children exposed to CBZ (N = 2001) and LTG (N = 2502) (<a href="./references#CD010224-fig-0067" title="">Analysis 16.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 25%). </p> </section> </section> <section id="CD010224-sec-0407"> <h6 class="title">16.2. Neural tube malformations</h6> <section id="CD010224-sec-0408"> <p><b>16.2.1: Cohort studies</b></p> <p>Pooled results from 12 cohort studies suggested no evidence of a difference in risk (RR 2.19, 95% CI 0.76 to 6.33; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 3935) and children exposed to LTG (N = 4406) (<a href="./references#CD010224-fig-0068" title="">Analysis 16.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube malformations in those exposed to CBZ was 0.36% (7/1957) and 0.04% for those exposed to LTG (1/2514). </p> </section> <section id="CD010224-sec-0409"> <p><b>16.2.2: Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0410"> <h6 class="title">16.3. Cardiac malformations</h6> <section id="CD010224-sec-0411"> <p><b>16.3.1: Cohort studies</b></p> <p>Pooled results from 12 cohort studies suggested no evidence of a difference in risk (RR 1.48, 95% CI 0.87 to 2.51; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to CBZ (N = 3933) and children exposed to LTG (N = 4407) (<a href="./references#CD010224-fig-0069" title="">Analysis 16.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac malformations in those exposed to CBZ was 1.43% (28/1957) and 0.59% (15/2514) for those exposed to lamotrigine. </p> </section> <section id="CD010224-sec-0412"> <p><b>16.3.2: Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0413"> <h6 class="title">16.4. Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0414"> <p><b>16.4.1: Cohort studies</b></p> <p>Pooled results from 11 studies suggested no evidence of a difference in risk (RR 1.22, 95% CI 0.57 to 2.61; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to CBZ (N = 3443) and children exposed to LTG (N = 4357) (<a href="./references#CD010224-fig-0070" title="">Analysis 16.4</a>). However, only three studies contained occurrences of oro‐facial cleft/craniofacial malformations. The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.11% for children exposed to LTG (3/2514). </p> </section> <section id="CD010224-sec-0415"> <p><b>16.4.2: Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0416"> <h6 class="title">16.5. Skeletal/limb malformations</h6> <section id="CD010224-sec-0417"> <p><b>16.5.1: Cohort studies</b></p> <p>Pooled results from 12 cohort studies suggested no evidence of a difference in risk (RR 1.86, 95% CI 0.82 to 4.22; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to CBZ (N = 3935) and children exposed to LTG (N = 4406) (<a href="./references#CD010224-fig-0071" title="">Analysis 16.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0418"> <p><b>16.5.2: Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0419"> <h5 class="title">17 CBZ versus OXC</h5> <section id="CD010224-sec-0420"> <h6 class="title">17.1. All major malformations</h6> <section id="CD010224-sec-0421"> <p><b>17.1.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested no evidence of a difference in risk (RR 1.26, 95% CI 0.74 to 2.15; I<sup>2</sup> = 20%), with no difference in the number of major malformations in children exposed to CBZ (N = 2499) and children exposed to OXC (N = 378) (<a href="./references#CD010224-fig-0072" title="">Analysis 17.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.03; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Carbamazepine dose and Oxcarbazepine dose sections). </p> </section> <section id="CD010224-sec-0422"> <p><b>17.1.2 Routine health record data studies</b></p> <p>Pooled results from four routine data suggested an increased risk with CBZ (RR 0.64, 95% CI 0.44 to 0.91; I<sup>2</sup> = 89%), with children exposed to CBZ (N = 2508) experiencing more malformations than the children exposed to OXC (N = 507) (<a href="./references#CD010224-fig-0072" title="">Analysis 17.1</a>). Due to heterogeneity, a random‐effects RR was calculated which found no difference in risk (RR 0.75, 95% CI 0.15 to 3.72; I<sup>2</sup> = 89%). The RD also suggested no difference in the level of risk (RD ‐0.03, 95% CI ‐0.06 to 0.00, I<sup>2</sup> = 89%). Due to heterogeneity, a random‐effects RD was calculated which upheld similar findings (RD ‐0.02, 95% CI ‐0.11 to 0.07; I<sup>2</sup> = 89%). </p> </section> </section> <section id="CD010224-sec-0423"> <h6 class="title">17.2 Neural tube malformations</h6> <section id="CD010224-sec-0424"> <p><b>17.2.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 0.93, 95% CI 0.22 to 3.96; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 2403) and children exposed to OXC (N = 364) (<a href="./references#CD010224-fig-0073" title="">Analysis 17.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0% for children exposed to OXC (0/333). </p> </section> <section id="CD010224-sec-0425"> <p><b>17.2.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0426"> <h6 class="title">17.3 Cardiac malformations</h6> <section id="CD010224-sec-0427"> <p><b>17.3.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested no evidence of a difference in risk (RR 0.56, 95% CI 0.23 to 1.38; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to CBZ (N = 2421) and children exposed to OXC (N = 368) (<a href="./references#CD010224-fig-0074" title="">Analysis 17.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 1.2% for children exposed to OXC (4/333). </p> </section> <section id="CD010224-sec-0428"> <p><b>17.3.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0429"> <h6 class="title">17.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0430"> <p><b>17.4.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 0.52, 95% CI 0.12 to 2.26; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to CBZ (N = 1918) and children exposed to OXC (N = 296) (<a href="./references#CD010224-fig-0075" title="">Analysis 17.4</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.30% for children exposed to OXC (1/333). </p> </section> <section id="CD010224-sec-0431"> <p><b>17.4.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0432"> <h6 class="title">17.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0433"> <p><b>17.5.1 Cohort studies</b></p> <p>Pooled results from nine studies suggested no evidence of a difference in risk (RR 0.53, 95% CI 0.17 to 1.66; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to CBZ (N = 2403) and children exposed to OXC (N = 364) (<a href="./references#CD010224-fig-0076" title="">Analysis 17.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0434"> <p><b>17.5.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0435"> <h5 class="title">18 CBZ versus PB</h5> <section id="CD010224-sec-0436"> <h6 class="title">18.1 All major malformations</h6> <section id="CD010224-sec-0437"> <p><b>18.1.1. Cohort studies</b></p> <p>Pooled results from 24 cohort studies suggested no evidence of a difference in risk (RR 0.83, 95% CI 0.61 to 1.13; I<sup>2</sup> = 3%), with no difference in the number of major malformations in children exposed to CBZ (N = 3235) and children exposed to PB (N = 832) (<a href="./references#CD010224-fig-0077" title="">Analysis 18.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.03 to 0.01; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 6.5% (95% CI 4.2 to 9.9) for children exposed to PB. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Carbamazepine dose and Phenobarbital dose sections). <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported 22 major malformation cases in 280 (8%) CBZ‐exposed children and five cases in 48 (10%) PB‐exposed children. </p> </section> <section id="CD010224-sec-0438"> <p><b>18.1.2 Routine health record data studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 0.35, 95% CI 0.12 to 1.09; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CBZ (N = 1388) and children exposed to PB (N = 34) (<a href="./references#CD010224-fig-0077" title="">Analysis 18.1</a>). The RD also suggested no difference in the level of risk (RD −0.06, 95% CI −0.15 to 0.04; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0439"> <h6 class="title">18.2 Neural tube malformations</h6> <section id="CD010224-sec-0440"> <p><b>18.2.1 Cohort studies</b></p> <p>Pooled results from 15 cohort studies suggested no evidence of a difference in risk (RR 1.28, 95% CI 0.35 to 4.75; I<sup>2</sup> = 32%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 2340) and children exposed to PB (N = 550) (<a href="./references#CD010224-fig-0078" title="">Analysis 18.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0.68% for children exposed to PB (2/294). </p> </section> <section id="CD010224-sec-0441"> <p><b>18.2.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0442"> <h6 class="title">18.3 Cardiac malformations</h6> <section id="CD010224-sec-0443"> <p><b>18.3.1 Cohort studies</b></p> <p>Pooled results from 15 cohort studies suggested an increased risk with PB (RR 0.26, 95% CI 0.14 to 0.47; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 2340) experiencing fewer cardiac malformations than children exposed to PB (N = 550) (<a href="./references#CD010224-fig-0081" title="">Analysis 18.5</a>). The RD also suggested a higher risk for PB (RD ‐0.03, 95% CI ‐0.05 to ‐0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 2.7% for children exposed to PB (8/333). </p> </section> <section id="CD010224-sec-0444"> <p><b>18.3.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0445"> <h6 class="title">18.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0446"> <p><b>18.4.1 Cohort studies</b></p> <p>Pooled results from 15 cohort studies suggested an increased risk with PB (RR 0.18, 95% CI 0.07 to 0.48; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 1857) experiencing fewer oro‐facial cleft/craniofacial malformations than children exposed to PB (N = 422) (<a href="./references#CD010224-fig-0080" title="">Analysis 18.4</a>). The RD suggested no difference in the level of risk for PB (RD ‐0.01, 95% CI ‐0.03 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.34% for children exposed to PB (1/294). </p> </section> <section id="CD010224-sec-0447"> <p><b>18.4.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0448"> <h6 class="title">18.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0449"> <p><b>18.5.1 Cohort studies</b></p> <p>Pooled results from 15 cohort studies suggested no evidence of a difference in risk (RR 1.08, 95% CI 0.45 to 2.61; I<sup>2</sup> = 6%), with no difference in the number of skeletal/limb malformations in children exposed to CBZ (N = 2340) and children exposed to PB (N = 550) (<a href="./references#CD010224-fig-0081" title="">Analysis 18.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0450"> <p><b>18.5.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0451"> <h5 class="title">19 CBZ versus PHT</h5> <section id="CD010224-sec-0452"> <h6 class="title">19.1 All major malformations</h6> <section id="CD010224-sec-0453"> <p><b>19.1.1 Cohort studies</b></p> <p>Pooled results from 23 cohort studies suggested no evidence of a difference in risk (RR 0.83, 95% CI 0.62 to 1.11; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CBZ (N = 4759) and children exposed to PHT (N = 1287) (<a href="./references#CD010224-fig-0082" title="">Analysis 19.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.02 to 0.01; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 6.4% (95% CI 2.8 to 12.2) for children exposed to PHT. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Carbamazepine dose and Phenytoin dose sections). <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported 22 cases of major malformation out of 280 (8%) CBZ‐exposed children and 9 cases from 141 PHT‐exposed children (9%). </p> </section> <section id="CD010224-sec-0454"> <p><b>19.1.2 Routine health record data studies</b></p> <p>Results from one routine health record data study suggested no evidence of a difference in risk (RR 0.59, 95% CI 0.26 to 1.31; I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to CBZ (N = 703) and children exposed to PHT (N = 103) (<a href="./references#CD010224-fig-0082" title="">Analysis 19.1</a>). The RD also suggested no difference in the level of risk (RD −0.03, 95% CI −0.08 to 0.02; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0455"> <h6 class="title">19.2 Neural tube malformations</h6> <section id="CD010224-sec-0456"> <p><b>19.2.1 Cohort studies</b></p> <p>Pooled results from 16 cohort studies suggested no evidence of a difference in risk (RR 1.12, 95% CI 0.45 to 2.83; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 4341) and children exposed to PHT (N = 1005) (<a href="./references#CD010224-fig-0083" title="">Analysis 19.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0.80% for children exposed to PB (1/125). </p> </section> <section id="CD010224-sec-0457"> <p><b>19.2.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0458"> <h6 class="title">19.3 Cardiac malformations</h6> <section id="CD010224-sec-0459"> <p><b>19.3.1 Cohort studies</b></p> <p>Pooled results from 16 cohort studies suggested an increased risk with PHT (RR 0.44, 95% CI 0.23 to 0.84; I<sup>2</sup> = 8%), with fewer cardiac malformations in children exposed to CBZ (N = 4341) than in children exposed to PHT (N = 1005) (<a href="./references#CD010224-fig-0084" title="">Analysis 19.3</a>). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.02 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 4% for children exposed to PHT (5/125). </p> </section> <section id="CD010224-sec-0460"> <p><b>19.3.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0461"> <h6 class="title">19.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0462"> <p><b>19.4.3 Cohort studies</b></p> <p>Pooled results from 16 cohort studies suggested no evidence of a difference in risk (RR 0.81, 95% CI 0.32 to 2.08; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to CBZ (N = 3858) and children exposed to PHT (N = 891) (<a href="./references#CD010224-fig-0085" title="">Analysis 19.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0% for children exposed to PHT (0/125). </p> </section> <section id="CD010224-sec-0463"> <p><b>19.4.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0464"> <h6 class="title">19.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0465"> <p><b>19.5.1 Cohort studies</b></p> <p>Pooled results from 16 cohort studies suggested no evidence of a difference in risk (RR 0.88, 95% CI 0.43 to 1.82; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to CBZ (N = 4341) and children exposed to PHT (N = 1005) (<a href="./references#CD010224-fig-0086" title="">Analysis 19.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0466"> <p><b>19.5.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0467"> <h5 class="title">20 CBZ versus PRM</h5> <section id="CD010224-sec-0468"> <h6 class="title">20.1 All major malformations</h6> <section id="CD010224-sec-0469"> <p><b>20.1.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 0.59, 95% CI 0.23 to 1.56; I<sup>2</sup> = 40%), with no difference in the number of major malformations in children exposed to CBZ (N = 1076) and children with PRM (N = 112) (<a href="./references#CD010224-fig-0087" title="">Analysis 20.1</a>). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.09 to 0.05; I<sup>2</sup> = 8%). </p> <p><a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported 22 cases of major malformation out of 280 (8%) CBZ‐exposed children and 4 cases out of 43 (9%) PRM‐exposed children. </p> </section> <section id="CD010224-sec-0470"> <p><b>20.1.2 Routine health record data studies</b></p> <p>Data from one included study suggested no evidence of a difference in risk (RR 0.32, 95% CI 0.02 to 4.44, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to CBZ (N = 703) and children exposed to PRM (N = 3) (<a href="./references#CD010224-fig-0087" title="">Analysis 20.1</a>). The RD also suggested no difference in the level of risk (RD 0.04, 95% CI −0.28 to 0.36; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0471"> <h6 class="title">20.2 Neural tube malformations</h6> <section id="CD010224-sec-0472"> <p><b>20.2.1 Cohort studies</b></p> <p>Pooled data from two studies suggested no evidence of a difference in risk (RR 0.95, 95% CI 0.04 to 22.75, I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 119) and children exposed to PRM (N = 39) (<a href="./references#CD010224-fig-0088" title="">Analysis 20.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.04 to 0.06; I<sup>2</sup> = 0%. </p> </section> <section id="CD010224-sec-0473"> <p><b>20.2.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0474"> <h6 class="title">20.3 Cardiac malformations</h6> <section id="CD010224-sec-0475"> <p><b>20.3.1 Cohort studies</b></p> <p>Pooled data from two studies suggested no evidence of a difference in risk (RR 0.11, 95% CI 0.00 to 2.53, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to CBZ (N = 119) and children exposed to PRM (N = 39) (<a href="./references#CD010224-fig-0089" title="">Analysis 20.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.03, 95% CI −0.10 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0476"> <p><b>20.3.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0477"> <h6 class="title">20.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0478"> <p><b>20.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to CBZ (N = 119) or children exposed to PRM (N = 39) (<a href="./references#CD010224-fig-0090" title="">Analysis 20.4</a>). </p> </section> <section id="CD010224-sec-0479"> <p><b>20.4.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0480"> <h6 class="title">20.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0481"> <p><b>20.5.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 2.84, 95% CI 0.16 to 51.53, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to CBZ (N = 119) and children exposed to PRM (N = 39) (<a href="./references#CD010224-fig-0091" title="">Analysis 20.5</a>). The RD also suggested no difference in the level of risk (RD 0.03, 95% CI −0.03 to 0.09; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0482"> <p><b>20.5.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0483"> <h5 class="title">21 CBZ versus TPM</h5> <section id="CD010224-sec-0484"> <h6 class="title">21.1 All major malformations</h6> <section id="CD010224-sec-0485"> <p><b>21.1.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 0.83, 95% CI 0.51 to 1.33; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CBZ (N = 3651) and children exposed to TPM (N = 505) (<a href="./references#CD010224-fig-0092" title="">Analysis 21.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.02 to 0.01; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Carbamazepine dose and Topiramate dose sections). </p> </section> <section id="CD010224-sec-0486"> <p><b>21.1.2 Routine health record data studies</b></p> <p>Pooled results from two routine health records suggested no evidence of a difference in risk (RR 0.59, 95% CI 0.17 to 2.06; I<sup>2</sup> = 12%), with children exposed to CBZ (N = 1388) experiencing more major malformations than children exposed to TPM (N = 49) (<a href="./references#CD010224-fig-0092" title="">Analysis 21.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.07 to 0.05; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0487"> <h6 class="title">21.2 Neural tube malformations</h6> <section id="CD010224-sec-0488"> <p><b>21.2.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 0.91, 95% CI 0.18 to 4.51; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to CBZ (N = 3568) and children exposed to TPM (N = 496) (<a href="./references#CD010224-fig-0093" title="">Analysis 21.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-0489"> <p><b>21.2.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0490"> <h6 class="title">21.3 Cardiac malformations</h6> <section id="CD010224-sec-0491"> <p><b>21.3.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 0.73, 95% CI 0.25 to 2.12; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to CBZ (N = 3573) and children exposed to TPM (N = 497) (<a href="./references#CD010224-fig-0094" title="">Analysis 21.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 1.97% for children exposed to TPM (3/152). </p> </section> <section id="CD010224-sec-0492"> <p><b>21.3.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0493"> <h6 class="title">21.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0494"> <p><b>21.4.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested an increased risk with CBZ (RR 0.33, 95% CI 0.13 to 0.82; I<sup>2</sup> = 40%), with children exposed to CBZ (N = 3083) experiencing more oro‐facial cleft/craniofacial malformations than children exposed to TPM (N = 488) (<a href="./references#CD010224-fig-0095" title="">Analysis 21.4</a>). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.02 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-0495"> <p><b>21.4.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0496"> <h6 class="title">21.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0497"> <p><b>21.5.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested an increased risk with CBZ (RR 0.34, 95% CI 0.12 to 0.94; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 3568) experiencing more skeletal/limb malformations than children exposed to TPM (N = 496). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.02 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0498"> <p><b>21.5.2 Routine health record data studies</b></p> <p>There were no studies that provided data for this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0499"> <h5 class="title">22 CBZ versus VPA</h5> <section id="CD010224-sec-0500"> <h6 class="title">22.1. All major malformations</h6> <section id="CD010224-sec-0501"> <p><b>22.1.1 Cohort studies</b></p> <p>Pooled results from 29 cohort studies suggested an increased risk with VPA (RR 0.44, 95% CI 0.37 to 0.53; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 5133) experiencing fewer major malformations than children exposed to VPA (N = 2957) (<a href="./references#CD010224-fig-0097" title="">Analysis 22.1</a>). The RD also suggested a higher risk for VPA (RD −0.05, 95% CI −0.06 to −0.04; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 5.5% (95% CI 4.5 to 6.6%) for children exposed to CBZ and 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Carbamazepine dose and Valproate dose sections). <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported 22 cases of major malformation out of 280 (8%) CBZ‐exposed children and six cases out of 184 (9%) VPA‐exposed children. </p> </section> <section id="CD010224-sec-0502"> <p><b>22.1.2 Routine health record data studies</b></p> <p>Pooled results from five routine health record studies suggested an increased risk with VPA (RR 0.42, 95% CI 0.33 to 0.54; I<sup>2</sup> = 14%), with children exposed to CBZ (N = 2806) experiencing fewer major malformations than children exposed to VPA (N = 1351) (<a href="./references#CD010224-fig-0097" title="">Analysis 22.1</a>). The RD also suggested a higher risk for VPA (RD −0.06, 95% CI −0.07 to −0.04; I<sup>2</sup> = 49%). Due to heterogeneity, a random‐effects RD was calculated which found a similar effect (RD ‐0.08, 95% CI ‐0.08 to ‐0.03, I<sup>2</sup> = 49%). </p> </section> </section> <section id="CD010224-sec-0503"> <h6 class="title">22.2 Neural tube malformations</h6> <section id="CD010224-sec-0504"> <p><b>22.2.1 Cohort studies</b></p> <p>Pooled results from 21 cohort studies suggested an increased risk with VPA (RR 0.124, 95% CI 0.14 to 0.41; I<sup>2</sup> = 7%), with children exposed to CBZ (N = 4738) experiencing fewer neural tube malformations than children exposed to VPA (N = 2721) (<a href="./references#CD010224-fig-0098" title="">Analysis 22.2</a>). The RD also suggested a higher risk for VPA (RD ‐0.01, 95% CI ‐0.02 to ‐0.01; I<sup>2</sup> = 14%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to CBZ was 0.36% (7/1957) and 1.6% for children exposed to VPA (16/1381). </p> </section> <section id="CD010224-sec-0505"> <p><b>22.2.2 Routine health record data studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.19, 95% CI 0.02 to 2.09; I<sup>2</sup> = NA), with children exposed to CBZ (N = 703) experiencing comparable neural tube malformations to children exposed to VPA (N = 268) (<a href="./references#CD010224-fig-0098" title="">Analysis 22.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.02 to 0.00; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0506"> <h6 class="title">22.3 Cardiac malformations</h6> <section id="CD010224-sec-0507"> <p><b>22.3.1 Cohort studies</b></p> <p>Pooled results from 22 cohort studies suggested an increased risk with VPA (RR 0.40, 95% CI 0.28 to 0.58; I<sup>2</sup> = 12%), with children exposed to CBZ (N = 4743) experiencing fewer cardiac malformations than children exposed to VPA (N = 2722) (<a href="./references#CD010224-fig-0099" title="">Analysis 22.3</a>). The RD also suggested a higher risk for VPA (RD ‐0.02, 95% CI ‐0.02 to ‐0.01; I<sup>2</sup> = 20%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to CBZ was 1.46% (28/1957) and 2.46% for children exposed to VPA (34/1381). </p> </section> <section id="CD010224-sec-0508"> <p><b>22.3.2 Routine health record data studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.38, 95% CI 0.13 to 1.08; I<sup>2</sup> = NA), with children exposed to CBZ (N = 703) experiencing comparable cardiac malformations to children exposed to VPA (N = 268) (<a href="./references#CD010224-fig-0099" title="">Analysis 22.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI ‐0.04 to 0.00; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0509"> <h6 class="title">22.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0510"> <p><b>22.4.1 Cohort studies</b></p> <p>Pooled results from 22 cohort studies suggested an increased risk with VPA (RR 0.31, 95% CI 0.18 to 0.54; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 4260) experiencing fewer oro‐facial cleft/craniofacial malformations than children exposed to VPA (N = 2387) (<a href="./references#CD010224-fig-0100" title="">Analysis 22.4</a>). The RD also suggested a higher risk for VPA (RD ‐0.01, 95% CI ‐0.02 to ‐0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to CBZ was 0.10% (2/1957) and 0.43% for children exposed to VPA (6/1381). </p> </section> <section id="CD010224-sec-0511"> <p><b>22.4.2 Routine health record data studies</b></p> <p>Results from one routine health record study suggested an increased risk with VPA (RR 0.15, 95% CI 0.03 to 0.78; I<sup>2</sup> = NA), with children exposed to CBZ (N = 703) experiencing fewer major malformations than children exposed to VPA (N = 268) (<a href="./references#CD010224-fig-0100" title="">Analysis 22.4</a>). The RD also suggested a higher risk for VPA (RD ‐0.02, 95% CI ‐0.03 to 0.01; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0512"> <h6 class="title">22.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0513"> <p><b>22.5.1 Cohort studies</b></p> <p>Pooled results from 21 cohort studies suggested an increased risk with VPA (RR 0.31, 95% CI 0.19 to 0.51; I<sup>2</sup> = 0%), with children exposed to CBZ (N = 4748) experiencing fewer skeletal/limb malformations than children exposed to VPA (N = 2711) (<a href="./references#CD010224-fig-0101" title="">Analysis 22.5</a>). The RD also suggested a higher risk for VPA (RD ‐0.01, 95% CI ‐0.02 to ‐0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0514"> <p><b>22.5.2 Routine health record data studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.38, 95% CI 0.02 to 6.07; I<sup>2</sup> = NA), with children exposed to CBZ (N = 703) experiencing comparable skeletal/limb malformations to children exposed to VPA (N = 268) (<a href="./references#CD010224-fig-0101" title="">Analysis 22.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> </section> </section> </section> <section id="CD010224-sec-0515"> <h5 class="title">23 CBZ versus ZNS</h5> <section id="CD010224-sec-0516"> <h6 class="title">23.1 All major malformations</h6> <section id="CD010224-sec-0517"> <p><b>23.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.94, 95% CI 0.36 to 2.44; I<sup>2</sup> = 75%), with no difference in the number of major malformations in children exposed to CBZ (N = 2711) and children exposed to ZNS (N = 130) (<a href="./references#CD010224-fig-0102" title="">Analysis 23.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which also found no difference (RR 0.86, 95% CI 0.07 to 10.35, I<sup>2</sup> =75%). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.03 to 0.03; I<sup>2</sup> = 74%). Due to heterogeneity, a random‐effects RD was calculated which upheld a similar result (RD ‐0.02, 95% CI ‐0.15 to 0.12). </p> </section> <section id="CD010224-sec-0518"> <p><b>23.1.2 Routine health record data studies</b></p> <p>Included studies did not report any data on this outcome.</p> </section> </section> <section id="CD010224-sec-0519"> <h6 class="title">23.2 Neural tube malformations</h6> <section id="CD010224-sec-0520"> <p><b>23.2.1 Cohort studies</b></p> <p>Pooled results from three studies suggested evidence of a difference in risk (RR 0.06, 95% CI 0.01 to 0.54, I<sup>2</sup> = NA), with children exposed to CBZ (N = 1678) experiencing more neural tube malformations than children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0103" title="">Analysis 23.2</a>). However, the RD suggested no difference in the level of risk (RD ‐0.03, 95% CI −0.10 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0521"> <p><b>23.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0522"> <h6 class="title">23.3 Cardiac malformations</h6> <section id="CD010224-sec-0523"> <p><b>23.3.1 Cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 0.47, 95% CI 0.03 to 7.72, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations between children exposed to CBZ (N = 1678) and children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0104" title="">Analysis 23.3</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0524"> <p><b>23.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0525"> <h6 class="title">23.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0526"> <p><b>23.4.1 Cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 0.15, 95% CI 0.01 to 2.66, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations between children exposed to CBZ (N = 1678) and children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0105" title="">Analysis 23.4</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.06 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0527"> <p><b>23.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0528"> <h6 class="title">23.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0529"> <p><b>23.5.1 Cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 0.15, 95% CI 0.01 to 2.66, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations between children exposed to CBZ (N = 1678) and children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0106" title="">Analysis 23.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.06 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0530"> <p><b>23.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0531"> <h5 class="title">24 GBP versus LTG</h5> <section id="CD010224-sec-0532"> <h6 class="title">24.1 All major malformations</h6> <section id="CD010224-sec-0533"> <p><b>24.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.92, 95% CI 0.34 to 2.47; I<sup>2</sup> = 58%), with no difference in the number of major malformations in children exposed to GBP (N = 192) and children exposed to LTG (N = 4103) (<a href="./references#CD010224-fig-0107" title="">Analysis 24.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which also found no difference (RR 1.54, 95% CI 0.25 to 9.55, I<sup>2</sup> =85%). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.03 to 0.01; I<sup>2</sup> = 37%). </p> </section> <section id="CD010224-sec-0534"> <p><b>24.1.2 Routine health record data studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.53, 95% CI 0.03 to 9.48; I<sup>2</sup> = NA), with children exposed to GBP (N = 18) experiencing more major malformations than children exposed to LTG (N = 90) (<a href="./references#CD010224-fig-0107" title="">Analysis 24.1</a>). The RD also suggested no difference in the level of risk (RD −0.04, 95% CI −0.13 to 0.01; I<sup>2</sup> = 37%). </p> </section> </section> <section id="CD010224-sec-0535"> <h6 class="title">24.2 Neural tube malformations</h6> <section id="CD010224-sec-0536"> <p><b>24.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to GBP (N = 14) or in children exposed to LTG (N = 314) (<a href="./references#CD010224-fig-0108" title="">Analysis 24.2</a>). </p> </section> <section id="CD010224-sec-0537"> <p><b>24.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0538"> <h6 class="title">24.3 Cardiac malformations</h6> <section id="CD010224-sec-0539"> <p><b>24.3.1 Cohort studies</b></p> <p>Pooled results from two studies suggested evidence of a difference in risk (RR 9.57, 95% CI 1.69 to 54.15, I<sup>2</sup> = 30%), with children exposed to GBP (N = 16) experiencing more cardiac malformations than children exposed to LTG (N = 352) (<a href="./references#CD010224-fig-0109" title="">Analysis 24.3</a>). However, the RD suggested no difference in the level of risk (RD 0.05, 95% CI −0.08 to 0.19; I<sup>2</sup> = 76%). </p> </section> <section id="CD010224-sec-0540"> <p><b>24.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0541"> <h6 class="title">24.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0542"> <p><b>24.4.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.92, 95% CI 0.11 to 33.05, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations between children exposed to GBP (N = 14) and children exposed to LTG (N = 315) (<a href="./references#CD010224-fig-0110" title="">Analysis 24.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.11 to 0.08; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0543"> <p><b>24.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0544"> <h6 class="title">24.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0545"> <p><b>24.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to GBP (N = 14) or children exposed to LTG (N = 315) (<a href="./references#CD010224-fig-0111" title="">Analysis 24.5</a>). </p> </section> <section id="CD010224-sec-0546"> <p><b>24.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0547"> <h5 class="title">25 GBP versus OXC</h5> <section id="CD010224-sec-0548"> <h6 class="title">25.1 All major malformations</h6> <section id="CD010224-sec-0549"> <p><b>25.1.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 0.53, 95% CI 0.13 to 2.17; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to GBP (N = 161) and children exposed to OXC (N = 202) (<a href="./references#CD010224-fig-0112" title="">Analysis 25.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.04 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0550"> <p><b>25.1.2 Routine health record data studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported major malformations in children exposed to GBP (N = 18) or children exposed to OXC (N = 4) (<a href="./references#CD010224-fig-0112" title="">Analysis 25.1</a>). </p> </section> </section> <section id="CD010224-sec-0551"> <h6 class="title">25.2 Neural tube malformations</h6> <section id="CD010224-sec-0552"> <p><b>25.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to GBP (N = 14) or children exposed to OXC (N = 12) (<a href="./references#CD010224-fig-0113" title="">Analysis 25.2</a>). </p> </section> <section id="CD010224-sec-0553"> <p><b>25.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0554"> <h6 class="title">25.3 Cardiac malformations</h6> <section id="CD010224-sec-0555"> <p><b>25.3.1 Cohort studies</b></p> <p>Included studies did not reach the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0114" title="">Analysis 25.3</a>). However, available data show that there were 1/15 cases of cardiac malformation in children exposed to GBP and 0/13 in OXC children, based on data from two studies (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>). </p> </section> <section id="CD010224-sec-0556"> <p><b>25.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0557"> <h6 class="title">25.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0558"> <p><b>25.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to GBP (N = 14) or children exposed to OXC (N = 12) (<a href="./references#CD010224-fig-0115" title="">Analysis 25.4</a>). </p> </section> <section id="CD010224-sec-0559"> <p><b>25.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0560"> <h6 class="title">25.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0561"> <p><b>25.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to GBP (N = 14) or children exposed to OXC (N = 12) (<a href="./references#CD010224-fig-0116" title="">Analysis 25.5</a>). </p> </section> <section id="CD010224-sec-0562"> <p><b>25.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0563"> <h5 class="title">26 GBP versus PB</h5> <section id="CD010224-sec-0564"> <h6 class="title">26.1 All major malformations</h6> <section id="CD010224-sec-0565"> <p><b>26.1.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 0.30, 95% CI 0.08 to 1.14; I<sup>2</sup> = 75%), with children exposed to GBP (N = 161) experiencing no difference in major malformations to children exposed to PB (N = 204) (<a href="./references#CD010224-fig-0117" title="">Analysis 26.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which also found no difference (RR 0.61, 95% CI 0.02 to 19.36, I<sup>2</sup> =85%). However, the RD suggested a higher risk for PB (RD −0.04, 95% CI −0.08 to ‐0.00; I<sup>2</sup> = 31%). </p> </section> <section id="CD010224-sec-0566"> <p><b>26.1.2 Routine health record data studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.14, 95% CI 0.01 to 3.09; I<sup>2</sup> = NA), with children exposed to GBP (N = 18) experiencing more major malformations than children exposed to PB (N = 1) (<a href="./references#CD010224-fig-0117" title="">Analysis 26.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.14, 95% CI ‐0.42 to 0.14). </p> </section> </section> <section id="CD010224-sec-0567"> <h6 class="title">26.2 Neural tube malformations</h6> <section id="CD010224-sec-0568"> <p><b>26.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to GBP (N = 14) or children exposed to PB (N = 5) (<a href="./references#CD010224-fig-0118" title="">Analysis 26.2</a>). </p> </section> <section id="CD010224-sec-0569"> <p><b>26.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0570"> <h6 class="title">26.3 Cardiac malformations</h6> <section id="CD010224-sec-0571"> <p><b>26.3.1 Cohort studies</b></p> <p>Included studies did not reach the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0119" title="">Analysis 26.3</a>). However, available data show that there were 1/16 cases of cardiac malformation in children exposed to GBP and 0/8 in children exposed to PB, based on data from two studies (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>). </p> </section> <section id="CD010224-sec-0572"> <p><b>26.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0573"> <h6 class="title">26.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0574"> <p><b>26.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to GBP (N = 14) or children exposed to PB (N = 5) (<a href="./references#CD010224-fig-0120" title="">Analysis 26.4</a>). </p> </section> <section id="CD010224-sec-0575"> <p><b>26.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0576"> <h6 class="title">26.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0577"> <p><b>26.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to GBP (N = 14) or children exposed to PB (N = 5) (<a href="./references#CD010224-fig-0121" title="">Analysis 26.5</a>). </p> </section> <section id="CD010224-sec-0578"> <p><b>26.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0579"> <h5 class="title">27 GBP versus PRM</h5> <section id="CD010224-sec-0580"> <h6 class="title">27.1 All major malformations</h6> <section id="CD010224-sec-0581"> <p><b>27.1.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0582"> <p><b>27.1.2 Routine health record data studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported major malformations in children exposed to GBP (N = 18) or children exposed to PRM (N = 8) (<a href="./references#CD010224-fig-0122" title="">Analysis 27.1</a>). </p> </section> </section> <section id="CD010224-sec-0583"> <h6 class="title">27.2 Neural tube malformations</h6> <section id="CD010224-sec-0584"> <p><b>27.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0585"> <p><b>27.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0586"> <h6 class="title">27.3 Cardiac malformations</h6> <section id="CD010224-sec-0587"> <p><b>27.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0588"> <p><b>27.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0589"> <h6 class="title">27.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0590"> <p><b>27.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0591"> <p><b>27.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0592"> <h6 class="title">27.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0593"> <p><b>27.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0594"> <p><b>27.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0595"> <h5 class="title">28 GBP versus TPM</h5> <section id="CD010224-sec-0596"> <h6 class="title">28.1 All major malformations</h6> <section id="CD010224-sec-0597"> <p><b>28.1.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 0.32, 95% CI 0.09 to 1.19; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to GBP (N = 190) and children exposed to TPM (N = 482) (<a href="./references#CD010224-fig-0123" title="">Analysis 28.1</a>). However, the RD suggested a higher risk for TPM (RD −0.03, 95% CI −0.05 to −0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0598"> <p><b>28.1.2 Routine health record data studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported major malformations in children exposed to GBP (N = 18) or children exposed to TPM (N = 1) (<a href="./references#CD010224-fig-0123" title="">Analysis 28.1</a>). </p> </section> </section> <section id="CD010224-sec-0599"> <h6 class="title">28.2 Neural tube malformations</h6> <section id="CD010224-sec-0600"> <p><b>28.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to GBP (N = 14) or children exposed to TPM (N = 44) (<a href="./references#CD010224-fig-0124" title="">Analysis 28.2</a>). </p> </section> <section id="CD010224-sec-0601"> <p><b>28.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0602"> <h6 class="title">28.3 Cardiac malformations</h6> <section id="CD010224-sec-0603"> <p><b>28.3.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported cardiac malformations in children exposed to GBP (N = 14) or children exposed to TPM (N = 44) (<a href="./references#CD010224-fig-0125" title="">Analysis 28.3</a>). </p> </section> <section id="CD010224-sec-0604"> <p><b>28.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0605"> <h6 class="title">28.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0606"> <p><b>28.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to GBP (N = 14) or children exposed to TPM (N = 44) (<a href="./references#CD010224-fig-0126" title="">Analysis 28.4</a>). </p> </section> <section id="CD010224-sec-0607"> <p><b>28.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0608"> <h6 class="title">28.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0609"> <p><b>28.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to GBP (N = 14) or children exposed to TPM (N = 44) (<a href="./references#CD010224-fig-0127" title="">Analysis 28.5</a>). </p> </section> <section id="CD010224-sec-0610"> <p><b>28.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0611"> <h5 class="title">29 GBP versus ZNS</h5> <section id="CD010224-sec-0612"> <h6 class="title">29.1 All major malformations</h6> <section id="CD010224-sec-0613"> <p><b>29.1.1 Cohort studies</b></p> <p>Data from two cohort studies suggested no evidence of a difference in risk (RR 0.53, 95% CI 0.10 to 2.76; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to GBP (N = 176) and children exposed to ZNS (N = 116) (<a href="./references#CD010224-fig-0128" title="">Analysis 29.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.04 to 0.02; I<sup>2</sup> = 72%). Due to heterogeneity, a random‐effects RD was calculated and upheld a similar finding (RD ‐0.03, 95% CI ‐0.15 to 0.10, I<sup>2</sup> =72%). </p> </section> <section id="CD010224-sec-0614"> <p><b>29.1.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0615"> <h6 class="title">29.2 Neural tube malformations</h6> <section id="CD010224-sec-0616"> <p><b>29.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0617"> <p><b>29.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0618"> <h6 class="title">29.3 Cardiac malformations</h6> <section id="CD010224-sec-0619"> <p><b>29.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0620"> <p><b>29.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0621"> <h6 class="title">29.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0622"> <p><b>29.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0623"> <p><b>29.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0624"> <h6 class="title">29.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0625"> <p><b>29.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0626"> <p><b>29.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0627"> <h5 class="title">30 LEV versus GBP</h5> <section id="CD010224-sec-0628"> <h6 class="title">30.1 All major malformations</h6> <section id="CD010224-sec-0629"> <p><b>30.1.1 Cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 1.61, 95% CI 0.46 to 5.63; I<sup>2</sup> = 43%), with no difference in the number of major malformations in children exposed to LEV (N = 893) and children exposed to GBP (N = 190) (<a href="./references#CD010224-fig-0129" title="">Analysis 30.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0630"> <p><b>30.1.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0631"> <h6 class="title">30.2 Neural tube malformations</h6> <section id="CD010224-sec-0632"> <p><b>30.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to LEV (N = 63) or children exposed to GBP (N = 14) (<a href="./references#CD010224-fig-0130" title="">Analysis 30.2</a>). </p> </section> <section id="CD010224-sec-0633"> <p><b>30.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0634"> <h6 class="title">30.3 Cardiac malformations</h6> <section id="CD010224-sec-0635"> <p><b>30.3.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.70, 95% CI 0.03 to 16.42, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to LEV (N = 63) and children exposed to GBP (N = 14) (<a href="./references#CD010224-fig-0131" title="">Analysis 30.3</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.08 to 0.11; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0636"> <p><b>30.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0637"> <h6 class="title">30.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0638"> <p><b>30.4.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.70, 95% CI 0.03 to 16.42, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to LEV (N = 63) and children exposed to GBP (N = 14) (<a href="./references#CD010224-fig-0132" title="">Analysis 30.4</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.08 to 0.11; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0639"> <p><b>30.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0640"> <h6 class="title">30.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0641"> <p><b>30.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to LEV (N = 63) or children exposed to GBP (N = 14) (<a href="./references#CD010224-fig-0133" title="">Analysis 30.5</a>). </p> </section> <section id="CD010224-sec-0642"> <p><b>30.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0643"> <h5 class="title">31 LEV versus LTG</h5> <section id="CD010224-sec-0644"> <h6 class="title">31.1. All major malformations</h6> <section id="CD010224-sec-0645"> <p><b>31.1.1 Cohort studies</b></p> <p>Pooled results from 10 cohort studies suggested no evidence of a difference in risk (RR 0.90, 95% CI 0.58 to 1.39; I<sup>2</sup> = 16%), with no difference in the number of major malformations in children exposed to LEV (N = 1223) and children exposed to LTG (N = 4389) (<a href="./references#CD010224-fig-0134" title="">Analysis 31.1</a>). The RD also suggested no difference in the level of risk (RD −0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 10%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 2.9% (95% CI 2.3 to 3.7) for children exposed to LTG. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Levetiracetam dose and Lamotrigine dose sections). </p> </section> <section id="CD010224-sec-0646"> <p><b>31.1.2 Routine health record data studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 0.79, 95% CI 0.37 to 1.69; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to LEV (N = 248) and children exposed to LTG (N = 2068) (<a href="./references#CD010224-fig-0134" title="">Analysis 31.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.03 to 0.01; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0647"> <h6 class="title">31.2 Neural tube malformations</h6> <section id="CD010224-sec-0648"> <p><b>31.2.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 1.59, 95% CI 0.24 to 10.38; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to LEV (N = 1128) and children exposed to LTG (N = 4245) (<a href="./references#CD010224-fig-0135" title="">Analysis 31.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0.04% for children exposed to LTG (1/2514). </p> </section> <section id="CD010224-sec-0649"> <p><b>31.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0650"> <h6 class="title">31.3 Cardiac malformations</h6> <section id="CD010224-sec-0651"> <p><b>31.3.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 1.20, 95% CI 0.51 to 2.85; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to LEV (N = 1125) and children exposed to LTG (N = 4246) (<a href="./references#CD010224-fig-0136" title="">Analysis 31.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.00 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 0.59% for children exposed to LTG (15/2514). </p> </section> <section id="CD010224-sec-0652"> <p><b>32.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0653"> <h6 class="title">31.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0654"> <p><b>31.4.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 0.63, 95% CI 0.15 to 2.68; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to LEV (N = 1019) and children exposed to LTG (N = 4196) (<a href="./references#CD010224-fig-0137" title="">Analysis 31.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LEV was 0.16% (1/599) and 0.43% for children exposed to LTG (3/2514). </p> </section> <section id="CD010224-sec-0655"> <p><b>31.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0656"> <h6 class="title">31.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0657"> <p><b>31.5.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 1.36, 95% CI 0.45 to 4.13; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to LEV (N = 1128) and children exposed to LTG (N = 4245) (<a href="./references#CD010224-fig-0138" title="">Analysis 31.5</a>). The RD also suggested no difference in the level of risk (RD −0.00, 95% CI −0.01 to 0.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0658"> <p><b>31.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0659"> <h5 class="title">32 LEV versus OXC</h5> <section id="CD010224-sec-0660"> <h6 class="title">32.1 All major malformations</h6> <section id="CD010224-sec-0661"> <p><b>32.1.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 1.04, 95% CI 0.51 to 2.09; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to LEV (N = 833) and children exposed to OXC (N = 333) (<a href="./references#CD010224-fig-0139" title="">Analysis 32.1</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.03; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Levetiracetam dose and Oxcarbazepine dose sections). </p> </section> <section id="CD010224-sec-0662"> <p><b>32.1.2 Routine health record data studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 1.17, 95% CI 0.45 to 3.06; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to LEV (N = 248) and children exposed to OXC (N = 373) (<a href="./references#CD010224-fig-0139" title="">Analysis 32.1</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.03; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0663"> <h6 class="title">32.2 Neural tube malformations</h6> <section id="CD010224-sec-0664"> <p><b>32.2.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 1.22, 95% CI 0.05 to 29.74; I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to LEV (N = 738) and children exposed to OXC (N = 320) (<a href="./references#CD010224-fig-0140" title="">Analysis 32.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0% for children exposed to OXC (0/333). </p> </section> <section id="CD010224-sec-0665"> <p><b>32.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0666"> <h6 class="title">32.3 Cardiac malformations</h6> <section id="CD010224-sec-0667"> <p><b>32.3.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 0.93, 95% CI 0.31 to 2.76; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to LEV (N = 747) and children exposed to OXC (N = 323) (<a href="./references#CD010224-fig-0141" title="">Analysis 32.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 1.2% for children exposed to OXC (4/333). </p> </section> <section id="CD010224-sec-0668"> <p><b>32.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0669"> <h6 class="title">32.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0670"> <p><b>32.4.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 0.25, 95% CI 0.03 to 2.12; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to LEV (N = 641) and children exposed to OXC (N = 252) (<a href="./references#CD010224-fig-0142" title="">Analysis 32.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.02 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 0.30% for children exposed to OXC (1/333). </p> </section> <section id="CD010224-sec-0671"> <p><b>32.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0672"> <h6 class="title">32.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0673"> <p><b>32.5.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 0.80, 95% CI 0.20 to 3.29; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to LEV (N = 738) children exposed to OXC (N = 320) (<a href="./references#CD010224-fig-0143" title="">Analysis 32.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.02 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0674"> <p><b>32.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0675"> <h5 class="title">33 LEV versus PB</h5> <section id="CD010224-sec-0676"> <h6 class="title">33.1 All major malformations</h6> <section id="CD010224-sec-0677"> <p><b>33.1.1 Cohort studies</b></p> <p>Results from five cohort studies suggested no evidence of a difference in risk (RR 0.54, 95% CI 0.29 to 1.02; I<sup>2</sup> = 0%), with children exposed to LEV (N = 726) experiencing comparable major malformations to children exposed to PB (N = 341) (<a href="./references#CD010224-fig-0144" title="">Analysis 33.1</a>). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.05 to 0.01; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 6.5% (95% CI 4.2 to 9.9) for children exposed to PB. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Levetiracetam dose and Phenobarbital dose sections). </p> </section> <section id="CD010224-sec-0678"> <p><b>33.1.2 Routine health record data studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.23, 95% CI 0.03 to 1.55; I<sup>2</sup> = NA), with children exposed to LEV (N = 118) experiencing comparable major malformation rates to children exposed to PB (N = 27). The RD also suggested no difference in the level of risk (RD −0.06, 95% CI −0.16 to 0.04; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0679"> <h6 class="title">33.2 Neural tube malformations</h6> <section id="CD010224-sec-0680"> <p><b>33.2.1 Cohort studies</b></p> <p>Results from five cohort studies suggested no evidence of a difference in risk (RR 0.74, 95% CI 0.08 to 6.51; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to LEV (N = 650) and children exposed to PB (N = 344) (<a href="./references#CD010224-fig-0145" title="">Analysis 33.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0.68% for children exposed to PB (2/294). </p> </section> <section id="CD010224-sec-0681"> <p><b>33.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0682"> <h6 class="title">33.3 Cardiac malformations</h6> <section id="CD010224-sec-0683"> <p><b>33.3.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested no evidence of a difference in risk (RR 0.33, 95% CI 0.12 to 0.88; I<sup>2</sup> = 17%), with no difference in the number of cardiac malformations in children exposed to LEV (N = 650) and PB (N = 344) (<a href="./references#CD010224-fig-0146" title="">Analysis 33.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI ‐0.04 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 2.72% for children exposed to PB (8/294%). </p> </section> <section id="CD010224-sec-0684"> <p><b>33.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0685"> <h6 class="title">33.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0686"> <p><b>33.4.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested an increased risk with PB (RR 0.08, 95% CI 0.01 to 0.67; I<sup>2</sup> = 0%), with children exposed to LEV (N = 544) experiencing fewer oro‐facial cleft/craniofacial malformations than children exposed to PB (N = 207) (<a href="./references#CD010224-fig-0147" title="">Analysis 33.4</a>). The RD suggested no difference in the level of risk (RD ‐0.02, 95% CI ‐0.04 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LEV was 0.16% (1/599) and 0.34% for children exposed to PB (1/294). </p> </section> <section id="CD010224-sec-0687"> <p><b>33.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0688"> <h6 class="title">33.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0689"> <p><b>33.5.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested no evidence of a difference in risk (RR 0.67, 95% CI 0.15 to 2.94; I<sup>2</sup> = 23%), with no difference in the number of skeletal/limb malformations in children exposed to LEV (N = 650) and children exposed to PB (N = 344) (<a href="./references#CD010224-fig-0148" title="">Analysis 33.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.02 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0690"> <p><b>33.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0691"> <h5 class="title">34 LEV versus PHT</h5> <section id="CD010224-sec-0692"> <h6 class="title">34.1 All major malformations</h6> <section id="CD010224-sec-0693"> <p><b>34.1.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested an increased risk with PHT (RR 0.58, 95% CI 0.34 to 0.97; I<sup>2</sup> = 58%), with children exposed to LEV (N = 1018) experiencing fewer major malformations than children exposed to PHT (N = 687) (<a href="./references#CD010224-fig-0149" title="">Analysis 34.1</a>). Due to high heterogeneity, we undertook a random‐effects analysis, which changed found no evidence of a difference in risk (RR 0.46, 95% CI 0.17 to 1.28; I<sup>2</sup> = 58%). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.04 to −0.00; I<sup>2</sup> = 52%). Due to high heterogeneity, we undertook a random‐effects analysis, which also found no difference (RD −0.02, 95% CI −0.05 to 0.02; I<sup>2</sup> = 52%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 6.4% (95% CI 2.8 to 12.2) for children exposed to PHT. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Levetiracetam dose and Phenytoin dose sections). </p> </section> <section id="CD010224-sec-0694"> <p><b>34.1.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0695"> <h6 class="title">34.2 Neural tube malformations</h6> <section id="CD010224-sec-0696"> <p><b>34.2.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.68, 95% CI 0.13 to 3.44; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to LEV (N = 913) and children exposed to PHT (N = 661) (<a href="./references#CD010224-fig-0150" title="">Analysis 34.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0.80% for children exposed to PHT (1/125). </p> </section> <section id="CD010224-sec-0697"> <p><b>34.2.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0698"> <h6 class="title">34.3 Cardiac malformations</h6> <section id="CD010224-sec-0699"> <p><b>34.3.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.43, 95% CI 0.16 to 1.13; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to LEV (N = 911) and children exposed to PHT (N = 611) (<a href="./references#CD010224-fig-0151" title="">Analysis 34.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.02 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 4.0% for children exposed to PHT (5/125). </p> </section> <section id="CD010224-sec-0700"> <p><b>34.3.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0701"> <h6 class="title">34.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0702"> <p><b>34.4.1 Cohort studies</b></p> <p>Pooled results from three studies suggested no evidence of a difference in risk (RR 0.37, 95% CI 0.09 to 1.61; I<sup>2</sup> = 4%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to LEV (N = 807) and children exposed to PHT (N = 542) (<a href="./references#CD010224-fig-0152" title="">Analysis 34.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LEV was 0.16% (1/599) and 0% for children exposed to PHT (0/125). </p> </section> <section id="CD010224-sec-0703"> <p><b>34.4.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0704"> <h6 class="title">34.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0705"> <p><b>34.5.1 Cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 0.46, 95% CI 0.11 to 1.96; I<sup>2</sup> = 63%), with no difference in the number of skeletal/limb malformations in children exposed to LEV (N = 913) and children exposed to PHT (N = 661) (<a href="./references#CD010224-fig-0153" title="">Analysis 34.5</a>). Due to high heterogeneity, a random‐effects RR was calculated, which also found no difference (RR 0.54, 95% CI 0.02 to 11.85, I<sup>2</sup> =63%). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI ‐0.01 to 0.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0706"> <p><b>34.5.2 Routine health record data studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0707"> <h5 class="title">35 LEV versus PRM</h5> <section id="CD010224-sec-0708"> <h6 class="title">35.1 All major malformations</h6> <section id="CD010224-sec-0709"> <p><b>35.1.1. Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.24, 95% CI 0.02 to 3.37, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to LEV (N = 139) and children exposed to PRM (N = 2) (<a href="./references#CD010224-fig-0154" title="">Analysis 35.1</a>). The RD also suggested no difference in the level of risk (RD 0.04, 95% CI −0.39 to 0.46; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0710"> <p><b>35.1.2. Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0711"> <h6 class="title">35.2 Neural tube malformations</h6> <section id="CD010224-sec-0712"> <p><b>35.2.1. Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0713"> <p><b>35.2.2. Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0714"> <h6 class="title">35.3 Cardiac malformations</h6> <section id="CD010224-sec-0715"> <p><b>35.3.1. Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0716"> <p><b>35.3.2. Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0717"> <h6 class="title">35.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0718"> <p><b>35.4.1. Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0719"> <p><b>35.4.2. Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0720"> <h6 class="title">35.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0721"> <p><b>35.5.1. Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0722"> <p><b>35.5.2. Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0723"> <h5 class="title">36 LEV versus TPM</h5> <section id="CD010224-sec-0724"> <h6 class="title">36.1 All major malformations</h6> <section id="CD010224-sec-0725"> <p><b>36.1.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 0.57, 95% CI 0.32 to 1.04; I<sup>2</sup> = 0%), with children exposed to LEV (N = 1124) experiencing comparable major malformations to children exposed to TPM (N = 505) (<a href="./references#CD010224-fig-0155" title="">Analysis 36.1</a>). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.04 to 0.00; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.8% (95% CI 1.7 to 4.5%) for children exposed to LEV and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Levetiracetam dose and Topiramate dose sections). </p> </section> <section id="CD010224-sec-0726"> <p><b>36.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.41, 95% CI 0.06 to 2.81; I<sup>2</sup> = NA), with children exposed to LEV (N = 118) experiencing comparable major malformation rate to children exposed to TPM (N = 48) (<a href="./references#CD010224-fig-0155" title="">Analysis 36.1</a>). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.09 to 0.04; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0727"> <h6 class="title">36.2 Neural tube malformations</h6> <section id="CD010224-sec-0728"> <p><b>36.2.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 2.39, 95% CI 0.10 to 58.61; I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to LEV (N = 1030) and children exposed to TPM (N = 496) (<a href="./references#CD010224-fig-0156" title="">Analysis 36.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LEV was 0% (0/599) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-0729"> <p><b>36.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0730"> <h6 class="title">36.3 Cardiac malformations</h6> <section id="CD010224-sec-0731"> <p><b>36.3.1 Cohort studies</b></p> <p>Pooled results from eight studies suggested no evidence of a difference in risk (RR 0.72, 95% CI 0.21 to 2.53; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to LEV (N = 1039) and children exposed to TPM (N = 497) (<a href="./references#CD010224-fig-0156" title="">Analysis 36.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LEV was 0.83% (5/599) and 1.97% for children exposed to TPM (3/152). </p> </section> <section id="CD010224-sec-0732"> <p><b>36.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0733"> <h6 class="title">36.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0734"> <p><b>36.4.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested an increased risk with TPM (RR 0.19, 95% CI 0.05 to 0.70; I<sup>2</sup> = 48%), with children exposed to LEV (N = 933) experiencing fewer oro‐facial/craniofacial malformations than children exposed to TPM (N = 488) (<a href="./references#CD010224-fig-0158" title="">Analysis 36.4</a>). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.03 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LEV was 0.16% (1/599) and 0% for children exposed to TPM (0/125). </p> </section> <section id="CD010224-sec-0735"> <p><b>36.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0736"> <h6 class="title">36.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0737"> <p><b>36.5.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested an increased risk with TPM (RR 0.12, 95% CI 0.02 to 0.98; I<sup>2</sup> = 0%), with children exposed to LEV (N = 1030) experiencing fewer skeletal/limb malformations than children exposed to TPM (N = 496) (<a href="./references#CD010224-fig-0159" title="">Analysis 36.5</a>). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.02 to 0.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0738"> <p><b>36.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0739"> <h5 class="title">37 LEV versus ZNS</h5> <section id="CD010224-sec-0740"> <h6 class="title">37.1 All major malformations</h6> <section id="CD010224-sec-0741"> <p><b>37.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.66, 95% CI 0.25 to 1.71; I<sup>2</sup> = 79%), with no difference in the number of major malformations in children exposed to LEV (N = 865) and children exposed to ZNS (N = 130) (<a href="./references#CD010224-fig-0160" title="">Analysis 37.1</a>). Due to high heterogeneity, a random‐effects RR was calculated, which also found no difference (RD 0.48, 95% CI 0.03 to 7.24, I<sup>2</sup> = 79%). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.04 to 0.03; I<sup>2</sup> = 76%). Due to heterogeneity, a random‐effects RD was calculated, which maintained similar findings (RD ‐0.03, 95% CI ‐0.16 to 0.10, I<sup>2</sup> = 76%). </p> </section> <section id="CD010224-sec-0742"> <p><b>37.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0743"> <h6 class="title">37.2 Neural tube malformations</h6> <section id="CD010224-sec-0744"> <p><b>37.2.1 Cohort studies</b></p> <p>Pooled results from three included studies suggested evidence of a difference in risk (RR 0.03, 95% CI 0.00 to 0.71, I<sup>2</sup> = NA), with children exposed to ZNS (N = 40) experiencing more neural tube malformations than children exposed to LEV (N = 415) (<a href="./references#CD010224-fig-0161" title="">Analysis 37.2</a>). However, the RD suggested no difference in the level of risk (RD ‐0.03, 95% CI −0.10 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0745"> <p><b>37.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0746"> <h6 class="title">37.3 Cardiac malformations</h6> <section id="CD010224-sec-0747"> <p><b>37.3.1 Cohort studies</b></p> <p>Pooled results from three included studies suggested no evidence of a difference in risk (RR 0.98, 95% CI 0.05 to 17.99, I<sup>2</sup> = NA), with no difference in cardiac malformations between children exposed to LEV (N = 415) and children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0162" title="">Analysis 37.3</a>). The RD suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.07; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0748"> <p><b>37.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0749"> <h6 class="title">37.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0750"> <p><b>37.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from three studies due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to LEV (N = 415) and ZNS (N = 40) (<a href="./references#CD010224-fig-0163" title="">Analysis 37.4</a>). </p> </section> <section id="CD010224-sec-0751"> <p><b>37.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0752"> <h6 class="title">37.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0753"> <p><b>37.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from three studies due to there being no reported skeletal/limb malformations in children exposed to LEV (N = 415) and ZNS (N = 40) (<a href="./references#CD010224-fig-0164" title="">Analysis 37.5</a>). </p> </section> <section id="CD010224-sec-0754"> <p><b>37.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0755"> <h5 class="title">38 LTG versus CZP</h5> <section id="CD010224-sec-0756"> <h6 class="title">38.1 All major malformations</h6> <section id="CD010224-sec-0757"> <p><b>38.1.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 0.92, 95% CI 0.29 to 2.91; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to LTG (N = 2018) and children exposed to CZP (N = 94) (<a href="./references#CD010224-fig-0165" title="">Analysis 38.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.03 to 0.04; I<sup>2</sup> = 33%). </p> </section> <section id="CD010224-sec-0758"> <p><b>38.1.2 Routine health record studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 1.54, 95% CI 0.53 to 4.54; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to LTG (N = 923) and children exposed to CZP (N = 161) (<a href="./references#CD010224-fig-0165" title="">Analysis 38.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.04; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0759"> <h6 class="title">38.2 Neural tube malformations</h6> <section id="CD010224-sec-0760"> <p><b>38.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0761"> <p><b>38.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0762"> <h6 class="title">38.3 Cardiac malformations</h6> <section id="CD010224-sec-0763"> <p><b>38.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0764"> <p><b>38.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0765"> <h6 class="title">38.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0766"> <p><b>38.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0767"> <p><b>38.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0768"> <h6 class="title">38.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0769"> <p><b>38.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0770"> <p><b>38.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0771"> <h5 class="title">39 LTG versus LAC</h5> <section id="CD010224-sec-0772"> <h6 class="title">39.1 All major malformations</h6> <section id="CD010224-sec-0773"> <p><b>39.1.1 Cohort studies</b></p> <p>We were unable to estimate the RR from one study due to there being no major malformations observed in children exposed to LTG (N = 19) or LAC (N = 1) (<a href="./references#CD010224-fig-0166" title="">Analysis 39.1</a>). </p> </section> <section id="CD010224-sec-0774"> <p><b>39.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0775"> <h6 class="title">39.2 Neural tube malformations</h6> <section id="CD010224-sec-0776"> <p><b>39.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported neural tube malformations in children exposed to LTG (N = 19) or LAC (N = 1) (<a href="./references#CD010224-fig-0167" title="">Analysis 39.2</a>). </p> </section> <section id="CD010224-sec-0777"> <p><b>39.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0778"> <h6 class="title">39.3 Cardiac malformations</h6> <section id="CD010224-sec-0779"> <p><b>39.3.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported cardiac malformations in children exposed to LTG (N = 19) or LAC (N = 1) (<a href="./references#CD010224-fig-0168" title="">Analysis 39.3</a>). </p> </section> <section id="CD010224-sec-0780"> <p><b>39.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0781"> <h6 class="title">39.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0782"> <p><b>39.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to LTG (N = 19) or LAC (N = 1) (<a href="./references#CD010224-fig-0168" title="">Analysis 39.3</a>). </p> </section> <section id="CD010224-sec-0783"> <p><b>39.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0784"> <h6 class="title">39.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0785"> <p><b>39.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to LTG (N = 19) or LAC (N = 1) (<a href="./references#CD010224-fig-0168" title="">Analysis 39.3</a>). </p> </section> <section id="CD010224-sec-0786"> <p><b>39.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0787"> <h5 class="title">40 LTG versus OXC</h5> <section id="CD010224-sec-0788"> <h6 class="title">40.1 All major malformations</h6> <section id="CD010224-sec-0789"> <p><b>40.1.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk(RR 0.73, 95% CI 0.33 to 1.62; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to LTG (N = 2208) and children exposed to OXC (N = 333) (<a href="./references#CD010224-fig-0171" title="">Analysis 40.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.03 to 0.02; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Lamotrigine dose and Oxcarbazepine dose sections). </p> </section> <section id="CD010224-sec-0790"> <p><b>40.1.2 Routine health record studies</b></p> <p>Pooled results from three routine health record studies suggested no evidence of a difference in risk (RR 1.24, 95% CI 0.67 to 2.30; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to LTG (N = 2158) and children exposed to OXC (N = 377) (<a href="./references#CD010224-fig-0171" title="">Analysis 40.1</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.03; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0791"> <h6 class="title">40.2 Neural tube malformations</h6> <section id="CD010224-sec-0792"> <p><b>40.2.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.59, 95% CI 0.03 to 12.15; I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to LTG (N = 2027) and children exposed to OXC (N = 319) (<a href="./references#CD010224-fig-0172" title="">Analysis 40.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LTG was 0.3% (1/2514) and 0% for children exposed to OXC (0/333). </p> </section> <section id="CD010224-sec-0793"> <p><b>40.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0794"> <h6 class="title">40.3 Cardiac malformations</h6> <section id="CD010224-sec-0795"> <p><b>40.3.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 0.59, 95% CI 0.15 to 2.30; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to LTG (N = 2084) and children exposed to OXC (N = 323) (<a href="./references#CD010224-fig-0173" title="">Analysis 40.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 1.2% for children exposed to OXC (4/333). </p> </section> <section id="CD010224-sec-0796"> <p><b>40.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0797"> <h6 class="title">40.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0798"> <p><b>40.4.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.64, 95% CI 0.12 to 3.46; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to LTG (N = 1997) and children exposed to OXC (N = 251) (<a href="./references#CD010224-fig-0174" title="">Analysis 40.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LTG was 0.11% (3/2514) and 0.30% for children exposed to OXC (1/333). </p> </section> <section id="CD010224-sec-0799"> <p><b>40.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0800"> <h6 class="title">40.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0801"> <p><b>40.5.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.29, 95% CI 0.06 to 1.56; I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to LTG (N = 2027) and children exposed to OXC (N = 319) (<a href="./references#CD010224-fig-0175" title="">Analysis 40.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.02 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0802"> <p><b>40.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0803"> <h5 class="title">41 LTG versus PB</h5> <section id="CD010224-sec-0804"> <h6 class="title">41.1 All major malformations</h6> <section id="CD010224-sec-0805"> <p><b>41.1.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested an increased risk with PB (RR 0.32, 95% CI 0.17 to 0.59; I<sup>2</sup> = 0%), with children exposed to LTG (N = 2156) experiencing fewer major malformations than children exposed to PB (N = 421) (<a href="./references#CD010224-fig-0176" title="">Analysis 41.1</a>). The RD also suggested a higher risk for PB (RD −0.04, 95% CI −0.07 to −0.01; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 6.5% (95% CI 4.2 to 9.9) for children exposed to PB. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Lamotrigine dose and Phenobarbital dose sections). </p> </section> <section id="CD010224-sec-0806"> <p><b>41.1.2 Routine health record studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 0.41, 95% CI 0.13 to 1.28; I<sup>2</sup> = 0%), with children exposed to LTG (N = 923) experiencing comparable major malformations to children exposed to PB (N = 34) (<a href="./references#CD010224-fig-0176" title="">Analysis 41.1</a>). The RD also suggested no difference in the level of risk (RD −0.05, 95% CI −0.15 to 0.04; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0807"> <h6 class="title">41.2 Neural tube malformations</h6> <section id="CD010224-sec-0808"> <p><b>41.2.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.76, 95% CI 0.09 to 6.88; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to LTG (N = 2009) and children exposed to PB (N = 412) (<a href="./references#CD010224-fig-0177" title="">Analysis 41.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LTG was 0.3% (1/2514) and 0.68% for children exposed to PB (2/294). </p> </section> <section id="CD010224-sec-0809"> <p><b>41.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0810"> <h6 class="title">41.3 Cardiac malformations</h6> <section id="CD010224-sec-0811"> <p><b>41.3.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested an increased risk with PB (RR 0.21, 95% CI 0.08 to 0.56; I<sup>2</sup> = 0%), with children exposed to LTG (N = 1990) experiencing fewer cardiac malformations than children exposed to PB (N = 411) (<a href="./references#CD010224-fig-0178" title="">Analysis 41.3</a>). The RD also suggested a higher risk for PB (RD ‐0.02, 95% CI −0.04 to ‐0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 2.72% for children exposed to PB (8/294). </p> </section> <section id="CD010224-sec-0812"> <p><b>41.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0813"> <h6 class="title">41.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0814"> <p><b>41.4.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested an increased risk with PB (RR 0.22, 95% CI 0.07 to 0.68; I<sup>2</sup> = 0%), with fewer oro‐facial cleft/craniofacial malformations in children exposed to LTG (N = 1940) compared to PB (N = 274) (<a href="./references#CD010224-fig-0179" title="">Analysis 41.4</a>). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.03 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LTG was 0.11% (3/2514) and 0.34% for children exposed to PB (1/294). </p> </section> <section id="CD010224-sec-0815"> <p><b>41.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0816"> <h6 class="title">41.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0817"> <p><b>41.5.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.38, 95% CI 0.06 to 2.58; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to LTG (N = 2009) and children exposed to PB (N = 413) (<a href="./references#CD010224-fig-0180" title="">Analysis 41.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.02 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0818"> <p><b>41.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0819"> <h5 class="title">42 LTG versus PHT</h5> <section id="CD010224-sec-0820"> <h6 class="title">42.1 All major malformations</h6> <section id="CD010224-sec-0821"> <p><b>42.1.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested an increased risk with PHT (RR 0.55, 95% CI 0.35 to 0.87; I<sup>2</sup> = 24%), with children exposed to LTG (N = 4251) experiencing fewer major malformations than children exposed to PHT (N = 742) (<a href="./references#CD010224-fig-0181" title="">Analysis 42.1</a>). The RD also suggested a higher risk for PHT (RD −0.02, 95% CI −0.03 to −0.00; I<sup>2</sup> = 31%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 6.4% (95% CI 2.8 to 12.2) for children exposed to PHT. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Lamotrigine dose and Phenytoin dose sections). </p> </section> <section id="CD010224-sec-0822"> <p><b>42.1.2 Routine health record studies</b></p> <p>One routine health record study suggested no evidence of a difference in risk (RR 0.65, 95% CI 0.20 to 2.16; I<sup>2</sup> = NA%), with children exposed to LTG (N = 90) experiencing comparable major malformations to children exposed to PHT (N = 103) (<a href="./references#CD010224-fig-0181" title="">Analysis 42.1</a>). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.09 to 0.04; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0823"> <h6 class="title">42.2 Neural tube malformations</h6> <section id="CD010224-sec-0824"> <p><b>43.2.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.40, 95% CI 0.11 to 1.51; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to LTG (N = 4127) and children exposed to PHT (N = 718) (<a href="./references#CD010224-fig-0182" title="">Analysis 42.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LTG was 0.3% (1/2514) and 0.80% for children exposed to PHT (1/125). </p> </section> <section id="CD010224-sec-0825"> <p><b>42.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0826"> <h6 class="title">42.3 Cardiac malformations</h6> <section id="CD010224-sec-0827"> <p><b>42.3.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested an increased risk with PHT (RR 0.41, 95% CI 0.17 to 0.98; I<sup>2</sup> = 0%), with children exposed to LTG (N = 4127) experiencing fewer cardiac malformations than children exposed to PHT (N = 718) (<a href="./references#CD010224-fig-0183" title="">Analysis 42.3</a>). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.02 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 4.0% for children exposed to PHT (5/125). </p> </section> <section id="CD010224-sec-0828"> <p><b>42.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0829"> <h6 class="title">42.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0830"> <p><b>42.4.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested no evidence of a difference in risk (RR 0.73, 95% CI 0.23 to 2.28; I<sup>2</sup> = 45%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to LTG (N = 4077) and children exposed to PHT (N = 599) (<a href="./references#CD010224-fig-0184" title="">Analysis 42.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LTG was 0.11% (3/2514) and 0% for children exposed to PHT (0/125). </p> </section> <section id="CD010224-sec-0831"> <p><b>42.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0832"> <h6 class="title">42.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0833"> <p><b>42.5.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested an increased risk with PHT (RR 0.28, 95% CI 0.09 to 0.86; I<sup>2</sup> = 0%), with children exposed to LTG (N = 4127) experiencing fewer skeletal/limb malformations than children exposed to PHT (N = 718) (<a href="./references#CD010224-fig-0185" title="">Analysis 42.5</a>). However, the RD suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.01 to 0.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0834"> <p><b>42.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0835"> <h5 class="title">43 LTG versus PRM</h5> <section id="CD010224-sec-0836"> <h6 class="title">43.1 All major malformations</h6> <section id="CD010224-sec-0837"> <p><b>43.1.1 Cohort studies</b></p> <p>One cohort study suggested no evidence of a difference in risk (RR 0.30, 95% CI 0.02 to 3.93; I<sup>2</sup> = NA), with children exposed to LTG (N = 406) experiencing comparable major malformations to children exposed to PRM (N = 2) (<a href="./references#CD010224-fig-0186" title="">Analysis 43.1</a>). The RD also suggested no difference in the level of risk (RD 0.05, 95% CI −0.37 to 0.47; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0838"> <p><b>43.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.40, 95% CI 0.03 to 6.16; I<sup>2</sup> = NA), with children exposed to LTG (N = 90) experiencing comparable major malformations to children exposed to PRM (N = 2) (<a href="./references#CD010224-fig-0186" title="">Analysis 43.1</a>). The RD also suggested no difference in the level of risk (RD 0.04, 95% CI −0.28 to 0.37; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0839"> <h6 class="title">43.2 Neural tube malformations</h6> <section id="CD010224-sec-0840"> <p><b>43.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0841"> <p><b>43.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0842"> <h6 class="title">43.3 Cardiac malformations</h6> <section id="CD010224-sec-0843"> <p><b>43.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0844"> <p><b>43.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0845"> <h6 class="title">43.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0846"> <p><b>43.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0847"> <p><b>43.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0848"> <h6 class="title">43.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0849"> <p><b>43.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-0850"> <p><b>43.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0851"> <h5 class="title">44 LTG versus TPM</h5> <section id="CD010224-sec-0852"> <h6 class="title">44.1 All major malformations</h6> <section id="CD010224-sec-0853"> <p><b>44.1.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested an increased risk with TPM (RR 0.59, 95% CI 0.36 to 0.96; I<sup>2</sup> = 0%), with children exposed to LTG (N = 4275) experiencing fewer major malformations than children exposed to TPM (N = 505) (<a href="./references#CD010224-fig-0187" title="">Analysis 44.1</a>). However, the RD suggested no difference in the level of risk (RD −0.02, 95% CI −0.03 to 0.00; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.9% (95% CI 2.3 to 3.7%) for children exposed to LTG and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Lamotrigine dose and Topiramate dose sections). </p> </section> <section id="CD010224-sec-0854"> <p><b>44.1.2 Routine health record studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 0.68, 95% CI 0.20 to 2.37; I<sup>2</sup> = 0%), with children exposed to LTG (N = 923) experiencing comparable major malformation rates to children exposed to TPM (N = 49) (<a href="./references#CD010224-fig-0187" title="">Analysis 44.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.07 to 0.06; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0855"> <h6 class="title">44.2 Neural tube malformations</h6> <section id="CD010224-sec-0856"> <p><b>44.2.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 0.62, 95% CI 0.08 to 4.94; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to LTG (N = 4131) and children exposed to TPM (N = 496) (<a href="./references#CD010224-fig-0188" title="">Analysis 44.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to LTG was 0.3% (1/2514) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-0857"> <p><b>44.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0858"> <h6 class="title">44.3 Cardiac malformations</h6> <section id="CD010224-sec-0859"> <p><b>44.3.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 0.58, 95% CI 0.19 to 1.81; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to LTG (N = 4151) and children exposed to TPM (N = 497) (<a href="./references#CD010224-fig-0189" title="">Analysis 44.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.01 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to LTG was 5.9% (15/2514) and 1.97% for children exposed to TPM (3/152). </p> </section> <section id="CD010224-sec-0860"> <p><b>44.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0861"> <h6 class="title">44.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0862"> <p><b>44.4.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested evidence of a difference in risk (RR 0.31, 95% CI 0.13 to 0.74; I<sup>2</sup> = 68%), with children exposed to LTG (N = 4101) experiencing less oro‐facial cleft/craniofacial malformations than children exposed to TPM (N = 488) (<a href="./references#CD010224-fig-0190" title="">Analysis 44.4</a>). Due to high heterogeneity, we undertook a random‐effects analysis, which found no difference (RR 0.22, 95% CI 0.03 to 1.48; I<sup>2</sup> = 68%). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.02 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to LTG was 0.11% (3/2514) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-0863"> <p><b>44.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome that could be included in the meta‐analysis. One study by Hernandez‐Diaz and colleagues using <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> could not be included in the meta‐analysis due to a lack of reporting of specific numbers of oral clefts. In this study, children born to women taking TPM had higher rates of oral clefts (N = 2425, 4.1 per 1000 live births) than the children born to women taking LTG (N = 2796, 1.5 per 1000 live births), but this was not reported to be statistically significant (RR 2.30, 95% CI 0.69 to 7.64). </p> </section> </section> <section id="CD010224-sec-0864"> <h6 class="title">44.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0865"> <p><b>44.5.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 0.17, 95% CI 0.06 to 0.52; I<sup>2</sup> = 0%), with children exposed to LTG (N = 4131) experiencing fewer skeletal/limb malformations than children exposed to TPM (N = 496) (<a href="./references#CD010224-fig-0191" title="">Analysis 44.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.02 to 0.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0866"> <p><b>44.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0867"> <h5 class="title">45 LTG versus ZNS</h5> <section id="CD010224-sec-0868"> <h6 class="title">45.1 All major malformations</h6> <section id="CD010224-sec-0869"> <p><b>45.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.66, 95% CI 0.26 to 1.65; I<sup>2</sup> = 66%), with no difference in the number of major malformations in children exposed to LTG (N = 3792) and children exposed to ZNS (N = 130) (<a href="./references#CD010224-fig-0192" title="">Analysis 45.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which also found no difference (RD 0.57, 95% CI 0.09 to 3.81, I<sup>2</sup> = 66%). The RD also suggested no difference in the level of riskThe RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.04 to 0.02; I<sup>2</sup> = 77%). Due to heterogeneity, a random‐effects RD was calculated, which upheld similar findings (RD ‐0.03, 95% CI ‐0.16 to 0.11, I<sup>2</sup> = 77%). </p> </section> <section id="CD010224-sec-0870"> <p><b>45.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0871"> <h6 class="title">45.2 Neural tube malformations</h6> <section id="CD010224-sec-0872"> <p><b>45.2.1 Cohort studies</b></p> <p>Pooled data from three included studies suggested evidence of a difference in risk (RR 0.02, 95% CI 0.00 to 0.26, I<sup>2</sup> = NA), with children exposed to ZNS (N = 40) experiencing more neural tube malformations than children exposed to LTG (N = 2230) (<a href="./references#CD010224-fig-0193" title="">Analysis 45.2</a>). However, the RD suggested no difference in the level of risk (RD ‐0.03, 95% CI −0.09 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0873"> <p><b>45.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0874"> <h6 class="title">45.3 Cardiac malformations</h6> <section id="CD010224-sec-0875"> <p><b>45.3.1 Cohort studies</b></p> <p>Pooled data from two included studies suggested no evidence of a difference in risk (RR 0.30, 95% CI 0.04 to 2.52, I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to LTG (N = 2211) and children exposed to ZNS (N = 39) (<a href="./references#CD010224-fig-0193" title="">Analysis 45.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.04 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0876"> <p><b>45.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0877"> <h6 class="title">45.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0878"> <p><b>45.4.1 Cohort studies</b></p> <p>Pooled data from two included studies suggested no evidence of a difference in risk (RR 0.06, 95% CI 0.00 to 1.31, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to LTG (N = 2211) and children exposed to ZNS (N = 39) (<a href="./references#CD010224-fig-0195" title="">Analysis 45.4</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.05 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0879"> <p><b>45.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0880"> <h6 class="title">45.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0881"> <p><b>45.5.1 Cohort studies</b></p> <p>Pooled data from three included studies suggested no evidence of a difference in risk (RR 0.22, 95% CI 0.03 to 1.93, I<sup>2</sup> = 0%, with no difference in the number of skeletal/limb malformations in children exposed to LTG (N = 2230) and children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0196" title="">Analysis 45.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.05 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0882"> <p><b>45.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0883"> <h5 class="title">46 PHT versus GBP</h5> <section id="CD010224-sec-0884"> <h6 class="title">46.1 All major malformations</h6> <section id="CD010224-sec-0885"> <p><b>46.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 2.15, 95% CI 0.69 to 6.73; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PHT (N = 567) and children exposed to GBP (N = 192) (<a href="./references#CD010224-fig-0197" title="">Analysis 46.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.00 to 0.04; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0886"> <p><b>46.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 2.74, 95% CI 0.16 to 46.00; I<sup>2</sup> = 0%), with children exposed to PHT (N = 103) experiencing comparable major malformations to children exposed to GBP (N = 18) (<a href="./references#CD010224-fig-0197" title="">Analysis 46.1</a>). The RD also suggested no difference in the level of risk (RD 0.07, 95% CI ‐0.02 to 0.16; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0887"> <h6 class="title">46.2 Neural tube malformations</h6> <section id="CD010224-sec-0888"> <p><b>46.2.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0198" title="">Analysis 46.2</a>). However, available data showed there were 1/45 cases of neural tube malformations in children exposed to PHT and 0/16 cases in children exposed to GBP, based on data from two studies (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>). </p> </section> <section id="CD010224-sec-0889"> <p><b>46.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0890"> <h6 class="title">46.3 Cardiac malformations</h6> <section id="CD010224-sec-0891"> <p><b>46.3.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0199" title="">Analysis 46.3</a>). However, available data showed there were 1/45 cases of cardiac malformations in children exposed to PHT and 1/16 cases in children exposed to GBP, based on data from two studies (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0033" title="MiskovS , Gjergja JuraskiR , MikulaI , BasicS , Bosnjak PasicM , KosecV , et al. The Croatian model of integrative prospective management of epilepsy and pregnancy. Acta Clinica Croatica2016;55(4):535-48. [PMID: 29116720]">Miskov 2016</a>). </p> </section> <section id="CD010224-sec-0892"> <p><b>46.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0893"> <h6 class="title">46.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0894"> <p><b>46.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to PHT (N = 45) or GBP (N = 16) (<a href="./references#CD010224-fig-0200" title="">Analysis 46.4</a>). </p> </section> <section id="CD010224-sec-0895"> <p><b>46.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0896"> <h6 class="title">46.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0897"> <p><b>46.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR due to there being no reported cases of skeletal/limb malformations in children exposed to PHT (N = 45) or GBP (N = 16) (<a href="./references#CD010224-fig-0201" title="">Analysis 46.5</a>). </p> </section> <section id="CD010224-sec-0898"> <p><b>46.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0899"> <h5 class="title">47 PHT versus OXC</h5> <section id="CD010224-sec-0900"> <h6 class="title">47.1 All major malformations</h6> <section id="CD010224-sec-0901"> <p><b>47.1.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.94, 95% CI 0.48 to 1.85; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PHT (N = 706) and children exposed to OXC (N = 283) (<a href="./references#CD010224-fig-0202" title="">Analysis 47.1</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.03 to 0.03; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 6.4% (95% CI 2.8 to 12.2) for children exposed to PHT and 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Phenytoin dose and Oxcarbazepine dose sections). </p> </section> <section id="CD010224-sec-0902"> <p><b>47.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested an increased risk with PHT (RR 0.72, 95% CI 0.05 to 0.93; I<sup>2</sup> = NA), with children exposed to PHT (N = 103) experiencing more major malformations than children exposed to OXC (N = 4) (<a href="./references#CD010224-fig-0202" title="">Analysis 47.1</a>). However, the RD suggested no difference in the level of risk (RD 0.07, 95% CI −0.20 to 0.34; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0903"> <h6 class="title">47.2 Neural tube malformations</h6> <section id="CD010224-sec-0904"> <p><b>47.2.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 1.16, 95% CI 0.13 to 10.29; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to PHT (N = 703) and children exposed to OXC (N = 271) (<a href="./references#CD010224-fig-0203" title="">Analysis 47.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to PHT was 0.80% (1/125) and 0% for children exposed to OXC (0/333). </p> </section> <section id="CD010224-sec-0905"> <p><b>47.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0906"> <h6 class="title">47.3 Cardiac malformations</h6> <section id="CD010224-sec-0907"> <p><b>47.3.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested no evidence of a difference in risk (RR 1.33, 95% CI 0.43 to 14.17; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to PHT (N = 704) and children exposed to OXC (N = 272) (<a href="./references#CD010224-fig-0204" title="">Analysis 47.3</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.03; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to PHT was 4.0% (5/125) and 1.2% for children exposed to OXC (4/333). </p> </section> <section id="CD010224-sec-0908"> <p><b>47.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0909"> <h6 class="title">47.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0910"> <p><b>47.4.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 0.62, 95% CI 0.10 to 4.05; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to PHT (N = 584) and children exposed to OXC (N = 200) (<a href="./references#CD010224-fig-0205" title="">Analysis 47.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to PHT was 0% (0/125) and 0.30% for children exposed to OXC (1/333). </p> </section> <section id="CD010224-sec-0911"> <p><b>47.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0912"> <h6 class="title">47.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0913"> <p><b>47.5.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 1.20, 95% CI 0.23 to 6.35; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to PHT (N = 703) and children exposed to OXC (N = 271) (<a href="./references#CD010224-fig-0206" title="">Analysis 47.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0914"> <p><b>47.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0915"> <h5 class="title">48 PHT versus PB</h5> <section id="CD010224-sec-0916"> <h6 class="title">48.1 All major malformations</h6> <section id="CD010224-sec-0917"> <p><b>48.1.1 Cohort studies</b></p> <p>Pooled results from 20 cohort studies suggested no evidence of a difference in risk (RR 0.84, 95% CI 0.57 to 1.23; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PHT (N = 1095) and children exposed to PB (N = 634) (<a href="./references#CD010224-fig-0207" title="">Analysis 48.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.03 to 0.02; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 6.4% (95% CI 2.8 to 12.2) for children exposed to PHT and 6.5% (95% CI 4.2 to 9.9) for children exposed to PHT. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Phenytoin dose and Phenobarbital dose sections). <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported nine cases of major malformation in 141 (6%) PHT cases and five cases in 48 (10%) PB‐exposed children. </p> </section> <section id="CD010224-sec-0918"> <p><b>48.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.48, 95% CI 0.07 to 3.35; I<sup>2</sup> = NA), with children exposed to PHT (N = 103) experiencing comparable major malformations to children exposed to PB (N = 7) (<a href="./references#CD010224-fig-0207" title="">Analysis 48.1</a>). The RD also suggested no difference in the level of risk (RD −0.07, 95% CI −0.34 to 0.19; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0919"> <h6 class="title">48.2 Neural tube malformations</h6> <section id="CD010224-sec-0920"> <p><b>48.2.1 Cohort studies</b></p> <p>Pooled results from 11 studies suggested no evidence of a difference in risk (RR 0.79, 95% CI 0.10 to 5.94; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to PHT (N = 707) and children exposed to PB (N = 475) (<a href="./references#CD010224-fig-0208" title="">Analysis 48.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to PHT was 0.80% (1/125) and 0.68% for children exposed to PB (2/294). </p> </section> <section id="CD010224-sec-0921"> <p><b>48.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0922"> <h6 class="title">48.3 Cardiac malformations</h6> <section id="CD010224-sec-0923"> <p><b>48.3.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested no evidence of a difference in risk (RR 0.56, 95% CI 0.29 to 1.07; I<sup>2</sup> = 0%), with children exposed to PHT (N = 707) experiencing no more cardiac malformations than children exposed to PB (N = 475) (<a href="./references#CD010224-fig-0209" title="">Analysis 48.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.04 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to PHT was 4.0% (5/125) and 2.72% for children exposed to PB (8/294). </p> </section> <section id="CD010224-sec-0924"> <p><b>48.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0925"> <h6 class="title">48.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0926"> <p><b>48.4.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested no evidence of a difference in risk (RR 0.25, 95% CI 0.07 to 0.82; I<sup>2</sup> = 0%), with children exposed to PHT (N = 593) experiencing fewer oro‐facial cleft/craniofacial malformations than children exposed to PB (N = 347) (<a href="./references#CD010224-fig-0210" title="">Analysis 48.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.04 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to PHT was 0% (0/125) and 0.34% for children exposed to PB (1/294). </p> </section> <section id="CD010224-sec-0927"> <p><b>48.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0928"> <h6 class="title">48.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0929"> <p><b>48.5.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested no evidence of a difference in risk (RR 1.31, 95% CI 0.39 to 4.39; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to PHT (N = 707) and children exposed to PB (N = 475) (<a href="./references#CD010224-fig-0211" title="">Analysis 48.5</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0930"> <p><b>48.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0931"> <h5 class="title">49 PHT versus PRM</h5> <section id="CD010224-sec-0932"> <h6 class="title">49.1 All major malformations</h6> <section id="CD010224-sec-0933"> <p><b>49.1.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.78, 95% CI 0.39 to 1.56; I<sup>2</sup> = 19%), with no difference in the number of major malformations in children exposed to PHT (N = 360) and children exposed to PRM (N = 103) (<a href="./references#CD010224-fig-0212" title="">Analysis 49.1</a>). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.09 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0934"> <p><b>49.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 0.58, 95% CI 0.04 to 8.44; I<sup>2</sup> = NA), with children exposed to PHT (N = 103) experiencing no more major malformations than children exposed to PRM (N = 3) (<a href="./references#CD010224-fig-0212" title="">Analysis 49.1</a>). The RD also suggested no difference in the level of risk (RD 0.07, 95% CI −0.26 to 0.40; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0935"> <h6 class="title">49.2 Neural tube malformations</h6> <section id="CD010224-sec-0936"> <p><b>49.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no cases of neural tube malformations in children exposed to PHT (N = 36) or PRM (N = 39) (<a href="./references#CD010224-fig-0213" title="">Analysis 49.2</a>). </p> </section> <section id="CD010224-sec-0937"> <p><b>49.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0938"> <h6 class="title">49.3 Cardiac malformations</h6> <section id="CD010224-sec-0939"> <p><b>49.3.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0214" title="">Analysis 49.3</a>). However, available data showed there were 0/36 cases of cardiac malformations in children exposed to PHT and 1/39 cases in children exposed to PRM, based on data from two studies (<a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>). </p> </section> <section id="CD010224-sec-0940"> <p><b>49.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0941"> <h6 class="title">49.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0942"> <p><b>49.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR due to there being no reported cases of oro‐facial cleft/craniofacial malformations in children exposed to PHT (N = 36) or PRM (N = 39) (<a href="./references#CD010224-fig-0213" title="">Analysis 49.2</a>). </p> </section> <section id="CD010224-sec-0943"> <p><b>49.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0944"> <h6 class="title">49.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0945"> <p><b>49.5.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0216" title="">Analysis 49.5</a>). However, available data showed there were 1/36 cases of skeletal/limb malformations in children exposed to PHT and 0/39 cases in children exposed to PRM, based on data from two studies (<a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>). </p> </section> <section id="CD010224-sec-0946"> <p><b>49.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0947"> <h5 class="title">50 PHT versus TPM</h5> <section id="CD010224-sec-0948"> <h6 class="title">50.1 All major malformations</h6> <section id="CD010224-sec-0949"> <p><b>50.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies showed no evidence of a difference in risk (RR 0.88, 95% CI 0.48 to 1.61; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PHT (N = 685) and children exposed to TPM (N = 491) (<a href="./references#CD010224-fig-0217" title="">Analysis 50.1</a>). The RD also suggested no difference in the level of risk (RD −0.00, 95% CI −0.03 to 0.02; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 2.9% (95% CI 2.3 to 3.7%) for children exposed to PHT and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Phenytoin dose and Topiramate dose sections). </p> </section> <section id="CD010224-sec-0950"> <p><b>50.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.29, 95% CI 0.02 to 3.51, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to PHT (N = 103) and children exposed to PRM (N = 1) (<a href="./references#CD010224-fig-0217" title="">Analysis 50.1</a>). The RD also suggested no difference in the level of risk (RD 0.07, 95% CI ‐0.53 to 0.67; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-0951"> <h6 class="title">50.2 Neural tube malformations</h6> <section id="CD010224-sec-0952"> <p><b>50.2.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 1.23, 95% CI 0.17 to 8.87; I<sup>2</sup> = 24%), with no difference in the number of neural tube malformations in children exposed to PHT (N = 661) and children exposed to TPM (N = 483) (<a href="./references#CD010224-fig-0218" title="">Analysis 50.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to PHT was 0.80% (1/125) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-0953"> <p><b>50.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0954"> <h6 class="title">50.3 Cardiac malformations</h6> <section id="CD010224-sec-0955"> <p><b>50.3.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 2.46, 95% CI 0.65 to 9.36; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to PHT (N = 661) and children exposed to TPM (N = 483) (<a href="./references#CD010224-fig-0219" title="">Analysis 50.3</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.00 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to PHT was 4.0% (5/125) and 1.97% for children exposed to TPM (3/152). </p> </section> <section id="CD010224-sec-0956"> <p><b>50.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0957"> <h6 class="title">50.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0958"> <p><b>50.4.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 0.37, 95% CI 0.10 to 1.42; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to PHT (N = 542) and children exposed to TPM (N = 474) (<a href="./references#CD010224-fig-0220" title="">Analysis 50.4</a>). The RD also suggested no difference in the level of risk(RD ‐0.01, 95% CI −0.02 to 0.00; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to PHT was 0% (0/125) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-0959"> <p><b>50.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0960"> <h6 class="title">50.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0961"> <p><b>50.5.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.63, 95% CI 0.19 to 2.09; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to PHT (N = 661) and children exposed to TPM (N = 483) (<a href="./references#CD010224-fig-0221" title="">Analysis 50.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.02 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0962"> <p><b>50.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0963"> <h5 class="title">51 PHT versus ZNS</h5> <section id="CD010224-sec-0964"> <h6 class="title">51.1 All major malformations</h6> <section id="CD010224-sec-0965"> <p><b>51.1.1 Cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk (RR 1.28, 95% CI 0.42 to 3.93; I<sup>2</sup> = 61%), with no difference in the number of major malformations in children exposed to PHT (N = 522) and children exposed to ZNS (N = 116) (<a href="./references#CD010224-fig-0222" title="">Analysis 51.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which found a similar effect (RR 1.28, 95% CI 0.42 to 3.93, I<sup>2</sup> = 61%). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.05; I<sup>2</sup> = 68%). Due to heterogeneity, a random‐effects RD was calculated which also found no difference in risk (RD 0.00, 95% CI ‐0.11 to 0.11, I<sup>2</sup> = 68%) </p> </section> <section id="CD010224-sec-0966"> <p><b>51.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0967"> <h6 class="title">51.2 Neural tube malformations</h6> <section id="CD010224-sec-0968"> <p><b>51.2.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.11, 95% CI 0.00 to 2.58, I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to PHT (N = 82) and children exposed to ZNS (N = 26) (<a href="./references#CD010224-fig-0223" title="">Analysis 51.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.13 to 0.05; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0969"> <p><b>51.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0970"> <h6 class="title">51.3 Cardiac malformations</h6> <section id="CD010224-sec-0971"> <p><b>51.3.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.98, 95% CI 0.04 to 23.26, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to PHT (N = 82) and children exposed to ZNS (N = 26) (<a href="./references#CD010224-fig-0224" title="">Analysis 51.3</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.07; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0972"> <p><b>51.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0973"> <h6 class="title">51.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0974"> <p><b>51.4.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.98, 95% CI 0.04 to 23.26, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to PHT (N = 82) and children exposed to ZNS (N = 26) (<a href="./references#CD010224-fig-0225" title="">Analysis 51.4</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.07; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-0975"> <p><b>51.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0976"> <h6 class="title">51.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0977"> <p><b>51.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported skeletal/limb malformations in children exposed to PHT (N = 82) or ZNS (N = 26) (<a href="./references#CD010224-fig-0226" title="">Analysis 51.5</a>). </p> </section> <section id="CD010224-sec-0978"> <p><b>51.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0979"> <h5 class="title">52 PB versus OXC</h5> <section id="CD010224-sec-0980"> <h6 class="title">52.1 All major malformations</h6> <section id="CD010224-sec-0981"> <p><b>52.1.1 Cohort studies</b></p> <p>Pooled results from eight cohort studies suggested no evidence of a difference in risk (RR 1.61, 95% CI 0.83 to 3.14; I<sup>2</sup> = 19%), with no difference in the number of major malformations in children exposed to PB (N = 354) and children exposed to OXC (N = 322) (<a href="./references#CD010224-fig-0227" title="">Analysis 52.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.02 to 0.06; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 6.5% (95% CI 4.2 to 9.9) for children exposed to PB and 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Phenobarbital dose and Oxcarbazepine dose sections). </p> </section> <section id="CD010224-sec-0982"> <p><b>52.1.2 Routine health record studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 3.07, 95% CI 0.50 to 18.92; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PB (N = 34) and children exposed to OXC (N = 61) (<a href="./references#CD010224-fig-0227" title="">Analysis 52.1</a>). The RD also suggested no difference in the level of risk (RD 0.07, 95% CI −0.04 to 0.17; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-0983"> <h6 class="title">52.2 Neural tube malformations</h6> <section id="CD010224-sec-0984"> <p><b>52.2.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 1.57, 95% CI 0.06 to 37.94; I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to PB (N = 349) and children exposed to OXC (N = 305) (<a href="./references#CD010224-fig-0228" title="">Analysis 52.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.01 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to PB was 0.68% (2/294) and 0% for children exposed to OXC (0/333). </p> </section> <section id="CD010224-sec-0985"> <p><b>52.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0986"> <h6 class="title">52.3 Cardiac malformations</h6> <section id="CD010224-sec-0987"> <p><b>52.3.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested no evidence of a difference in risk (RR 2.58, 95% CI 0.94 to 7.09; I<sup>2</sup> = 51%), with children exposed to PB (N = 352) experiencing comparable cardiac malformations to children exposed to OXC (N = 306) (<a href="./references#CD010224-fig-0229" title="">Analysis 52.3</a>). Due to high heterogeneity, a random‐effects RR was calculated which also found no difference (RR 3.84, 95% CI 0.54 to 27.19, I<sup>2</sup> = 51%). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.01 to 0.05; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to PB was 2.72% (8/294) and 1.20% for children exposed to OXC (4/333). </p> </section> <section id="CD010224-sec-0988"> <p><b>52.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0989"> <h6 class="title">52.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-0990"> <p><b>52.4.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested no evidence of a difference in risk (RR 3.66, 95% CI 0.41 to 32.43; I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to PB (N = 212) and children exposed to TPM (N = 234) (<a href="./references#CD010224-fig-0230" title="">Analysis 52.4</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.01 to 0.04; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to PB was 0.34% (1/294) and 0.30% for children exposed to OXC (1/333). </p> </section> <section id="CD010224-sec-0991"> <p><b>52.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-0992"> <h6 class="title">52.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-0993"> <p><b>52.5.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.98, 95% CI 0.16 to 5.97; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to PB (N = 349) and children exposed to OXC (N = 305) (<a href="./references#CD010224-fig-0231" title="">Analysis 52.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.00, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0994"> <p><b>52.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-0995"> <h5 class="title">53 PB versus PRM</h5> <section id="CD010224-sec-0996"> <h6 class="title">53.1 All major malformations</h6> <section id="CD010224-sec-0997"> <p><b>53.1.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.50, 95% CI 0.21 to 1.16; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PB (N = 241) and children exposed to PRM (N = 110) (<a href="./references#CD010224-fig-0232" title="">Analysis 53.1</a>). The RD also suggested no difference in the level of risk (RD −0.05, 95% CI −0.12 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-0998"> <p><b>53.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0232" title="">Analysis 53.1</a>). However, available data showed there were 1/7 cases of major malformations in children exposed to PB and 0/3 cases in children exposed to PRM, based on data from one study (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> </section> </section> <section id="CD010224-sec-0999"> <h6 class="title">53.2 Neural tube malformations</h6> <section id="CD010224-sec-1000"> <p><b>53.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported no cases of neural tube malformations in children exposed to PB (N = 95) or PRM (N = 39) (<a href="./references#CD010224-fig-0233" title="">Analysis 53.2</a>). </p> </section> <section id="CD010224-sec-1001"> <p><b>53.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1002"> <h6 class="title">53.3 Cardiac malformations</h6> <section id="CD010224-sec-1003"> <p><b>53.3.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.42, 95% CI 0.03 to 6.55, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to PB (N = 95) and children exposed to PRM (N = 39) (<a href="./references#CD010224-fig-0232" title="">Analysis 53.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.08 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1004"> <p><b>53.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1005"> <h6 class="title">53.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1006"> <p><b>53.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported cases of oro‐facial cleft/craniofacial malformations in children exposed to PB (N = 95) or PRM (N = 39) (<a href="./references#CD010224-fig-0235" title="">Analysis 53.4</a>). </p> </section> <section id="CD010224-sec-1007"> <p><b>53.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1008"> <h6 class="title">53.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1009"> <p><b>53.5.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 1.29, 95% CI 0.05 to 30.82, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to PB (N = 95) and children exposed to PRM (N = 39) (<a href="./references#CD010224-fig-0236" title="">Analysis 53.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.07; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1010"> <p><b>53.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1011"> <h5 class="title">54 PB versus TPM</h5> <section id="CD010224-sec-1012"> <h6 class="title">54.1 All major malformations</h6> <section id="CD010224-sec-1013"> <p><b>54.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 1.38, 95% CI 0.68 to 2.81; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to PB (N = 340) and children exposed to TPM (N = 426) (<a href="./references#CD010224-fig-0237" title="">Analysis 54.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.02 to 0.05; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 6.5% (95% CI 4.2 to 9.9) for children exposed to PB and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Phenobarbital dose and Topiramate dose sections). </p> </section> <section id="CD010224-sec-1014"> <p><b>54.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0237" title="">Analysis 54.1</a>). However, available data showed there were 3/34 cases of major malformations in children exposed to PB and 2/49 cases in children exposed to TPM, based on data from two studies (<a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> </section> </section> <section id="CD010224-sec-1015"> <h6 class="title">54.2 Neural tube malformations</h6> <section id="CD010224-sec-1016"> <p><b>54.2.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.22, 95% CI 0.01 to 5.00; I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to PB (N = 343) and children exposed to TPM (N = 417) (<a href="./references#CD010224-fig-0238" title="">Analysis 54.2</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to PB was 0.68% (2/294) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-1017"> <p><b>54.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1018"> <h6 class="title">54.3 Cardiac malformations</h6> <section id="CD010224-sec-1019"> <p><b>54.3.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested an increased risk with PB (RR 4.44, 95% CI 0.98 to 20.12; I<sup>2</sup> = 37%), with children exposed to PB (N = 343) experiencing more cardiac malformations than children exposed to TPM (N = 417) (<a href="./references#CD010224-fig-0239" title="">Analysis 54.3</a>). However, the RD suggested no difference in the level of risk (RD 0.02, 95% CI −0.00 to 0.05; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to PB was 2.72% (8/294) and 1.97% for children exposed to TPM (3/152). </p> </section> <section id="CD010224-sec-1020"> <p><b>54.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1021"> <h6 class="title">54.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1022"> <p><b>54.4.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 1.44, 95% CI 0.39 to 5.31; I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to PB (N = 206) and children exposed to TPM (N = 408) (<a href="./references#CD010224-fig-0240" title="">Analysis 54.4</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.02 to 0.03; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to PB was 0.34% (1/294) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-1023"> <p><b>54.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1024"> <h6 class="title">54.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1025"> <p><b>54.5.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.36, 95% CI 0.06 to 2.19; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to PB (N = 343) and children exposed to TPM (N = 417) (<a href="./references#CD010224-fig-0241" title="">Analysis 54.5</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.03 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1026"> <p><b>54.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1027"> <h5 class="title">55 PB versus ZNS</h5> <section id="CD010224-sec-1028"> <h6 class="title">55.1 All major malformations</h6> <section id="CD010224-sec-1029"> <p><b>55.1.1 Cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk (RR 10.46, 95% CI 0.62 to 175.67; I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to PB (N = 201) and children exposed to ZNS (N = 91) (<a href="./references#CD010224-fig-0242" title="">Analysis 55.1</a>). The RD suggested a higher rate of major malformation observed in the PB‐exposed group (RD 0.05, 95% CI 0.02 to 0.09; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1030"> <p><b>55.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1031"> <h6 class="title">55.2 Neural tube malformations</h6> <section id="CD010224-sec-1032"> <p><b>55.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of neural tube malformations in children exposed to PB (N = 2) or ZNS (N = 1) (<a href="./references#CD010224-fig-0243" title="">Analysis 55.2</a>). </p> </section> <section id="CD010224-sec-1033"> <p><b>55.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1034"> <h6 class="title">55.3 Cardiac malformations</h6> <section id="CD010224-sec-1035"> <p><b>55.3.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of cardiac malformations in children exposed to PB (N = 2) or ZNS (N = 1) (<a href="./references#CD010224-fig-0244" title="">Analysis 55.3</a>). </p> </section> <section id="CD010224-sec-1036"> <p><b>55.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1037"> <h6 class="title">55.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1038"> <p><b>55.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of oro‐facial cleft /craniofacial malformations PB (N = 2) or ZNS (N = 1) (<a href="./references#CD010224-fig-0245" title="">Analysis 55.4</a>). </p> </section> <section id="CD010224-sec-1039"> <p><b>55.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1040"> <h6 class="title">55.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1041"> <p><b>55.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of skeletal/limb malformations in children exposed to PB (N = 2) or ZNS (N = 1) (<a href="./references#CD010224-fig-0246" title="">Analysis 55.5</a>). </p> </section> <section id="CD010224-sec-1042"> <p><b>55.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1043"> <h5 class="title">56 TPM versus ZNS</h5> <section id="CD010224-sec-1044"> <h6 class="title">56.1 All major malformations</h6> <section id="CD010224-sec-1045"> <p><b>56.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 1.59, 95% CI 0.54 to 4.66; I<sup>2</sup> = 58%), with no difference in the number of major malformations in children exposed to TPM (N = 440) and children exposed to ZNS (N = 130) (<a href="./references#CD010224-fig-0247" title="">Analysis 56.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which also found no difference (RD 1.44, 95% CI 0.19 to 10.82, I<sup>2</sup> =58%). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.02 to 0.06; I<sup>2</sup> = 35%). </p> </section> <section id="CD010224-sec-1046"> <p><b>56.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1047"> <h6 class="title">56.2 Neural tube malformations</h6> <section id="CD010224-sec-1048"> <p><b>56.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no cases of neural tube malformations in children exposed to TPM (N = 11) or ZNS (N = 14) (<a href="./references#CD010224-fig-0248" title="">Analysis 56.2</a>). </p> </section> <section id="CD010224-sec-1049"> <p><b>56.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1050"> <h6 class="title">56.3 Cardiac malformations</h6> <section id="CD010224-sec-1051"> <p><b>56.3.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 6.00 95% CI 0.28 to 129.16, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to TPM (N = 81) and children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0249" title="">Analysis 56.3</a>). The RD also suggested no difference in the level of risk (RD 0.03, 95% CI −0.06 to 0.12; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1052"> <p><b>56.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1053"> <h6 class="title">56.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1054"> <p><b>56.4.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 1.90 95% CI 0.09 to 38.34, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to TPM (N = 81) and children exposed to ZNS (N = 40) (<a href="./references#CD010224-fig-0250" title="">Analysis 56.4</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.06 to 0.10; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1055"> <p><b>56.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1056"> <h6 class="title">56.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1057"> <p><b>56.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from three studies due to there being no cases of skeletal/limb malformations in children exposed to TPM (N = 81) or ZNS (N = 40) (<a href="./references#CD010224-fig-0251" title="">Analysis 56.5</a>). </p> </section> <section id="CD010224-sec-1058"> <p><b>56.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1059"> <h5 class="title">57 TPM vs LAC</h5> <section id="CD010224-sec-1060"> <h6 class="title">57.1 All major malformations</h6> <section id="CD010224-sec-1061"> <p><b>57.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one cohort study due to there being no major malformations observed in children exposed to TPM (N = 5) or LAC (N = 1) (<a href="./references#CD010224-fig-0252" title="">Analysis 57.1</a>). </p> </section> <section id="CD010224-sec-1062"> <p><b>57.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1063"> <h6 class="title">57.2 Neural tube malformations</h6> <section id="CD010224-sec-1064"> <p><b>57.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of neural tube malformations in children exposed to TPM (N = 5) or LAC (N = 1) (<a href="./references#CD010224-fig-0253" title="">Analysis 57.2</a>). </p> </section> <section id="CD010224-sec-1065"> <p><b>57.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1066"> <h6 class="title">57.3 Cardiac malformations</h6> <section id="CD010224-sec-1067"> <p><b>57.3.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of cardiac malformations in children exposed to TPM (N = 5) or LAC (N = 1) (<a href="./references#CD010224-fig-0254" title="">Analysis 57.3</a>). </p> </section> <section id="CD010224-sec-1068"> <p><b>57.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1069"> <h6 class="title">57.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1070"> <p><b>57.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of oro‐facial cleft/ craniofacial malformations in children exposed to TPM (N = 5) or LAC (N = 1) (<a href="./references#CD010224-fig-0255" title="">Analysis 57.4</a>). </p> </section> <section id="CD010224-sec-1071"> <p><b>57.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1072"> <h6 class="title">57.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1073"> <p><b>57.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no cases of skeletal/limb malformations in children exposed to TPM (N = 5) or LAC (N = 1) (<a href="./references#CD010224-fig-0256" title="">Analysis 57.5</a>). </p> </section> <section id="CD010224-sec-1074"> <p><b>57.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1075"> <h5 class="title">58 VPA versus GBP</h5> <section id="CD010224-sec-1076"> <h6 class="title">58.1 All major malformations</h6> <section id="CD010224-sec-1077"> <p><b>58.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested an increased risk with VPA (RR 4.27, 95% CI 1.60 to 11.35; I<sup>2</sup> = 58%), with children exposed to VPA (N = 1839) experiencing more major malformations than children exposed to GBP (N = 192) (<a href="./references#CD010224-fig-0257" title="">Analysis 58.1</a>). Due to high heterogeneity, a random‐effects RR was calculated which found no difference in the level of risk (RD 2.43, 95% CI 0.40 to 14.64, I<sup>2</sup> = 58%). However, both the fixed‐effect RD analysis (RD 0.08, 95% CI 0.04 to 0.11; I<sup>2</sup> = 60%) and a random‐effects RD also suggested a higher absolute risk for VPA (RD 0.08, 95% CI 0.01 to 0.14, I<sup>2</sup> = 60%). </p> </section> <section id="CD010224-sec-1078"> <p><b>58.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 3.74, 95% CI 0.24 to 59.08, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VPA (N = 268) and children exposed to GBP (N = 18) (<a href="./references#CD010224-fig-0257" title="">Analysis 58.1</a>). However, the RD suggested a difference in the level of risk (RD 0.10, 95% CI 0.02 to 0.18; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-1079"> <h6 class="title">58.2 Neural tube malformations</h6> <section id="CD010224-sec-1080"> <p><b>58.2.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.83, 95% CI 0.05 to 13.81, I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 18) (<a href="./references#CD010224-fig-0258" title="">Analysis 58.2</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.09 to 0.13; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1081"> <p><b>58.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1082"> <h6 class="title">58.3 Cardiac malformations</h6> <section id="CD010224-sec-1083"> <p><b>58.3.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.46, 95% CI 0.08 to 2.70, I<sup>2</sup> = 4%), with no difference in the number of cardiac malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 16) (<a href="./references#CD010224-fig-0259" title="">Analysis 58.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI ‐0.14 to 0.11; I<sup>2</sup> = 74%). </p> </section> <section id="CD010224-sec-1084"> <p><b>58.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1085"> <h6 class="title">58.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1086"> <p><b>58.4.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 1.38, 95% CI 0.09 to 22.19, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 16) (<a href="./references#CD010224-fig-0260" title="">Analysis 58.4</a>). The RD also suggested no difference in the level of risk (RD 0.04, 95% CI ‐0.07 to 0.15; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1087"> <p><b>58.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1088"> <h6 class="title">58.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1089"> <p><b>58.5.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.72, 95% CI 0.04 to 12.14, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to VPA (N = 277) and children exposed to GBP (N = 16)(<a href="./references#CD010224-fig-0261" title="">Analysis 58.5</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.09 to 0.13; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1090"> <p><b>58.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1091"> <h5 class="title">59 VPA vs LAC</h5> <section id="CD010224-sec-1092"> <h6 class="title">59.1 All major malformations</h6> <section id="CD010224-sec-1093"> <p><b>59.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0262" title="">Analysis 59.1</a>). However, available data showed there were 4/17 cases of major malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>). </p> </section> <section id="CD010224-sec-1094"> <p><b>59.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1095"> <h6 class="title">59.2 Neural tube malformations</h6> <section id="CD010224-sec-1096"> <p><b>59.2.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0264" title="">Analysis 59.3</a>). However, available data showed there were 1/17 cases of neural tube malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>). </p> </section> <section id="CD010224-sec-1097"> <p><b>59.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1098"> <h6 class="title">59.3 Cardiac malformations</h6> <section id="CD010224-sec-1099"> <p><b>59.3.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0265" title="">Analysis 59.4</a>). However, available data showed there were 1/17 cases of cardiac malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>). </p> </section> <section id="CD010224-sec-1100"> <p><b>59.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1101"> <h6 class="title">59.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1102"> <p><b>59.4.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0266" title="">Analysis 59.5</a>). However, available data showed there were 1/17 cases of oro‐facial cleft/craniofacial malformations in children exposed to VPA and 0/1 cases in children exposed to LAC, based on data from one study (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>). </p> </section> <section id="CD010224-sec-1103"> <p><b>59.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1104"> <h6 class="title">59.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1105"> <p><b>59.5.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0263" title="">Analysis 59.2</a>). However, available data showed that there were 0/17 cases of skeletal/limb malformations in children exposed to VPA (N = 17) and 0/1 in children exposed to LAC, based on data from one study (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>). </p> </section> <section id="CD010224-sec-1106"> <p><b>59.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1107"> <h5 class="title">60 VPA versus LEV</h5> <section id="CD010224-sec-1108"> <h6 class="title">60.1 All major malformations</h6> <section id="CD010224-sec-1109"> <p><b>60.1.1 Cohort studies</b></p> <p>Pooled results from 10 cohort studies suggested an increased risk with VPA (RR 3.77, 95% CI 2.48 to 5.74; I<sup>2</sup> = 17%), with children exposed to VPA (N = 2342) experiencing more major malformations than children exposed to LEV (N = 1143) (<a href="./references#CD010224-fig-0267" title="">Analysis 60.1</a>). The RD also suggested a higher absolute risk for VPA (RD 0.07, 95% CI 0.05 to 0.08; I<sup>2</sup> = 11%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 2.8% (95% CI 1.7 to 4.5) for children exposed to LEV. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Valproate dose and Levetiracetam dose sections). </p> </section> <section id="CD010224-sec-1110"> <p><b>60.1.2 Routine health record studies</b></p> <p>Pooled results from two routine health record studies suggested an increased risk with VPA (RR 3.26, 95% CI 1.51 to 7.03; I<sup>2</sup> = 0%), with children exposed to VPA (N = 663) experiencing more major malformations than children exposed to LEV (N = 248) (<a href="./references#CD010224-fig-0267" title="">Analysis 60.1</a>). The RD also suggested a higher risk for VPA (RD 0.06, 95% CI 0.03 to 0.09; I<sup>2</sup> = 28%). </p> </section> </section> <section id="CD010224-sec-1111"> <h6 class="title">60.2 Neural tube malformations</h6> <section id="CD010224-sec-1112"> <p><b>60.2.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested an increased risk with VPA (RR 3.76, 95% CI 1.22 to 11.55; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2298) experiencing more neural tube malformations than children exposed to LEV (N = 1048) (<a href="./references#CD010224-fig-0268" title="">Analysis 60.2</a>). The RD also suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0% for children exposed to LEV (0/599). </p> </section> <section id="CD010224-sec-1113"> <p><b>60.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1114"> <h6 class="title">60.3 Cardiac malformations</h6> <section id="CD010224-sec-1115"> <p><b>60.3.1 Cohort studies</b></p> <p>Pooled results from 10 cohort studies suggested an increased risk with VPA (RR 3.04, 95% CI 1.46 to 6.34; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2299) experiencing more cardiac malformations than children exposed to LEV (N = 1057) (<a href="./references#CD010224-fig-0269" title="">Analysis 60.3</a>). The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.01 to 0.03; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 0.83% for children exposed to LEV 0.83% (5/599). </p> </section> <section id="CD010224-sec-1116"> <p><b>60.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1117"> <h6 class="title">60.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1118"> <p><b>60.4.1 Cohort studies</b></p> <p>Pooled results from nine studies suggested an increased risk with VPA (RR 3.75, 95% CI 1.19 to 11.77; I<sup>2</sup> = 0%), with children exposed to VPA (N = 1958) experiencing more oro‐facial cleft/craniofacial malformations than children exposed to LEV (N = 951) (<a href="./references#CD010224-fig-0270" title="">Analysis 60.4</a>). The RD also suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.16% for children exposed to LEV (1/599). </p> </section> <section id="CD010224-sec-1119"> <p><b>60.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1120"> <h6 class="title">60.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1121"> <p><b>60.5.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested an increased risk with VPA (RR 2.41, 95% CI 0.99 to 5.85; I<sup>2</sup> = 55%), with children exposed to VPA (N = 2298) experiencing more skeletal/limb malformations than children exposed to LEV (N = 1048) (<a href="./references#CD010224-fig-0271" title="">Analysis 60.5</a>). Due to high heterogeneity, a random‐effects RR was calculated which found no difference in the level of risk (RR 1.89, 95% CI 0.34 to 10.60, I<sup>2</sup> = 55%). However, both the fixed‐effect RD analysis (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 12%) and the random‐effects RD analysis (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 12%) also suggested a higher absolute risk for VPA. </p> </section> <section id="CD010224-sec-1122"> <p><b>60.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1123"> <h5 class="title">61 VPA versus LTG</h5> <section id="CD010224-sec-1124"> <h6 class="title">61.1 All major malformations</h6> <section id="CD010224-sec-1125"> <p><b>61.1.1 Cohort studies</b></p> <p>Pooled results from 12 cohort studies suggested an increased risk with VPA (RR 3.50, 95% CI 2.76 to 4.46; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2459) experiencing more major malformations than children exposed to LTG (N = 4437) (<a href="./references#CD010224-fig-0272" title="">Analysis 61.1</a>). The RD suggested an increased risk for VPA (RD 0.06, 95% CI 0.05 to 0.08; I<sup>2</sup> = 34%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 2.9% (95% CI 2.3 to 3.7) for children exposed to LTG. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Valproate dose and Lamotrigine dose sections). </p> </section> <section id="CD010224-sec-1126"> <p><b>61.1.2 Routine health record studies</b></p> <p>Pooled results from four routine health record studies suggested an increased risk with VPA (RR 2.49, 95% CI 1.86 to 3.35; I<sup>2</sup> = 0%), with children exposed to VPA (N = 1088) experiencing more major malformations than children exposed to LTG (N = 2502) (<a href="./references#CD010224-fig-0272" title="">Analysis 61.1</a>). The RD also suggested an increased level of risk for VPA (RD 0.05, 95% CI 0.03 to 0.07; I<sup>2</sup> = 42%). </p> </section> </section> <section id="CD010224-sec-1127"> <h6 class="title">61.2 Neural tube malformations</h6> <section id="CD010224-sec-1128"> <p><b>61.2.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested an increased risk with VPA (RR 7.48, 95% CI 3.27 to 17.13; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2415) experiencing more neural tube malformations than children exposed to LTG (N = 4293) (<a href="./references#CD010224-fig-0273" title="">Analysis 61.2</a>). The RD also suggested an increased level of risk for VPA (RD 0.01, 95% CI 0.01 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0.3% for children exposed to LTG (1/2514). </p> </section> <section id="CD010224-sec-1129"> <p><b>61.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1130"> <h6 class="title">61.3 Cardiac malformations</h6> <section id="CD010224-sec-1131"> <p><b>61.3.1 Cohort studies</b></p> <p>Pooled results from 12 cohort studies suggested an increased risk with VPA (RR 3.39, 95% CI 2.06 to 5.60; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2416) experiencing more neural tube malformations than children exposed to LTG (N = 4313) (<a href="./references#CD010224-fig-0274" title="">Analysis 61.3</a>). The RD also suggested an increased level of risk for VPA (RD 0.02, 95% CI 0.01 to 0.02; I<sup>2</sup> = 3%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 5.9% for children exposed to LTG (15/2514). </p> </section> <section id="CD010224-sec-1132"> <p><b>61.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1133"> <h6 class="title">61.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1134"> <p><b>61.4.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested an increased risk with VPA (RR 4.16, 95% CI 2.14 to 8.08; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2075) experiencing more craniofacial malformations than children exposed to LTG (N = 4263) (<a href="./references#CD010224-fig-0275" title="">Analysis 61.4</a>). The RD also suggested an increased level of risk for VPA (RD 0.01, 95% CI 0.01 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.11% for children exposed to LTG (3/2514). </p> </section> <section id="CD010224-sec-1135"> <p><b>61.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1136"> <h6 class="title">61.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1137"> <p><b>61.5.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested an increased risk with VPA (RR 6.09, 95% CI 2.91 to 12.76; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2415) experiencing more craniofacial malformations than children exposed to LTG (N = 4293) (<a href="./references#CD010224-fig-0276" title="">Analysis 61.5</a>). The RD also suggested an increased level of risk for VPA (RD 0.01, 95% CI 0.01 to 0.02; I<sup>2</sup> = 26%). </p> </section> <section id="CD010224-sec-1138"> <p><b>61.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1139"> <h5 class="title">62 VPA versus TPM</h5> <section id="CD010224-sec-1140"> <h6 class="title">62.1 All major malformations</h6> <section id="CD010224-sec-1141"> <p><b>62.1.1 Cohort studies</b></p> <p>Pooled results from seven cohort studies suggested an increased risk with VPA (RR 2.47, 95% CI 1.50 to 4.08; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2219) experiencing more major malformations than children exposed to TPM (N = 504) (<a href="./references#CD010224-fig-0277" title="">Analysis 62.1</a>). The RD also suggested a higher absolute risk for VPA (RD 0.06, 95% CI 0.03 to 0.09; I<sup>2</sup> = 41%). Due to high heterogeneity, we undertook a random‐effects analysis which found a similar effect (RD 0.07, 95% CI 0.02 to 0.11; I<sup>2</sup> = 41%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Valproate dose and Topiramate dose sections). </p> </section> <section id="CD010224-sec-1142"> <p><b>62.1.2 Routine health record studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 1.27, 95% CI 0.36 to 4.39, I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to VPA (N = 601) and children exposed to TPM (N = 49) (<a href="./references#CD010224-fig-0277" title="">Analysis 62.1</a>). The RD also suggested no difference in the level of risk (RD 1.27, 95% CI 0.36 to 4.39; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-1143"> <h6 class="title">62.2 Neural tube malformations</h6> <section id="CD010224-sec-1144"> <p><b>62.2.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 2.39, 95% CI 0.73 to 7.80; I<sup>2</sup> = 2%), with no difference in the number of neural tube malformations in children exposed to VPA (N = 2175) and children exposed to TPM (N = 490) (<a href="./references#CD010224-fig-0278" title="">Analysis 62.2</a>). The RD suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.03; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-1145"> <p><b>62.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1146"> <h6 class="title">62.3 Cardiac malformations</h6> <section id="CD010224-sec-1147"> <p><b>62.3.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested an increased risk with VPA (RR 3.48, 95% CI 1.16 to 10.48; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2175) experiencing more cardiac malformations than children exposed to TPM (N = 495) (<a href="./references#CD010224-fig-0279" title="">Analysis 62.3</a>). The RD also suggested a higher absolute risk for VPA (RD 0.02, 95% CI 0.01 to 0.04; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 1.97% for children exposed to TPM (3/152). </p> </section> <section id="CD010224-sec-1148"> <p><b>62.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1149"> <h6 class="title">62.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1150"> <p><b>62.4.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.89 95% CI 0.37 to 2.13; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to VPA (N = 1835) and children exposed to TPM (N = 482) (<a href="./references#CD010224-fig-0280" title="">Analysis 62.4</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-1151"> <p><b>62.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1152"> <h6 class="title">62.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1153"> <p><b>62.5.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 1.45, 95% CI 0.55 to 3.82; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to VPA (N = 2199) and children exposed to TPM (N = 490) (<a href="./references#CD010224-fig-0281" title="">Analysis 62.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.00 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1154"> <p><b>62.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1155"> <h5 class="title">63 VPA versus OXC</h5> <section id="CD010224-sec-1156"> <h6 class="title">63.1 All major malformations</h6> <section id="CD010224-sec-1157"> <p><b>63.1.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested an increased risk with VPA (RR 2.48, 95% CI 1.42 to 4.31; I<sup>2</sup> = 13%), with children exposed to VPA (N = 1183) experiencing more major malformations than children exposed to OXC (N = 378) (<a href="./references#CD010224-fig-0282" title="">Analysis 63.1</a>). The RD also suggested a higher risk for VPA (RD 0.06, 95% CI 0.03 to 0.09; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Valproate dose and Oxcarbazepine dose sections). </p> </section> <section id="CD010224-sec-1158"> <p><b>63.1.2 Routine health record studies</b></p> <p>Results from four routine health record studies suggested an increased risk with VPA (RR 1.60, 95% CI 1.11 to 2.29; I<sup>2</sup> = 80%), with children exposed to VPA (N = 1194) experiencing more major malformations than children exposed to OXC (N = 507) (<a href="./references#CD010224-fig-0282" title="">Analysis 63.1</a>). Due to heterogeneity, a random‐effects RR was calculated, which showed no evidence of a difference in risk (RR 1.80, 95% CI 0.57 to 5.67; I<sup>2</sup> = 80%). The RD suggested a higher risk for VPA (RD 0.04, 95% CI 0.01 to 0.08; I<sup>2</sup> = 65%). Due to heterogeneity, a random‐effects RD was calculated which showed no evidence of a difference in risk (RD 0.04, 95% CI ‐0.01 to 0.10, I<sup>2</sup> = 65%). </p> </section> <section id="CD010224-sec-1159"> <p><b>63.2.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 1.55, 95% CI 0.49 to 4.89; I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to VPA (N = 1133) and children exposed to OXC (N = 364) (<a href="./references#CD010224-fig-0283" title="">Analysis 63.2</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.00 to 0.03; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0% for children exposed to OXC (0/333). </p> </section> <section id="CD010224-sec-1160"> <p><b>63.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1161"> <h6 class="title">63.3 Cardiac malformations</h6> <section id="CD010224-sec-1162"> <p><b>63.3.1 Cohort studies</b></p> <p>Pooled results from 11 cohort studies suggested no evidence of a difference in risk (RR 1.80, 95% CI 0.84 to 3.88; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to VPA (N = 1140) and children exposed to OXC (N = 457) (<a href="./references#CD010224-fig-0284" title="">Analysis 63.3</a>). The RD suggested a higher risk for VPA (RD 0.02, 95% CI 0.00 to 0.04; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 1.20% for children exposed to OXC (4/333). </p> </section> <section id="CD010224-sec-1163"> <p><b>63.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1164"> <h6 class="title">63.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1165"> <p><b>63.4.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 2.14, 95% CI 0.76 to 6.06; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to VPA (N = 793) and children exposed to OXC (N = 385) (<a href="./references#CD010224-fig-0285" title="">Analysis 63.4</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI ‐0.00 to 0.04; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.30% for children exposed to OXC (1/333). </p> </section> <section id="CD010224-sec-1166"> <p><b>63.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1167"> <h6 class="title">63.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1168"> <p><b>63.5.1 Cohort studies</b></p> <p>Pooled results from nine cohort studies suggested no evidence of a difference in risk (RR 1.37, 95% CI 0.42 to 4.49; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to VPA (N = 1133) and children exposed to OXC (N = 364) (<a href="./references#CD010224-fig-0286" title="">Analysis 63.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.01 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1169"> <p><b>63.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1170"> <h5 class="title">64 VPA versus PB</h5> <section id="CD010224-sec-1171"> <h6 class="title">64.1 All major malformations</h6> <section id="CD010224-sec-1172"> <p><b>64.1.1 Cohort studies</b></p> <p>Pooled results from 23 cohort studies suggested an increased risk with VPA (RR 1.49, 95% CI 1.08 to 2.07; I<sup>2</sup> = 0%), with children exposed to VPA (N = 1557) experiencing more major malformations than children exposed to PB (N = 759) (<a href="./references#CD010224-fig-0287" title="">Analysis 64.1</a>). The RD also suggested a higher risk for VPA (RD 0.04, 95% CI 0.01 to 0.06; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 6.5% (95% CI 4.2 to 9.9) for children exposed to PB. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Valproate dose and Phenobarbital dose sections). <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported six cases of major malformation out of 184 (9%) VPA‐exposed children and five cases from 48 (10%) PB‐exposed children. </p> </section> <section id="CD010224-sec-1173"> <p><b>64.1.2 Routine health record studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.79, 95% CI 0.26 to 2.42, I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to VPA (N = 601) and children exposed to PRM (N = 34) (<a href="./references#CD010224-fig-0287" title="">Analysis 64.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.12 to 0.08; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-1174"> <h6 class="title">64.2 Neural tube malformations</h6> <section id="CD010224-sec-1175"> <p><b>64.2.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested evidence of a difference in risk (RR 3.04, 95% CI 1.27 to 7.30; I<sup>2</sup> = 1%), with children exposed to VPA (N = 1174) experiencing more neural tube malformations to children exposed to PB (N = 546) (<a href="./references#CD010224-fig-0288" title="">Analysis 64.2</a>). The RD also suggested a difference in the level of risk (RD 0.02, 95% CI 0.01 to 0.04; I<sup>2</sup> = 7%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0.68% for children exposed to PB (2/294). </p> </section> <section id="CD010224-sec-1176"> <p><b>64.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1177"> <h6 class="title">64.3 Cardiac malformations</h6> <section id="CD010224-sec-1178"> <p><b>64.3.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested no evidence of a difference in risk (RR 0.84, 95% CI 0.50 to 1.43; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to VPA (N = 1174) and children exposed to PB (N = 546) (<a href="./references#CD010224-fig-0289" title="">Analysis 64.3</a>). The RD also suggested no difference in the level of risk (RD −0.00, 95% CI −0.03 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 2.72% for children exposed to PB (8/294). </p> </section> <section id="CD010224-sec-1179"> <p><b>64.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1180"> <h6 class="title">64.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1181"> <p><b>64.4.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested no evidence of a difference in risk (RR 0.54, 95% CI 0.23 to 1.27; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to VPA (N = 839) and children exposed to PB (N = 418) (<a href="./references#CD010224-fig-0290" title="">Analysis 64.4</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.03 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0.34% for children exposed to PB (1/294). </p> </section> <section id="CD010224-sec-1182"> <p><b>64.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1183"> <h6 class="title">64.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1184"> <p><b>64.5.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested no evidence of a difference in risk (RR 1.62, 95% CI 0.70 to 3.74; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to VPA (N = 1174) and children exposed to PB (N = 546) (<a href="./references#CD010224-fig-0291" title="">Analysis 64.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.01 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1185"> <p><b>64.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1186"> <h5 class="title">65 VPA versus PHT</h5> <section id="CD010224-sec-1187"> <h6 class="title">65.1 All major malformations</h6> <section id="CD010224-sec-1188"> <p><b>65.1.1 Cohort studies</b></p> <p>Pooled results from 21 cohort studies suggested an increased risk with VPA (RR 1.92, 95% CI 1.44 to 2.56; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2650) experiencing more major malformations than children exposed to PHT (N = 1247) (<a href="./references#CD010224-fig-0292" title="">Analysis 65.1</a>). The RD also suggested a higher risk for VPA (RD 0.05, 95% CI 0.03 to 0.07; I<sup>2</sup> = 4%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 10.3% (95% CI 8.8 to 12.0) for children exposed to VPA and 6.4% (95% CI 2.8 to 12.2) for children exposed to PHT. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see Valproate dose and Phenytoin dose sections). <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> reported six cases of major malformation in 184 (9%) children exposed to VPA and nine in 141 (6%) PHT‐exposed children. </p> </section> <section id="CD010224-sec-1189"> <p><b>65.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 1.43, 95% CI 0.64 to 3.19; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to VPA (N = 268) and children exposed to PHT (N = 103) (<a href="./references#CD010224-fig-0292" title="">Analysis 65.1</a>). The RD also suggested no difference in the level of risk (RD 0.03, 95% CI −0.03 to 0.09; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-1190"> <h6 class="title">65.2 Neural tube malformations</h6> <section id="CD010224-sec-1191"> <p><b>65.2.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested an increased risk with VPA (RR 3.75, 95% CI 1.57 to 8.94; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2419) experiencing more neural tube malformations than children exposed to PHT (N = 974) (<a href="./references#CD010224-fig-0293" title="">Analysis 65.2</a>). The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.01 to 0.03; I<sup>2</sup> = 2%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to VPA was 1.15% (16/1381) and 0.80% for children exposed to PHT (1/125). </p> </section> <section id="CD010224-sec-1192"> <p><b>65.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1193"> <h6 class="title">65.3 Cardiac malformations</h6> <section id="CD010224-sec-1194"> <p><b>65.3.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested an increased risk with VPA (RR 1.90, 95% CI 1.07 to 3.36; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2419) experiencing more cardiac malformations than children exposed to PHT (N = 974) (<a href="./references#CD010224-fig-0294" title="">Analysis 65.3</a>). The RD also suggested a higher risk for VPA (RD 0.02, 95% CI 0.00 to 0.03; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to VPA was 2.46% (34/1381) and 4.0% for children exposed to PHT (5/125). </p> </section> <section id="CD010224-sec-1195"> <p><b>65.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1196"> <h6 class="title">65.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1197"> <p><b>65.4.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested no evidence of a difference in risk (RR 2.24, 95% CI 0.89 to 5.58; I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to VPA (N = 2084) and children exposed to PHT (N = 860) (<a href="./references#CD010224-fig-0295" title="">Analysis 65.4</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI ‐0.00 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to VPA was 0.43% (6/1381) and 0% for children exposed to PHT (0/125). </p> </section> <section id="CD010224-sec-1198"> <p><b>65.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1199"> <h6 class="title">65.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1200"> <p><b>65.5.1 Cohort studies</b></p> <p>Pooled results from 14 cohort studies suggested an increased risk with VPA (RR 2.12, 95% CI 1.01 to 4.45; I<sup>2</sup> = 0%), with children exposed to VPA (N = 2419) experiencing more skeletal/limb malformations than children exposed to PHT (N = 975) (<a href="./references#CD010224-fig-0296" title="">Analysis 65.5</a>). The RD also suggested a higher risk for VPA (RD 0.01, 95% CI 0.00 to 0.02; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1201"> <p><b>65.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1202"> <h5 class="title">66 VPA versus ZNS</h5> <section id="CD010224-sec-1203"> <h6 class="title">66.1 All major malformations</h6> <section id="CD010224-sec-1204"> <p><b>66.1.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 2.34, 95% CI 0.95 to 5.80; I<sup>2</sup> = 77%), with children exposed to VPA (N = 1560) experiencing comparable major malformations to children exposed to ZNS (N = 117) (<a href="./references#CD010224-fig-0297" title="">Analysis 66.1</a>). Due to high heterogeneity, a random‐effects RR analysis was completed which also found no difference (RR 1.81, 95% CI 0.14 to 22.75; I<sup>2</sup> = 77%). The RD suggested a higher risk for VPA (RD 0.06, 95% CI 0.01 to 0.10; I<sup>2</sup> = 72%). However, due to heterogeneity, a random‐effects RD was calculated which found no difference in the level of risk (RD 0.04, 95% CI ‐0.11 to 0.19, I<sup>2</sup> = 72%). </p> </section> <section id="CD010224-sec-1205"> <p><b>66.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1206"> <h6 class="title">66.2 Neural tube malformations</h6> <section id="CD010224-sec-1207"> <p><b>66.2.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.29, 95% CI 0.06 to 1.51, I<sup>2</sup> = 0%), with no difference in the number of neural tube malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (<a href="./references#CD010224-fig-0298" title="">Analysis 66.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.11 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1208"> <p><b>66.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1209"> <h6 class="title">66.3 Cardiac malformations</h6> <section id="CD010224-sec-1210"> <p><b>66.3.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.49, 95% CI 0.07 to 3.65, I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (<a href="./references#CD010224-fig-0299" title="">Analysis 66.3</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.08; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1211"> <p><b>66.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1212"> <h6 class="title">66.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1213"> <p><b>66.4.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.47, 95% CI 0.06 to 3.49, I<sup>2</sup> = 0%), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (<a href="./references#CD010224-fig-0300" title="">Analysis 66.4</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.05 to 0.08; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1214"> <p><b>66.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1215"> <h6 class="title">66.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1216"> <p><b>66.5.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.46, 95% CI 0.03 to 7.72, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to VPA (N = 1237) and children exposed to ZNS (N = 27) (<a href="./references#CD010224-fig-0301" title="">Analysis 66.5</a>). The RD also suggested no difference in the level of risk (RD 0.01, 95% CI −0.06 to 0.07; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1217"> <p><b>66.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1218"> <h5 class="title">67 CZP vs VPA</h5> <section id="CD010224-sec-1219"> <h6 class="title">67.1 All major malformations</h6> <section id="CD010224-sec-1220"> <p><b>67.1.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested an increased risk with VPA (RR 0.29, 95% CI 0.09 to 0.90; I<sup>2</sup> = 0%), with children exposed to VPA (N = 955) experiencing more major malformations than children exposed to CZP (N = 95) (<a href="./references#CD010224-fig-0302" title="">Analysis 67.1</a>). The RD also suggested a higher risk for VPA (RD −0.09, 95% CI −0.13 to ‐0.04; I<sup>2</sup> = 30%). </p> </section> <section id="CD010224-sec-1221"> <p><b>67.1.2 Routine health record studies</b></p> <p>Pooled results from two routine health record studies suggested an increased risk with VPA (RR 0.34, 95% CI 0.13 to 0.94; I<sup>2</sup> = 0%), with children exposed to VPA (N = 601) experiencing more major malformations than children exposed to CZP (N = 161) (<a href="./references#CD010224-fig-0302" title="">Analysis 67.1</a>). The RD suggested no difference in the level of risk (RD −0.05, 95% CI −0.12 to 0.01; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-1222"> <h6 class="title">67.2 Neural tube malformations</h6> <section id="CD010224-sec-1223"> <p><b>67.2.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 9.77, 95% CI 0.58 to 165.35, I<sup>2</sup> = NA), with no difference in the number of neural tube malformations in children exposed to CZP (N = 4) and children exposed to VPA (N = 341) (<a href="./references#CD010224-fig-0303" title="">Analysis 67.2</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.27 to 0.25; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1224"> <p><b>67.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1225"> <h6 class="title">67.3 Cardiac malformations</h6> <section id="CD010224-sec-1226"> <p><b>67.3.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.67, 95% CI 0.12 to 23.92, I<sup>2</sup> = NA), with no difference in the number of cardiac malformations in children exposed to CZP (N = 4) and children exposed to VPA (N = 341) (<a href="./references#CD010224-fig-0304" title="">Analysis 67.3</a>). The RD also suggested no difference in the level of risk (RD ‐0.06, 95% CI −0.32 to 0.21; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1227"> <p><b>67.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1228"> <h6 class="title">67.4 Skeletal/limb malformations</h6> <section id="CD010224-sec-1229"> <p><b>67.4.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 7.60, 95% CI 0.47 to 123.14, I<sup>2</sup> = NA), with no difference in the number of skeletal/limb malformations in children exposed to CZP (N = 4) and children exposed to VPA (N = 341) (<a href="./references#CD010224-fig-0305" title="">Analysis 67.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI −0.27 to 0.25; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1230"> <p><b>67.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1231"> <h6 class="title">67.5 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1232"> <p><b>67.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1233"> <p><b>67.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1234"> <h5 class="title">68 CZP versus LEV</h5> <section id="CD010224-sec-1235"> <h6 class="title">68.1 All major malformations</h6> <section id="CD010224-sec-1236"> <p><b>68.1.1 Cohort studies</b></p> <p>Pooled results from three cohort studies suggested no evidence of a difference in risk (RR 1.06, 95% CI 0.32 to 3.44; I<sup>2</sup> = 0%), with children exposed to CZP (N = 94) experiencing more major malformations than children exposed to LEV (N = 695) (<a href="./references#CD010224-fig-0306" title="">Analysis 68.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.05 to 0.03; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1237"> <p><b>68.1.2 Routine health record studies</b></p> <p>Results from one routine health record study suggested no evidence of a difference in risk (RR 1.04, 95% CI 0.15 to 7.29; I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to CZP (N = 113) and children exposed to LEV (N = 118) (<a href="./references#CD010224-fig-0306" title="">Analysis 68.1</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI −0.03 to 0.03; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD010224-sec-1238"> <h6 class="title">68.2 Neural tube malformations</h6> <section id="CD010224-sec-1239"> <p><b>68.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1240"> <p><b>68.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1241"> <h6 class="title">68.3 Cardiac malformations</h6> <section id="CD010224-sec-1242"> <p><b>68.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1243"> <p><b>68.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1244"> <h6 class="title">68.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1245"> <p><b>68.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1246"> <p><b>68.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1247"> <h6 class="title">68.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1248"> <p><b>68.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1249"> <p><b>68.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1250"> <h5 class="title">69 OXC versus PRM</h5> <section id="CD010224-sec-1251"> <h6 class="title">69.1 All major malformations</h6> <section id="CD010224-sec-1252"> <p><b>69.1.1 Cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk (RR 0.58, 95% CI 0.08 to 4.03; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to OXC (N = 28) and children exposed to PRM (N = 8) (<a href="./references#CD010224-fig-0307" title="">Analysis 69.1</a>). The RD also suggested no difference in the level of risk (RD −0.02, 95% CI −0.34 to 0.30; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1253"> <p><b>69.1.2 Routine health record studies</b></p> <p>We were unable to estimate the RR for one routine health record study due to there being no reported major malformations observed in children exposed to OXC (N = 4) or PRM (N = 3) (<a href="./references#CD010224-fig-0307" title="">Analysis 69.1</a>). </p> </section> </section> <section id="CD010224-sec-1254"> <h6 class="title">69.2 Neural tube malformations</h6> <section id="CD010224-sec-1255"> <p><b>69.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1256"> <p><b>69.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1257"> <h6 class="title">69.3 Cardiac malformations</h6> <section id="CD010224-sec-1258"> <p><b>69.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1259"> <p><b>69.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1260"> <h6 class="title">69.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1261"> <p><b>69.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1262"> <p><b>69.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1263"> <h6 class="title">69.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1264"> <p><b>69.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1265"> <p><b>69.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1266"> <h5 class="title">70 OXC versus TPM</h5> <section id="CD010224-sec-1267"> <h6 class="title">70.1 All major malformations</h6> <section id="CD010224-sec-1268"> <p><b>70.1.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested no evidence of a difference in risk (RR 0.71, 95% CI 0.28 to 1.77; I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to OXC (N = 279) and children exposed to TPM (N = 427) (<a href="./references#CD010224-fig-0308" title="">Analysis 70.1</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.04 to 0.02; I<sup>2</sup> = 0%). </p> <p>The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration reported the prevalence of MCM was 3.0% (95% CI 1.4 to 5.4) for children exposed to OXC and 3.9% (95% CI 1.5 to 8.4) for children exposed to TPM. No direct statistical comparison was made at the group level; investigations were made across different doses of the two ASMs (see oxcarbazepine dose and topiramate dose sections). </p> </section> <section id="CD010224-sec-1269"> <p><b>70.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0308" title="">Analysis 70.1</a>). However, available data showed there were 1/61 cases of major malformations in children exposed to OXC and 2/49 cases in children exposed to TPM, based on data from two studies (<a href="./references#CD010224-bbs2-0038" title="BorthenI , EideMG , VeibyG , DaltveitAK , GilhusNE . Complications during pregnancy in women with epilepsy: population-based cohort study. British Journal of Obstetrics and Gynecology2009;116(13):1736–42. [PMID: 19781049]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology2014;261(13):579-88. [PMID: 24449062]VeibyG , DaltveitAK , EngelsenBA , GilhusNE . Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia2009;50(9):2130-9. [PMID: 19490036]">Norwegian Health Record Registers</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> </section> </section> <section id="CD010224-sec-1270"> <h6 class="title">70.2 Neural tube malformations</h6> <section id="CD010224-sec-1271"> <p><b>70.2.1 Cohort studies</b></p> <p>We could not estimate a RR from four cohort studies due to there being no reported neural tube malformations in children exposed to OXC (N = 266) or children exposed to TPM (N = 418) (<a href="./references#CD010224-fig-0309" title="">Analysis 70.2</a>). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of neural tube anomalies in those exposed to OXC was 0% (0/333) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-1272"> <p><b>70.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1273"> <h6 class="title">70.3 Cardiac malformations</h6> <section id="CD010224-sec-1274"> <p><b>70.3.1 Cohort studies</b></p> <p>Pooled results from five cohort studies suggested no evidence of a difference in risk (RR 0.80, 95% CI 0.09 to 6.81; I<sup>2</sup> = 0%), with no difference in the number of cardiac malformations in children exposed to OXC (N = 269) and children exposed to TPM (N = 419) (<a href="./references#CD010224-fig-0310" title="">Analysis 70.3</a>). The RD also suggested no difference in the level of risk (RD 0.00, 95% CI ‐0.02 to 0.02; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cardiac anomalies in those exposed to OXC was 1.20% (4/333) and 1.97% for children exposed to TPM (3/152). </p> </section> <section id="CD010224-sec-1275"> <p><b>70.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1276"> <h6 class="title">70.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1277"> <p><b>70.4.1 Cohort studies</b></p> <p>Pooled results from four studies suggested no evidence of a difference in risk (RR 0.39, 95% CI 0.05 to 3.35, I<sup>2</sup> = NA), with no difference in the number of oro‐facial cleft/craniofacial malformations in children exposed to OXC (N = 198) and children exposed to TPM (N = 410) (<a href="./references#CD010224-fig-0311" title="">Analysis 70.4</a>). The RD also suggested no difference in the level of risk (RD ‐0.01, 95% CI ‐0.03 to 0.01; I<sup>2</sup> = 0%). </p> <p>In the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> data, the prevalence of cleft malformations (other oro‐facial not specifically reported) in those exposed to OXC was 0.30% (1/333) and 0% for children exposed to TPM (0/152). </p> </section> <section id="CD010224-sec-1278"> <p><b>70.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1279"> <h6 class="title">70.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1280"> <p><b>70.5.1 Cohort studies</b></p> <p>Pooled results from four cohort studies suggested no evidence of a difference in risk (RR 0.40, 95% CI 0.07 to 2.44; I<sup>2</sup> = 0%), with no difference in the number of skeletal/limb malformations in children exposed to OXC (N = 266) and children exposed to TPM (N = 418) (<a href="./references#CD010224-fig-0312" title="">Analysis 70.5</a>). The RD also suggested no difference in the level of risk (RD −0.01, 95% CI −0.03 to 0.01; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1281"> <p><b>70.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1282"> <h5 class="title">71 OXC versus ZNS</h5> <section id="CD010224-sec-1283"> <h6 class="title">71.1 All major malformations</h6> <section id="CD010224-sec-1284"> <p><b>71.1.1 Cohort studies</b></p> <p>Pooled results from two cohort studies suggested no evidence of a difference in risk (RR 4.48, 95% CI 0.24 to 82.23; I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to OXC (N = 186) and children exposed to ZNS (N = 91) ( <a href="./references#CD010224-fig-0313" title="">Analysis 71.1</a>). The RD also suggested no difference in the level of risk (RD 0.02, 95% CI −0.01 to 0.05; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1285"> <p><b>71.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1286"> <h6 class="title">71.2 Neural tube malformations</h6> <section id="CD010224-sec-1287"> <p><b>71.2.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported cases of neural tube malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (<a href="./references#CD010224-fig-0314" title="">Analysis 71.2</a>). </p> </section> <section id="CD010224-sec-1288"> <p><b>71.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1289"> <h6 class="title">71.3 Cardiac malformations</h6> <section id="CD010224-sec-1290"> <p><b>71.3.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported cases of cardiac malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (<a href="./references#CD010224-fig-0315" title="">Analysis 71.3</a>). </p> </section> <section id="CD010224-sec-1291"> <p><b>71.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1292"> <h6 class="title">71.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1293"> <p><b>71.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported cases of oro‐facial cleft/ craniofacial malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (<a href="./references#CD010224-fig-0316" title="">Analysis 71.4</a>). </p> </section> <section id="CD010224-sec-1294"> <p><b>71.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1295"> <h6 class="title">71.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1296"> <p><b>71.5.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported cases of skeletal/limb malformations in children exposed to OXC (N = 4) or ZNS (N = 1) (<a href="./references#CD010224-fig-0317" title="">Analysis 71.5</a>). </p> </section> <section id="CD010224-sec-1297"> <p><b>71.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1298"> <h5 class="title">72 PRM versus TPM</h5> <section id="CD010224-sec-1299"> <h6 class="title">72.1 All major malformations</h6> <section id="CD010224-sec-1300"> <p><b>72.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 6.00, 95% CI 0.30 to 118.36, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to PRM (N = 2) and children exposed to TPM (N = 53) (<a href="./references#CD010224-fig-0318" title="">Analysis 72.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.44 to 0.41; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1301"> <p><b>72.1.2 Routine health record studies</b></p> <p>We were unable to estimate a RR from one study due to there being no reported cases of major malformations in children exposed to PRM (N = 3) or TPM (N = 1) (<a href="./references#CD010224-fig-0318" title="">Analysis 72.1</a>). </p> </section> </section> <section id="CD010224-sec-1302"> <h6 class="title">72.2 Neural tube malformations</h6> <section id="CD010224-sec-1303"> <p><b>72.2.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1304"> <p><b>72.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1305"> <h6 class="title">72.3 Cardiac malformations</h6> <section id="CD010224-sec-1306"> <p><b>72.3.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1307"> <p><b>72.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1308"> <h6 class="title">72.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1309"> <p><b>72.4.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1310"> <p><b>72.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1311"> <h6 class="title">72.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1312"> <p><b>72.5.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1313"> <p><b>72.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1314"> <h5 class="title">73 PRM versus VPA</h5> <section id="CD010224-sec-1315"> <h6 class="title">73.1 All major malformations</h6> <section id="CD010224-sec-1316"> <p><b>73.1.1 Cohort studies</b></p> <p>Pooled results from six cohort studies suggested no evidence of a difference in risk (RR 0.74, 95% CI 0.39 to 1.40; I<sup>2</sup> = 21%), with no difference in the number of major malformations in children exposed to PRM (N = 103) and children exposed to VPA (N = 491), (<a href="./references#CD010224-fig-0319" title="">Analysis 73.1</a>). The RD also suggested no difference in the level of risk (RD −0.04, 95% CI −0.13 to 0.04; I<sup>2</sup> = 1%). </p> </section> <section id="CD010224-sec-1317"> <p><b>73.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.27, 95% CI 0.09 to 17.39, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to PRM (N = 3) and children exposed to VPA (N = 268) (<a href="./references#CD010224-fig-0319" title="">Analysis 73.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.10, 95% CI −0.42 to 0.23; I<sup>2</sup> = NA). </p> </section> </section> <section id="CD010224-sec-1318"> <h6 class="title">73.2 Neural tube malformations</h6> <section id="CD010224-sec-1319"> <p><b>73.2.1 Cohort studies</b></p> <p>Included studies did not reach the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0320" title="">Analysis 73.2</a>). However, available data showed there were 0/39 cases of neural tube malformations in children exposed to PRM and 5/45 cases in children exposed to VPA, based on data from two studies (<a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>). </p> </section> <section id="CD010224-sec-1320"> <p><b>73.2.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1321"> <h6 class="title">73.3 Cardiac malformations</h6> <section id="CD010224-sec-1322"> <p><b>73.3.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0321" title="">Analysis 73.3</a>). However, available data showed there were 1/39 cases of cardiac malformations in children exposed to PRM and 0/45 cases in children exposed to VPA, based on data from two studies (<a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>). </p> </section> <section id="CD010224-sec-1323"> <p><b>73.3.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1324"> <h6 class="title">73.4 Oro‐facial cleft/craniofacial malformations</h6> <section id="CD010224-sec-1325"> <p><b>73.4.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two studies due to there being no reported oro‐facial cleft/craniofacial malformations in children exposed to PRM (N = 39) or VPA (N = 45). (<a href="./references#CD010224-fig-0322" title="">Analysis 73.4</a>). </p> </section> <section id="CD010224-sec-1326"> <p><b>73.4.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> <section id="CD010224-sec-1327"> <h6 class="title">73.5 Skeletal/limb malformations</h6> <section id="CD010224-sec-1328"> <p><b>73.5.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0323" title="">Analysis 73.5</a>). However, available data showed there were 0/39 cases of skeletal/limb malformations in children exposed to PRM and 1/45 cases in children exposed to VPA, based on data from two studies (<a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0040" title="PardiG , ComoML , De GiambattistaM , OldriniA , PifarottiG . Epilepsy and pregnancy: obstetrical aspects of a prospective multidisciplinary study [Epilessia e gravidanza: aspetti ostetrici di uno studio prospettico multidisciplinare]. Annali di Ostetricia, Ginecologia, Medicina Perinatale1982;103(4):254-63. [PMID: 7181355]">Pardi 1982</a>). </p> </section> <section id="CD010224-sec-1329"> <p><b>73.5.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1330"> <h5 class="title">74 LEV vs LAC</h5> <section id="CD010224-sec-1331"> <h6 class="title">74.1 All major malformations</h6> <section id="CD010224-sec-1332"> <p><b>74.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to LEV (N = 12) or LAC (N = 1) (<a href="./references#CD010224-fig-0324" title="">Analysis 74.1</a>). </p> </section> <section id="CD010224-sec-1333"> <p><b>74.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1334"> <h5 class="title">75 CBZ versus LAC</h5> <section id="CD010224-sec-1335"> <h6 class="title">75.1 All major malformations</h6> <section id="CD010224-sec-1336"> <p><b>75.1.1 Cohort studies</b></p> <p>We could not estimate RR from one cohort study as there were no malformations observed in children exposed to CBZ (N = 7) and children exposed to LAC (N = 1) (<a href="./references#CD010224-fig-0325" title="">Analysis 75.1</a>). </p> </section> <section id="CD010224-sec-1337"> <p><b>75.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1338"> <h5 class="title">76 OXC vs LAC</h5> <section id="CD010224-sec-1339"> <h6 class="title">76.1 All major malformations</h6> <section id="CD010224-sec-1340"> <p><b>76.1.1 Cohort studies</b></p> <p>We were unable to estimate the RR for one cohort study due to there being no major malformations observed in children exposed to OXC (N = 4) or LAC (N = 1) (<a href="./references#CD010224-fig-0326" title="">Analysis 76.1</a>). </p> </section> <section id="CD010224-sec-1341"> <p><b>76.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1342"> <h5 class="title">77 PB versus LAC</h5> <section id="CD010224-sec-1343"> <h6 class="title">77.1 All major malformations</h6> <section id="CD010224-sec-1344"> <p><b>77.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one cohort study due to there being no malformations observed in children exposed to PB (N = 2) and children exposed to LAC (N = 1) (<a href="./references#CD010224-fig-0327" title="">Analysis 77.1</a>). </p> </section> <section id="CD010224-sec-1345"> <p><b>77.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1346"> <h5 class="title">78 LAC vs ZNS</h5> <section id="CD010224-sec-1347"> <h6 class="title">78.1 All major malformations</h6> <section id="CD010224-sec-1348"> <p><b>78.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one cohort study due to there being no major malformations observed in children exposed to LAC (N = 1) or ZNS (N = 1) (<a href="./references#CD010224-fig-0328" title="">Analysis 78.1</a>). </p> </section> <section id="CD010224-sec-1349"> <p><b>78.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1350"> <h5 class="title">79 GPB versus PGB</h5> <section id="CD010224-sec-1351"> <h6 class="title">79.1 All major malformations</h6> <section id="CD010224-sec-1352"> <p><b>79.1.1 Cohort studies</b></p> <p>We could not estimate RR from one cohort study as there were no malformations observed in children exposed to GPB (N = 14) and children exposed to PGB (N = 1) (<a href="./references#CD010224-fig-0329" title="">Analysis 79.1</a>). </p> </section> <section id="CD010224-sec-1353"> <p><b>79.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1354"> <h5 class="title">80 GBP vs CZP</h5> <section id="CD010224-sec-1355"> <h6 class="title">80.1 All major malformations</h6> <section id="CD010224-sec-1356"> <p><b>80.1.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1357"> <p><b>80.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0330" title="">Analysis 80.1</a>). However, available data showed there were 0/18 cases of major malformations in children exposed to GBP and 2/48 cases in children exposed to CZP from one study (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1358"> <h5 class="title">81 VPA vs BNZ</h5> <section id="CD010224-sec-1359"> <h6 class="title">81.1 All major malformations</h6> <section id="CD010224-sec-1360"> <p><b>81.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0331" title="">Analysis 81.1</a>). However, available data showed there were 4/44 cases of major malformations in children exposed to VPA and 0/5 cases in children exposed to BNZ from two studies (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>). </p> </section> <section id="CD010224-sec-1361"> <p><b>81.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1362"> <h5 class="title">82 LTG versus BNZ</h5> <section id="CD010224-sec-1363"> <h6 class="title">82.1 All major malformations</h6> <section id="CD010224-sec-1364"> <p><b>82.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two cohort studies due to there being no malformations observed in children exposed to LTG (N = 26) and children exposed to BNZ (N = 5) (<a href="./references#CD010224-fig-0332" title="">Analysis 82.1</a>). </p> </section> <section id="CD010224-sec-1365"> <p><b>82.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1366"> <h5 class="title">83 LEV versus BNZ</h5> <section id="CD010224-sec-1367"> <h6 class="title">83.1 All major malformations</h6> <section id="CD010224-sec-1368"> <p><b>83.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR from two cohort studies due to there being no malformations observed in children exposed to LEV (N = 18) and children exposed to BNZ (N = 5) (<a href="./references#CD010224-fig-0333" title="">Analysis 83.1</a>). </p> </section> <section id="CD010224-sec-1369"> <p><b>83.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1370"> <h5 class="title">84 CBZ vs BNZ</h5> <section id="CD010224-sec-1371"> <h6 class="title">84.1 All major malformations</h6> <section id="CD010224-sec-1372"> <p><b>84.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0334" title="">Analysis 84.1</a>). However, available data showed there were 1/43 cases of major malformations in children exposed to CBZ and 0/5 cases in children exposed to BNZ, based on data from two studies (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0031" title="MelikovaS , BagirovaH , MagalovS . The impact of maternal epilepsy on delivery and neonatal outcomes. Child's Nervous System2020;36(4):775-82. [PMID: 31786631]">Melikova 2020</a>). </p> </section> <section id="CD010224-sec-1373"> <p><b>84.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1374"> <h5 class="title">85 OXC versus BNZ</h5> <section id="CD010224-sec-1375"> <h6 class="title">85.1 All major malformations</h6> <section id="CD010224-sec-1376"> <p><b>85.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one cohort study due to there being no malformations observed in children exposed to OXC (N = 4) and children exposed to BNZ (N = 2) (<a href="./references#CD010224-fig-0335" title="">Analysis 85.1</a>). </p> </section> <section id="CD010224-sec-1377"> <p><b>85.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1378"> <h5 class="title">86 PB vs BNZ</h5> <section id="CD010224-sec-1379"> <h6 class="title">86.1 All major malformations</h6> <section id="CD010224-sec-1380"> <p><b>86.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to PB (N = 2) or BNZ (N = 2) (<a href="./references#CD010224-fig-0336" title="">Analysis 86.1</a>). </p> </section> <section id="CD010224-sec-1381"> <p><b>86.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1382"> <h5 class="title">87 LAC versus BNZ</h5> <section id="CD010224-sec-1383"> <h6 class="title">87.1 All major malformations</h6> <section id="CD010224-sec-1384"> <p><b>87.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR from one cohort study due to there being no malformations observed in children exposed to OXC (N = 4) and children exposed to BNZ (N = 2) (<a href="./references#CD010224-fig-0337" title="">Analysis 87.1</a>). </p> </section> <section id="CD010224-sec-1385"> <p><b>87.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1386"> <h5 class="title">88 ZNS vs BNZ</h5> <section id="CD010224-sec-1387"> <h6 class="title">88.1 All major malformations</h6> <section id="CD010224-sec-1388"> <p><b>88.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to ZNS (N = 1) or BNZ (N = 2) (<a href="./references#CD010224-fig-0338" title="">Analysis 88.1</a>). </p> </section> <section id="CD010224-sec-1389"> <p><b>88.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1390"> <h5 class="title">89 CZP versus TPM</h5> <section id="CD010224-sec-1391"> <h6 class="title">89.1 All major malformations</h6> <section id="CD010224-sec-1392"> <p><b>89.1.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.67, 95% CI 0.07 to 1.87, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to CZP (N = 26) and children exposed to TPM (N = 53) (<a href="./references#CD010224-fig-0339" title="">Analysis 89.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.09 to 0.05; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1393"> <p><b>89.1.2 Routine health record studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.37, 95% CI 0.03 to 15.83, I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CZP (N = 26) and children exposed to TPM (N = 53) (<a href="./references#CD010224-fig-0339" title="">Analysis 89.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.09 to 0.05; I<sup>2</sup> = 0%). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1394"> <h5 class="title">90 CZP vs OXC</h5> <section id="CD010224-sec-1395"> <h6 class="title">90.1 All major malformations</h6> <section id="CD010224-sec-1396"> <p><b>90.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0340" title="">Analysis 90.1</a>). However, available data showed there were 0/26 cases of major malformations in children exposed to CZP and 1/19 cases in children exposed to OXC, based on data from one study (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>). </p> </section> <section id="CD010224-sec-1397"> <p><b>90.1.2 Routine health record studies</b></p> <p>Pooled results from two routine health record studies suggested no evidence of a difference in risk (RR 0.81, 95% CI 0.13 to 5.06; I<sup>2</sup> = 0%), with no difference between children exposed to CZP (N = 161) and children exposed to OXC (N = 61) (<a href="./references#CD010224-fig-0340" title="">Analysis 90.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.04 to 0.05; I<sup>2</sup> = 0%). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1398"> <h5 class="title">91 CZP versus COZ</h5> <section id="CD010224-sec-1399"> <h6 class="title">91.1 All major malformations</h6> <section id="CD010224-sec-1400"> <p><b>91.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or COZ (N = 2) (<a href="./references#CD010224-fig-0341" title="">Analysis 91.1</a>). </p> </section> <section id="CD010224-sec-1401"> <p><b>91.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1402"> <h5 class="title">92 CZP vs ESM</h5> <section id="CD010224-sec-1403"> <h6 class="title">92.1 All major malformations</h6> <section id="CD010224-sec-1404"> <p><b>92.1.1 Cohort studies</b></p> <p>We were unable to estimate the RR for one cohort study due to there being no reported major malformations observed in children exposed to CZP (N = 48) or ESM (N = 8) (<a href="./references#CD010224-fig-0342" title="">Analysis 92.1</a>). </p> </section> <section id="CD010224-sec-1405"> <p><b>92.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0342" title="">Analysis 92.1</a>). However, available data showed there were 2/48 cases of major malformations in children exposed to CZP and 0/8 cases in children exposed to ESM, based on data from one study (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1406"> <h5 class="title">93 CZP versus PRG</h5> <section id="CD010224-sec-1407"> <h6 class="title">93.1 All major malformations</h6> <section id="CD010224-sec-1408"> <p><b>93.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or children exposed to PRG (N = 1) (<a href="./references#CD010224-fig-0343" title="">Analysis 93.1</a>). </p> </section> <section id="CD010224-sec-1409"> <p><b>93.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1410"> <h5 class="title">94 CZP vs PRM</h5> <section id="CD010224-sec-1411"> <h6 class="title">94.1 All major malformations</h6> <section id="CD010224-sec-1412"> <p><b>94.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or PRM (N = 2) (<a href="./references#CD010224-fig-0344" title="">Analysis 94.1</a>). </p> </section> <section id="CD010224-sec-1413"> <p><b>94.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0344" title="">Analysis 94.1</a>). However, available data showed there were 2/48 cases of major malformations in children exposed to CZP and 0/3 cases in children exposed to PRM, based on data from one study (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1414"> <h5 class="title">95 CZP versus VGB</h5> <section id="CD010224-sec-1415"> <h6 class="title">95.1 All major malformations</h6> <section id="CD010224-sec-1416"> <p><b>95.1.1 Cohort studies</b></p> <p>We were unable to estimate RR for one cohort study due to there being no major malformations observed in children exposed to CZP (N = 26) or VGB (N = 1) (<a href="./references#CD010224-fig-0345" title="">Analysis 95.1</a>). </p> </section> <section id="CD010224-sec-1417"> <p><b>95.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0345" title="">Analysis 95.1</a>). However, available data showed there were 2/48 cases of major malformations in children exposed to CZP and 0/3 cases in children exposed to VGB, based on data from one study (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1418"> <h5 class="title">96 TPM vs BNZ</h5> <section id="CD010224-sec-1419"> <h6 class="title">96.1 All major malformations</h6> <section id="CD010224-sec-1420"> <p><b>96.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for two cohort studies due to there being no major malformations observed in children exposed to TPM (N = 7) or BNZ (N = 5) (<a href="./references#CD010224-fig-0346" title="">Analysis 96.1</a>). </p> </section> <section id="CD010224-sec-1421"> <p><b>96.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1422"> <h5 class="title">97 ESM versus VPA</h5> <section id="CD010224-sec-1423"> <h6 class="title">97.1 All major malformations</h6> <section id="CD010224-sec-1424"> <p><b>97.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.56, 95% CI 0.04 to 8.03, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 5) and children exposed to VPA (N = 290) (<a href="./references#CD010224-fig-0347" title="">Analysis 97.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.15, 95% CI −0.37 to 0.08; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1425"> <p><b>97.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.56, 95% CI 0.04 to 8.84, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 8) and children exposed to VPA (N = 268) (<a href="./references#CD010224-fig-0347" title="">Analysis 97.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.10, 95% CI −0.25 to 0.06; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1426"> <h5 class="title">98 ESM vs CBZ</h5> <section id="CD010224-sec-1427"> <h6 class="title">98.1 All major malformations</h6> <section id="CD010224-sec-1428"> <p><b>98.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.39, 95% CI 0.10 to 20.37, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 4) and children exposed to CBZ (N = 409) (<a href="./references#CD010224-fig-0348" title="">Analysis 98.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.06, 95% CI −0.28 to 0.16; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1429"> <p><b>98.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.37, 95% CI 0.09 to 20.78, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 8) and children exposed to CBZ (N = 703) (<a href="./references#CD010224-fig-0348" title="">Analysis 98.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.19 to 0.11; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1430"> <h5 class="title">99 ESM versus PRM</h5> <section id="CD010224-sec-1431"> <h6 class="title">99.1 All major malformations</h6> <section id="CD010224-sec-1432"> <p><b>99.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to ESM (N = 5) or PRM (N = 2) (<a href="./references#CD010224-fig-0349" title="">Analysis 99.1</a>). </p> </section> <section id="CD010224-sec-1433"> <p><b>99.1.2 Routine health record studies</b></p> <p>We were unable to estimate a RR for one routine health record study due to there being no major malformations observed in children exposed to ESM (N = 8) or PRM (N = 3) (<a href="./references#CD010224-fig-0349" title="">Analysis 99.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1434"> <h5 class="title">100 ESM vs PB</h5> <section id="CD010224-sec-1435"> <h6 class="title">100.1 All major malformations</h6> <section id="CD010224-sec-1436"> <p><b>100.1.1 Cohort studies</b></p> <p>We were unable to estimate the RR for one cohort study due to there being no reported major malformations observed in children exposed to ESM (N = 5) or PB (N = 2) (<a href="./references#CD010224-fig-0350" title="">Analysis 100.1</a>). </p> </section> <section id="CD010224-sec-1437"> <p><b>100.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0350" title="">Analysis 100.1</a>). However, available data showed there were 0/8 cases of major malformations in children exposed to ESM and 1/7 cases in children exposed to PB, based on data from one study (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1438"> <h5 class="title">101 ESM versus PHT</h5> <section id="CD010224-sec-1439"> <h6 class="title">101.1 All major malformations</h6> <section id="CD010224-sec-1440"> <p><b>101.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0351" title="">Analysis 101.1</a>). However, available data showed there were 0/5 cases of major malformations in children exposed to ESM and 1/44 cases in children exposed to PHT, based on data from one study (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>). </p> </section> <section id="CD010224-sec-1441"> <p><b>101.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.77, 95% CI 0.05 to 12.42, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 8) and children exposed to PHT (N = 103) (<a href="./references#CD010224-fig-0351" title="">Analysis 101.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.07, 95% CI −0.23 to 0.09; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1442"> <h5 class="title">102 ESM vs OXC</h5> <section id="CD010224-sec-1443"> <h6 class="title">102.1 All major malformations</h6> <section id="CD010224-sec-1444"> <p><b>102.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0352" title="">Analysis 102.1</a>). However, available data showed there were 0/5 cases of major malformations in children exposed to ESM and 1/19 cases in children exposed to OXC, based on data from one study (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>). </p> </section> <section id="CD010224-sec-1445"> <p><b>102.1.2 Routine health record studies</b></p> <p>We were unable to estimate the RR for one routine health record study due to there being no reported no major malformations observed in children exposed to ESM (N = 8) or OXC (N = 4) (<a href="./references#CD010224-fig-0352" title="">Analysis 102.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1446"> <h5 class="title">103 ESM versus VGB</h5> <section id="CD010224-sec-1447"> <h6 class="title">103.1 All major malformations</h6> <section id="CD010224-sec-1448"> <p><b>103.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to ESM (N = 5) or VBG (N = 1) (<a href="./references#CD010224-fig-0353" title="">Analysis 103.1</a>). </p> </section> <section id="CD010224-sec-1449"> <p><b>103.1.2 Routine health record studies</b></p> <p>We were unable to estimate a RR for one routine health record study due to there being no major malformations observed in children exposed to ESM (N = 8) or VGB (N = 3) (<a href="./references#CD010224-fig-0353" title="">Analysis 103.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1450"> <h5 class="title">104 ESM vs LTG</h5> <section id="CD010224-sec-1451"> <h6 class="title">104.1 All major malformations</h6> <section id="CD010224-sec-1452"> <p><b>104.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.65, 95% CI 0.11 to 24.30, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 5) and children exposed to LTG (N = 406) (<a href="./references#CD010224-fig-0354" title="">Analysis 104.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.05, 95% CI −0.27 to 0.17; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1453"> <p><b>104.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.12, 95% CI 0.07 to 19.24, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 8) and children exposed to LTG (N = 90) (<a href="./references#CD010224-fig-0354" title="">Analysis 104.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.20 to 0.11; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1454"> <h5 class="title">105 ESM versus TPM</h5> <section id="CD010224-sec-1455"> <h6 class="title">105.1 All major malformations</h6> <section id="CD010224-sec-1456"> <p><b>105.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 3.00, 95% CI 0.14 to 65.77, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 8) and children exposed to TPM (N = 53) (<a href="./references#CD010224-fig-0355" title="">Analysis 105.1</a>) The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.24 to 0.21; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1457"> <p><b>105.1.2 Routine health record studies</b></p> <p>We were unable to estimate the RR for one routine health record study due to there being no major malformations observed in children exposed to ESM (N = 8) or TPM (N = 1) (<a href="./references#CD010224-fig-0355" title="">Analysis 105.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1458"> <h5 class="title">106 ESM vs GBP</h5> <section id="CD010224-sec-1459"> <h6 class="title">106.1 All major malformations</h6> <section id="CD010224-sec-1460"> <p><b>106.1.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1461"> <p><b>106.1.2 Routine health record studies</b></p> <p>We were unable to estimate the RR for one routine health record study due to there being no reported major malformations observed in children exposed to ESM (N = 8) or GBP (N = 18) (<a href="./references#CD010224-fig-0356" title="">Analysis 106.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1462"> <h5 class="title">107 VGB versus VPA</h5> <section id="CD010224-sec-1463"> <h6 class="title">107.1 All major malformations</h6> <section id="CD010224-sec-1464"> <p><b>107.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.67, 95% CI 0.15 to 18.73, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 1) and children exposed to VPA (N = 290) (<a href="./references#CD010224-fig-0357" title="">Analysis 107.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.15, 95% CI −0.75 to 0.45; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1465"> <p><b>107.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.27, 95% CI 0.09 to 17.39, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 3) and children exposed to VPA (N = 268) (<a href="./references#CD010224-fig-0357" title="">Analysis 107.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.10, 95% CI −0.42 to 0.23; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1466"> <h5 class="title">108 VGB vs CBZ</h5> <section id="CD010224-sec-1467"> <h6 class="title">108.1 All major malformations</h6> <section id="CD010224-sec-1468"> <p><b>108.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 4.18, 95% CI 0.37 to 47.57, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 1) and children exposed to CBZ (N = 409) (<a href="./references#CD010224-fig-0358" title="">Analysis 108.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.06, 95% CI −0.66 to 0.54; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1469"> <p><b>108.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 3.09, 95% CI 0.23 to 42.31, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 3) and children exposed to CBZ (N = 703) (<a href="./references#CD010224-fig-0358" title="">Analysis 108.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.36 to 0.28; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1470"> <h5 class="title">109 VGB versus PRM</h5> <section id="CD010224-sec-1471"> <h6 class="title">109.1 All major malformations</h6> <section id="CD010224-sec-1472"> <p><b>109.1.1 Cohort studies</b></p> <p>We were unable to estimate a RR for one cohort study due to there being no major malformations observed in children exposed to VGB (N = 1) or PRM (N = 2) (<a href="./references#CD010224-fig-0359" title="">Analysis 109.1</a>). </p> </section> <section id="CD010224-sec-1473"> <p><b>109.1.2 Routine health record studies</b></p> <p>We were unable to estimate a RR for one routine health record study due to there being no major malformations observed in children exposed to VGB (N = 3) or PRM (N = 3) (<a href="./references#CD010224-fig-0359" title="">Analysis 109.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1474"> <h5 class="title">110 VGB vs PB</h5> <section id="CD010224-sec-1475"> <h6 class="title">110.1 All major malformations</h6> <section id="CD010224-sec-1476"> <p><b>110.1.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1477"> <p><b>110.1.2 Routine health record studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0360" title="">Analysis 110.1</a>). However, available data showed there were 0/3 cases of major malformations in children exposed to VGB and 1/7 cases in children exposed to PB, based on data from one study (<a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1478"> <h5 class="title">111 VGB versus PHT</h5> <section id="CD010224-sec-1479"> <h6 class="title">111.1 All major malformations</h6> <section id="CD010224-sec-1480"> <p><b>111.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0361" title="">Analysis 111.1</a>). However, available data showed there were 0/1 cases of major malformations in children exposed to VGB and 1/44 cases in children exposed to PHT, based on data from one study (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>). </p> </section> <section id="CD010224-sec-1481"> <p><b>111.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 1.73, 95% CI 0.13 to 25.35, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 3) and children exposed to PHT (N = 103) (<a href="./references#CD010224-fig-0361" title="">Analysis 111.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.07, 95% CI −0.40 to 0.28; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1482"> <h5 class="title">112 VGB vs OXC</h5> <section id="CD010224-sec-1483"> <h6 class="title">112.1 All major malformations</h6> <section id="CD010224-sec-1484"> <p><b>112.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for reporting of the meta‐analysis (<a href="./references#CD010224-fig-0362" title="">Analysis 112.1</a>). However, available data showed there were 0/1 cases of major malformations in children exposed to VGB and 1/19 cases in children exposed to OXC, based on data from one study (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>). </p> </section> <section id="CD010224-sec-1485"> <p><b>112.1.2 Routine health record studies</b></p> <p>We were unable to estimate the RR for one routine health record study due to there being no reported major malformations observed in children exposed to VGB (N = 3) or OXC (N = 4) (<a href="./references#CD010224-fig-0362" title="">Analysis 112.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1486"> <h5 class="title">113 VGB versus LTG</h5> <section id="CD010224-sec-1487"> <h6 class="title">113.1 All major malformations</h6> <section id="CD010224-sec-1488"> <p><b>113.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 3.31, 95% CI 0.25 to 43.03, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 2) and children exposed to LTG (N = 406) (<a href="./references#CD010224-fig-0363" title="">Analysis 113.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.05, 95% CI −0.47 to 0.37; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1489"> <p><b>113.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 2.53, 95% CI 0.16 to 39.34, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 3) and children exposed to LTG (N = 90) (<a href="./references#CD010224-fig-0363" title="">Analysis 113.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.37 to 0.28; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1490"> <h5 class="title">114 VGB vs TPM</h5> <section id="CD010224-sec-1491"> <h6 class="title">114.1 All major malformations</h6> <section id="CD010224-sec-1492"> <p><b>114.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 9.00, 95% CI 0.51 to 159.15, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 1) and children exposed to TPM (N = 53) (<a href="./references#CD010224-fig-0364" title="">Analysis 114.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.02, 95% CI −0.62 to 0.58; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1493"> <p><b>114.1.2 Routine health record studies</b></p> <p>We were unable to estimate the RR for one routine health record study due to there being no reported major malformations observed in children exposed to VGB (N = 3) or TPM (N = 1) (<a href="./references#CD010224-fig-0364" title="">Analysis 114.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1494"> <h5 class="title">115 VGB vs GBP</h5> <section id="CD010224-sec-1495"> <h6 class="title">115.1 All major malformations</h6> <section id="CD010224-sec-1496"> <p><b>115.1.1 Cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1497"> <p><b>115.1.2 Routine health record studies</b></p> <p>We were unable to estimate the RR for one routine health record study due to there being no reported no major malformations observed in children exposed to VGB (N = 3) or GBP (N = 18) (<a href="./references#CD010224-fig-0365" title="">Analysis 115.1</a>). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1498"> <h5 class="title">116 CZP vs PB</h5> <section id="CD010224-sec-1499"> <h6 class="title">116.1 All major malformations</h6> <section id="CD010224-sec-1500"> <p><b>116.1.1 Cohort studies</b></p> <p>Included studies did not meet the threshold for inclusion in the meta‐analysis (<a href="./references#CD010224-fig-0366" title="">Analysis 116.1</a>). However, available data showed there were 0/27 cases of major malformations in children exposed to CZP and 1/6 cases in children exposed to PB, based on data from two studies (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0007" title="D'SouzaSW , RobertsonIG , DonnaiD , MawerG . Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood1991;65(3):320-4. [PMID: 2025009]">D'Souza 1991</a>). </p> </section> <section id="CD010224-sec-1501"> <p><b>116.1.2 Routine health record studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.26, 95% CI 0.06 to 1.12, I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CZP (N = 161) and children exposed to PB (N = 34) (<a href="./references#CD010224-fig-0366" title="">Analysis 116.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.07, 95% CI −0.16 to 0.03; I<sup>2</sup> = 0%). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1502"> <h5 class="title">117 CZP vs PHT</h5> <section id="CD010224-sec-1503"> <h6 class="title">117.1 All major malformations</h6> <section id="CD010224-sec-1504"> <p><b>117.1.1 Cohort studies</b></p> <p>Pooled results from two studies suggested no evidence of a difference in risk (RR 0.71, 95% CI 0.10 to 5.11, I<sup>2</sup> = 0%), with no difference in the number of major malformations in children exposed to CZP (N = 27) and children exposed to PHT (N = 66) (<a href="./references#CD010224-fig-0367" title="">Analysis 117.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.13 to 0.06; I<sup>2</sup> = 0%). </p> </section> <section id="CD010224-sec-1505"> <p><b>117.1.2 Routine health record studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 0.61, 95% CI 0.13 to 2.48, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to CZP (N = 48) and children exposed to PHT (N = 103) (<a href="./references#CD010224-fig-0367" title="">Analysis 117.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.03, 95% CI −0.10 to 0.05; I<sup>2</sup> = NA). </p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1506"> <h5 class="title">118 ESM vs LEV</h5> <section id="CD010224-sec-1507"> <h6 class="title">118.1 All major malformations</h6> <section id="CD010224-sec-1508"> <p><b>118.1.1 Cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 2.12, 95% CI 0.13 to 34.10, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 5) and children exposed to LEV (N = 139) (<a href="./references#CD010224-fig-0368" title="">Analysis 118.1</a>) The RD also suggested no difference in the level of risk (RD ‐0.04, 95% CI −0.26 to 0.19; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1509"> <p><b>118.1.2 Routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> <section id="CD010224-sec-1510"> <h5 class="title">119 ESM vs Controls</h5> <section id="CD010224-sec-1511"> <h6 class="title">119.1 All major malformations</h6> <section id="CD010224-sec-1512"> <p><b>119.1.1 ESM versus no medication (in women without epilepsy): cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1513"> <p><b>119.1.2 ESM versus no medication (in women with epilepsy): cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 2.68, 95% CI 0.17 to 43.16, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to ESM (N = 5) and control children (N = 176) (<a href="./references#CD010224-fig-0369" title="">Analysis 119.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.03, 95% CI −0.25 to 0.19; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1514"> <p><b>119.1.3 ESM versus no medication (in women without epilepsy): routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1515"> <p><b>119.1.4 ESM versus no medication (in women with epilepsy): routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD010224-sec-1516"> <h5 class="title">120 VGB vs Control</h5> <section id="CD010224-sec-1517"> <h6 class="title">120.1 All major malformations</h6> <section id="CD010224-sec-1518"> <p><b>120.1.1 VGB versus no medication (in women without epilepsy): cohort studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1519"> <p><b>120.1.2 VGB versus no medication (in women with epilepsy): cohort studies</b></p> <p>Results from one study suggested no evidence of a difference in risk (RR 8.05, 95% CI 0.64 to 101.76, I<sup>2</sup> = NA), with no difference in the number of major malformations in children exposed to VGB (N = 1) and control children (N = 176) (<a href="./references#CD010224-fig-0370" title="">Analysis 120.1</a>). The RD also suggested no difference in the level of risk (RD ‐0.03, 95% CI −0.63 to 0.57; I<sup>2</sup> = NA). </p> </section> <section id="CD010224-sec-1520"> <p><b>120.1.3 VGB versus no medication (in women without epilepsy): routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> </section> <section id="CD010224-sec-1521"> <p><b>120.1.4 VGB versus no medication (in women with epilepsy): routine health record studies</b></p> <p>No included studies reported data on this outcome.</p> <p>Due to limited numbers, we did not investigate specific malformation types.</p> </section> </section> </section> </section> <section id="CD010224-sec-1522"> <h4 class="title">Studies not included in the meta‐analysis and not narratively reported</h4> <p>The publications of <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> required narrative reporting due to their overlap with other research initiatives. <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a> showed variability in its reporting and, therefore, required narrative reporting for certain outcomes. Further, studies using <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> also required narrative review due to the format of reporting of the monotherapy TPM and GBP pregnancies in women with epilepsy. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010224-sec-1523" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010224-sec-1523"></div> <p>We reported results from three study types, meta‐analysis of data from cohort studies, data from <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> and others, and meta‐analysis of data from epidemiological health record studies. Each study design has its inherent methodological strengths and weaknesses. We undertook a stratified approach to evidence synthesis to ensure a sensitive approach to combining data and to allow for the development of evidence groupings; this will allow for replication of findings across different study types and will also allow for increased confidence in the evidence . </p> <p>The meta‐analyses included 17,964 ASM‐exposed pregnancies from cohort studies and 7913 from routine health record studies; additional exposed pregnancies from the EURAP collaboration and other studies were reviewed narratively. Individual ASM prevalence of major malformation ranged from 2.0% to 9.8% for cohort study data and 3.6% to 9.7% for studies utilising routine health record data (<a href="#CD010224-tbl-0003">Table 1</a>, <a href="#CD010224-fig-0003">Figure 3</a>). <a href="./full#CD010224-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD010224-tbl-0002">summary of findings Table 2</a> along with <a href="#CD010224-tbl-0003">Table 1</a>, <a href="#CD010224-tbl-0004">Table 2</a>, <a href="#CD010224-tbl-0005">Table 3</a>, <a href="#CD010224-tbl-0006">Table 4</a>, <a href="#CD010224-tbl-0007">Table 5</a>, <a href="#CD010224-tbl-0008">Table 6</a> and <a href="#CD010224-tbl-0009">Table 7</a> provide a summary of the meta‐analysis results for all comparisons for risk of major malformation. This update has included the most recent study data, which strengthens the previously identified risk associations for older ASMs such as CBZ, PB and VPA, where the comparisons include large numbers of exposed pregnancies. For other ASMs, there are some differences in the results across the comparisons, but the better powered comparisons demonstrate an increased risk for PHT and for an overall major malformation risk with CBZ and for TPM. </p> <p>Whilst CBZ, PB, PHT, TPM and VPA are associated with an increase in the risk of major malformation, the level of risk varies between the four ASMs. For example, CBZ showed a lower overall major malformation risk rate than PB and VPA, and a lower risk for specific major malformation types compared to some ASMs (e.g. PB or TPM). All ASMs, regardless of their own association with an increased risk, carried a lower risk than VPA‐exposure which had the highest prevalence from both cohort (9.8%) and routine health record data (9.7%). LTG remains the lowest risk ASM with adequate cohort size (N =&gt; 4700 pregnancies from cohort studies and N = 2502 from routine health record studies). LTG does appear to have a dose effect, as do CBZ, PB and VPA. The number of LEV‐exposed pregnancies remains more limited than LTG but, in direct comparison, there is currently no significant difference between these two ASMs, and LEV‐exposed children have a lower overall major malformation risk than CBZ, VPA and PHT. TPM exposure was associated with a higher overall major malformation risk in comparison to LTG, but not other ASMs; this finding may be due to relatively small numbers of participants in the TPM studies and only a few malformation events. TPM exposure, however, was associated with higher specific risks of oro‐facial, craniofacial, skeletal and limb malformations in comparison to LTG, LEV, CBZ, but not in comparison to the two control groups; but specific major malformation data were limited for the control cohorts. </p> <p>There remains limited information for GBP, OXC, TPM and ZNS and other ‘newer’ medications. The evidence for each ASM monotherapy is summarised below. </p> <section id="CD010224-sec-1524"> <h3 class="title" id="CD010224-sec-1524">Summary of main results</h3> <section id="CD010224-sec-1525"> <h4 class="title">Carbamazepine (CBZ)</h4> <p>CBZ was the most frequently investigated ASM both in terms of the number of publications and the number of included pregnancies (over 8220). The pooled major malformation prevalence for CBZ was 4.7% (95% CI, 3.7 to 5.9) from cohort studies, 4.0% (95% CI 3.0 to 5.4) for routine health record studies and 2.9% (95% CI 2.9 to 5.4); these were relatively consistent with the 5.5% (95% CI 4.5 to 6.6) prevalence from <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> (<a href="#CD010224-fig-0003">Figure 3</a>). </p> <p>In comparison to both children born to women without epilepsy and children born to women with untreated epilepsy, pooled data from the cohort studies found that children exposed to CBZ in utero had an increased risk of having a major malformation, with the difference in risk ranging from 1% to 2%, respectively. The findings from routine health record studies are more mixed. In the larger of the two comparisons, CBZ was significantly associated with a higher risk of a major malformation, which was consistent with the cohort study data. </p> <p>In comparison to unexposed control children (both groups), there was no specific malformation which was increased above the background rate provided by the control children. Data were limited in terms of the specific malformation risk, mainly due to the absence of control data from some large pregnancy and epilepsy registry studies (e.g. <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>) and reporting of this level of detail from the population datasets (e.g. <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a>; <a href="./references#CD010224-bbs2-0047" title="BanL , FlemingKM , DoyleP , SmeethL , HubbardRB , FiaschiL , et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLOS One2015;10(7):e0131130. [PMID: 26147467]PetersenI , Collings S-L, McCreaRL , NazarethI , OsbornDP , CowenPJ , et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology2017;9:95-103. [PMID: 28243149]">UK Health Record THIN Register</a>). This likely contributed to the non‐significant outcomes found for neural tube malformations, which has been an association found by others using different methodologies (<a href="./references#CD010224-bbs2-0116" title="JentinkJ , DolkH , LoaneMA , MorrisJK , WellesleyD , GarneE , et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ2010;341:c6581. [PMID: 21127116]">Jentink 2010b</a>). </p> <p>Data from the cohort studies were more numerous for CBZ‐exposed pregnancies compared to other monotherapy ASMs. There was a higher risk of major malformation in comparison to children exposed to LEV or LTG in comparisons which included over 500 pregnancies in each arm, with the risk being 1% higher. However, comparisons at the specific malformation level were not significant; this was likely due to fewer data being available at this level of investigation. The increased risk observed in data from cohort studies was not replicated in studies using databases containing routine health records, however, patient/event numbers in the databases were smaller than the pooled experience from cohort studies. </p> <p>Despite its associated higher risk, CBZ exposure was associated with a lower level of risk than VPA exposure, with a 5% difference in overall major malformation risk and a lower risk across neural tube, cardiac, oro‐facial and skeletal/limb malformations. Further, while CBZ is comparable to the increased risk from PB, PHT or TPM in data from cohort studies for overall major malformation, the specific malformation risk varied. The association of CBZ exposure with cardiac malformations was lower in comparison to PB or to PHT exposure and lower for skeletal/limb or oro‐facial/craniofacial malformation risk when compared to TPM exposure. </p> <p>There was no significant increase in risk in comparison to OXC, GBP, PRM or CZP exposure from both cohort and health record studies, but data were more limited for these comparator ASMs currently and caution is required. </p> <p>Dose is a key feature of teratogenic malformation risk (<a href="./references#CD010224-bbs2-0102" title="BrentRL . Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics2004;113(4 Suppl):957-68. [PMID: 15060188]">Brent 2004</a>). Data from <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> is the most reliable to investigate dose associations due to its large number of CBZ‐exposed pregnancies and its low risk of bias on the domain of outcome measurement. It demonstrates a dose‐related risk for CBZ with doses over 700 mg/d carrying a higher risk, although even their lower dose group had a high level of risk in comparison to children exposed to LTG (<a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>). </p> </section> <section id="CD010224-sec-1526"> <h4 class="title">Clonazepam (CZP)</h4> <p>Data relating to the use of monotherapy clonazepam during pregnancy and child major malformation risk is substantially limited with fewer than 150 pregnancies reported across both cohort and routine health record studies. The generated prevalence reported here was 2.1% (95% CI 0.2 to 17.3%) to 2.5% (95% CI 0.0 to 131.8) but the confidence intervals were very wide, due to the limited data. When compared to other ASMs, however, a lower risk was identified in comparison to VPA exposure, with a risk difference of 9%. Due to the current limited data available, no firm conclusion can be made currently whether CZP is associated with an increased risk in comparison to control children. </p> </section> <section id="CD010224-sec-1527"> <h4 class="title">Gabapentin (GBP)</h4> <p>Experience with GBP exposure in pregnancy was also limited. Outcomes from only 210 reported pregnancies could be included in our meta‐analysis. The pooled prevalence of major malformation was 2.0% (95% CI 0.1 to 32.2) from cohort studies, with too few data being available from studies using routine health records to provide a pooled prevalence rate. We found no difference between the children exposed to GBP compared with either type of control group, but caution is warranted due to limited numbers. Data which could not be included in meta‐analysis, from the <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>, found that children exposed to GBP (N = 347) for the indication of maternal epilepsy were not at a greater risk of major malformation, which matched the wider finding from 3745 GBP‐exposed pregnancies (any indication). Whilst this study may offer reassurance, caution is required as the indications were not predominantly epilepsy and, therefore, there may be differences in typically prescribed doses; replication of this finding is also required in another adequately powered cohort. </p> <p>We found no difference in overall major malformation rate or in the specific malformations investigated for the children exposed to GBP compared to CBZ, LTG, LEV, OXC, PHT, PB, TPM and ZNS, but there was a very limited number of GBP‐exposed children. In comparison to the children exposed to VPA, children exposed to GBP in utero had a significantly lower risk (8%) of having a malformation than children exposed to VPA, but data were too limited to investigate specific malformation differences. </p> <p>Data for GBP dose and malformation rate were limited from cohort studies but data from the <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> failed to find an association between higher doses of GBP and a higher risk of malformation. However, the vast majority of women taking GBP were doing so for conditions other than epilepsy and, therefore, caution is warranted. </p> </section> <section id="CD010224-sec-1528"> <h4 class="title">Lamotrigine (LTG)</h4> <p>The use of LTG has increased over the last decade in women of childbearing age (<a href="./references#CD010224-bbs2-0099" title="AckersR , BesagFM , WadeA , MurrayML , WongIC . Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Archives of Disease in Childhood2009;94(6):443–7. [PMID: 19307197]">Ackers 2009</a>; <a href="./references#CD010224-bbs2-0118" title="ManSL , PetersenI , ThompsonM , NazarethI . Antiepileptic drugs during pregnancy in primary care: a UK population based study. PLOS One2012;7:e52339. [PMID: 23272239]">Man 2012</a>; <a href="./references#CD010224-bbs2-0131" title="WenX , MeadorKJ , HartzemaA . Antiepileptic drug use by pregnant women enrolled in Florida Medicaid. Neurology2015;84(9):944-50. [PMID: 25653296]">Wen 2015</a>). The pooled prevalence of major malformation for LTG was 2.7% (95% CI 1.9 to 3.8%) from cohort studies, 3.5% (95% CI 2.5 to 4.9) from routine health record studies, and 2.9% (95% CI 2.3 to 3.7) from the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration. Most of the evidence indicated no difference in the overall major malformation rate between the children exposed to LTG and either type of control group. However, in comparison to children born to women without epilepsy, there was a significant difference from the pooled cohort data, with the risk being increased by 1% for the children exposed to LTG. Whilst levels of heterogeneity were not increased overall, one study had a much higher rate of malformation in the LTG group. Further, a larger LTG‐exposed group was available for comparison to the women with epilepsy who were not treated, which showed the LTG major malformation risk was not significantly different from the control children for overall malformation rate or for the specific malformation types investigated; this was consistent with the non‐significant finding from the routine health record studies in comparison to both control groups. Further, no increase in specific malformation types were identified, and data from the <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> failed to find an association with oral cleft malformations in over 2000 LTG‐exposed children in comparison to control children who were not exposed to ASMs. </p> <p>In comparison to LEV, which has also seen a significant increase in use in women of childbearing age in a lot of countries (<a href="./references#CD010224-bbs2-0122" title="MeadorKJ , PenovichP , BakerGA , PennellPB , BromfieldE , PackA , et al, NEAD Study Group. Antiepileptic drug use in women of childbearing age. Epilepsy and Behaviour2009;15(3):339-43. [PMID: 19410654]">Meador 2009</a>; <a href="./references#CD010224-bbs2-0131" title="WenX , MeadorKJ , HartzemaA . Antiepileptic drug use by pregnant women enrolled in Florida Medicaid. Neurology2015;84(9):944-50. [PMID: 25653296]">Wen 2015</a>), there were no significant differences for LTG in either the overall major malformation rate or the specific malformation types investigated. Children exposed to LTG also did not differ either in terms of overall major malformation rate or in terms of specific malformations compared with children exposed to OXC, CZP, GBP and ZNS; however, data were limited for all of these comparisons due to small numbers of OXC, CZP, GBP and ZNS‐exposed pregnancies. </p> <p>The children exposed to LTG were at a significantly lower risk of overall major malformation compared with children exposed to CBZ, PB, PHT and TPM exposures (see results for specific risk levels) in cohort study data. Routine health record studies did not replicate this, however, were limited in terms of numbers of included LTG‐exposed pregnancies in comparison to PB, PHT and TPM and, therefore, were perceived as less reliable. Analyses of cohort study data showed that, at the specific malformation level, children exposed to LTG were at a lower risk of cardiac malformations in comparison to PB and PHT exposures and fewer skeletal malformations than children exposed to TPM and PHT. This latter finding was also observed in the large cohort from the <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>. Finally, children exposed to LTG had a three‐fold lower risk of overall major malformation when compared to the children exposed to VPA, with a risk difference showing that the significant reduction in risk was 6% for children exposed to LTG. Neural tube, cardiac, oro‐facial cleft, craniofacial, skeletal and limb malformations were all significantly lower for the LTG‐exposed children. </p> <p>The large, well‐designed <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> study has demonstrated a dose relationship between LTG treatment and major malformation risk, with exposures to LTG ≤ 325 mg/d associated with the lowest malformation prevalence. Other studies did not find a dose relationship, however, the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration is by far the largest and most standardised in their assessment of the malformation, comprising of participants from 42 countries (N = 2514). Therefore, higher doses of LTG may be associated with higher levels of risk and this should be considered when prescribing doses over 325 mg/d. It is possible that this dose association may account, at least in part, for the variation seen in the outcome in one of the control comparisons. </p> </section> <section id="CD010224-sec-1529"> <h4 class="title">Levetiracetam (LEV)</h4> <p>The frequency of data and the number of included pregnancies exposed to LEV were more limited than for CBZ, LTG or VPA. There were 1242 LEV‐exposed pregnancies included from cohort data across all comparisons and just 248 from studies employing routine health record data currently. This delay is likely due in part to the time it takes for adequate numbers of women taking newer ASMs to accumulate, however, it undermines counselling for a now commonly established medication (<a href="./references#CD010224-bbs2-0122" title="MeadorKJ , PenovichP , BakerGA , PennellPB , BromfieldE , PackA , et al, NEAD Study Group. Antiepileptic drug use in women of childbearing age. Epilepsy and Behaviour2009;15(3):339-43. [PMID: 19410654]">Meador 2009</a>; <a href="./references#CD010224-bbs2-0131" title="WenX , MeadorKJ , HartzemaA . Antiepileptic drug use by pregnant women enrolled in Florida Medicaid. Neurology2015;84(9):944-50. [PMID: 25653296]">Wen 2015</a>). </p> <p>The pooled prevalence for major malformation occurrences following LEV‐exposure was 2.6% (95% CI 1.6 to 4.4) for cohort study data, 2.8% (95% CI 0.0 to 321.9) for routine health record study data (which had large confidence intervals) and 2.8% (95% CI 1.7 to 4.5) from <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>. There was no significant difference between the children exposed to LEV and control children in the meta‐analysis for overall major malformation rate; these comparisons also both contained &gt; 1000 pregnancies in each arm. Data pertaining to specific malformation types in comparison to control children were limited, however, and it is not possible to draw conclusions until more data are available. </p> <p>In comparison to other ASM treatments, children exposed to LEV were not significantly different from children exposed to LTG in terms of overall major malformation prevalence or the specific malformation types investigated. In addition, we found no significant difference between children exposed to LEV compared with those exposed to GBP, OXC, CZP, TPM ZNS or PRM, although data within these comparisons were somewhat limited. Children exposed to LEV had a lower overall MCM rate than the children exposed to CBZ, PB and PHT exposures, but there was no difference in terms of the specific malformation types investigated. While the overall major malformation risk was not significantly different for the children exposed to LEV versus those exposed to TPM, the children exposed to LEV were at lower risk of having an oro‐facial/craniofacial, skeletal or limb malformation in comparison to the TPM‐exposed children. Additionally, children exposed to LEV had a lower specific risk of developing a cardiac malformation in comparison to PB‐exposed children. Finally, the children exposed to LEV had a 7 to 8% lower risk of overall malformations compared with the children exposed to VPA, with a lower risk identified for all investigated specific types of malformations for the children exposed to LEV. </p> <p>Investigation between dose of LEV and major malformation outcome was limited by numbers included within the individual studies (i.e. <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>), including the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> study. In 599 LEV‐exposed pregnancies, <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> did not investigate lower versus higher‐dose LEV. Caution is required, therefore, regarding the malformation risk with above average doses of LEV, until more data are available. </p> </section> <section id="CD010224-sec-1530"> <h4 class="title">Oxcarbazepine (OXC)</h4> <p>Data for pregnancy outcomes following exposure to OXC were limited to just under 400 pregnancies in cohort studies and 507 pregnancies from routine health record studies. The prevalence of major malformation was 2.8% (95% CI 1.1 to 6.6) versus 4.8% (95% CI 0.7 to 31.5) with routine health record studies containing more OXC‐exposed pregnancies across comparisons. The prevalence reported from <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> for 333 OXC monotherapy‐exposed pregnancies was 3.0% (95% CI 1.4 to 5.4). </p> <p>In comparison to control children, the pooled routine health record study data found no elevated risk for OXC exposure in comparison to controls; these results were similar in the cohort study data. Given the numbers of included OXC‐exposed pregnancies across both study types, further research is required for conclusions to be drawn in regard to OXC exposure and major malformation outcome. While limited comparisons to other ASMs could be made, where evidence was available, there was no significant difference between the overall major malformation rate or the specific malformations investigated compared with children exposed to CBZ, CZP, LEV, LTG, GBP, PHT, PB, TPM, PRM and ZNS. Children exposed to OXC were at a significantly lower risk of having an major malformation of any type compared with children exposed to VPA, with the risk difference being 4 to 6% depending on the study type. There were very limited data pertaining to specific malformation types, and caution is required. </p> <p>Only <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> reported dose and malformation rates for OXC‐exposed pregnancies. Whilst they did not compare lower versus higher OXC dose, they did report that certain dose levels of OXC were comparable to lower‐dose LTG. More studies of OXC‐exposed pregnancies are required, however, before it is determined whether a higher level of OXC dose carries a higher malformation risk. </p> </section> <section id="CD010224-sec-1531"> <h4 class="title">Phenobarbital (PB)</h4> <p>Despite years of use, data from prospective studies investigating PB as monotherapy were surprisingly limited, with only 840 monotherapy‐exposed pregnancies across the different comparisons and study types. The data pooled from included studies generated a major malformation prevalence of 6.3% (95% CI 4.8 to 8.3) from cohort studies and 8.8% (95% CI 0.0 to 9722.4) from routine health record studies; the latter was limited in cohort size and the prevalence should be interpreted with caution. There was a prevalence of 6.5% (95% CI 4.2 to 9.9) from <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>. </p> <p>The results regarding PB‐exposure in comparison to control children demonstrated variable results. We found a significantly increased risk of overall major malformation compared with children born to women without epilepsy, with a risk difference of 4%. However, we found no significant difference compared with children born to women without epilepsy. However, both comparisons included under 500 PB‐exposed pregnancies, which may account for the unstable pattern of the findings. Routine health record data studies included too few PB‐exposed pregnancies at this time to provide reliable estimates. Data pertaining to specific malformations were extremely limited or missing and likely contributed to the non‐significant differences found for PB in comparison to the control children. This is certainly the case for cardiac malformations, where rates of cardiac malformations are increased in comparison to numerous other ASMs exposures. </p> <p>In comparison to other ASMs, children exposed to PB were not at a significantly increased rate of overall major malformation compared with children exposed to CBZ, CZP, GBP, PHT, OXC, TPM, PRM, LEV and ZNS exposures; but the comparison to CBZ exposure was the only one where the PB‐exposed group had over 500 pregnancies. PB exposure was significantly associated with an increased risk of oro‐facial clefts and craniofacial malformations when compared to LEV or LTG exposures. Children exposed to PB had a higher overall major malformation than the children exposed to LTG, but a lower risk compared with the children exposed to VPA, with the risk being 4% lower. Therefore, despite both PB and VPA being associated with an increased risk of being born with an major malformation, the risk associated with VPA is significantly higher, including for cardiac malformations. </p> <p>The majority of studies did not investigate or report on a potential relationship between dose of PB and major malformation risk, due to limited included pregnancies. A dose‐mediated risk was also apparent for cardiac malformations, with the prevalence increasing from 1% to 8% for doses &lt; 150 mg/d and those ≥ 150 mg/d, respectively (<a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>). <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a> also found a dose effect for PB. Given the size of the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> cohort and their standardised approach to reviewing, it is concluded that there is likely a strong dose relationship for PB. </p> </section> <section id="CD010224-sec-1532"> <h4 class="title">Phenytoin (PHT)</h4> <p>The pooled prevalence of major malformation in the PHT‐exposed children was 5.4% (95% CI 3.6 to 8.1%) for cohort studies, 6.8% (95% CI 0.1 to 701.2%) for routine health record studies and 6.4% (95% CI 2.8 to 12.2%) for <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>. There were 1327 PHT‐exposed pregnancies included in the cohort studies, but just 103 children reported from routine health record studies. The children exposed to PHT were at a significantly increased risk in comparison with both types of control group, with the difference in risk being 3% in the cohort data. However, we found no association between PHT and specific major malformation types; although data were limited in these comparisons due to the limited control data reported in publications from the epilepsy and pregnancy registers. </p> <p>In comparison to other ASMs, children exposed to PHT were not at an increased risk of overall major malformation compared with children exposed to CZP, CBZ, GBP, OXC, TPM, PRM, PB or ZNS; however, data comparing PHT with the 'newer' ASMs were limited and caution is needed in the interpretation of these non‐significant findings. In contrast, compared to studies with a greater number of included children, the children exposed to PHT were at an increased risk of overall major malformation compared with children exposed to LTG or LEV, with the risk difference indicating a 2% increase in major malformation; however, these RDs were not statistically significant. In contrast, the children exposed to PHT were significantly less likely to have a major malformation than the children exposed to VPA, with the difference in risk being 5% lower. Further, the children exposed to PHT were also at a lower risk than those exposed to VPA for their risk of neural tube, cardiac and skeletal/limb malformations. </p> <p>In terms of specific malformations, children exposed to PHT were less likely than those exposed to PB to have a craniofacial malformation. There was a noted increase in cardiac, skeletal and limb malformations for the PHT‐exposed children compared with those exposed to LTG, which was one of the larger comparisons in terms of PHT‐exposed pregnancies. Finally, the rates of neural tube, cardiac, skeletal and limb malformations were significantly lower for the children exposed to PHT in comparison to the VPA‐exposed children. </p> <p>The majority of studies did not report on whether the risk of being born with a major malformation was associated with dose of PHT; however, those that did investigate such an association did not show a consistent pattern (<a href="./references#CD010224-bbs2-0020" title="KaajaE , KaajaR , HiilesmaaV . Major malformations in offspring of women with epilepsy. Neurology2003;60(4):575-9. [PMID: 12601095]">Kaaja 2003</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0036" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257-61. [PMID: 1591483]NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18-24. [PMID: 8986270]">Motherisk Registry</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>), therefore, the conclusion around dose effects is uncertain. </p> </section> <section id="CD010224-sec-1533"> <h4 class="title">Primidone (PRM)</h4> <p>This is an old ASM with limited utilisation currently. Evidence pertaining to PRM was extremely limited to 112 pregnancies and caution is warranted when interpreting results. Pooled data from included cohort studies gave a malformation prevalence of 7.9% (95% CI 2.6 to 21.5%). There were just 3 PRM‐exposed cases reported in the routine health record studies. The children exposed to PRM were at a higher risk of overall major malformation in comparison to the children born to women with an untreated epilepsy, which contained the larger number of PRM‐exposed pregnancies. A comparable major malformation risk was found for PRM in comparison to PHT, PB and VPA exposures, but the data were limited. There was either extremely limited or no data available to compare risks to other monotherapy ASMs. </p> <p>Only one study of 19 PRM cases investigated the dose of PRM and outcome (<a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>). Therefore, it remains unknown whether there is an association between PRM dose and increased major malformation risk. </p> </section> <section id="CD010224-sec-1534"> <h4 class="title">Topiramate (TPM)</h4> <p>Experience with TPM was limited to 510 exposed pregnancies in cohort studies (3.9%, 95% CI 2.3 to 6.5%). There were 49 cases from routine health record investigations which met the criteria for being included in the meta‐analyses (4.1%, 95% CI 0.0 to 27,060.0); therefore, caution is required when considering our results. The <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration is also limited currently in its experience with TPM exposures with just 152 exposed pregnancies with a major malformation prevalence of 3.9% (95% CI 1.5 to 8.4%). </p> <p>In pooled cohort data, in comparison to children born to women without epilepsy, children exposed to TPM had a higher rate of being born with an major malformation with the risk difference being 3%. We found no significant difference compared with the no medication control group, but this comparison had even fewer TPM cases. Pooled data were too limited here to allow for the investigation of specific malformation outcomes in comparison to control children. We found no significant difference in the rate of major malformation compared with children exposed to CBZ, CZP GBP, PHT, PB, PRM, OXC and ZNS. We found a significant increase in the rate of major malformation for the children exposed to TPM compared with the children exposed to LTG, with skeletal/limb and oro‐facial cleft/craniofacial being specifically increased. </p> <p>Data from <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> provides the largest dataset regarding oro‐facial clefts and reported an association between topiramate and oral clefts from medical reimbursement databases (4.1 per 1000 live births). This is similar to a retrospective study which was not included in this review (<a href="./references#CD010224-bbs2-0123" title="MinesD , TennisP , CurkendallSM , LiDK , PetersonC , AndrewsEB , et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiology and Drug Safety2014;23(10):1017–25. [PMID: 24692316]">Mines 2014</a>), in a case‐control study (<a href="./references#CD010224-bbs2-0119" title="MargulisAV , MitchellAA , GilboaSM , WerlerMM , MittlemanMA , GlynnRJ , et al, National Birth Defects Prevention Study. Use of topiramate in pregnancy and risk of oral clefts. American Journal of Obstetrics and Gynecology2012;207(5):405.e1-7. [PMID: 22917484]">Margulis 2012</a>), and in a previous meta‐analysis (<a href="./references#CD010224-bbs2-0100" title="AlsaadAM , ChaudhrySA , KorenG . First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis. Reproductive Toxicology2015;53:45-50. [PMID: 25797654]">Alsaad 2015</a>) which were beyond the inclusion criteria of this review. This demonstrates the cohort sizes which are required to investigate very specific rare events, such as specific types of major malformation. </p> <p>The overall major malformation risk was comparable to that for LEV or CBZ‐exposed children, but the LEV‐exposed children were at a lower risk of skeletal and limb malformations, as were the CBZ‐exposed children. The children exposed to TPM had a lower cardiac risk than the children exposed to PB, and they were less likely to have a malformation of any type compared with the children exposed to VPA, with the difference in risk being 7%. </p> <p>Most studies were too limited to be able to provide reliable investigations into a dose association, however, Hernandez‐Diaz, using (<a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>) data, found that the adjusted RRs for oro‐facial clefts at doses ≤ 100 mg/d and &gt; 100 mg/d were 1.64 (95% CI 0.53 to 5.07) and 5.16 (95% CI 1.94 to 13.73) for lower and higher doses, respectively. </p> </section> <section id="CD010224-sec-1535"> <h4 class="title">Valproate (VPA)</h4> <p>In utero exposure to VPA and its possible association with an increased teratological risk has been discussed in the literature since the 1980s, when the first case reports emerged documenting children with a specific constellation of malformations following exposure to VPA (<a href="./references#CD010224-bbs2-0101" title="ArdingerHH , AtkinJF , BlackstonRD , ElsasLJ , ClarrenSK , LivingstoneS , et al. Verification of the fetal valproate syndrome phenotype. American Journal of Medical Genetics1988;29(1):171-85. [PMID: 3125743]">Ardinger 1988</a>; <a href="./references#CD010224-bbs2-0110" title="DiLibertiJH , FarndonPA , DennisNR , CurryCJ . The fetal valproate syndrome. American Journal of Medical Genetics1984;19(3):473-81. [PMID: 6439041]">DiLiberti 1984</a>). Larger cohorts such as <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> and data from population‐based health records studies (e.g. <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>) as well as the pregnancy registries (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0024" title="BegumS , SarmaSP , ThomasSV . Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia2013;54(12):e163-7. [PMID: 24138300]KeniRR , JoseM , ReshmaAS , BaishyaJ , Sankara SarmaP , ThomasSV . Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research2020;159:106250. [PMID: 31855827]KeniRR , JoseM , SarmaPS , ThomasSV , Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?Neurology2018;90(9):e790-6. [PMID: 29429975]SeshachalaBB , JoseM , LathikakumariAM , MuraliS , KumarAS , ThomasSV . Valproate usage in pregnancy: an audit from the Kerala Registry of Epilepsy and Pregnancy. Epilepsia2021;62(5):1141-7. [PMID: 33782943]ThomasSV , AjaykumarB , SindhuK , FrancisE , NamboodiriN , SivasankaranS , et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatric Cardiology2008;29(3):604-8. [PMID: 18188637]ThomasSV , IndraniL , DeviGC , JacobS , BeegumJ , JacobPP , et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India2001;49(1):60-6. [PMID: 11303244]ThomasSV , JeemonP , PillaiR , JoseM , LalithakumariAM , MuraliS , et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala Registry of Epilepsy and Pregnancy (KREP). Seizure2021;93:127-32. [PMID: 34740142]ThomasSV , JoseM , DivakaranS , Sankara SarmaP . Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia2017;58(2):274-81. [PMID: 28084641]">Kerala Epilepsy and Pregnancy Registry</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>) and observational studies (e.g. <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0039" title="OmtzigtJG , LosFJ , GrobbeeDE , PijpersL , JahodaMG , BrandenburgH , et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology1992;42(4 Suppl 5):119-25. [PMID: 1574165]OmtzigtJG , LosFJ , HagenaarsAM , StewartPA , SachsES , LindhoutD . Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal Diagnosis1992;12(11):893-7. [PMID: 1283633]">Omtzigt 1992</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>) included here, have all provided evidence to confirm that VPA is a significant human teratogen which is associated with an increase is a variety of malformation types. Here, we reported on 3018 VPA‐exposed children from prospective cohort style studies and 1482 VPA‐exposed pregnancies from routine health record studies. </p> <p>In the meta‐analyses reported here a consistent pattern emerged: children exposed to VPA were at an increased risk of both a higher overall major malformation risk and risk of specific malformations including neural tube, cardiac, oro‐facial cleft, craniofacial, skeletal and limb malformations. The prevalence of major malformation following exposure to VPA in the womb was 9.8% (95% CI 8.1 to 11.9) for cohort studies, with similar rates from routine health record studies (9.7%, 95% CI 7.1 to 13.4) and from <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> (10.3, 95% CI 8.8 to 12.0%). Children exposed to VPA were at an increased risk of being born with a major malformation compared with both the children of women without epilepsy and the children of women with untreated epilepsy, with the risk difference being 7% and 6% compared with the respective control groups. Analysis of the risks associated with VPA treatment at the specific malformation level was limited by a lack of control data; however, children exposed to VPA remained at a significantly increased risk for neural tube, cardiac and skeletal malformations compared with control children. </p> <p>In comparison to other ASMs, in the meta‐analyses reported here, children exposed to VPA were at an increased risk of major malformation compared with children exposed to CBZ, CZP, GBP, LEV, LTG, TPM, OXC, PB and PHT, with the ZNS group being non‐significant but too being small to make a reliable comparison. The increased risk associated with VPA exposure ranged from 4% to 9%, depending on the comparator ASM. </p> <p>At the specific malformation level, children exposed to VPA were at an increased risk of neural tube malformation compared with the children exposed to CBZ, LEV, LTG and PHT. We did not note any increase in the specific malformation type analyses compared to children exposed to GBP, OXC, PB or TPM, but this is most likely due to limited data. However, we found an increased rate of cardiac malformation compared to CBZ, LEV, LTG, TPM, PHT and an equal cardiac risk in comparison to the increased risk for PB‐exposed children. Oro‐facial cleft and craniofacial malformations were also significantly more common in the children exposed to VPA compared with children exposed to CBZ, LEV and LTG. There was no difference in the rate of oro‐facial cleft or craniofacial malformations compared with TPM, PB or PHT, but these are found to carry their own risks of this malformation type (<a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>). Finally, skeletal or limb malformations in children exposed to VPA compared with children exposed to CBZ, LEV, LTG or PHT were significantly higher. All specific malformation comparisons that the data compared with CZP, GBP, ZNS and OXC were too limited for conclusions to be made. </p> <p>When weighing up the risks and benefits of VPA treatment, the effects of VPA on other developmental outcomes including the developing brain should also be considered when considering the level of risk posed by VPA. VPA exposure is now also recognised as a neurobehavioural teratogen, with implications for the future cognitive functioning of the exposed child (<a href="./references#CD010224-bbs2-0103" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010236. [DOI: 10.1002/14651858.CD010236.pub2]">Bromley 2014</a>), and an increased risk of neurodevelopmental disorders such as autistic spectrum disorders (<a href="./references#CD010224-bbs2-0106" title="ChristensenJ , GrønborgTK , SørensenMJ , SchendelD , ParnerET , PedersenLH , et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA2013;309(16):1696-703. [PMID: 23613074]">Christensen 2013</a>) and attention deficit hyperactivity disorder (<a href="./references#CD010224-bbs2-0107" title="ChristensenJ , PedersenL , SunY , DreierJW , BrikellI , DalsgaardS . Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Network Open2019;2(1):e186606. [PMID: 30646190]">Christensen 2019</a>). </p> <p>More than any other ASM, studies have reported dose associations with level of major malformation risk for VPA (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0012" title="FairgrieveSD , JacksonM , JonasP , WalshawD , WhiteK , MontgomeryTL , et al. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal2000;321(7262):674-5. [PMID: 10987772]">Fairgrieve 2000</a>; <a href="./references#CD010224-bbs2-0017" title="Diav-CitrinO , ShechtmanS , ArnonJ , OrnoyA . Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology2001;57(2):321-4. [PMID: 11468320]Diav-CitrinO , ShechtmanS , Bar-OzB , CantrellD , ArnonJ , OrnoyA . Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs2008;22(4):325-34. [PMID: 18336060]Diav-CitrinO , ShechtmanS , ZviN , Finkel-PekarskyV , OrnoyA . Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Research2017;109(15):1196-1203. [PMID: 28657171]OrnoyA , CohenE . Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood1996;75(6):517-20. [PMID: 9014606]OrnoyA , ZviN , ArnonJ , WajnbergR , ShechtmanS , Diav-CitrinO . The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reproductive Toxicology2008;25(3):388-9. [PMID: 18424066]">Israeli Teratogen Service</a>; <a href="./references#CD010224-bbs2-0021" title="FukushimaY , NakamuraY , OgawaY , SaitoY , KanR , KumashiroH , et al. Teratogenicity of antiepileptic drugs: is the prevention possible?Japanese Journal of Psychiatry and Neurology1991;45(2):478-81. [PMID: 1762253]KanekoS , BattinoD , AndermannE , WadaK , KanR , TakedaA , et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research1999;33(2-3):141-58. [PMID: 10094426]KanekoS , OtaniK , FukushimaY , OgawaY , NomuraY , OnoT , et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia1988;29(4):459-67. [PMID: 3134192]KanekoS , OtaniK , KondoT , FukushimaY , KanR , TakedaA , et al. Teratogenicity of antiepileptic drugs and drug specific malformations. Japanese Journal of Psychiatry and Neurology1993;47(2):306-8. [PMID: 8271575]KanekoS , OtaniK , KondoT , FukushimaY , NakamuraY , OgawaY , et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology1992;42(4 Suppl 5):68-74. [PMID: 1574179]">Kaneko 1999</a>; <a href="./references#CD010224-bbs2-0026" title="LindhoutD , HöppenerRJ , MeinardiH . Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia1984;25(1):77-83. [PMID: 6692794]LindhoutD , MeinardiH , MeijerJW , NauH . Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology1992;42(4 Suppl 5):94-110. [PMID: 1574185]">Lindhout 1992</a>; <a href="./references#CD010224-bbs2-0032" title="BattinoD , BinelliS , CaccamoML , CaneviniMP , CangerR , ComoML , et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurologica Scandinavica1992;85(3):204-7. [PMID: 1575005]BattinoD , KanekoS , AndermannE , AvanziniG , CaneviniMP , CangerR , et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research1999;36(1):53-60. [PMID: 10463850]CangerR , BattinoD , CaneviniMP , FumarolaC , GuidolinL , VignoliA , et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia1999;40(9):1231-6. [PMID: 10487185]">Milan Study 1999</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0041" title="SamrénEB , Van DuijnCM , KochS , HiilesmaaVK , KlepelH , BardyAH , et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia1997;38(9):981-90. [PMID: 9579936]">Samren 1997</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>). The largest data set with clear dose comparisons is the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration, which found that the prevalence of major congenital malformations increased from 6.3% at doses &lt; 650 mg daily to 25.2% for doses ≥ 1450 mg daily. Interestingly, pregnancy registers have reported a decrease in the mean dose for new registrations (<a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>) and have noted that this is associated with a reduction in the number of observed cases of neural tube malformations and hypospadias (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>). </p> </section> <section id="CD010224-sec-1536"> <h4 class="title">Zonisamide</h4> <p>Experience with ZNS exposure was limited to 130 cases described in four studies (<a href="./references#CD010224-bbs2-0019" title="JiménezM , Grau-LópezL , CiuransJ , García-EsperónC , FumanalA , BarambioS , ChíesE , CodinaM , BecerraJL . Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. Neurologia (Engl Ed) 2020 [Epub ahead of print];38(2):106-113. [DOI: 10.1016/j.nrl.2020.04.024] [PMID: 32690333]">Jimenez 2020</a>; <a href="./references#CD010224-bbs2-0034" title="MeadorKJ , PennellPB , MayRC , Van MarterL , McElrathTF , BrownC , et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology2020;94(14):e1502-11. [PMID: 31806691]Van MarterLJ , PennellPB , BrownC , HartmanAL , MayRC , McElrathT , et al. Neonatal outcomes in the MONEAD study of pregnant women with epilepsy. Journal of Pediatrics2021;7:100073. [DOI: 10.1016/j.ympdx.2021.100073]">MONEAD 2020</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>), therefore, it is not possible to draw conclusions at this time. Further efforts are needed to develop experience with this medication in pregnancy, as it has been in use for a long period in certain parts of the world (<a href="./references#CD010224-bbs2-0125" title="OommenKJ , MathewsS . Zonisamide: a new antiepileptic drug. Clinical Neuropharmacology1999;22(4):192-200. [PMID: 10442247]">Oommen 1999</a>). </p> </section> <section id="CD010224-sec-1537"> <h4 class="title">Other antiepileptic drugs</h4> <p>Either no, or very limited numbers, of pregnancies were found for other ASMs from the searches such as ethosuximide, sulthiame, perampanel, lacosamide or vigabatrin. </p> </section> </section> <section id="CD010224-sec-1538"> <h3 class="title" id="CD010224-sec-1538">Overall completeness and applicability of evidence</h3> <p>Efforts were made to ensure that the evidence presented here was as complete as possible by including the two dominant research study designs for this area of research; cohort study designs and datasets which contain routinely collected health records. However, we did not include case‐control congenital anomaly registers. In these registers, children are enrolled when the presence or absence of a malformation is known and, therefore, we classified recruitment as retrospective (e.g. <a href="./references#CD010224-bbs2-0115" title="JentinkJ , LoaneMA , DolkH , BarisicI , GarneE , MorrisJK , et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine2010;362(23):2185-93. [PMID: 20558369]">Jentink 2010a</a>; <a href="./references#CD010224-bbs2-0116" title="JentinkJ , DolkH , LoaneMA , MorrisJK , WellesleyD , GarneE , et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ2010;341:c6581. [PMID: 21127116]">Jentink 2010b</a>). Further, the nature of this data meant that it could not be directly combined into meta‐analysis with the data from the prospective observational studies. Additionally, in order to make the results of this review applicable to the treatment of women with epilepsy, included studies were required to include 70% or greater proportions of women taking ASMs for the treatment of epilepsy. This, however, will have reduced the sample size and may not be necessary. Whilst Christensen and colleagues (<a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>) in 2021 found no difference in risk estimates in the children of women with epilepsy in comparison to the children born to women with other indications, Hernandez Diaz and colleagues, using <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a>, derived data found that, in the context of TPM, the indication did alter the outcome reported. Further investigations are required to answer whether limiting this review to a high proportion of women with epilepsy is required. </p> <p>Efforts were made to ensure that the most up‐to‐date information from the longitudinal research initiatives was utilised, which meant that we often had to take outcomes for different ASMs from a number of different papers, or that authors investigated malformation types separately over different papers, or published updates for certain ASMs only. The largest challenge in terms of the completeness of the evidence came from some studies not reporting specific monotherapy outcomes or reporting monotherapy and polytherapy outcomes for a particular ASM together (e.g. <a href="./references#CD010224-bbs2-0081" title="RichmondJR , KrishnamoorthyP , AndermannE , BenjaminA . Epilepsy and pregnancy: an obstetric perspective. American Journal of Obstetrics and Gynecology2004;190(2):371-9. [PMID: 14981376]">Richmond 2004</a>; <a href="./references#CD010224-bbs2-0083" title="SabersA , DamM , A-Rogvi-HansenB , BoasJ , SideniusP , Laue FriisM , et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurologica Scandinavica2004;109(1):9-13. ">Sabers 2004</a>). However, this appeared to be a more frequent finding with older studies and there was a noticeable trend regarding separate reporting for each ASM for monotherapy exposures. </p> <p>The final challenge to the completeness of the data was in regard to the risk of specific types of malformations, due in a large part to the failure of included studies to publish specific malformation outcomes for all included groups. Whilst this is undoubtedly due to publication space, providing such information is critical for understanding the risks associated with specific malformation types. As demonstrated, in the case of PB or TPM, an ASM exposure may be associated with specific malformations, so reporting only an overall malformation figure may mask important associations. Further, unclear reporting and differences in the defining of certain malformation types or groups meant that we could not investigate hypospadias or gastrointestinal malformations, which have been linked to certain ASM exposures (<a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a>; <a href="./references#CD010224-bbs2-0043" title="KällénB . A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurologica Scandinavica1986;73(3):253-9. [PMID: 3716762]WideK , WinbladhB , KällénB . Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica2004;93(2):174-6. [PMID: 15046269]">Sweden Health Record Registers</a>). </p> <p>A few points of heterogeneity were found between included studies, which may limit the completeness of the evidence. Studies varied in how they dealt with the inclusion of foetal deaths or interruptions of pregnancy (with and without malformations) and in whether they counted genetic causes of malformation in their overall prevalence. At the outset of this review, we decided to use the author‐defined major malformation rate, as the review authors would be unlikely to have all the data required to determine information about reported major malformations. Considering this, however, we cannot confirm that all the studies applied the same criteria for classifying a major malformation. Further, there were differences between studies in the time at which the outcome was reported. For example, the <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a> has a major malformation reporting time before three months of age, whilst others included malformation presence at birth (e.g. <a href="./references#CD010224-bbs2-0055" title="BozhinovP , BozhinovaC , MarkovaC . [Fetal malformations in women with epilepsy]. Akusherstvo i Ginekologiia2009;48(1):16-21. [PMID: 19496458]BozhinovaS , BozhinovP . The course of pregnancy and labor in patients with epilepsy [Protichane na bremennostta i razhdaneto pri bremenni s epilepsiia]. Akusherstvo i Ginekologiia1998;37(4):12-4. [PMID: 10360042]">Bozhinov 2009</a>). Data from the <a href="./references#CD010224-bbs2-0011" title="Huber-MollemaY , Van ItersonL , OortFJ , LindhoutD , RodenburgR . Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. Journal of Neurology2020;267(6):1724-36. [PMID: 32112258]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurology2018;17(6):530-8. [PMID: 29680205]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology2019;93(9):e831-40. [PMID: 31391249]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , PeruccaE , et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology2015;85(10):866-72. [PMID: 26085607]TomsonT , BattinoD , BonizzoniE , CraigJ , LindhoutD , SabersA , et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology2011;10(7):609-17. [PMID: 21652013]TomsonT , BattinoD , BonizzoniE , CraigJJ , LindhoutD , PeruccaE , et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. Neurology2015;85(7):580-8. [PMID: 26187231]">EURAP 2018</a> collaboration and by Christensen and colleagues (2021) using <a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a> demonstrates that the reviewing of major malformation outcome at 12 months of age leads to an increased detection and, therefore, higher prevalence. Thus, data reported from some studies may in fact be an underestimation of the prevalence of major malformation if the assessment of the child occurs prior to 12 months of age. </p> <p>Finally, major malformation risk is not the only outcome of importance in pregnancy exposures. Beyond the scope of this review, small‐for‐gestational‐age, prematurity, minor congential malformations as well as longer‐term child health and neurodevelopmental outcomes can be altered, with life impacting consequences (<a href="./references#CD010224-bbs2-0103" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010236. [DOI: 10.1002/14651858.CD010236.pub2]">Bromley 2014</a>; <a href="./references#CD010224-bbs2-0108" title="Clayton-SmithJ , BromleyR , DeanJ , JournelH , OdentS , WoodA , et al. Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet Journal of Rare Diseases2019;14(1):180. [PMID: 31324220]">Clayton‐Smith 2019</a>; <a href="./references#CD010224-bbs2-0109" title="DeanJC , MooreSJ , TurnpennyPD . Developing diagnostic criteria for the fetal anticonvulsant syndromes. Seizure2000;9(3):233–4. [PMID: 10775521]">Dean 2000</a>) and, therefore, require consideration when understanding the total impact of an ASM exposure on the developing child. Minor malformations, for example, are an important part of the diagnostic criteria for foetal anticonvulsant syndromes, in particular (<a href="./references#CD010224-bbs2-0108" title="Clayton-SmithJ , BromleyR , DeanJ , JournelH , OdentS , WoodA , et al. Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet Journal of Rare Diseases2019;14(1):180. [PMID: 31324220]">Clayton‐Smith 2019</a>; <a href="./references#CD010224-bbs2-0109" title="DeanJC , MooreSJ , TurnpennyPD . Developing diagnostic criteria for the fetal anticonvulsant syndromes. Seizure2000;9(3):233–4. [PMID: 10775521]">Dean 2000</a>) and their presence may lead to a more detailed physical examination to check for more severe physical symptoms of exposure or neurodevelopmental impairment. Neurodevelopmental impairments are also a more commonly occurring outcome in the general population and, therefore, will occur more frequently in the ASM‐exposed populations and can have a significant impact on quality of life (<a href="./references#CD010224-bbs2-0103" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD010236. [DOI: 10.1002/14651858.CD010236.pub2]">Bromley 2014</a>; <a href="./references#CD010224-bbs2-0108" title="Clayton-SmithJ , BromleyR , DeanJ , JournelH , OdentS , WoodA , et al. Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet Journal of Rare Diseases2019;14(1):180. [PMID: 31324220]">Clayton‐Smith 2019</a>). </p> <p>Strengths of this review update include the creation and advance publication of the review protocol, the clear inclusion criteria, extensive searches, the acquisition of unpublished data, the inclusion of articles not written in English, meta‐analysis for all possible comparisons, the consideration of specific as well as overall major malformation risk, the balance of both systematic reviewing and content expertise and the assessment of risk of bias and quality in the non‐randomised evidence. Further, we improved the quality of the meta‐analyses by stratifying by type of control group and importantly study design. The results across the different study types were summarised in meta‐analysis separately due to the potential overlap in the cases (e.g. a national epilepsy and pregnancy register may contain the same children with a malformation as a population dataset which utilised routine health records for that same region or population). Further, at the start of this review, there were concerns about likely heterogeneity coming from different measurement approaches, periods of follow‐up and different patterns of maternal indications. However, in comparisons with larger numbers of included exposed pregnancies, the prevalences were similar (<a href="#CD010224-tbl-0003">Table 1</a>, <a href="#CD010224-fig-0003">Figure 3</a>). We therefore take the view that cohort studies and studies utilising population level health records offer complimentary evidence which can be viewed as replicating the results of each other, to ensure evidence consistency across the total available data. </p> <p>Under the Cochrane guidelines, this review will continue to be updated every two years, or following the publication of a significant amount of new data, to ensure it remains up‐to‐date which adds further strength. </p> </section> <section id="CD010224-sec-1539"> <h3 class="title" id="CD010224-sec-1539">Quality of the evidence</h3> <p>The methodological quality for each individual study is displayed in the <a href="#CD010224-sec-0048">Risk of bias in included studies</a> and in <a href="#CD010224-fig-0002">Figure 2</a>. Randomised controlled trials are thought to be unethical in this area due to the permanence of potential adverse effects for the foetus. Gold standard evidence for this area would, therefore, comprise data coming from a recruitment approach with low selection bias, prospective follow‐up, blinded outcome assessment to a standardised protocol and statistical methods to limit the influence of confounding or mediating variables. Obtaining all of these features in a single study is difficult and different study designs have a different set of strengths and weaknesses. </p> <p>The RoB ratings provided by an adaption of ROBINS‐I, for example, showed that the certain routine health record studies scored at a lower risk of bias than the cohort studies for risk of selection biases, yet the routine health record studies were at higher risk for outcome measurement which was completed in a non‐standardised manner by clinicians who were not blinded to the ASM exposure of the child. To balance these strengths and weaknesses which are inherent within these study designs, a complimentary set of pharmacovigilance approaches are required in order to have an accurate understanding of the data pertaining to possible risk associated with ASM exposures. </p> <p>It should be considered that ROBINS‐I is not optimised for pregnancy pharmacovigilance studies where the person taking the medication (mother) is not the person in which the outcome in is being assessed (child) and it was challenging to adopt the signalling questions and ratings to function for this review. Further, the recommended GRADE framework for rating the certainty of evidence was not used, as it would produce differential ratings depending on whether there were differences between the medications or not. For reviews of pregnancy pharmacovigilance data, bespoke risk of bias and certainty of evidence tools are required. </p> <p>In conclusion, our risk of bias review indicates that, across the included studies, there are a number of important biases assessed as high risk which should be taken into account when interpreting the results. The biases, however, were thought to be balanced across the ASMs investigated and, therefore, it is not felt that the findings were due solely to these biases. </p> </section> <section id="CD010224-sec-1540"> <h3 class="title" id="CD010224-sec-1540">Potential biases in the review process</h3> <p>Review authors RB and JCS were authors on three included studies (<a href="./references#CD010224-bbs2-0028" title="MawerG , BriggsM , BakerGA , BromleyR , CoyleH , EatockJ , et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure2010;19(2):112-9. [PMID: 20036166]">Mawer 2010</a>; <a href="./references#CD010224-bbs2-0029" title="MeadorKJ , BakerGA , FinnellRH , KalayjianLA , LiporaceJD , LoringDW , et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology2006;67(3):407-12. [PMID: 16894099]">Meador 2006</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>) and author JC on one (<a href="./references#CD010224-bbs2-0009" title="ChristensenJ , TrabjergBB , SunY , GilhusNE , Bjork M-H, TomsonT , et al. Prenatal exposure to valproate and risk of congenital malformations - could we have known earlier? A population-based cohort study. Epilepsia2021;62(12):2981-93. [PMID: 34585373]Mølgaard-NielsenD , HviidA . Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA2011;305(19):1996-2002. [PMID: 21586715]">Denmark Health Record Registers</a>). This potential bias was reduced by delegating data extraction and risk of bias assessments to other review authors. The ROBINS‐I adaptation, all analyses and interpretation were provided to all authors for review and input. </p> </section> <section id="CD010224-sec-1541"> <h3 class="title" id="CD010224-sec-1541">Agreements and disagreements with other studies or reviews</h3> <p>Despite many review articles in this area, there are few systematic reviews where meta‐analysis has been conducted and, where they have been completed, there are variations in study methodology (i.e. inclusion criteria). For example, the reviews by <a href="./references#CD010224-bbs2-0130" title="VeronikiAA , CogoE , RiosP , StrausSE , FinkelsteinY , KealeyR , et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Medicine2017;15(1):95. [PMID: 28472982]">Veroniki 2017</a> and <a href="./references#CD010224-bbs2-0121" title="MeadorK , ReynoldsMW , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81(1):1-13. [PMID: 18565732]">Meador 2008</a>, included both prospective and retrospective studies, studies using population‐based electronic healthcare records, and data from case‐control studies. Whilst such a wide inclusion criteria led to increased numbers of included pregnancies within the meta‐analysis, the comparability of data from these different methodological types is unclear. <a href="./references#CD010224-bbs2-0104" title="CharltonRA , CunningtonMC , De VriesCS , WeilJG . Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Safety2008;31(1):39-51. [PMID: 18095745]">Charlton 2008</a>, for example, had demonstrated different rates of malformations from the <a href="./references#CD010224-bbs2-0046" title="CharltonRA , WeilJG , CunningtonMC , De VriesCS . Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Safety2010;33(9):741-50. [PMID: 20701407]CharltonRA , WeilJG , CunningtonMC , RayS , De VriesCS . Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety2011;34(2):157-71. [PMID: 21247222]">UK Clinical Research Practice Database</a> in comparison to the <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>. Further, combining data from population studies using healthcare records with national epilepsy and pregnancy registers may lead to cases being represented twice; which, for rare outcomes, could alter the analyses significantly. We took a more cautious approach and did not combine data from cohort studies with data from studies that used population‐level routine health records. Whilst our findings were comparable to the more recent <a href="./references#CD010224-bbs2-0130" title="VeronikiAA , CogoE , RiosP , StrausSE , FinkelsteinY , KealeyR , et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Medicine2017;15(1):95. [PMID: 28472982]">Veroniki 2017</a> review in regard to VPA, PTM, PB, PHT, and CBZ, we did not have enough data to investigate their finding that ethosuximide is associated with an increased risk of major malformation. Overall, our approach of reviewing and undertaking meta‐analysis separately for primary and secondary data sources provides internal comparison and validation of the results which, we feel, is a strength. </p> <p>Further consistent findings were reported by <a href="./references#CD010224-bbs2-0116" title="JentinkJ , DolkH , LoaneMA , MorrisJK , WellesleyD , GarneE , et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ2010;341:c6581. [PMID: 21127116]">Jentink 2010b</a> who found the prevalence of malformation following CBZ to be 3.3% based on 2680 CBZ children from eight studies. In contrast to our review, however, <a href="./references#CD010224-bbs2-0116" title="JentinkJ , DolkH , LoaneMA , MorrisJK , WellesleyD , GarneE , et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ2010;341:c6581. [PMID: 21127116]">Jentink 2010b</a> found a significant association between CBZ exposure and spina bifida. However, as in our review, <a href="./references#CD010224-bbs2-0115" title="JentinkJ , LoaneMA , DolkH , BarisicI , GarneE , MorrisJK , et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine2010;362(23):2185-93. [PMID: 20558369]">Jentink 2010a</a> found that eight studies (N = 1565 pregnancies) showed a prevalence rate of 7.5% (95% CI 6.3 to 9.0) in those exposed to VPA, and noted an increase in terms of specific malformations. The data reported here pertaining to LEV is consistent with a previous systematic review (<a href="./references#CD010224-bbs2-0105" title="ChaudhrySA , JongG , KorenG . The fetal safety of levetiracetam: a systematic review. Reproductive Toxicology2014;46:40-5. [PMID: 24602560]">Chaudhry 2014</a>), which also included the three prospective studies reported here (<a href="./references#CD010224-bbs2-0003" title="JazayeriD , GrahamJ , HitchcockA , O'BrienTJ , VajdaFJ . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure2018;56:111-4. [PMID: 29471258]VajdaF , LanderC , O'BrienT , HitchcockA , GrahamJ , SolinasC , et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia2004;45(11):1466. [PMID: 15509252]VajdaF , O'BrienT , GrahamJ , LanderC , EadieM . Dose dependence of fetal malformations associated with valproate. Neurology2013;81(11):999-1003. [PMID: 23911758]VajdaFJ , EadieMJ . Maternal valproate dosage and foetal malformations. Acta Neurologica Scandinavica2005;112(3):137-43. [PMID: 16097954]VajdaFJ , GrahamJ , LanderCM , O'BrienTJ , EadieM . Teratogenicity of the newer antiepileptic drugs - the Australian experience. Journal of Clinical Neuroscience2012;19(1):57-9. [PMID: 22104350]VajdaFJ , GrahamJE , HitchcockAA , LanderCM , O'BrienTJ , EadieMJ . Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure2019;65:6-11. [PMID: 30593875]VajdaFJ , GrahamJE , HitchcockAA , O'BrienTJ , LanderCM , EadieMJ . Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure2010;19(9):558-61. [PMID: 20739196]VajdaFJ , HitchcockA , GrahamJ , O'BrienT , LanderC , EadieM . The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47(6):468-74. [PMID: 17991111]VajdaFJ , LanderCM , HitchcockA , GrahamJ , SolinasC , O'BrienT , et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience2007;14(7):611-7. [PMID: 17400456]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurologica Scandinavica2013;128(4):228-34. [PMID: 23461556]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Is carbamazepine a human teratogen?Journal of Clinical Neuroscience2016;23:34-7. [PMID: 26521756]VajdaFJ , O'BrienTJ , GrahamJ , LanderCM , EadieMJ . Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research2014;108(6):1013-7. [PMID: 24880523]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Antiepileptic drugs, foetal malformations and spontaneous abortions. Acta Neurologica Scandinavica2017;135(3):360-5. [PMID: 27573510]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy &amp; Behavior2020;103(Pt A):106481. [PMID: 31711866]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Pregnancy after valproate withdrawal - fetal malformations and seizure control. Epilepsia2020;61(5):944-50. [PMID: 32314363]VajdaFJ , O'BrienTJ , GrahamJE , HitchcockAA , LanderCM , EadieMJ . Valproate-associated foetal malformations - rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica2019;139(1):42-8. [PMID: 30109700]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , CookM , LanderC , et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience2004;11(8):854-8. [PMID: 15519862]VajdaFJ , O'BrienTJ , HitchcockA , GrahamJ , LanderC . The Australian Registry of Anti-Epileptic Drugs in Pregnancy: experience after 30 months. Journal of Clinical Neuroscience2003;10(5):543-9. [PMID: 12948456]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , EadieMJ . Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia2016;57(7):1048-52. [PMID: 27265509]VajdaFJ , O'BrienTJ , LanderCM , GrahamJ , RotenA , EadieMJ . Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia2013;54(1):181-6. [PMID: 22882134]">Australian Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0037" title="BokhariA , CoullBA , HolmesLB . Effect of prenatal exposure to anticonvulsant drugs on dermal ridge patterns of fingers. Teratology2002;66(1):19-23. [PMID: 12115776]BromfieldEB , DworetzkyBA , WyszynskiDF , SmithCR , BaldwinEJ , HolmesLB . Valproate teratogenicity and epilepsy syndrome. Epilepsia2008;49(12):2122-4. [PMID: 18557775]Hernandez-DiazS , SmithCR , ShenA , MittendorfR , HauserWA , YerbyM , et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology2012;78(21):1692-9. [PMID: 22551726]Hernández-DíazS , MittendorfR , SmithCR , HauserWA , YerbyM , HolmesLB , et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics and Gynecology2014;123(1):21-8. [PMID: 24463659]HolmesLB , BaldwinEJ , SmithCR , HabeckerE , GlassmanL , WongSL , et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology2008;70(22 Pt 2):2152-8. [PMID: 18448870]HolmesLB , CoullBA , DorfmanJ , RosenbergerPB . The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics2005;146(1):118-22. [PMID: 15644835]HolmesLB , MittendorfR , ShenA , SmithCR , Hernandez-DiazS . Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Archives of Neurology2011;68(10):1275-81. [PMID: 21670385]HolmesLB , RosenbergerPB , HarveyEA , KhoshbinS , RyanL . Intelligence and physical features of children of women with epilepsy. Teratology2000;61(3):196-202. [PMID: 10661909]HolmesLB , WyszynskiDF . North American Antiepileptic Drug Pregnancy Registry. Epilepsia2004;45(11):1465. [PMID: 15509251]WyszynskiDF , NambisanM , SurveT , AlsdorfRM , SmithCR , HolmesLB , et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology2005;64(6):961-5. [PMID: 15781808]">North American Epilepsy and Pregnancy Register</a>; <a href="./references#CD010224-bbs2-0045" title="CampbellE , DevenneyE , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia2013;54(1):165-71. [PMID: 23167802]CampbellE , KennedyF , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery &amp; Psychiatry2014;85(9):1029-34. [PMID: 24444855]HuntS , CraigJ , RussellA , GuthrieE , ParsonsL , RobertsonI , et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology2006;67(10):1876-9. [PMID: 17130430]HuntS , RussellA , SmithsonWH , ParsonsL , RobertsonI , WaddellR , et al. Topiramate in pregnancy. Neurology2008;71(4):272-6. [PMID: 18645165]KinneyMO , MorrowJ , PattersonCC , CampbellE , RussellA , SmithsonHW , et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. Journal of Neurology, Neurosurgery, and Psychiatry2018;89(12):1320-3. [PMID: 29661925]MawhinneyE , CampbellJ , CraigJ , RussellA , SmithsonW , ParsonsL , et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?Seizure2012;21(3):215-8. [PMID: 22364656]MawhinneyE , CraigJ , MorrowJ , RussellA , SmithsonWH , ParsonsL , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology2013;80(4):400-5. [PMID: 23303847]McCluskeyG , KinneyMO , RussellA , SmithsonWH , ParsonsL , MorrisonPJ , et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure2021;91:311-5. [PMID: 34273670]MorrowJ , RussellA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(2):193-8. [PMID: 16157661]">UK and Ireland Epilepsy and Pregnancy Register</a>) as well as studies utilising other methodologies and reported a prevalence rate of 2.2% (27/1213, 95% CI 1.53 to 3.22). </p> <p>This updated meta‐analysis did not consistently replicate the reported association between TPM exposure and oral clefts, but we did narratively review data from the large <a href="./references#CD010224-bbs2-0048" title="Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , PennellPB , et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology2018;90(4):e342-51. [PMID: 29282333]PatornoE , Hernandez-DiazS , HuybrechtsKF , DesaiRJ , CohenJM , MogunH , et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine2020;17(9):e1003322. [PMID: 32870921]">US Medicaid Registers</a> study, which reported an association. In a previously completed meta‐analysis, <a href="./references#CD010224-bbs2-0100" title="AlsaadAM , ChaudhrySA , KorenG . First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis. Reproductive Toxicology2015;53:45-50. [PMID: 25797654]">Alsaad 2015</a> had wider inclusion criteria which included 3420 patients taking TPM (mixed aetiologies and study design types) and 1,204,981 controls and reported a significant odds ratio (OR 6.26, 95% CI: 3.13 to 12.51). As noted throughout this discussion, data were limited pertaining to the newer ASMs and by the reporting of specific malformations in included studies, therefore, it is possible that the limited data that contributed to this meta‐analysis do not consistently uphold this association across all comparisons. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010224-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram*50 studies were included in the original review but, due to changes to the inclusion criteria, 16 studies were excluded.** for some studies only certain data were able to be included in the meta‐analysis." data-id="CD010224-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> <p>*50 studies were included in the original review but, due to changes to the inclusion criteria, 16 studies were excluded. </p> <p>** for some studies only certain data were able to be included in the meta‐analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias for included studies by individual domain" data-id="CD010224-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-02.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias for included studies by individual domain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-02.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Prevalence and 95% CI of major congenital malformations for each anti‐seizure medication by data source" data-id="CD010224-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Prevalence and 95% CI of major congenital malformations for each anti‐seizure medication by data source </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ vs Controls, Outcome 1: CBZ vs Controls: All Major Malformations" data-id="CD010224-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: CBZ vs Controls, Outcome 1: CBZ vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ vs Controls, Outcome 2: CBZ vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: CBZ vs Controls, Outcome 2: CBZ vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ vs Controls, Outcome 3: CBZ vs Controls: Cardiac Malformations" data-id="CD010224-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: CBZ vs Controls, Outcome 3: CBZ vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ vs Controls, Outcome 4: CBZ vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: CBZ vs Controls, Outcome 4: CBZ vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBZ vs Controls, Outcome 5: CBZ vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: CBZ vs Controls, Outcome 5: CBZ vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CZP vs Controls, Outcome 1: CZP vs Controls: All Major Malformations" data-id="CD010224-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: CZP vs Controls, Outcome 1: CZP vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GBP vs Controls, Outcome 1: GBP vs Controls: All Major Malformations" data-id="CD010224-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: GBP vs Controls, Outcome 1: GBP vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GBP vs Controls, Outcome 2: GBP vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: GBP vs Controls, Outcome 2: GBP vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GBP vs Controls, Outcome 3: GBP vs Controls: Cardiac Malformations" data-id="CD010224-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: GBP vs Controls, Outcome 3: GBP vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GBP vs Controls, Outcome 4: GBP vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: GBP vs Controls, Outcome 4: GBP vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GBP vs Controls, Outcome 5: GBP vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: GBP vs Controls, Outcome 5: GBP vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LEV vs Controls, Outcome 1: LEV vs Controls: All Major Malformations" data-id="CD010224-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: LEV vs Controls, Outcome 1: LEV vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LEV vs Controls, Outcome 2: LEV vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: LEV vs Controls, Outcome 2: LEV vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LEV vs Controls, Outcome 3: LEV vs Controls: Cardiac Malformations" data-id="CD010224-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: LEV vs Controls, Outcome 3: LEV vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LEV vs Controls, Outcome 4: LEV vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: LEV vs Controls, Outcome 4: LEV vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LEV vs Controls, Outcome 5: LEV vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: LEV vs Controls, Outcome 5: LEV vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LTG vs Controls, Outcome 1: LTG vs Controls: All Major Malformations" data-id="CD010224-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: LTG vs Controls, Outcome 1: LTG vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LTG vs Controls, Outcome 2: LTG vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: LTG vs Controls, Outcome 2: LTG vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LTG vs Controls, Outcome 3: LTG vs Controls: Cardiac Malformations" data-id="CD010224-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: LTG vs Controls, Outcome 3: LTG vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LTG vs Controls, Outcome 4: LTG vs Controls: Oro‐Facial Cleft/Crainofacial Malformations" data-id="CD010224-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: LTG vs Controls, Outcome 4: LTG vs Controls: Oro‐Facial Cleft/Crainofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LTG vs Controls, Outcome 5: LTG vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: LTG vs Controls, Outcome 5: LTG vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OXC vs Controls, Outcome 1: OXC vs Controls: All Major Malformations" data-id="CD010224-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: OXC vs Controls, Outcome 1: OXC vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OXC vs Controls, Outcome 2: OXC vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: OXC vs Controls, Outcome 2: OXC vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OXC vs Controls, Outcome 3: OXC vs Controls: Cardiac Malformations" data-id="CD010224-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: OXC vs Controls, Outcome 3: OXC vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OXC vs Controls, Outcome 4: OXC vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: OXC vs Controls, Outcome 4: OXC vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OXC vs Controls, Outcome 5: OXC vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: OXC vs Controls, Outcome 5: OXC vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PB vs Controls, Outcome 1: PB vs Controls: All Major Malformations" data-id="CD010224-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: PB vs Controls, Outcome 1: PB vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PB vs Controls, Outcome 2: PB vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: PB vs Controls, Outcome 2: PB vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PB vs Controls, Outcome 3: PB vs Controls: Cardiac Malformations" data-id="CD010224-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: PB vs Controls, Outcome 3: PB vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PB vs Controls, Outcome 4: PB vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: PB vs Controls, Outcome 4: PB vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PB vs Controls, Outcome 5: PB vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: PB vs Controls, Outcome 5: PB vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PHT vs Controls, Outcome 1: PHT vs Controls: All Major Malformations" data-id="CD010224-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: PHT vs Controls, Outcome 1: PHT vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PHT vs Controls, Outcome 2: PHT vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: PHT vs Controls, Outcome 2: PHT vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PHT vs Controls, Outcome 3: PHT vs Controls: Cardiac Malformations" data-id="CD010224-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: PHT vs Controls, Outcome 3: PHT vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PHT vs Controls, Outcome 4: PHT vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: PHT vs Controls, Outcome 4: PHT vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PHT vs Controls, Outcome 5: PHT vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: PHT vs Controls, Outcome 5: PHT vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: PRM vs Controls, Outcome 1: PRM vs Controls: All Major Malformations" data-id="CD010224-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: PRM vs Controls, Outcome 1: PRM vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TPM vs Controls, Outcome 1: TPM vs Controls: All Major Malformations" data-id="CD010224-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: TPM vs Controls, Outcome 1: TPM vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TPM vs Controls, Outcome 2: TPM vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: TPM vs Controls, Outcome 2: TPM vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TPM vs Controls, Outcome 3: TPM vs Controls: Cardiac Malformations" data-id="CD010224-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: TPM vs Controls, Outcome 3: TPM vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TPM vs Controls, Outcome 4: TPM vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: TPM vs Controls, Outcome 4: TPM vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: TPM vs Controls, Outcome 5: TPM vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: TPM vs Controls, Outcome 5: TPM vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: VPA vs Controls, Outcome 1: VPA vs Controls: All Major Malformations" data-id="CD010224-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: VPA vs Controls, Outcome 1: VPA vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: VPA vs Controls, Outcome 2: VPA vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: VPA vs Controls, Outcome 2: VPA vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: VPA vs Controls, Outcome 3: VPA vs Controls: Cardiac Malformations" data-id="CD010224-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: VPA vs Controls, Outcome 3: VPA vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: VPA vs Controls, Outcome 4: VPA vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: VPA vs Controls, Outcome 4: VPA vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: VPA vs Controls, Outcome 5: VPA vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: VPA vs Controls, Outcome 5: VPA vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ZNS vs Controls, Outcome 1: ZNS vs Controls: All Major Malformations" data-id="CD010224-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: ZNS vs Controls, Outcome 1: ZNS vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ZNS vs Controls, Outcome 2: ZNS vs Controls: Neural Tube Malformations" data-id="CD010224-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: ZNS vs Controls, Outcome 2: ZNS vs Controls: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ZNS vs Controls, Outcome 3: ZNS vs Controls: Cardiac Malformations" data-id="CD010224-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: ZNS vs Controls, Outcome 3: ZNS vs Controls: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ZNS vs Controls, Outcome 4: ZNS vs Controls: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0054" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: ZNS vs Controls, Outcome 4: ZNS vs Controls: Oro‐Facial Cleft/Craniofacial Malformations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ZNS vs Controls, Outcome 5: ZNS vs Controls: Skeletal/Limb Malformations" data-id="CD010224-fig-0055" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: ZNS vs Controls, Outcome 5: ZNS vs Controls: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: CBZ vs CZP, Outcome 1: CBZ vs CZP: All Major Malformations" data-id="CD010224-fig-0056" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: CBZ vs CZP, Outcome 1: CBZ vs CZP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: CBZ vs GBP, Outcome 1: CBZ vs GBP: All Major Malformations" data-id="CD010224-fig-0057" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: CBZ vs GBP, Outcome 1: CBZ vs GBP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: CBZ vs GBP, Outcome 2: CBZ vs GBP: Neural Tube Malformations" data-id="CD010224-fig-0058" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: CBZ vs GBP, Outcome 2: CBZ vs GBP: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: CBZ vs GBP, Outcome 3: CBZ vs GBP: Cardiac Malformations" data-id="CD010224-fig-0059" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: CBZ vs GBP, Outcome 3: CBZ vs GBP: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: CBZ vs GBP, Outcome 4: CBZ vs GBP: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0060" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: CBZ vs GBP, Outcome 4: CBZ vs GBP: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: CBZ vs GBP, Outcome 5: CBZ vs GBP: Skeletal/Limb Malformations" data-id="CD010224-fig-0061" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: CBZ vs GBP, Outcome 5: CBZ vs GBP: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: CBZ vs LEV, Outcome 1: CBZ vs LEV: All Major Malformations" data-id="CD010224-fig-0062" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: CBZ vs LEV, Outcome 1: CBZ vs LEV: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: CBZ vs LEV, Outcome 2: CBZ vs LEV: Neural Tube Malformations" data-id="CD010224-fig-0063" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: CBZ vs LEV, Outcome 2: CBZ vs LEV: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: CBZ vs LEV, Outcome 3: CBZ vs LEV: Cardiac Malformations" data-id="CD010224-fig-0064" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: CBZ vs LEV, Outcome 3: CBZ vs LEV: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: CBZ vs LEV, Outcome 4: CBZ vs LEV: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0065" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: CBZ vs LEV, Outcome 4: CBZ vs LEV: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: CBZ vs LEV, Outcome 5: CBZ vs LEV: Skeletal/Limb Malformations" data-id="CD010224-fig-0066" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: CBZ vs LEV, Outcome 5: CBZ vs LEV: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: CBZ vs LTG, Outcome 1: CBZ vs LTG: All Major Malformations" data-id="CD010224-fig-0067" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: CBZ vs LTG, Outcome 1: CBZ vs LTG: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: CBZ vs LTG, Outcome 2: CBZ vs LTG: Neural Tube Malformations" data-id="CD010224-fig-0068" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: CBZ vs LTG, Outcome 2: CBZ vs LTG: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: CBZ vs LTG, Outcome 3: CBZ vs LTG: Cardiac Malformations" data-id="CD010224-fig-0069" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: CBZ vs LTG, Outcome 3: CBZ vs LTG: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-016.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: CBZ vs LTG, Outcome 4: CBZ vs LTG: Oro‐Facial Cleft/Crainofacial Malformations" data-id="CD010224-fig-0070" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-016.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16: CBZ vs LTG, Outcome 4: CBZ vs LTG: Oro‐Facial Cleft/Crainofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-016.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: CBZ vs LTG, Outcome 5: CBZ vs LTG: Skeletal/Limb Malformations" data-id="CD010224-fig-0071" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-016.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16: CBZ vs LTG, Outcome 5: CBZ vs LTG: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-016.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ vs OXC, Outcome 1: CBZ vs OXC: All Major Malformations" data-id="CD010224-fig-0072" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: CBZ vs OXC, Outcome 1: CBZ vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ vs OXC, Outcome 2: CBZ vs OXC: Neural Tube Malformations" data-id="CD010224-fig-0073" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: CBZ vs OXC, Outcome 2: CBZ vs OXC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ vs OXC, Outcome 3: CBZ vs OXC: Cardiac Malformations" data-id="CD010224-fig-0074" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: CBZ vs OXC, Outcome 3: CBZ vs OXC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-017.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ vs OXC, Outcome 4: CBZ vs OXC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0075" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-017.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17: CBZ vs OXC, Outcome 4: CBZ vs OXC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-017.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: CBZ vs OXC, Outcome 5: CBZ vs OXC: Skeletal/Limb Malformations" data-id="CD010224-fig-0076" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-017.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17: CBZ vs OXC, Outcome 5: CBZ vs OXC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-017.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: CBZ vs PB, Outcome 1: CBZ vs PB: All Major Malformations" data-id="CD010224-fig-0077" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: CBZ vs PB, Outcome 1: CBZ vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: CBZ vs PB, Outcome 2: CBZ vs PB: Neural Tube Malformations" data-id="CD010224-fig-0078" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: CBZ vs PB, Outcome 2: CBZ vs PB: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: CBZ vs PB, Outcome 3: CBZ vs PB: Cardiac Malformations" data-id="CD010224-fig-0079" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: CBZ vs PB, Outcome 3: CBZ vs PB: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-018.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: CBZ vs PB, Outcome 4: CBZ vs PB: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0080" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-018.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18: CBZ vs PB, Outcome 4: CBZ vs PB: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-018.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: CBZ vs PB, Outcome 5: CBZ vs PB: Skeletal/Limb Malformation" data-id="CD010224-fig-0081" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-018.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18: CBZ vs PB, Outcome 5: CBZ vs PB: Skeletal/Limb Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-018.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ vs PHT, Outcome 1: CBZ vs PHT: All Major Malformations" data-id="CD010224-fig-0082" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: CBZ vs PHT, Outcome 1: CBZ vs PHT: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ vs PHT, Outcome 2: CBZ vs PHT: Neural Tube Malformations" data-id="CD010224-fig-0083" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: CBZ vs PHT, Outcome 2: CBZ vs PHT: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ vs PHT, Outcome 3: CBZ vs PHT: Cardiac Malformations" data-id="CD010224-fig-0084" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: CBZ vs PHT, Outcome 3: CBZ vs PHT: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-019.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ vs PHT, Outcome 4: CBZ vs PHT: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0085" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-019.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19: CBZ vs PHT, Outcome 4: CBZ vs PHT: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-019.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: CBZ vs PHT, Outcome 5: CBZ vs PHT: Skeletal/Limb Malformation" data-id="CD010224-fig-0086" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-019.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.5</div> <div class="figure-caption"> <p>Comparison 19: CBZ vs PHT, Outcome 5: CBZ vs PHT: Skeletal/Limb Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-019.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: CBZ vs PRM, Outcome 1: CBZ vs PRM: All Major Malformations" data-id="CD010224-fig-0087" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: CBZ vs PRM, Outcome 1: CBZ vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: CBZ vs PRM, Outcome 2: CBZ vs PRM: Neural Tube Malformations" data-id="CD010224-fig-0088" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: CBZ vs PRM, Outcome 2: CBZ vs PRM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-020.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: CBZ vs PRM, Outcome 3: CBZ vs PRM: Cardiac Malformations" data-id="CD010224-fig-0089" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-020.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.3</div> <div class="figure-caption"> <p>Comparison 20: CBZ vs PRM, Outcome 3: CBZ vs PRM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-020.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: CBZ vs PRM, Outcome 4: CBZ vs PRM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0090" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-020.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.4</div> <div class="figure-caption"> <p>Comparison 20: CBZ vs PRM, Outcome 4: CBZ vs PRM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-020.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: CBZ vs PRM, Outcome 5: CBZ vs PRM: Skeletal/Limb Malformations" data-id="CD010224-fig-0091" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-020.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.5</div> <div class="figure-caption"> <p>Comparison 20: CBZ vs PRM, Outcome 5: CBZ vs PRM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-020.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: CBZ vs TPM, Outcome 1: CBZ vs TPM: All Major Malformations" data-id="CD010224-fig-0092" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: CBZ vs TPM, Outcome 1: CBZ vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: CBZ vs TPM, Outcome 2: CBZ vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0093" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: CBZ vs TPM, Outcome 2: CBZ vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-021.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: CBZ vs TPM, Outcome 3: CBZ vs TPM: Cardiac Malformations" data-id="CD010224-fig-0094" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-021.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21: CBZ vs TPM, Outcome 3: CBZ vs TPM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-021.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: CBZ vs TPM, Outcome 4: CBZ vs TPM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0095" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-021.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.4</div> <div class="figure-caption"> <p>Comparison 21: CBZ vs TPM, Outcome 4: CBZ vs TPM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-021.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: CBZ vs TPM, Outcome 5: CBZ vs TPM: Skeletal/Limb Malformations" data-id="CD010224-fig-0096" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-021.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.5</div> <div class="figure-caption"> <p>Comparison 21: CBZ vs TPM, Outcome 5: CBZ vs TPM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-021.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: CBZ vs VPA, Outcome 1: CBZ vs VPA: All Major Malformations" data-id="CD010224-fig-0097" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: CBZ vs VPA, Outcome 1: CBZ vs VPA: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: CBZ vs VPA, Outcome 2: CBZ vs VPA: Neural Tube Malformations" data-id="CD010224-fig-0098" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: CBZ vs VPA, Outcome 2: CBZ vs VPA: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: CBZ vs VPA, Outcome 3: CBZ vs VPA: Cardiac Malformations" data-id="CD010224-fig-0099" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: CBZ vs VPA, Outcome 3: CBZ vs VPA: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-022.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: CBZ vs VPA, Outcome 4: CBZ vs VPA: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0100" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-022.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.4</div> <div class="figure-caption"> <p>Comparison 22: CBZ vs VPA, Outcome 4: CBZ vs VPA: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-022.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: CBZ vs VPA, Outcome 5: CBZ vs VPA: Skeletal/Limb Malformations" data-id="CD010224-fig-0101" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-022.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.5</div> <div class="figure-caption"> <p>Comparison 22: CBZ vs VPA, Outcome 5: CBZ vs VPA: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-022.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: CBZ vs ZNS, Outcome 1: CBZ vs ZNS: All Major Malformations" data-id="CD010224-fig-0102" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: CBZ vs ZNS, Outcome 1: CBZ vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: CBZ vs ZNS, Outcome 2: CBZ vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0103" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: CBZ vs ZNS, Outcome 2: CBZ vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-023.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: CBZ vs ZNS, Outcome 3: CBZ vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0104" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-023.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23: CBZ vs ZNS, Outcome 3: CBZ vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-023.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: CBZ vs ZNS, Outcome 4: CBZ vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0105" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-023.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.4</div> <div class="figure-caption"> <p>Comparison 23: CBZ vs ZNS, Outcome 4: CBZ vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-023.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: CBZ vs ZNS, Outcome 5: CBZ vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0106" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-023.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.5</div> <div class="figure-caption"> <p>Comparison 23: CBZ vs ZNS, Outcome 5: CBZ vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-023.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-024.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: GBP vs LTG, Outcome 1: GPB vs LTG: All Major Malformations" data-id="CD010224-fig-0107" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-024.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24: GBP vs LTG, Outcome 1: GPB vs LTG: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-024.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: GBP vs LTG, Outcome 2: GPB vs LTG: Neural Tube Malformations" data-id="CD010224-fig-0108" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-024.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24: GBP vs LTG, Outcome 2: GPB vs LTG: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-024.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: GBP vs LTG, Outcome 3: GPB vs LTG: Cardiac Malformations" data-id="CD010224-fig-0109" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-024.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.3</div> <div class="figure-caption"> <p>Comparison 24: GBP vs LTG, Outcome 3: GPB vs LTG: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-024.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: GBP vs LTG, Outcome 4: GPB vs LTG: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0110" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-024.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.4</div> <div class="figure-caption"> <p>Comparison 24: GBP vs LTG, Outcome 4: GPB vs LTG: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-024.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: GBP vs LTG, Outcome 5: GPB vs LTG: Skeletal/Limb Malformations" data-id="CD010224-fig-0111" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-024.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.5</div> <div class="figure-caption"> <p>Comparison 24: GBP vs LTG, Outcome 5: GPB vs LTG: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-024.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-025.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: GBP vs OXC, Outcome 1: GBP vs OXC: All Major Malformations" data-id="CD010224-fig-0112" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-025.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25: GBP vs OXC, Outcome 1: GBP vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-025.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: GBP vs OXC, Outcome 2: GBP vs OXC: Neural Tube Malformations" data-id="CD010224-fig-0113" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-025.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25: GBP vs OXC, Outcome 2: GBP vs OXC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-025.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: GBP vs OXC, Outcome 3: GBP vs OXC: Cardiac Malformations" data-id="CD010224-fig-0114" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-025.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.3</div> <div class="figure-caption"> <p>Comparison 25: GBP vs OXC, Outcome 3: GBP vs OXC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-025.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: GBP vs OXC, Outcome 4: GBP vs OXC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0115" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-025.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.4</div> <div class="figure-caption"> <p>Comparison 25: GBP vs OXC, Outcome 4: GBP vs OXC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-025.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: GBP vs OXC, Outcome 5: GBP vs OXC: Skeletal/Limb Malformations" data-id="CD010224-fig-0116" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-025.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.5</div> <div class="figure-caption"> <p>Comparison 25: GBP vs OXC, Outcome 5: GBP vs OXC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-025.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-026.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: GBP vs PB, Outcome 1: GBP vs PB: All Major Malformations" data-id="CD010224-fig-0117" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-026.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26: GBP vs PB, Outcome 1: GBP vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-026.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: GBP vs PB, Outcome 2: GBP vs PB: Neural Tube Malformations" data-id="CD010224-fig-0118" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-026.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26: GBP vs PB, Outcome 2: GBP vs PB: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-026.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: GBP vs PB, Outcome 3: GBP vs PB: Cardiac Malformations" data-id="CD010224-fig-0119" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-026.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.3</div> <div class="figure-caption"> <p>Comparison 26: GBP vs PB, Outcome 3: GBP vs PB: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-026.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: GBP vs PB, Outcome 4: GBP vs PB: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0120" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-026.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.4</div> <div class="figure-caption"> <p>Comparison 26: GBP vs PB, Outcome 4: GBP vs PB: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-026.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: GBP vs PB, Outcome 5: GBP vs PB: Skeletal/Limb Malformations" data-id="CD010224-fig-0121" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-026.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.5</div> <div class="figure-caption"> <p>Comparison 26: GBP vs PB, Outcome 5: GBP vs PB: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-026.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-027.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 27: GBP vs PRM, Outcome 1: GBP vs PRM: All Major Malformations" data-id="CD010224-fig-0122" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-027.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-027.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27: GBP vs PRM, Outcome 1: GBP vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-027.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-028.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: GBP vs TPM, Outcome 1: GBP vs TPM: All Major Malformations" data-id="CD010224-fig-0123" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-028.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28: GBP vs TPM, Outcome 1: GBP vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-028.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: GBP vs TPM, Outcome 2: GBP vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0124" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-028.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28: GBP vs TPM, Outcome 2: GBP vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-028.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: GBP vs TPM, Outcome 3: GBP vs TPM: Cardiac Malformations" data-id="CD010224-fig-0125" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-028.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.3</div> <div class="figure-caption"> <p>Comparison 28: GBP vs TPM, Outcome 3: GBP vs TPM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-028.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: GBP vs TPM, Outcome 4: GBP vs TPM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0126" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-028.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.4</div> <div class="figure-caption"> <p>Comparison 28: GBP vs TPM, Outcome 4: GBP vs TPM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-028.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: GBP vs TPM, Outcome 5: GBP vs TPM: Skeletal/Limb Malformations" data-id="CD010224-fig-0127" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-028.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.5</div> <div class="figure-caption"> <p>Comparison 28: GBP vs TPM, Outcome 5: GBP vs TPM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-028.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-029.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: GBP vs ZNS, Outcome 1: GBP vs ZNS: All Major Malformations" data-id="CD010224-fig-0128" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-029.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-029.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29: GBP vs ZNS, Outcome 1: GBP vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-029.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-030.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: LEV vs GBP, Outcome 1: LEV vs GBP: All Major Malformations" data-id="CD010224-fig-0129" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-030.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30: LEV vs GBP, Outcome 1: LEV vs GBP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-030.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: LEV vs GBP, Outcome 2: LEV vs GBP: Neural Tube Malformations" data-id="CD010224-fig-0130" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-030.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30: LEV vs GBP, Outcome 2: LEV vs GBP: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-030.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: LEV vs GBP, Outcome 3: LEV vs GBP: Cardiac Malformations" data-id="CD010224-fig-0131" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-030.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.3</div> <div class="figure-caption"> <p>Comparison 30: LEV vs GBP, Outcome 3: LEV vs GBP: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-030.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: LEV vs GBP, Outcome 4: LEV vs GBP: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0132" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-030.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.4</div> <div class="figure-caption"> <p>Comparison 30: LEV vs GBP, Outcome 4: LEV vs GBP: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-030.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: LEV vs GBP, Outcome 5: LEV vs GBP: Skeletal/Limb Malformation" data-id="CD010224-fig-0133" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-030.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.5</div> <div class="figure-caption"> <p>Comparison 30: LEV vs GBP, Outcome 5: LEV vs GBP: Skeletal/Limb Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-030.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-031.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: LEV vs LTG, Outcome 1: LEV vs LTG: All Major Malformations" data-id="CD010224-fig-0134" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-031.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31: LEV vs LTG, Outcome 1: LEV vs LTG: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-031.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: LEV vs LTG, Outcome 2: LEV vs LTG: Neural Tube Malformations" data-id="CD010224-fig-0135" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-031.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.2</div> <div class="figure-caption"> <p>Comparison 31: LEV vs LTG, Outcome 2: LEV vs LTG: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-031.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: LEV vs LTG, Outcome 3: LEV vs LTG: Cardiac Malformations" data-id="CD010224-fig-0136" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-031.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.3</div> <div class="figure-caption"> <p>Comparison 31: LEV vs LTG, Outcome 3: LEV vs LTG: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-031.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: LEV vs LTG, Outcome 4: LEV vs LTG: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0137" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-031.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.4</div> <div class="figure-caption"> <p>Comparison 31: LEV vs LTG, Outcome 4: LEV vs LTG: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-031.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: LEV vs LTG, Outcome 5: LEV vs LTG: Skeletal/Limb Malformation" data-id="CD010224-fig-0138" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-031.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.5</div> <div class="figure-caption"> <p>Comparison 31: LEV vs LTG, Outcome 5: LEV vs LTG: Skeletal/Limb Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-031.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-032.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: LEV vs OXC, Outcome 1: LEV vs OXC: All Major Malformations" data-id="CD010224-fig-0139" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-032.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32: LEV vs OXC, Outcome 1: LEV vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-032.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: LEV vs OXC, Outcome 2: LEV vs OXC: Neural Tube Malformations" data-id="CD010224-fig-0140" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-032.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.2</div> <div class="figure-caption"> <p>Comparison 32: LEV vs OXC, Outcome 2: LEV vs OXC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-032.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: LEV vs OXC, Outcome 3: LEV vs OXC: Cardiac Malformations" data-id="CD010224-fig-0141" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-032.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.3</div> <div class="figure-caption"> <p>Comparison 32: LEV vs OXC, Outcome 3: LEV vs OXC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-032.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: LEV vs OXC, Outcome 4: LEV vs OXC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0142" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-032.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.4</div> <div class="figure-caption"> <p>Comparison 32: LEV vs OXC, Outcome 4: LEV vs OXC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-032.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: LEV vs OXC, Outcome 5: LEV vs OXC: Skeletal/Limb Malformations" data-id="CD010224-fig-0143" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-032.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.5</div> <div class="figure-caption"> <p>Comparison 32: LEV vs OXC, Outcome 5: LEV vs OXC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-032.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-033.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: LEV vs PB, Outcome 1: LEV vs PB: All Major Malformations" data-id="CD010224-fig-0144" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-033.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33: LEV vs PB, Outcome 1: LEV vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-033.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: LEV vs PB, Outcome 2: LEV vs PB: Neural Tube Malformations" data-id="CD010224-fig-0145" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-033.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.2</div> <div class="figure-caption"> <p>Comparison 33: LEV vs PB, Outcome 2: LEV vs PB: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-033.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: LEV vs PB, Outcome 3: LEV vs PB: Cardiac Malformations" data-id="CD010224-fig-0146" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-033.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.3</div> <div class="figure-caption"> <p>Comparison 33: LEV vs PB, Outcome 3: LEV vs PB: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-033.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: LEV vs PB, Outcome 4: LEV vs PB: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0147" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-033.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.4</div> <div class="figure-caption"> <p>Comparison 33: LEV vs PB, Outcome 4: LEV vs PB: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-033.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: LEV vs PB, Outcome 5: LEV vs PB: Skeletal/Limb Malformation" data-id="CD010224-fig-0148" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-033.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.5</div> <div class="figure-caption"> <p>Comparison 33: LEV vs PB, Outcome 5: LEV vs PB: Skeletal/Limb Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-033.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-034.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: LEV vs PHT, Outcome 1: LEV vs PHT: All Major Malformations" data-id="CD010224-fig-0149" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-034.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34: LEV vs PHT, Outcome 1: LEV vs PHT: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-034.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: LEV vs PHT, Outcome 2: LEV vs PHT: Neural Tube Malformations" data-id="CD010224-fig-0150" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-034.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.2</div> <div class="figure-caption"> <p>Comparison 34: LEV vs PHT, Outcome 2: LEV vs PHT: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-034.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: LEV vs PHT, Outcome 3: LEV vs PHT: Cardiac Malformations" data-id="CD010224-fig-0151" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-034.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.3</div> <div class="figure-caption"> <p>Comparison 34: LEV vs PHT, Outcome 3: LEV vs PHT: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-034.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: LEV vs PHT, Outcome 4: LEV vs PHT: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0152" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-034.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.4</div> <div class="figure-caption"> <p>Comparison 34: LEV vs PHT, Outcome 4: LEV vs PHT: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-034.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: LEV vs PHT, Outcome 5: LEV vs PHT: Skeletal/Limb Malformations" data-id="CD010224-fig-0153" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-034.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.5</div> <div class="figure-caption"> <p>Comparison 34: LEV vs PHT, Outcome 5: LEV vs PHT: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-034.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-035.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: LEV vs PRM, Outcome 1: LEV vs PRM: All Major Malformations" data-id="CD010224-fig-0154" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-035.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-035.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.1</div> <div class="figure-caption"> <p>Comparison 35: LEV vs PRM, Outcome 1: LEV vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-035.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-036.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 36: LEV vs TPM, Outcome 1: LEV vs TPM: All Major Malformations" data-id="CD010224-fig-0155" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-036.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.1</div> <div class="figure-caption"> <p>Comparison 36: LEV vs TPM, Outcome 1: LEV vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-036.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 36: LEV vs TPM, Outcome 2: LEV vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0156" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-036.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.2</div> <div class="figure-caption"> <p>Comparison 36: LEV vs TPM, Outcome 2: LEV vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-036.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 36: LEV vs TPM, Outcome 3: LEV vs TPM: Cardiac Malformations" data-id="CD010224-fig-0157" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-036.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.3</div> <div class="figure-caption"> <p>Comparison 36: LEV vs TPM, Outcome 3: LEV vs TPM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-036.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 36: LEV vs TPM, Outcome 4: LEV vs TPM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0158" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-036.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.4</div> <div class="figure-caption"> <p>Comparison 36: LEV vs TPM, Outcome 4: LEV vs TPM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-036.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 36: LEV vs TPM, Outcome 5: LEV vs TPM: Skeletal/Limb Malformations" data-id="CD010224-fig-0159" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-036.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.5</div> <div class="figure-caption"> <p>Comparison 36: LEV vs TPM, Outcome 5: LEV vs TPM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-036.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-037.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: LEV vs ZNS, Outcome 1: LEV vs ZNS: All Major Malformations" data-id="CD010224-fig-0160" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-037.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.1</div> <div class="figure-caption"> <p>Comparison 37: LEV vs ZNS, Outcome 1: LEV vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-037.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: LEV vs ZNS, Outcome 2: LEV vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0161" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-037.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.2</div> <div class="figure-caption"> <p>Comparison 37: LEV vs ZNS, Outcome 2: LEV vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-037.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: LEV vs ZNS, Outcome 3: LEV vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0162" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-037.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.3</div> <div class="figure-caption"> <p>Comparison 37: LEV vs ZNS, Outcome 3: LEV vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-037.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: LEV vs ZNS, Outcome 4: LEV vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0163" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-037.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.4</div> <div class="figure-caption"> <p>Comparison 37: LEV vs ZNS, Outcome 4: LEV vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-037.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: LEV vs ZNS, Outcome 5: LEV vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0164" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-037.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.5</div> <div class="figure-caption"> <p>Comparison 37: LEV vs ZNS, Outcome 5: LEV vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-037.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-038.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 38: LTG vs CZP, Outcome 1: LTG vs CZP: All Major Malformations" data-id="CD010224-fig-0165" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-038.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-038.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.1</div> <div class="figure-caption"> <p>Comparison 38: LTG vs CZP, Outcome 1: LTG vs CZP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-038.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-039.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: LTG vs LAC, Outcome 1: LTG vs LAC: All Major Malformations" data-id="CD010224-fig-0166" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-039.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.1</div> <div class="figure-caption"> <p>Comparison 39: LTG vs LAC, Outcome 1: LTG vs LAC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-039.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: LTG vs LAC, Outcome 2: LTG vs LAC: Neural Tube Malformations" data-id="CD010224-fig-0167" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-039.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.2</div> <div class="figure-caption"> <p>Comparison 39: LTG vs LAC, Outcome 2: LTG vs LAC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-039.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: LTG vs LAC, Outcome 3: LTG vs LAC: Cardiac Malformations" data-id="CD010224-fig-0168" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-039.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.3</div> <div class="figure-caption"> <p>Comparison 39: LTG vs LAC, Outcome 3: LTG vs LAC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-039.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: LTG vs LAC, Outcome 4: LTG vs LAC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0169" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-039.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.4</div> <div class="figure-caption"> <p>Comparison 39: LTG vs LAC, Outcome 4: LTG vs LAC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-039.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: LTG vs LAC, Outcome 5: LTG vs LAC: Skeletal/Limb Malformations" data-id="CD010224-fig-0170" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-039.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.5</div> <div class="figure-caption"> <p>Comparison 39: LTG vs LAC, Outcome 5: LTG vs LAC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-039.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-040.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: LTG vs OXC, Outcome 1: LTG vs OXC: All Major Malformations" data-id="CD010224-fig-0171" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-040.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.1</div> <div class="figure-caption"> <p>Comparison 40: LTG vs OXC, Outcome 1: LTG vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-040.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: LTG vs OXC, Outcome 2: LTG vs OXC: Neural Tube Malformations" data-id="CD010224-fig-0172" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-040.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.2</div> <div class="figure-caption"> <p>Comparison 40: LTG vs OXC, Outcome 2: LTG vs OXC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-040.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: LTG vs OXC, Outcome 3: LTG vs OXC: Cardiac Malformation" data-id="CD010224-fig-0173" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-040.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.3</div> <div class="figure-caption"> <p>Comparison 40: LTG vs OXC, Outcome 3: LTG vs OXC: Cardiac Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-040.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: LTG vs OXC, Outcome 4: LTG vs OXC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0174" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-040.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.4</div> <div class="figure-caption"> <p>Comparison 40: LTG vs OXC, Outcome 4: LTG vs OXC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-040.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: LTG vs OXC, Outcome 5: LTG vs OXC: Skeletal/Limb Malformation" data-id="CD010224-fig-0175" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-040.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.5</div> <div class="figure-caption"> <p>Comparison 40: LTG vs OXC, Outcome 5: LTG vs OXC: Skeletal/Limb Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-040.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-041.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 41: LTG vs PB, Outcome 1: LTG vs PB: All Major Malformations" data-id="CD010224-fig-0176" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-041.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 41.1</div> <div class="figure-caption"> <p>Comparison 41: LTG vs PB, Outcome 1: LTG vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-041.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 41: LTG vs PB, Outcome 2: LTG vs PB: Neural Tube Malformations" data-id="CD010224-fig-0177" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-041.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 41.2</div> <div class="figure-caption"> <p>Comparison 41: LTG vs PB, Outcome 2: LTG vs PB: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-041.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 41: LTG vs PB, Outcome 3: LTG vs PB: Cardiac Malformations" data-id="CD010224-fig-0178" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-041.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 41.3</div> <div class="figure-caption"> <p>Comparison 41: LTG vs PB, Outcome 3: LTG vs PB: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-041.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 41: LTG vs PB, Outcome 4: LTG vs PB: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0179" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-041.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 41.4</div> <div class="figure-caption"> <p>Comparison 41: LTG vs PB, Outcome 4: LTG vs PB: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-041.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 41: LTG vs PB, Outcome 5: LTG vs PB: Skeletal/Limb Malformations" data-id="CD010224-fig-0180" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-041.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 41.5</div> <div class="figure-caption"> <p>Comparison 41: LTG vs PB, Outcome 5: LTG vs PB: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-041.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-042.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 42: LTG vs PHT, Outcome 1: LTG vs PHT: All Major Malformations" data-id="CD010224-fig-0181" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-042.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 42.1</div> <div class="figure-caption"> <p>Comparison 42: LTG vs PHT, Outcome 1: LTG vs PHT: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-042.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 42: LTG vs PHT, Outcome 2: LTG vs PHT: Neural Tube Malformations" data-id="CD010224-fig-0182" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-042.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 42.2</div> <div class="figure-caption"> <p>Comparison 42: LTG vs PHT, Outcome 2: LTG vs PHT: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-042.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 42: LTG vs PHT, Outcome 3: LTG vs PHT: Cardiac Malformations" data-id="CD010224-fig-0183" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-042.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 42.3</div> <div class="figure-caption"> <p>Comparison 42: LTG vs PHT, Outcome 3: LTG vs PHT: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-042.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 42: LTG vs PHT, Outcome 4: LTG vs PHT: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0184" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-042.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 42.4</div> <div class="figure-caption"> <p>Comparison 42: LTG vs PHT, Outcome 4: LTG vs PHT: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-042.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 42: LTG vs PHT, Outcome 5: LTG vs PHT: Skeletal/Limb Malformations" data-id="CD010224-fig-0185" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-042.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 42.5</div> <div class="figure-caption"> <p>Comparison 42: LTG vs PHT, Outcome 5: LTG vs PHT: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-042.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-043.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 43: LTG vs PRM, Outcome 1: LTG vs PRM: All Major Malformations" data-id="CD010224-fig-0186" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-043.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-043.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 43.1</div> <div class="figure-caption"> <p>Comparison 43: LTG vs PRM, Outcome 1: LTG vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-043.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-044.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: LTG vs TPM, Outcome 1: LTG vs TPM: All Major Malformations" data-id="CD010224-fig-0187" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-044.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.1</div> <div class="figure-caption"> <p>Comparison 44: LTG vs TPM, Outcome 1: LTG vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-044.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: LTG vs TPM, Outcome 2: LTG vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0188" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-044.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.2</div> <div class="figure-caption"> <p>Comparison 44: LTG vs TPM, Outcome 2: LTG vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-044.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: LTG vs TPM, Outcome 3: LTG vs TPM: Cardiac Malformations" data-id="CD010224-fig-0189" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-044.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.3</div> <div class="figure-caption"> <p>Comparison 44: LTG vs TPM, Outcome 3: LTG vs TPM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-044.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: LTG vs TPM, Outcome 4: LTG vs TPM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0190" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-044.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.4</div> <div class="figure-caption"> <p>Comparison 44: LTG vs TPM, Outcome 4: LTG vs TPM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-044.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: LTG vs TPM, Outcome 5: LTG vs TPM: Skeletal/Limb Malformations" data-id="CD010224-fig-0191" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-044.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.5</div> <div class="figure-caption"> <p>Comparison 44: LTG vs TPM, Outcome 5: LTG vs TPM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-044.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-045.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 45: LTG vs ZNS, Outcome 1: LTG vs ZNS: All Major Malformations" data-id="CD010224-fig-0192" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-045.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 45.1</div> <div class="figure-caption"> <p>Comparison 45: LTG vs ZNS, Outcome 1: LTG vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-045.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 45: LTG vs ZNS, Outcome 2: LTG vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0193" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-045.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 45.2</div> <div class="figure-caption"> <p>Comparison 45: LTG vs ZNS, Outcome 2: LTG vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-045.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 45: LTG vs ZNS, Outcome 3: LTG vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0194" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-045.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 45.3</div> <div class="figure-caption"> <p>Comparison 45: LTG vs ZNS, Outcome 3: LTG vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-045.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 45: LTG vs ZNS, Outcome 4: LTG vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0195" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-045.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 45.4</div> <div class="figure-caption"> <p>Comparison 45: LTG vs ZNS, Outcome 4: LTG vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-045.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 45: LTG vs ZNS, Outcome 5: LTG vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0196" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-045.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 45.5</div> <div class="figure-caption"> <p>Comparison 45: LTG vs ZNS, Outcome 5: LTG vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-045.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-046.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 46: PHT vs GBP, Outcome 1: PHT vs GBP: All Major Malformations" data-id="CD010224-fig-0197" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-046.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 46.1</div> <div class="figure-caption"> <p>Comparison 46: PHT vs GBP, Outcome 1: PHT vs GBP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-046.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 46: PHT vs GBP, Outcome 2: PHT vs GBP: Neural Tube Malformations" data-id="CD010224-fig-0198" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-046.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 46.2</div> <div class="figure-caption"> <p>Comparison 46: PHT vs GBP, Outcome 2: PHT vs GBP: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-046.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 46: PHT vs GBP, Outcome 3: PHT vs GBP: Cardiac Malformations" data-id="CD010224-fig-0199" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-046.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 46.3</div> <div class="figure-caption"> <p>Comparison 46: PHT vs GBP, Outcome 3: PHT vs GBP: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-046.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 46: PHT vs GBP, Outcome 4: PHT vs GBP: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0200" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-046.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 46.4</div> <div class="figure-caption"> <p>Comparison 46: PHT vs GBP, Outcome 4: PHT vs GBP: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-046.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 46: PHT vs GBP, Outcome 5: PHT vs GBP: Skeletal/Limb Malformations" data-id="CD010224-fig-0201" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-046.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 46.5</div> <div class="figure-caption"> <p>Comparison 46: PHT vs GBP, Outcome 5: PHT vs GBP: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-046.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-047.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 47: PHT vs OXC, Outcome 1: PHT vs OXC: All Major Malformations" data-id="CD010224-fig-0202" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-047.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 47.1</div> <div class="figure-caption"> <p>Comparison 47: PHT vs OXC, Outcome 1: PHT vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-047.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 47: PHT vs OXC, Outcome 2: PHT vs OXC: Neural Tube Malformations" data-id="CD010224-fig-0203" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-047.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 47.2</div> <div class="figure-caption"> <p>Comparison 47: PHT vs OXC, Outcome 2: PHT vs OXC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-047.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 47: PHT vs OXC, Outcome 3: PHT vs OXC: Cardiac Malformations" data-id="CD010224-fig-0204" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-047.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 47.3</div> <div class="figure-caption"> <p>Comparison 47: PHT vs OXC, Outcome 3: PHT vs OXC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-047.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 47: PHT vs OXC, Outcome 4: PHT vs OXC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0205" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-047.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 47.4</div> <div class="figure-caption"> <p>Comparison 47: PHT vs OXC, Outcome 4: PHT vs OXC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-047.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 47: PHT vs OXC, Outcome 5: PHT vs OXC: Skeletal/Limb Malformations" data-id="CD010224-fig-0206" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-047.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 47.5</div> <div class="figure-caption"> <p>Comparison 47: PHT vs OXC, Outcome 5: PHT vs OXC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-047.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-048.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: PHT vs PB, Outcome 1: PHT vs PB: All Major Malformations" data-id="CD010224-fig-0207" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-048.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.1</div> <div class="figure-caption"> <p>Comparison 48: PHT vs PB, Outcome 1: PHT vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-048.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: PHT vs PB, Outcome 2: PHT vs PB: Neural Tube Malformations" data-id="CD010224-fig-0208" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-048.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.2</div> <div class="figure-caption"> <p>Comparison 48: PHT vs PB, Outcome 2: PHT vs PB: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-048.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: PHT vs PB, Outcome 3: PHT vs PB: Cardiac Malformations" data-id="CD010224-fig-0209" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-048.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.3</div> <div class="figure-caption"> <p>Comparison 48: PHT vs PB, Outcome 3: PHT vs PB: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-048.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: PHT vs PB, Outcome 4: PHT vs PB: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0210" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-048.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.4</div> <div class="figure-caption"> <p>Comparison 48: PHT vs PB, Outcome 4: PHT vs PB: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-048.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: PHT vs PB, Outcome 5: PHT vs PB: Skeletal/Limb Malformations" data-id="CD010224-fig-0211" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-048.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.5</div> <div class="figure-caption"> <p>Comparison 48: PHT vs PB, Outcome 5: PHT vs PB: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-048.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-049.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: PHT vs PRM, Outcome 1: PHT vs PRM: All Major Malformations" data-id="CD010224-fig-0212" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-049.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.1</div> <div class="figure-caption"> <p>Comparison 49: PHT vs PRM, Outcome 1: PHT vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-049.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: PHT vs PRM, Outcome 2: PHT vs PRM: Neural Tube Malformations" data-id="CD010224-fig-0213" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-049.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.2</div> <div class="figure-caption"> <p>Comparison 49: PHT vs PRM, Outcome 2: PHT vs PRM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-049.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: PHT vs PRM, Outcome 3: PHT vs PRM: Cardiac Malformations" data-id="CD010224-fig-0214" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-049.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.3</div> <div class="figure-caption"> <p>Comparison 49: PHT vs PRM, Outcome 3: PHT vs PRM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-049.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: PHT vs PRM, Outcome 4: PHT vs PRM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0215" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-049.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.4</div> <div class="figure-caption"> <p>Comparison 49: PHT vs PRM, Outcome 4: PHT vs PRM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-049.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: PHT vs PRM, Outcome 5: PHT vs PRM: Skeletal/Limb Malformations" data-id="CD010224-fig-0216" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-049.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.5</div> <div class="figure-caption"> <p>Comparison 49: PHT vs PRM, Outcome 5: PHT vs PRM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-049.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-050.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: PHT vs TPM, Outcome 1: PHT vs TPM: All Major Malformations" data-id="CD010224-fig-0217" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-050.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.1</div> <div class="figure-caption"> <p>Comparison 50: PHT vs TPM, Outcome 1: PHT vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-050.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: PHT vs TPM, Outcome 2: PHT vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0218" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-050.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.2</div> <div class="figure-caption"> <p>Comparison 50: PHT vs TPM, Outcome 2: PHT vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-050.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: PHT vs TPM, Outcome 3: PHT vs TPM: Cardiac Malformations" data-id="CD010224-fig-0219" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-050.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.3</div> <div class="figure-caption"> <p>Comparison 50: PHT vs TPM, Outcome 3: PHT vs TPM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-050.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: PHT vs TPM, Outcome 4: PHT vs TPM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0220" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-050.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.4</div> <div class="figure-caption"> <p>Comparison 50: PHT vs TPM, Outcome 4: PHT vs TPM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-050.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: PHT vs TPM, Outcome 5: PHT vs TPM: Skeletal/Limb Malformations" data-id="CD010224-fig-0221" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-050.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.5</div> <div class="figure-caption"> <p>Comparison 50: PHT vs TPM, Outcome 5: PHT vs TPM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-050.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-051.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: PHT vs ZNS, Outcome 1: PHT vs ZNS: All Major Malformations" data-id="CD010224-fig-0222" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-051.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.1</div> <div class="figure-caption"> <p>Comparison 51: PHT vs ZNS, Outcome 1: PHT vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-051.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: PHT vs ZNS, Outcome 2: PHT vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0223" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-051.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.2</div> <div class="figure-caption"> <p>Comparison 51: PHT vs ZNS, Outcome 2: PHT vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-051.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: PHT vs ZNS, Outcome 3: PHT vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0224" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-051.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.3</div> <div class="figure-caption"> <p>Comparison 51: PHT vs ZNS, Outcome 3: PHT vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-051.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: PHT vs ZNS, Outcome 4: PHT vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0225" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-051.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.4</div> <div class="figure-caption"> <p>Comparison 51: PHT vs ZNS, Outcome 4: PHT vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-051.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: PHT vs ZNS, Outcome 5: PHT vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0226" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-051.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.5</div> <div class="figure-caption"> <p>Comparison 51: PHT vs ZNS, Outcome 5: PHT vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-051.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-052.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: PB vs OXC, Outcome 1: PB vs OXC: All Major Malformations" data-id="CD010224-fig-0227" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-052.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.1</div> <div class="figure-caption"> <p>Comparison 52: PB vs OXC, Outcome 1: PB vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-052.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: PB vs OXC, Outcome 2: PB vs OXC: Neural Tube Malformations" data-id="CD010224-fig-0228" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-052.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.2</div> <div class="figure-caption"> <p>Comparison 52: PB vs OXC, Outcome 2: PB vs OXC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-052.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: PB vs OXC, Outcome 3: PB vs OXC: Cardiac Malformations" data-id="CD010224-fig-0229" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-052.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.3</div> <div class="figure-caption"> <p>Comparison 52: PB vs OXC, Outcome 3: PB vs OXC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0230"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-052.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: PB vs OXC, Outcome 4: PB vs OXC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0230" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-052.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.4</div> <div class="figure-caption"> <p>Comparison 52: PB vs OXC, Outcome 4: PB vs OXC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0230">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0231"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-052.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: PB vs OXC, Outcome 5: PB vs OXC: Skeletal/Limb Malformations" data-id="CD010224-fig-0231" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-052.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.5</div> <div class="figure-caption"> <p>Comparison 52: PB vs OXC, Outcome 5: PB vs OXC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0231">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-052.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0232"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-053.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: PB vs PRM, Outcome 1: PB vs PRM: All Major Malformations" data-id="CD010224-fig-0232" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-053.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.1</div> <div class="figure-caption"> <p>Comparison 53: PB vs PRM, Outcome 1: PB vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0232">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0233"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-053.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: PB vs PRM, Outcome 2: PB vs PRM: Neural Tube Malformations" data-id="CD010224-fig-0233" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-053.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.2</div> <div class="figure-caption"> <p>Comparison 53: PB vs PRM, Outcome 2: PB vs PRM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0233">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0234"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-053.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: PB vs PRM, Outcome 3: PB vs PRM: Cardiac Malformations" data-id="CD010224-fig-0234" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-053.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.3</div> <div class="figure-caption"> <p>Comparison 53: PB vs PRM, Outcome 3: PB vs PRM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0234">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0235"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-053.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: PB vs PRM, Outcome 4: PB vs PRM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0235" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-053.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.4</div> <div class="figure-caption"> <p>Comparison 53: PB vs PRM, Outcome 4: PB vs PRM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0235">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0236"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-053.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: PB vs PRM, Outcome 5: PB vs PRM: Skeletal/Limb Malformations" data-id="CD010224-fig-0236" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-053.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.5</div> <div class="figure-caption"> <p>Comparison 53: PB vs PRM, Outcome 5: PB vs PRM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0236">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-053.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0237"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-054.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 54: PB vs TPM, Outcome 1: PB vs TPM: All Major Malformations" data-id="CD010224-fig-0237" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-054.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 54.1</div> <div class="figure-caption"> <p>Comparison 54: PB vs TPM, Outcome 1: PB vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0237">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0238"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-054.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 54: PB vs TPM, Outcome 2: PB vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0238" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-054.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 54.2</div> <div class="figure-caption"> <p>Comparison 54: PB vs TPM, Outcome 2: PB vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0238">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0239"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-054.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 54: PB vs TPM, Outcome 3: PB vs TPM: Cardiac Malformations" data-id="CD010224-fig-0239" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-054.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 54.3</div> <div class="figure-caption"> <p>Comparison 54: PB vs TPM, Outcome 3: PB vs TPM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0239">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0240"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-054.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 54: PB vs TPM, Outcome 4: PB vs TPM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0240" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-054.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 54.4</div> <div class="figure-caption"> <p>Comparison 54: PB vs TPM, Outcome 4: PB vs TPM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0240">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0241"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-054.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 54: PB vs TPM, Outcome 5: PB vs TPM: Skeletal/Limb Malformations" data-id="CD010224-fig-0241" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-054.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 54.5</div> <div class="figure-caption"> <p>Comparison 54: PB vs TPM, Outcome 5: PB vs TPM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0241">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-054.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0242"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-055.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: PB vs ZNS, Outcome 1: PB vs ZNS: All Major Malformations" data-id="CD010224-fig-0242" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-055.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.1</div> <div class="figure-caption"> <p>Comparison 55: PB vs ZNS, Outcome 1: PB vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0242">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0243"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-055.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: PB vs ZNS, Outcome 2: PB vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0243" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-055.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.2</div> <div class="figure-caption"> <p>Comparison 55: PB vs ZNS, Outcome 2: PB vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0243">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0244"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-055.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: PB vs ZNS, Outcome 3: PB vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0244" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-055.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.3</div> <div class="figure-caption"> <p>Comparison 55: PB vs ZNS, Outcome 3: PB vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0244">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0245"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-055.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: PB vs ZNS, Outcome 4: PB vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0245" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-055.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.4</div> <div class="figure-caption"> <p>Comparison 55: PB vs ZNS, Outcome 4: PB vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0245">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0246"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-055.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: PB vs ZNS, Outcome 5: PB vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0246" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-055.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.5</div> <div class="figure-caption"> <p>Comparison 55: PB vs ZNS, Outcome 5: PB vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0246">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-055.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0247"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-056.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: TPM vs ZNS, Outcome 1: TPM vs ZNS: All Major Malformations" data-id="CD010224-fig-0247" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-056.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.1</div> <div class="figure-caption"> <p>Comparison 56: TPM vs ZNS, Outcome 1: TPM vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0247">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0248"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-056.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: TPM vs ZNS, Outcome 2: TPM vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0248" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-056.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.2</div> <div class="figure-caption"> <p>Comparison 56: TPM vs ZNS, Outcome 2: TPM vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0248">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0249"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-056.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: TPM vs ZNS, Outcome 3: TPM vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0249" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-056.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.3</div> <div class="figure-caption"> <p>Comparison 56: TPM vs ZNS, Outcome 3: TPM vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0249">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0250"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-056.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: TPM vs ZNS, Outcome 4: TPM vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0250" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-056.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.4</div> <div class="figure-caption"> <p>Comparison 56: TPM vs ZNS, Outcome 4: TPM vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0250">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0251"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-056.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: TPM vs ZNS, Outcome 5: TPM vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0251" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-056.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.5</div> <div class="figure-caption"> <p>Comparison 56: TPM vs ZNS, Outcome 5: TPM vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0251">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-056.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0252"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-057.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: TPM vs LAC, Outcome 1: TPM vs LAC: All Major Malformations" data-id="CD010224-fig-0252" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-057.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.1</div> <div class="figure-caption"> <p>Comparison 57: TPM vs LAC, Outcome 1: TPM vs LAC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0252">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0253"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-057.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: TPM vs LAC, Outcome 2: TPM vs LAC: Neural Tube Malformations" data-id="CD010224-fig-0253" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-057.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.2</div> <div class="figure-caption"> <p>Comparison 57: TPM vs LAC, Outcome 2: TPM vs LAC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0253">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0254"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-057.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: TPM vs LAC, Outcome 3: TPM vs LAC: Cardiac Malformations" data-id="CD010224-fig-0254" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-057.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.3</div> <div class="figure-caption"> <p>Comparison 57: TPM vs LAC, Outcome 3: TPM vs LAC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0254">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0255"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-057.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: TPM vs LAC, Outcome 4: TPM vs LAC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0255" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-057.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.4</div> <div class="figure-caption"> <p>Comparison 57: TPM vs LAC, Outcome 4: TPM vs LAC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0255">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0256"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-057.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: TPM vs LAC, Outcome 5: TPM vs LAC: Skeletal/Limb Malformations" data-id="CD010224-fig-0256" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-057.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.5</div> <div class="figure-caption"> <p>Comparison 57: TPM vs LAC, Outcome 5: TPM vs LAC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0256">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-057.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0257"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-058.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: VPA vs GBP, Outcome 1: VPA vs GBP: All Major Malformations" data-id="CD010224-fig-0257" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-058.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.1</div> <div class="figure-caption"> <p>Comparison 58: VPA vs GBP, Outcome 1: VPA vs GBP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0257">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0258"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-058.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: VPA vs GBP, Outcome 2: VPA vs GBP: Neural Tube Malformations" data-id="CD010224-fig-0258" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-058.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.2</div> <div class="figure-caption"> <p>Comparison 58: VPA vs GBP, Outcome 2: VPA vs GBP: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0258">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0259"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-058.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: VPA vs GBP, Outcome 3: VPA vs GBP: Cardiac Malformations" data-id="CD010224-fig-0259" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-058.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.3</div> <div class="figure-caption"> <p>Comparison 58: VPA vs GBP, Outcome 3: VPA vs GBP: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0259">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0260"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-058.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: VPA vs GBP, Outcome 4: VPA vs GBP: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0260" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-058.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.4</div> <div class="figure-caption"> <p>Comparison 58: VPA vs GBP, Outcome 4: VPA vs GBP: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0260">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0261"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-058.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: VPA vs GBP, Outcome 5: VPA vs GBP: Skeletal/Limb Malformations" data-id="CD010224-fig-0261" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-058.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.5</div> <div class="figure-caption"> <p>Comparison 58: VPA vs GBP, Outcome 5: VPA vs GBP: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0261">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-058.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0262"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-059.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 59: VPA vs LAC, Outcome 1: VPA vs LAC: All Major Malformations" data-id="CD010224-fig-0262" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-059.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 59.1</div> <div class="figure-caption"> <p>Comparison 59: VPA vs LAC, Outcome 1: VPA vs LAC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0262">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0263"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-059.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 59: VPA vs LAC, Outcome 2: VPA vs LAC: Neural Tube Malformations" data-id="CD010224-fig-0263" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-059.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 59.2</div> <div class="figure-caption"> <p>Comparison 59: VPA vs LAC, Outcome 2: VPA vs LAC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0263">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0264"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-059.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 59: VPA vs LAC, Outcome 3: VPA vs LAC: Cardiac Malformations" data-id="CD010224-fig-0264" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-059.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 59.3</div> <div class="figure-caption"> <p>Comparison 59: VPA vs LAC, Outcome 3: VPA vs LAC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0264">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0265"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-059.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 59: VPA vs LAC, Outcome 4: VPA vs LAC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0265" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-059.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 59.4</div> <div class="figure-caption"> <p>Comparison 59: VPA vs LAC, Outcome 4: VPA vs LAC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0265">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0266"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-059.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 59: VPA vs LAC, Outcome 5: VPA vs LAC: Skeletal/Limb Malformations" data-id="CD010224-fig-0266" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-059.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 59.5</div> <div class="figure-caption"> <p>Comparison 59: VPA vs LAC, Outcome 5: VPA vs LAC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0266">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-059.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0267"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-060.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: VPA vs LEV, Outcome 1: VPA vs LEV: All Major Malformations" data-id="CD010224-fig-0267" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-060.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.1</div> <div class="figure-caption"> <p>Comparison 60: VPA vs LEV, Outcome 1: VPA vs LEV: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0267">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0268"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-060.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: VPA vs LEV, Outcome 2: VPA vs LEV: Neural Tube Malformations" data-id="CD010224-fig-0268" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-060.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.2</div> <div class="figure-caption"> <p>Comparison 60: VPA vs LEV, Outcome 2: VPA vs LEV: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0268">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0269"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-060.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: VPA vs LEV, Outcome 3: VPA vs LEV: Cardiac Malformations" data-id="CD010224-fig-0269" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-060.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.3</div> <div class="figure-caption"> <p>Comparison 60: VPA vs LEV, Outcome 3: VPA vs LEV: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0269">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0270"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-060.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: VPA vs LEV, Outcome 4: VPA vs LEV: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0270" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-060.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.4</div> <div class="figure-caption"> <p>Comparison 60: VPA vs LEV, Outcome 4: VPA vs LEV: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0270">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0271"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-060.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: VPA vs LEV, Outcome 5: VPA vs LEV: Skeletal/Limb Malformations" data-id="CD010224-fig-0271" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-060.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.5</div> <div class="figure-caption"> <p>Comparison 60: VPA vs LEV, Outcome 5: VPA vs LEV: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0271">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-060.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0272"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-061.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: VPA vs LTG, Outcome 1: VPA vs LTG: All Major Malformations" data-id="CD010224-fig-0272" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-061.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.1</div> <div class="figure-caption"> <p>Comparison 61: VPA vs LTG, Outcome 1: VPA vs LTG: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0272">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0273"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-061.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: VPA vs LTG, Outcome 2: VPA vs LTG: Neural Tube Malformations" data-id="CD010224-fig-0273" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-061.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.2</div> <div class="figure-caption"> <p>Comparison 61: VPA vs LTG, Outcome 2: VPA vs LTG: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0273">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0274"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-061.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: VPA vs LTG, Outcome 3: VPA vs LTG: Cardiac Malformations" data-id="CD010224-fig-0274" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-061.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.3</div> <div class="figure-caption"> <p>Comparison 61: VPA vs LTG, Outcome 3: VPA vs LTG: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0274">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0275"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-061.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: VPA vs LTG, Outcome 4: VPA vs LTG: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0275" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-061.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.4</div> <div class="figure-caption"> <p>Comparison 61: VPA vs LTG, Outcome 4: VPA vs LTG: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0275">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0276"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-061.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: VPA vs LTG, Outcome 5: VPA vs LTG: Skeletal/Limb Malformations" data-id="CD010224-fig-0276" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-061.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.5</div> <div class="figure-caption"> <p>Comparison 61: VPA vs LTG, Outcome 5: VPA vs LTG: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0276">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-061.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0277"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-062.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: VPA vs TPM, Outcome 1: VPA vs TPM: All Major Malformations" data-id="CD010224-fig-0277" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-062.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.1</div> <div class="figure-caption"> <p>Comparison 62: VPA vs TPM, Outcome 1: VPA vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0277">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0278"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-062.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: VPA vs TPM, Outcome 2: VPA vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0278" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-062.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.2</div> <div class="figure-caption"> <p>Comparison 62: VPA vs TPM, Outcome 2: VPA vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0278">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0279"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-062.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: VPA vs TPM, Outcome 3: VPA vs TPM: Cardiac Malformations" data-id="CD010224-fig-0279" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-062.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.3</div> <div class="figure-caption"> <p>Comparison 62: VPA vs TPM, Outcome 3: VPA vs TPM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0279">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0280"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-062.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: VPA vs TPM, Outcome 4: VPA vs TPM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0280" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-062.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.4</div> <div class="figure-caption"> <p>Comparison 62: VPA vs TPM, Outcome 4: VPA vs TPM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0280">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0281"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-062.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: VPA vs TPM, Outcome 5: VPA vs TPM: Skeletal/Limb Malformation" data-id="CD010224-fig-0281" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-062.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.5</div> <div class="figure-caption"> <p>Comparison 62: VPA vs TPM, Outcome 5: VPA vs TPM: Skeletal/Limb Malformation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0281">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-062.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0282"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-063.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 63: VPA vs OXC, Outcome 1: VPA vs OXC: All Major Malformations" data-id="CD010224-fig-0282" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-063.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 63.1</div> <div class="figure-caption"> <p>Comparison 63: VPA vs OXC, Outcome 1: VPA vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0282">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0283"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-063.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 63: VPA vs OXC, Outcome 2: VPA vs OXC: Neural Tube Malformations" data-id="CD010224-fig-0283" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-063.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 63.2</div> <div class="figure-caption"> <p>Comparison 63: VPA vs OXC, Outcome 2: VPA vs OXC: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0283">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0284"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-063.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 63: VPA vs OXC, Outcome 3: VPA vs OXC: Cardiac Malformations" data-id="CD010224-fig-0284" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-063.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 63.3</div> <div class="figure-caption"> <p>Comparison 63: VPA vs OXC, Outcome 3: VPA vs OXC: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0284">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0285"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-063.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 63: VPA vs OXC, Outcome 4: VPA vs OXC: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0285" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-063.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 63.4</div> <div class="figure-caption"> <p>Comparison 63: VPA vs OXC, Outcome 4: VPA vs OXC: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0285">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0286"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-063.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 63: VPA vs OXC, Outcome 5: VPA vs OXC: Skeletal/Limb Malformations" data-id="CD010224-fig-0286" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-063.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 63.5</div> <div class="figure-caption"> <p>Comparison 63: VPA vs OXC, Outcome 5: VPA vs OXC: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0286">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-063.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0287"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-064.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: VPA vs PB, Outcome 1: VPA vs PB: All Major Malformations" data-id="CD010224-fig-0287" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-064.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.1</div> <div class="figure-caption"> <p>Comparison 64: VPA vs PB, Outcome 1: VPA vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0287">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0288"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-064.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: VPA vs PB, Outcome 2: VPA vs PB: Neural Tube Malformations" data-id="CD010224-fig-0288" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-064.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.2</div> <div class="figure-caption"> <p>Comparison 64: VPA vs PB, Outcome 2: VPA vs PB: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0288">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0289"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-064.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: VPA vs PB, Outcome 3: VPA vs PB: Cardiac Malformations" data-id="CD010224-fig-0289" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-064.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.3</div> <div class="figure-caption"> <p>Comparison 64: VPA vs PB, Outcome 3: VPA vs PB: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0289">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0290"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-064.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: VPA vs PB, Outcome 4: VPA vs PB: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0290" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-064.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.4</div> <div class="figure-caption"> <p>Comparison 64: VPA vs PB, Outcome 4: VPA vs PB: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0290">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0291"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-064.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: VPA vs PB, Outcome 5: VPA vs PB: Skeletal/Limb Malformations" data-id="CD010224-fig-0291" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-064.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.5</div> <div class="figure-caption"> <p>Comparison 64: VPA vs PB, Outcome 5: VPA vs PB: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0291">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-064.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0292"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-065.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: VPA vs PHT, Outcome 1: VPA vs PHT: All Major Malformations" data-id="CD010224-fig-0292" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-065.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.1</div> <div class="figure-caption"> <p>Comparison 65: VPA vs PHT, Outcome 1: VPA vs PHT: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0292">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0293"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-065.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: VPA vs PHT, Outcome 2: VPA vs PHT: Neural Tube Malformations" data-id="CD010224-fig-0293" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-065.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.2</div> <div class="figure-caption"> <p>Comparison 65: VPA vs PHT, Outcome 2: VPA vs PHT: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0293">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0294"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-065.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: VPA vs PHT, Outcome 3: VPA vs PHT: Cardiac Malformations" data-id="CD010224-fig-0294" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-065.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.3</div> <div class="figure-caption"> <p>Comparison 65: VPA vs PHT, Outcome 3: VPA vs PHT: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0294">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0295"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-065.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: VPA vs PHT, Outcome 4: VPA vs PHT: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0295" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-065.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.4</div> <div class="figure-caption"> <p>Comparison 65: VPA vs PHT, Outcome 4: VPA vs PHT: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0295">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0296"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-065.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: VPA vs PHT, Outcome 5: VPA vs PHT: Skeletal/Limb Malformations" data-id="CD010224-fig-0296" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-065.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.5</div> <div class="figure-caption"> <p>Comparison 65: VPA vs PHT, Outcome 5: VPA vs PHT: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0296">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-065.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0297"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-066.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: VPA vs ZNS, Outcome 1: VPA vs ZNS: All Major Malformations" data-id="CD010224-fig-0297" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-066.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.1</div> <div class="figure-caption"> <p>Comparison 66: VPA vs ZNS, Outcome 1: VPA vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0297">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0298"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-066.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: VPA vs ZNS, Outcome 2: VPA vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0298" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-066.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.2</div> <div class="figure-caption"> <p>Comparison 66: VPA vs ZNS, Outcome 2: VPA vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0298">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0299"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-066.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: VPA vs ZNS, Outcome 3: VPA vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0299" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-066.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.3</div> <div class="figure-caption"> <p>Comparison 66: VPA vs ZNS, Outcome 3: VPA vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0299">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0300"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-066.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: VPA vs ZNS, Outcome 4: VPA vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0300" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-066.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.4</div> <div class="figure-caption"> <p>Comparison 66: VPA vs ZNS, Outcome 4: VPA vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0300">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-066.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: VPA vs ZNS, Outcome 5: VPA vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0301" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-066.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.5</div> <div class="figure-caption"> <p>Comparison 66: VPA vs ZNS, Outcome 5: VPA vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-066.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-067.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: CZP vs VPA, Outcome 1: CZP vs VPA: All Major Malformations" data-id="CD010224-fig-0302" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-067.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.1</div> <div class="figure-caption"> <p>Comparison 67: CZP vs VPA, Outcome 1: CZP vs VPA: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0303"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-067.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: CZP vs VPA, Outcome 2: CZP vs VPA: Neural Tube Malformations" data-id="CD010224-fig-0303" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-067.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.2</div> <div class="figure-caption"> <p>Comparison 67: CZP vs VPA, Outcome 2: CZP vs VPA: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0303">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0304"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-067.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: CZP vs VPA, Outcome 3: CZP vs VPA: Cardiac Malformations" data-id="CD010224-fig-0304" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-067.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.3</div> <div class="figure-caption"> <p>Comparison 67: CZP vs VPA, Outcome 3: CZP vs VPA: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0304">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0305"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-067.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: CZP vs VPA, Outcome 4: CZP vs VPA: Skeletal/Limb Malformations" data-id="CD010224-fig-0305" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-067.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.4</div> <div class="figure-caption"> <p>Comparison 67: CZP vs VPA, Outcome 4: CZP vs VPA: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0305">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-067.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0306"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-068.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 68: CZP vs LEV, Outcome 1: CZP vs LEV: All Major Malformations" data-id="CD010224-fig-0306" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-068.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-068.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 68.1</div> <div class="figure-caption"> <p>Comparison 68: CZP vs LEV, Outcome 1: CZP vs LEV: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0306">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-068.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0307"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-069.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 69: OXC vs PRM, Outcome 1: OXC vs PRM: All Major Malformations" data-id="CD010224-fig-0307" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-069.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-069.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 69.1</div> <div class="figure-caption"> <p>Comparison 69: OXC vs PRM, Outcome 1: OXC vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0307">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-069.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0308"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-070.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: OXC vs TPM, Outcome 1: OXC vs TPM: All Major Malformations" data-id="CD010224-fig-0308" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-070.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.1</div> <div class="figure-caption"> <p>Comparison 70: OXC vs TPM, Outcome 1: OXC vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0308">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0309"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-070.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: OXC vs TPM, Outcome 2: OXC vs TPM: Neural Tube Malformations" data-id="CD010224-fig-0309" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-070.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.2</div> <div class="figure-caption"> <p>Comparison 70: OXC vs TPM, Outcome 2: OXC vs TPM: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0309">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0310"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-070.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: OXC vs TPM, Outcome 3: OXC vs PRM: Cardiac Malformations" data-id="CD010224-fig-0310" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-070.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.3</div> <div class="figure-caption"> <p>Comparison 70: OXC vs TPM, Outcome 3: OXC vs PRM: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0310">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0311"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-070.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: OXC vs TPM, Outcome 4: OXC vs PRM: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0311" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-070.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.4</div> <div class="figure-caption"> <p>Comparison 70: OXC vs TPM, Outcome 4: OXC vs PRM: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0311">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0312"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-070.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: OXC vs TPM, Outcome 5: OXC vs PRM: Skeletal/Limb Malformations" data-id="CD010224-fig-0312" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-070.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.5</div> <div class="figure-caption"> <p>Comparison 70: OXC vs TPM, Outcome 5: OXC vs PRM: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0312">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-070.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0313"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-071.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: OXC vs ZNS, Outcome 1: OXC vs ZNS: All Major Malformations" data-id="CD010224-fig-0313" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-071.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.1</div> <div class="figure-caption"> <p>Comparison 71: OXC vs ZNS, Outcome 1: OXC vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0313">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0314"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-071.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: OXC vs ZNS, Outcome 2: OXC vs ZNS: Neural Tube Malformations" data-id="CD010224-fig-0314" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-071.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.2</div> <div class="figure-caption"> <p>Comparison 71: OXC vs ZNS, Outcome 2: OXC vs ZNS: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0314">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0315"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-071.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: OXC vs ZNS, Outcome 3: OXC vs ZNS: Cardiac Malformations" data-id="CD010224-fig-0315" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-071.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.3</div> <div class="figure-caption"> <p>Comparison 71: OXC vs ZNS, Outcome 3: OXC vs ZNS: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0315">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0316"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-071.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: OXC vs ZNS, Outcome 4: OXC vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0316" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-071.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.4</div> <div class="figure-caption"> <p>Comparison 71: OXC vs ZNS, Outcome 4: OXC vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0316">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0317"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-071.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: OXC vs ZNS, Outcome 5: OXC vs ZNS: Skeletal/Limb Malformations" data-id="CD010224-fig-0317" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-071.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.5</div> <div class="figure-caption"> <p>Comparison 71: OXC vs ZNS, Outcome 5: OXC vs ZNS: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0317">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-071.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0318"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-072.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 72: PRM vs TPM, Outcome 1: PRM vs TPM: All Major Malformations" data-id="CD010224-fig-0318" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-072.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-072.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 72.1</div> <div class="figure-caption"> <p>Comparison 72: PRM vs TPM, Outcome 1: PRM vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0318">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-072.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0319"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-073.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: PRM vs VPA, Outcome 1: PRM vs VPA: All Major Malformations" data-id="CD010224-fig-0319" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-073.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.1</div> <div class="figure-caption"> <p>Comparison 73: PRM vs VPA, Outcome 1: PRM vs VPA: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0319">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0320"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-073.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: PRM vs VPA, Outcome 2: PRM vs VPA: Neural Tube Malformations" data-id="CD010224-fig-0320" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-073.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.2</div> <div class="figure-caption"> <p>Comparison 73: PRM vs VPA, Outcome 2: PRM vs VPA: Neural Tube Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0320">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0321"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-073.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: PRM vs VPA, Outcome 3: PRM vs VPA: Cardiac Malformations" data-id="CD010224-fig-0321" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-073.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.3</div> <div class="figure-caption"> <p>Comparison 73: PRM vs VPA, Outcome 3: PRM vs VPA: Cardiac Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0321">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0322"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-073.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: PRM vs VPA, Outcome 4: PRM vs VPA: Oro‐Facial Cleft/Craniofacial Malformations" data-id="CD010224-fig-0322" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-073.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.4</div> <div class="figure-caption"> <p>Comparison 73: PRM vs VPA, Outcome 4: PRM vs VPA: Oro‐Facial Cleft/Craniofacial Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0322">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0323"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-073.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: PRM vs VPA, Outcome 5: PRM vs VPA: Skeletal/Limb Malformations" data-id="CD010224-fig-0323" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-073.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.5</div> <div class="figure-caption"> <p>Comparison 73: PRM vs VPA, Outcome 5: PRM vs VPA: Skeletal/Limb Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0323">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-073.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0324"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-074.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 74: LEV vs LAC, Outcome 1: LEV vs LAC: All Major Malformations" data-id="CD010224-fig-0324" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-074.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-074.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 74.1</div> <div class="figure-caption"> <p>Comparison 74: LEV vs LAC, Outcome 1: LEV vs LAC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0324">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-074.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0325"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-075.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 75: CBZ vs LAC, Outcome 1: CBZ vs LAC: All Major Malformations" data-id="CD010224-fig-0325" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-075.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-075.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 75.1</div> <div class="figure-caption"> <p>Comparison 75: CBZ vs LAC, Outcome 1: CBZ vs LAC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0325">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-075.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0326"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-076.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 76: OXC vs LAC, Outcome 1: OXC vs LAC: All Major Malformations" data-id="CD010224-fig-0326" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-076.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-076.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 76.1</div> <div class="figure-caption"> <p>Comparison 76: OXC vs LAC, Outcome 1: OXC vs LAC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0326">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-076.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0327"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-077.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 77: PB vs LAC, Outcome 1: PB vs LAC: All Major Malformations" data-id="CD010224-fig-0327" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-077.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-077.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 77.1</div> <div class="figure-caption"> <p>Comparison 77: PB vs LAC, Outcome 1: PB vs LAC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0327">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-077.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0328"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-078.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 78: LAC vs ZNS, Outcome 1: LAC vs ZNS: All Major Malformations" data-id="CD010224-fig-0328" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-078.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-078.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 78.1</div> <div class="figure-caption"> <p>Comparison 78: LAC vs ZNS, Outcome 1: LAC vs ZNS: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0328">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-078.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0329"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-079.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 79: GBP vs PGB, Outcome 1: GBP vs PGB: All Major Malformations" data-id="CD010224-fig-0329" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-079.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-079.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 79.1</div> <div class="figure-caption"> <p>Comparison 79: GBP vs PGB, Outcome 1: GBP vs PGB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0329">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-079.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0330"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-080.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 80: GBP vs CZP, Outcome 1: GBP vs CZP: All Major Malformations" data-id="CD010224-fig-0330" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-080.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-080.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 80.1</div> <div class="figure-caption"> <p>Comparison 80: GBP vs CZP, Outcome 1: GBP vs CZP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0330">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-080.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0331"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-081.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 81: VPA vs BNZ, Outcome 1: VPA vs BNZ: All Major Malformations" data-id="CD010224-fig-0331" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-081.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-081.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 81.1</div> <div class="figure-caption"> <p>Comparison 81: VPA vs BNZ, Outcome 1: VPA vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0331">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-081.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0332"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-082.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 82: LTG vs BNZ, Outcome 1: LTG vs BNZ: All Major Malformations" data-id="CD010224-fig-0332" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-082.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-082.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 82.1</div> <div class="figure-caption"> <p>Comparison 82: LTG vs BNZ, Outcome 1: LTG vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0332">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-082.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0333"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-083.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 83: LEV vs BNZ, Outcome 1: LEV vs BNZ: All Major Malformations" data-id="CD010224-fig-0333" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-083.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-083.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 83.1</div> <div class="figure-caption"> <p>Comparison 83: LEV vs BNZ, Outcome 1: LEV vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0333">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-083.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0334"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-084.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 84: CBZ vs BNZ, Outcome 1: CBZ vs BNZ: All Major Malformations" data-id="CD010224-fig-0334" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-084.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-084.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 84.1</div> <div class="figure-caption"> <p>Comparison 84: CBZ vs BNZ, Outcome 1: CBZ vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0334">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-084.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0335"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-085.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 85: OXC vs BNZ, Outcome 1: OXC vs BNZ: All Major Malformations" data-id="CD010224-fig-0335" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-085.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-085.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 85.1</div> <div class="figure-caption"> <p>Comparison 85: OXC vs BNZ, Outcome 1: OXC vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0335">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-085.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0336"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-086.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 86: PB vs BNZ, Outcome 1: PB vs BNZ: All Major Malformations" data-id="CD010224-fig-0336" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-086.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-086.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 86.1</div> <div class="figure-caption"> <p>Comparison 86: PB vs BNZ, Outcome 1: PB vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0336">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-086.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0337"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-087.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 87: LAC vs BNZ, Outcome 1: LAC vs BNZ: All Major Malformations" data-id="CD010224-fig-0337" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-087.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-087.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 87.1</div> <div class="figure-caption"> <p>Comparison 87: LAC vs BNZ, Outcome 1: LAC vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0337">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-087.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0338"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-088.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 88: ZNS vs BNZ, Outcome 1: ZNS vs BNZ: All Major Malformations" data-id="CD010224-fig-0338" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-088.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-088.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 88.1</div> <div class="figure-caption"> <p>Comparison 88: ZNS vs BNZ, Outcome 1: ZNS vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0338">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-088.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0339"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-089.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 89: CZP vs TPM, Outcome 1: CZP vs TPM: All Major Malformations" data-id="CD010224-fig-0339" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-089.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-089.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 89.1</div> <div class="figure-caption"> <p>Comparison 89: CZP vs TPM, Outcome 1: CZP vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0339">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-089.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0340"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-090.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 90: CZP vs OXC, Outcome 1: CZP vs OXC: All Major Malformations" data-id="CD010224-fig-0340" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-090.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-090.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 90.1</div> <div class="figure-caption"> <p>Comparison 90: CZP vs OXC, Outcome 1: CZP vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0340">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-090.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0341"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-091.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 91: CZP vs COZ, Outcome 1: CZP vs COZ: All Major Malformations" data-id="CD010224-fig-0341" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-091.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-091.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 91.1</div> <div class="figure-caption"> <p>Comparison 91: CZP vs COZ, Outcome 1: CZP vs COZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0341">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-091.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0342"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-092.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 92: CZP vs ESM, Outcome 1: CZP vs ESM: All Major Malformations" data-id="CD010224-fig-0342" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-092.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-092.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 92.1</div> <div class="figure-caption"> <p>Comparison 92: CZP vs ESM, Outcome 1: CZP vs ESM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0342">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-092.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0343"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-093.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 93: CZP vs PRG, Outcome 1: CZP vs PRG: All Major Malformations" data-id="CD010224-fig-0343" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-093.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-093.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 93.1</div> <div class="figure-caption"> <p>Comparison 93: CZP vs PRG, Outcome 1: CZP vs PRG: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0343">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-093.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0344"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-094.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 94: CZP vs PRM, Outcome 1: CZP vs PRM: All Major Malformations" data-id="CD010224-fig-0344" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-094.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-094.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 94.1</div> <div class="figure-caption"> <p>Comparison 94: CZP vs PRM, Outcome 1: CZP vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0344">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-094.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0345"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-095.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 95: CZP vs VGB, Outcome 1: CZP vs VGB: All Major Malformations" data-id="CD010224-fig-0345" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-095.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-095.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 95.1</div> <div class="figure-caption"> <p>Comparison 95: CZP vs VGB, Outcome 1: CZP vs VGB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0345">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-095.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0346"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-096.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 96: TPM vs BNZ, Outcome 1: TPM vs BNZ: All Major Malformations" data-id="CD010224-fig-0346" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-096.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-096.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 96.1</div> <div class="figure-caption"> <p>Comparison 96: TPM vs BNZ, Outcome 1: TPM vs BNZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0346">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-096.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0347"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-097.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 97: ESM vs VPA, Outcome 1: ESM vs VPA: All Major Malformations" data-id="CD010224-fig-0347" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-097.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-097.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 97.1</div> <div class="figure-caption"> <p>Comparison 97: ESM vs VPA, Outcome 1: ESM vs VPA: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0347">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-097.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0348"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-098.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 98: ESM vs CBZ, Outcome 1: ESM vs CBZ: All Major Malformations" data-id="CD010224-fig-0348" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-098.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-098.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 98.1</div> <div class="figure-caption"> <p>Comparison 98: ESM vs CBZ, Outcome 1: ESM vs CBZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0348">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-098.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0349"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-099.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 99: ESM vs PRM, Outcome 1: ESM vs PRM: All Major Malformations" data-id="CD010224-fig-0349" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-099.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-099.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 99.1</div> <div class="figure-caption"> <p>Comparison 99: ESM vs PRM, Outcome 1: ESM vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0349">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-099.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0350"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-100.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 100: ESM vs PB, Outcome 1: ESM vs PB: All Major Malformations" data-id="CD010224-fig-0350" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-100.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-100.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 100.1</div> <div class="figure-caption"> <p>Comparison 100: ESM vs PB, Outcome 1: ESM vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0350">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-100.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0351"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-101.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 101: ESM vs PHT, Outcome 1: ESM vs PHT: All Major Malformations" data-id="CD010224-fig-0351" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-101.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-101.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 101.1</div> <div class="figure-caption"> <p>Comparison 101: ESM vs PHT, Outcome 1: ESM vs PHT: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0351">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-101.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0352"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-102.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 102: ESM vs OXC, Outcome 1: ESM vs OXC: All Major Malformations" data-id="CD010224-fig-0352" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-102.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-102.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 102.1</div> <div class="figure-caption"> <p>Comparison 102: ESM vs OXC, Outcome 1: ESM vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0352">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-102.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0353"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-103.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 103: ESM vs VGB, Outcome 1: ESM vs VGB: All Major Malformations" data-id="CD010224-fig-0353" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-103.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-103.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 103.1</div> <div class="figure-caption"> <p>Comparison 103: ESM vs VGB, Outcome 1: ESM vs VGB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0353">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-103.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0354"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-104.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 104: ESM vs LTG, Outcome 1: ESM vs LTG: All Major Malformations" data-id="CD010224-fig-0354" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-104.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-104.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 104.1</div> <div class="figure-caption"> <p>Comparison 104: ESM vs LTG, Outcome 1: ESM vs LTG: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0354">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-104.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0355"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-105.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 105: ESM vs TPM, Outcome 1: ESM vs TPM: All Major Malformations" data-id="CD010224-fig-0355" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-105.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-105.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 105.1</div> <div class="figure-caption"> <p>Comparison 105: ESM vs TPM, Outcome 1: ESM vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0355">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-105.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0356"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-106.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 106: ESM vs GBP, Outcome 1: ESM vs GBP: All Major Malformations" data-id="CD010224-fig-0356" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-106.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-106.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 106.1</div> <div class="figure-caption"> <p>Comparison 106: ESM vs GBP, Outcome 1: ESM vs GBP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0356">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-106.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0357"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-107.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 107: VGB vs VPA, Outcome 1: VGB vs VPA: All Major Malformations" data-id="CD010224-fig-0357" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-107.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-107.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 107.1</div> <div class="figure-caption"> <p>Comparison 107: VGB vs VPA, Outcome 1: VGB vs VPA: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0357">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-107.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0358"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-108.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 108: VGB vs CBZ, Outcome 1: VGB vs CBZ: All Major Malformations" data-id="CD010224-fig-0358" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-108.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-108.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 108.1</div> <div class="figure-caption"> <p>Comparison 108: VGB vs CBZ, Outcome 1: VGB vs CBZ: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0358">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-108.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0359"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-109.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 109: VGB vs PRM, Outcome 1: VGB vs PRM: All Major Malformations" data-id="CD010224-fig-0359" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-109.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-109.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 109.1</div> <div class="figure-caption"> <p>Comparison 109: VGB vs PRM, Outcome 1: VGB vs PRM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0359">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-109.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0360"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-110.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 110: VGB vs PB, Outcome 1: VGB vs PB: All Major Malformations" data-id="CD010224-fig-0360" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-110.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-110.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 110.1</div> <div class="figure-caption"> <p>Comparison 110: VGB vs PB, Outcome 1: VGB vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0360">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-110.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0361"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-111.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 111: VGB vs PHT, Outcome 1: VGB vs PHT: All Major Malformations" data-id="CD010224-fig-0361" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-111.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-111.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 111.1</div> <div class="figure-caption"> <p>Comparison 111: VGB vs PHT, Outcome 1: VGB vs PHT: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0361">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-111.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0362"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-112.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 112: VGB vs OXC, Outcome 1: VGB vs OXC: All Major Malformations" data-id="CD010224-fig-0362" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-112.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-112.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 112.1</div> <div class="figure-caption"> <p>Comparison 112: VGB vs OXC, Outcome 1: VGB vs OXC: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0362">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-112.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0363"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-113.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 113: VGB vs LTG, Outcome 1: VGB vs LTG: All Major Malformations" data-id="CD010224-fig-0363" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-113.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-113.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 113.1</div> <div class="figure-caption"> <p>Comparison 113: VGB vs LTG, Outcome 1: VGB vs LTG: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0363">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-113.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0364"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-114.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 114: VGB vs TPM, Outcome 1: VGB vs TPM: All Major Malformations" data-id="CD010224-fig-0364" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-114.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-114.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 114.1</div> <div class="figure-caption"> <p>Comparison 114: VGB vs TPM, Outcome 1: VGB vs TPM: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0364">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-114.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0365"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-115.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 115: VGB vs GBP, Outcome 1: VGB vs GBP: All Major Malformations" data-id="CD010224-fig-0365" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-115.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-115.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 115.1</div> <div class="figure-caption"> <p>Comparison 115: VGB vs GBP, Outcome 1: VGB vs GBP: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0365">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-115.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0366"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-116.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 116: CZP vs PB, Outcome 1: CZP vs PB: All Major Malformations" data-id="CD010224-fig-0366" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-116.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-116.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 116.1</div> <div class="figure-caption"> <p>Comparison 116: CZP vs PB, Outcome 1: CZP vs PB: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0366">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-116.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0367"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-117.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 117: CZP vs PHT, Outcome 1: CZP vs PHT: All Major Malformations" data-id="CD010224-fig-0367" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-117.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-117.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 117.1</div> <div class="figure-caption"> <p>Comparison 117: CZP vs PHT, Outcome 1: CZP vs PHT: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0367">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-117.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0368"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-118.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 118: ESM vs LEV, Outcome 1: ESM vs LEV: All Major Malformations" data-id="CD010224-fig-0368" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-118.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-118.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 118.1</div> <div class="figure-caption"> <p>Comparison 118: ESM vs LEV, Outcome 1: ESM vs LEV: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0368">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-118.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0369"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-119.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 119: ESM vs Controls, Outcome 1: ESM vs Controls: All Major Malformations" data-id="CD010224-fig-0369" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-119.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-119.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 119.1</div> <div class="figure-caption"> <p>Comparison 119: ESM vs Controls, Outcome 1: ESM vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0369">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-119.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010224-fig-0370"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/urn:x-wiley:14651858:media:CD010224:CD010224-CMP-120.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 120: VGB vs Controls, Outcome 1: VGB vs Controls: All Major Malformations" data-id="CD010224-fig-0370" src="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-120.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_t/tCD010224-CMP-120.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 120.1</div> <div class="figure-caption"> <p>Comparison 120: VGB vs Controls, Outcome 1: VGB vs Controls: All Major Malformations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-fig-0370">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/media/CDSR/CD010224/image_n/nCD010224-CMP-120.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010224-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ Lamotrigine</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Lamotrigine in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in the exposed children</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence LTG</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lamotrigine vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.99 (1.16, 3.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4862 (7)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 3.3% (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19 (0.86, 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,288 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lamotrigine vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0% (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.66, 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3918 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2% (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.79, 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,445 (3)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58, 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5612 (10)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.37, 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2316 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3113</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (1.06, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8568 (13)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.88, 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4503 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4471</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.36, 0.96)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4780 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 270.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2666</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50 (2.76, 4.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6896 (12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.49 (1.86, 3.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3590 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3895</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33, 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2541 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.67, 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2535 (3)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2847</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.26, 1.65)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3922 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> RD was non‐significant; <sup>b</sup> Random‐effects RR was calculated due to heterogeneity. </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>MED: Medication<br/>N/A: not available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ Lamotrigine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010224-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Levetiracetam</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Levetiracetam in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in the exposed children</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Prevalence LEV (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Prevalence</b> </p> <p><b>comparator (95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Levetiracetam vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.98, 4.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1596 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.3% (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0,17, 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369,385 (1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Levetiracetam vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.0% (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.39, 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1825 (6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.2% (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.39, 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,625 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58‐ 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5612 (10)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.37, 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2316 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3113</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 (1.01, 2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5056 (11)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.78, 3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1248 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2556</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32, 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1629 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.06, 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.77 (2.48, 5.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3485 (10)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.26 (1.51, 7.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>911 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51, 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1166 (8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (0.45, 3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621 (2)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>932</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.25, 1.71)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>995 (4)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> RD was non‐significant; <sup>b</sup> Random‐effects RR was calculated due to heterogeneity. </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Levetiracetam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010224-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prevalence of major congenital malformations for each monotherapy ASM stratified by study type</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Database</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>All</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ASM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Upper 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Upper 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Upper 95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>CZP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GBP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>321.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9722.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,060.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No med</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12,994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen POP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>376,565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>Specific prevalences are weighted for cohort size.</p> <p>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>CZP: Clonazepam<br/>GBP: Gabapentin<br/>LAC: Lacosamide<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>ND: No Data<br/>OXC: Oxcarbazepine<br/>PB: Phenobarbital<br/>PHT: Phenytoin<br/>POP: Population <br/>PRM: Primidone<br/>TPM: Topiramate<br/>VPA: Sodium Valproate<br/>ZNS: Zonisamide </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prevalence of major congenital malformations for each monotherapy ASM stratified by study type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010224-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of findings table ‐ Carbamazepine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Carbamazepine in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence CBZ</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Carbamazepine vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.30 (1.47, 3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5047 (13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3% (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (0.80, 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,094 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Carbamazepine vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0% (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.44 (1.05, 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5289 (20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2% (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 (1.10, 1.83)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,334 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 (1.01, 2.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5056 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.78, 3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1248 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2556</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (1.06, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8568 (13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.88, 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4503 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4471</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51, 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4156 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27,060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.17, 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1437 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2109</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (0.37, 0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8090 (29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.33, 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4157 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3338</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74, 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2877 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.44, 0.91)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3015 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2290</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.07, 10.35)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2841 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> RD was non‐significant; <sup>b</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of findings table ‐ Carbamazepine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010224-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of findings table ‐ Oxcarbazepine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Oxcarbazepine in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC Prevalence</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.67, 7.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>951(2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 3.3 (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.10, 4.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369,324 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0 (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.40 (0.68, 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>922 (6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2 (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75 (1.22, 2.52)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,819 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51, 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1166 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (0.45, 3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>932</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine Vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33, 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2541 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 3.5% (2.5, 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.67, 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2535 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2847</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oxcarbazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>706 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.04, 4.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48 (1.42, 4.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1561 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 (1.11, 2.29)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1701 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1714</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74, 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2887 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.44, 0.91)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3015 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2290</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oxcarbazepine vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.48 (0.24, 82.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of findings table ‐ Oxcarbazepine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010224-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings table ‐ Topiramate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Topiramate in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM Prevalence</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.07 (1.64, 10.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1192 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 3.3 (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.43, 6.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369,315 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0 (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.57, 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1219 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2 (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.62 (0.40, 6.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1948 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Levetiracetam vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32, 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1629 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.06, 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Lamotrigine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.36, 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4780 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 0.68% (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2666</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oxcarbazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28, 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>706 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.04, 4.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.47 (1.50, 4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2723 (7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.27 (0.36, 4.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1533</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51, 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4156 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.17, 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1437 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2109</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Topiramate vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.54, 4.66)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>Gen pop: General population<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of findings table ‐ Topiramate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010224-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings table ‐ Valproate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Population: Pregnant women with epilepsy</p> <p>Intervention: ASM monotherapy</p> <p>Comparison: Valproate in comparison to other ASMs</p> <p>Outcome: Major congenital malformation rate in exposed children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks across data types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA Prevalence</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence</b> </p> <p><b>comparator</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Valproate vs no medication (women without epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 2.1% (1.5, 3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.53 (3.29, 9.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3135 (10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gen Pop 3.3 (1.5, 7.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.29 (1.71, 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373,649 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Valproate vs no medication (women with epilepsy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.0 (2.1, 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.77 (2.03, 3.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3998 (17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No Med 3.2 (1.7, 6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.01 (2.42, 3.75)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,369 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.6% (1.6, 4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.77 (2.48, 5.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3485(10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (0.0, 321.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.26 (1.51, 7.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>911 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LEV 2.8% (1.7, 4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs lamotrigine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.7% (1.9, 3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50 (2.76, 4.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6896 (12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 0.68% (0.20, 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.49 (1.86, 3.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3590 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG 2.9% (2.3, 3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3894</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 2.8% (1.1, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48 (1.42, 4.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1561 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 4.8% (0.7, 31.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 (1.11, 2.29)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1701 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OXC 3.0% (1.4, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1714</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (2.3, 6.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.47 (1.50, 4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2723 (7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 4.1% (0.0, 27060.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.27 (0.36, 4.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TPM 3.9% (1.5, 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Carbamazepine vs valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.7% (3.7, 5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (0.37, 0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8090 (29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 4.0% (2.9, 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (0.33, 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4157 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ 5.5% (4.5, 6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3338</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Valproate vs zonisamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.8% (8.1, 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZNS 2.7% (0.1, 47.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.34 (0.95, 5.80)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1677 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Database studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 9.7% (7.1, 13.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EURAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VPA 10.3% (8.8, 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Random‐effects RR calculated due to heterogeneity </p> <p>ASM: Anti‐Seizure Medication <br/>CBZ: Carbamazepine<br/>CI: Confidence Interval<br/>Gen pop: General population<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>N/A: Not Available<br/>OXC: Oxcarbazepine<br/>TPM: Topiramate<br/>VPA: Sodium Valproate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings table ‐ Valproate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010224-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Relative risks (RRs) for specific ASM comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gen Pop</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No Med</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.30 (1.47 to 3.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.44 (1.05 to 1.96)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82 (0.63 to 5.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.55 (0.57 to 4.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.51 (1.01 to 2.26)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.37 (1.06 to 1.77)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74 to 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.61 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.62 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.23 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.44 (0.37 to 0.53)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94, (0.36 to 2.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.76 (0.55 to 13.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.21 to 5.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82 (0.63 to 5.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.32 to 3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.29 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.01 to 5.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.05 to 13.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.10 to 5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.03 to 15.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.29 (0.09 to 0.90)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.78 (0.50 to 6.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.77 (0.46 to 6.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.55 (0.57 to 4.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.46 to 5.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.34 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.13 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.08 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.15 (0.69 to 6.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32 (0.09 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.27 (1.60 to 11.35)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.10 to 2.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.98 to 4.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.39 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.51 (1.01 to 2.26)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.32 to 3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.46 to 5.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.29 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.58 (0.34 to 0.97)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.02 to 3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.77 (2.48 to 5.74)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.25 to 1.71)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.99 (1.16 to 3.39)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.66 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.37 (1.06 to 1.77)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.29 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.34 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.58 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.32 (0.17 to 0.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55 (0.35 to 0.87)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.02 to 3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.59 (0.36 to 0.96)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.50 (2.76 to 4.46)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.26 to 1.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.67 to 7.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.40 (0.68 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.74 to 2.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.01 to 5.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.13 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.51 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.33 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.83 to 3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.48 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (0.08 to 4.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.48 (1.42 to 4.31)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.48 (0.24 to 82.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.22 (1.84 to 5.65)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.64 (0.94 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.61 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.05 to 13.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.08 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.29 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.32 (0.17 to 0.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.61 (0.83 to 3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.57 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.21 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38 (0.68 to 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.49 (1.08 to 2.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.46 (0.62 to 175.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.81 (1.91 to 7.57)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.01 (1.29 to 3.12)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.62 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.10 to 5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.15 (0.69 to 6.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.58 (0.34 to 0.97)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55 (0.35 to 0.87)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.48 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.57 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.39 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.48 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.92 (1.44 to 2.56)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.42 to 3.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.61 (1.41 to 9.23)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.23 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.02 to 3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.02 to 3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (0.08 to 4.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.21 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.39 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.00 (0.30 to 118.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.39 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.07 (1.64 to 10.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.57 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.51 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.03 to 15.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32 (0.09 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.32 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.59 (0.36 to 0.96)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.28 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38 (0.680 to 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.48 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.00 (0.30 to 118.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.47 (1.50 to 4.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.54 to 4.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.53 (3.29 to 9.29)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.77 (2.03 to 3.79)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.44 (0.37 to 0.53)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.29 (0.09 to 0.90)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.27 (1.60 to 11.35)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.77 (2.48 to 5.74)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.50 (2.76 to 4.46)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.48 (1.42 to 4.31)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.49 (1.08 to 2.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.92 (1.44 to 2.56)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.39 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.47 (1.50 to 4.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.34 (0.95 to 5.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.21 to 6.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.20 (1.09 to 9.43)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94, (0.36 to 2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53 (0.10 to 2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.25 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.26 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.48 (0.24 to 82.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.46 (0.62 to 175.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.42to 3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.54 to 4.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.34 (0.95 to 5.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="15"> <div class="table-footnote"> <p>Bold indicates statistically significant</p> <p>ASM: Anti‐Seizure Medication<br/>CBZ: Carbamazepine<br/>CZP: Clonazepam<br/>GBP: Gabapentin<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>ND: No Data<br/>NE: Not Estimable<br/>OXC: Oxcarbazepine<br/>PB: Phenobarbital<br/>PHT: Phenytoin<br/>POP: Population <br/>PRM: Primidone<br/>RR: Relative Risk <br/>TPM: Topiramate<br/>VPA: Sodium Valproate<br/>ZNS: Zonisamide </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Relative risks (RRs) for specific ASM comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010224-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Risk differences (RDs) for specific ASM comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gen Pop</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No Med</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.02 (0.01 to 0.03)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04,</b> </p> <p><b>(‐0.00 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>( −0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05 (−0.06 to −0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.03 to 0.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CZP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.03 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.11 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04,</b> </p> <p><b>(‐0.00 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.14 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.05 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.18 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.08 (−0.66 to 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.13 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.09 (−0.13 to 0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (‐0.37 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.05 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.14 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.08 to 0.00)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.03 (−0.05 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.08 (0.01 to 0.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.15 to 0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LEV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.00 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.05 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.01 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.02 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.05 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to −0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.39 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.04 to 0.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.03)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.01 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01 (0.00 to 0.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.01 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.07 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.02 (−0.03 to −0.00)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (−0.37 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.03 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.16 to 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OXC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.02 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (−0.03 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>( −0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.18 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.02 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.03 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.34 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.03 to 0.09)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.01 to 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04 (0.01 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (−0.01 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.08 (−0.66 to 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.08 to 0.00)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.05 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.04 (−0.07 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.12 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.02 to 0.09)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03 (0.01 to 0.05)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.04 (−0.13 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to −0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.00 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 (−0.03 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.03 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.11 to 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.00 to 0.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.39 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (−0.37 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.34 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.05 (−0.12 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02</p> <p>(−0.44 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.13 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TPM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (−0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.02 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.09 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.03 (−0.05 to −0.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.04 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02 (−0.03 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.01 (−0.04 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(−0.02 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.02</p> <p>(−0.44 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.02 to 0.11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.02 to 0.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VPA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.04 to 0.10)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.04 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05 (−0.06 to −0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.09 (−0.13 to 0.04)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.08 (0.01 to 0.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.05 to 0.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.06 (0.03 to 0.09)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.04 (0.01 to 0.06)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.03 to 0.07)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> <p>(‐0.13 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.07 (0.02 to 0.11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.11 to 0.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ZNS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.00 (−0.03 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (−0.03 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.03 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.15 to 0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> <p>(‐0.04 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03</p> <p>(‐0.16 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> <p>(‐0.01 to 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.05 (0.02 to 0.09)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> <p>(‐0.11 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.02 to 0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.11 to 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="15"> <div class="table-footnote"> <p>Bold indicates statistical significance</p> <p>ASM: Anti‐Seizure Medication<br/>CBZ: Carbamazepine<br/>CZP: Clonazepam<br/>GBP: Gabapentin<br/>LEV: Levetiracetam <br/>LTG: Lamotrigine<br/>ND: No Data<br/>NE: Not Estimable<br/>OXC: Oxcarbazepine<br/>PB: Phenobarbital<br/>PHT: Phenytoin<br/>POP: Population <br/>PRM: Primidone<br/>TPM: Topiramate<br/>VPA: Sodium Valproate<br/>ZNS: Zonisamide </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Risk differences (RDs) for specific ASM comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/full#CD010224-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CBZ vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 CBZ vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 CBZ vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.47, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 CBZ vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.05, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 CBZ vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.80, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 CBZ vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.10, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 CBZ vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 CBZ vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.38, 25.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 CBZ vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.63, 10.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 CBZ vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 CBZ vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.43, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 CBZ vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.41, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 CBZ vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 CBZ vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.04 [2.16, 37.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 CBZ vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.27, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 CBZ vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 CBZ vs Woment Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.13 [0.52, 50.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 CBZ vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.33, 2.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CBZ vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CZP vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 CZP vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 CZP vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.55, 13.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 CZP vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.21, 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 CZP vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.18, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 CZP vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.17, 2.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CZP vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">GBP vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 GBP vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 GBP vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.50, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 GBP vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.46, 6.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 GBP vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 GBP vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 GBP vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 GBP vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>129.00 [6.49, 2562.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 GBP vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.29, 87.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 GBP vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 GBP vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 GBP vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 GBP vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">GBP vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LEV vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 LEV vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 LEV vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.98, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 LEV vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.39, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 LEV vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.17, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 LEV vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.39, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 LEV vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 LEV vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 LEV vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 LEV vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 LEV vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [0.57, 27.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 LEV vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.31, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 LEV vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 LEV vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 LEV vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 LEV vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 LEV vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 LEV vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.46, 22.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LEV vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">LTG vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 LTG vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 LTG vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.16, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 LTG vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.66, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 LTG vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.86, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 LTG vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 LTG vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 LTG vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.55 [1.05, 54.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 LTG vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 LTG vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 LTG vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.05, 6.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 LTG vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.28, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 LTG vs Controls: Oro‐Facial Cleft/Crainofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 LTG vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 LTG vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.29, 6.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 LTG vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 LTG vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.29 [2.37, 53.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 LTG vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.20, 2.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">LTG vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">OXC vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 OXC vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 OXC vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.67, 7.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 OXC vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.68, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 OXC vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.10, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.4 OXC vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.22, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 OXC vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 OXC vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 OXC vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 OXC vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 OXC vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.36, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 OXC vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 OXC vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.04, 14.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 OXC vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 OXC vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.22, 26.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">OXC vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PB vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 PB vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 PB vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [1.84, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 PB vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.94, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 PB vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.77, 11.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 PB vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1927</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.74, 11.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 PB vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 PB vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 PB vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [0.47, 31.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 PB vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 PB vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [0.36, 168.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 PB vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.69, 4.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 PB vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 PB vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.34 [0.20, 56.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 PB vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 PB vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 PB vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [0.36, 168.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 PB vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [0.56, 16.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PB vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PHT vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 PHT vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 PHT vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.81 [1.91, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 PHT vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.29, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 PHT vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 PHT vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.17 [0.58, 299.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 PHT vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [0.64, 10.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 PHT vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 PHT vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.31 [0.75, 52.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 PHT vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.72, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 PHT vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 PHT vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.04, 12.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.2 PHT vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 PHT vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 PHT vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.07, 37.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 PHT vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.31, 7.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PHT vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">PRM vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 PRM vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 PRM vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.03, 8.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 PRM vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.61 [1.41, 9.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">PRM vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">TPM vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 TPM vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 TPM vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [1.64, 10.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 TPM vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.57, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.3 TPM vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.43, 6.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.4 TPM vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.40, 6.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 TPM vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 TPM vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 TPM vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 TPM vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 TPM vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.71 [2.64, 162.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.2 TPM vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [0.49, 12.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 TPM vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 TPM vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.2 TPM vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.09, 24.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 TPM vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 TPM vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.2 TPM vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.24, 17.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">TPM vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">VPA vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 VPA vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 VPA vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.53 [3.29, 9.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 VPA vs WWE ‐ No Med Controls (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [2.03, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.3 VPA vs Women Without Epilepsy (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.71, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.4 VPA vs WWE ‐ No Med Controls (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [2.42, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 VPA vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 VPA vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.05 [0.94, 38.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 VPA vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.64 [1.37, 23.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.3 VPA vs WWE ‐ No Medication (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.02 [1.48, 43.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 VPA vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 VPA vs Women without Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.89 [2.88, 49.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 VPA vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.42, 5.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 VPA vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 VPA vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.31, 24.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.2 VPA vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.44 [1.14, 17.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 VPA vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 VPA vs Women Without Epilepsy (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.48 [2.46, 110.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.2 VPA vs WWE ‐ No Medication (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.93, 6.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">VPA vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">ZNS vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 ZNS vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 ZNS vs Women Without Epilepsy (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.21, 6.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 ZNS vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [1.09, 9.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 ZNS vs Controls: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 ZNS vs Women Without Epilepsy (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 ZNS vs WWE ‐ No Medication (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 ZNS vs Controls: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 ZNS vs Women Without Epilepsy (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.11, 59.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 ZNS vs WWE ‐ No Medication (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 ZNS vs Controls: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.1 ZNS vs Women Without Epilepsy (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.2 ZNS vs WWE ‐ No Medication (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 ZNS vs Controls: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.1 ZNS vs Women without Epilepsy (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.2 ZNS vs WWE ‐ No Medication (cohort study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">ZNS vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">CBZ vs CZP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 CBZ vs CZP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 CBZ vs CZP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.63, 5.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 CBZ vs CZP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.47, 3.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">CBZ vs CZP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">CBZ vs GBP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 CBZ vs GBP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 CBZ vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.57, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 CBZ vs GBP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.10, 24.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 CBZ vs GBP: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 CBZ vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 CBZ vs GBP: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 CBZ vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 CBZ vs GBP: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.1 CBZ vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 CBZ vs GBP: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.1 CBZ vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">CBZ vs GBP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">CBZ vs LEV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 CBZ vs LEV: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 CBZ vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.01, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 CBZ vs LEV (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.78, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 CBZ vs LEV: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 CBZ vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.41, 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 CBZ vs LEV: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.1 CBZ vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.57, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 CBZ vs LEV: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.1 CBZ vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.43, 7.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 CBZ vs LEV: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.1 CBZ vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.37, 2.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">CBZ vs LEV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">CBZ vs LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 CBZ vs LTG: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 CBZ vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.06, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.2 CBZ vs LTG (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.88, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 CBZ vs LTG: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 CBZ vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.76, 6.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 CBZ vs LTG: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 CBZ vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.87, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.4 CBZ vs LTG: Oro‐Facial Cleft/Crainofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4.1 CBZ vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.57, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.5 CBZ vs LTG: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.1 CBZ vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.82, 4.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">CBZ vs LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">CBZ vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 CBZ vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1.1 CBZ vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.74, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1.2 CBZ vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.44, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 CBZ vs OXC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.1 CBZ vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.22, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 CBZ vs OXC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3.1 CBZ vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.23, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.4 CBZ vs OXC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4.1 CBZ vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.12, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.5 CBZ vs OXC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5.1 CBZ vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.17, 1.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">CBZ vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">CBZ vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 CBZ vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.1 CBZ vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.61, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.2 CBZ vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.12, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 CBZ vs PB: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.1 CBZ vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.35, 4.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 CBZ vs PB: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.1 CBZ vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.4 CBZ vs PB: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.1 CBZ vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.07, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.5 CBZ vs PB: Skeletal/Limb Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5.1 CBZ vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.45, 2.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">CBZ vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">CBZ vs PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 CBZ vs PHT: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.1 CBZ vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.2 CBZ vs PHT (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.26, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 CBZ vs PHT: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.1 CBZ vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.45, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 CBZ vs PHT: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3.1 CBZ vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.23, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.4 CBZ vs PHT: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4.1 CBZ vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.32, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.5 CBZ vs PHT: Skeletal/Limb Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5.1 CBZ vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.43, 1.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">CBZ vs PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">CBZ vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 CBZ vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.1 CBZ vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.41, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.2 CBZ vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.02, 4.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 CBZ vs PRM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.1 CBZ vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.04, 22.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.3 CBZ vs PRM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3.1 CBZ vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.00, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.4 CBZ vs PRM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4.1 CBZ vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.5 CBZ vs PRM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5.1 CBZ vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.16, 51.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">CBZ vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">CBZ vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 CBZ vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 CBZ vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.51, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.2 CBZ vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.17, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 CBZ vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 CBZ vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.18, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.3 CBZ vs TPM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.1 CBZ vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.25, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.4 CBZ vs TPM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4.1 CBZ vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.13, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.5 CBZ vs TPM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.1 CBZ vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">CBZ vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">CBZ vs VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 CBZ vs VPA: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.1 CBZ vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.2 CBZ vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.33, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 CBZ vs VPA: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.1 CBZ vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.14, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.2 CBZ vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 CBZ vs VPA: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.1 CBZ vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.28, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.2 CBZ vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.13, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.4 CBZ vs VPA: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4.1 CBZ vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.18, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4.2 CBZ vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.03, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.5 CBZ vs VPA: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.1 CBZ vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.19, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5.2 CBZ vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.02, 6.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">CBZ vs VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">CBZ vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 CBZ vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1.1 CBZ vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.07, 10.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 CBZ vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.1 CBZ vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.3 CBZ vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3.1 CBZ vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.03, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.4 CBZ vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4.1 CBZ vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.5 CBZ vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5.1 CBZ vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">CBZ vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">GBP vs LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.1 GPB vs LTG: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.1 GBP vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.34, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.2 GBP vs LTG (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.03, 9.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.2 GPB vs LTG: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2.1 GBP vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.3 GPB vs LTG: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3.1 GBP vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.57 [1.69, 54.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.4 GPB vs LTG: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4.1 GBP vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.11, 33.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.5 GPB vs LTG: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5.1 GBP vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">GBP vs LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">GBP vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.1 GBP vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.1 GBP vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.13, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.2 GBP vs OXC (database study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.2 GBP vs OXC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2.1 GBP vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.3 GBP vs OXC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3.1 GBP vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.24, 37.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.4 GBP vs OXC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4.1 GBP vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.5 GBP vs OXC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.5.1 GBP vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">GBP vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">GBP vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.1 GBP vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.1 GBP vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.08, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.2 GBP vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.2 GBP vs PB: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2.1 GBP vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.3 GBP vs PB: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3.1 GBP vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.24, 67.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.4 GBP vs PB: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4.1 GBP vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.5 GBP vs PB: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5.1 GBP vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">GBP vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">GBP vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27.1 GBP vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.1 GBP vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">GBP vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">GBP vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.1 GBP vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1.1 GBP vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.09, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1.2 GBP vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.2 GBP vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2.1 GBP vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.3 GBP vs TPM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3.1 GBP vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.4 GBP vs TPM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.4.1 GBP vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.5 GBP vs TPM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.5.1 GBP vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">GBP vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">GBP vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.1 GBP vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.1 GBP vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.10, 2.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">GBP vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">LEV vs GBP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.1 LEV vs GBP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1.1 LEV vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.46, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.2 LEV vs GBP: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2.1 LEV vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.3 LEV vs GBP: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3.1 LEV vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.03, 16.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.4 LEV vs GBP: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.4.1 LEV vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.03, 16.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.5 LEV vs GBP: Skeletal/Limb Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.5.1 LEV vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">LEV vs GBP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">LEV vs LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.1 LEV vs LTG: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1.1 LEV vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1.2 LEV vs LTG (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.37, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.2 LEV vs LTG: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2.1 LEV vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.24, 10.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.3 LEV vs LTG: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3.1 LEV vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.51, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.4 LEV vs LTG: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4.1 LEV vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.15, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.5 LEV vs LTG: Skeletal/Limb Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.5.1 LEV vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.45, 4.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">LEV vs LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">LEV vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.1 LEV vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.1 LEV vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.51, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.2 LEV vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.45, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.2 LEV vs OXC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2.1 LEV vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.05, 29.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.3 LEV vs OXC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3.1 LEV vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.31, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.4 LEV vs OXC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.4.1 LEV vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.5 LEV vs OXC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.5.1 LEV vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.20, 3.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">LEV vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0042"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">LEV vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.1 LEV vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1.1 LEV vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.29, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1.2 LEV vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.03, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.2 LEV vs PB: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2.1 LEV vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.08, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.3 LEV vs PB: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3.1 LEV vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.12, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.4 LEV vs PB: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.4.1 LEV vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.5 LEV vs PB: Skeletal/Limb Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.5.1 LEV vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.15, 2.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">LEV vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0043"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">LEV vs PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.1 LEV vs PHT: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.1 LEV vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.34, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.2 LEV vs PHT: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2.1 LEV vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.13, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.3 LEV vs PHT: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3.1 LEV vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.16, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.4 LEV vs PHT: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.4.1 LEV vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.09, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.5 LEV vs PHT: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.5.1 LEV vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.11, 1.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">LEV vs PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0044"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">LEV vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.1 LEV vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.1 LEV vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.02, 3.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">LEV vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0045"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">LEV vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36.1 LEV vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1.1 LEV vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.32, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1.2 LEV vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.06, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36.2 LEV vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2.1 LEV vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.10, 58.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36.3 LEV vs TPM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.3.1 LEV vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.21, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36.4 LEV vs TPM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.4.1 LEV vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.05, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36.5 LEV vs TPM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.5.1 LEV vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">LEV vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0046"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">LEV vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.1 LEV vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1.1 LEV vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.25, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.2 LEV vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2.1 LEV vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.3 LEV vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3.1 LEV vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.05, 17.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.4 LEV vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.4.1 LEV vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.5 LEV vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.5.1 LEV vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">LEV vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0047"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">LTG vs CZP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38.1 LTG vs CZP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1.1 LTG vs CZP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.29, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1.2 LTG vs CZP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.53, 4.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">LTG vs CZP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0047">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0048"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">LTG vs LAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.1 LTG vs LAC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1.1 LTG vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.2 LTG vs LAC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2.1 LTG vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.3 LTG vs LAC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.3.1 LTG vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.4 LTG vs LAC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.4.1 LTG vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.5 LTG vs LAC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.5.1 LTG vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">LTG vs LAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0048">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0049"> <div class="table-heading"><span class="table-label">Comparison 40.</span> <span class="table-title">LTG vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.1 LTG vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1.1 LTG vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.33, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1.2 LTG vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.67, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.2 LTG vs OXC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2.1 LTG vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.03, 12.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.3 LTG vs OXC: Cardiac Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.3.1 LTG vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.4 LTG vs OXC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.4.1 LTG vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.12, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.5 LTG vs OXC: Skeletal/Limb Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.5.1 LTG vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 40.</span> <span class="table-title">LTG vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0049">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0050"> <div class="table-heading"><span class="table-label">Comparison 41.</span> <span class="table-title">LTG vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41.1 LTG vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1.1 LTG vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.17, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1.2 LTG vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41.2 LTG vs PB: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2.1 LTG vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.09, 6.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41.3 LTG vs PB: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.3.1 LTG vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.08, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41.4 LTG vs PB: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.4.1 LTG vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.07, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41.5 LTG vs PB: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.5.1 LTG vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.06, 2.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 41.</span> <span class="table-title">LTG vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0050">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0051"> <div class="table-heading"><span class="table-label">Comparison 42.</span> <span class="table-title">LTG vs PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42.1 LTG vs PHT: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1.1 LTG vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1.2 LTG vs PHT (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.20, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42.2 LTG vs PHT: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2.1 LTG vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.11, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42.3 LTG vs PHT: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.3.1 LTG vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.17, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42.4 LTG vs PHT: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.4.1 LTG vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.23, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42.5 LTG vs PHT: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.5.1 LTG vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.09, 0.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 42.</span> <span class="table-title">LTG vs PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0051">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0052"> <div class="table-heading"><span class="table-label">Comparison 43.</span> <span class="table-title">LTG vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43.1 LTG vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1.1 LTG vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.02, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1.2 LTG vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.03, 6.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 43.</span> <span class="table-title">LTG vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0052">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0053"> <div class="table-heading"><span class="table-label">Comparison 44.</span> <span class="table-title">LTG vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.1 LTG vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1.1 LTG vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.36, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1.2 LTG vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.20, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.2 LTG vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2.1 LTG vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.08, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.3 LTG vs TPM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.3.1 LTG vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.19, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.4 LTG vs TPM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.4.1 LTG vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.03, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.5 LTG vs TPM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.5.1 LTG vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.06, 0.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 44.</span> <span class="table-title">LTG vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0053">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0054"> <div class="table-heading"><span class="table-label">Comparison 45.</span> <span class="table-title">LTG vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45.1 LTG vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1.1 LTG vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.26, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45.2 LTG vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.2.1 LTG vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45.3 LTG vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.3.1 LTG vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.04, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45.4 LTG vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.4.1 LTG vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45.5 LTG vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.5.1 LTG vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.03, 1.93]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 45.</span> <span class="table-title">LTG vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0054">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0055"> <div class="table-heading"><span class="table-label">Comparison 46.</span> <span class="table-title">PHT vs GBP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46.1 PHT vs GBP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1.1 PHT vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.69, 6.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1.2 PHT vs GBP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.16, 46.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46.2 PHT vs GBP: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2.1 PHT vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.04, 23.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46.3 PHT vs GBP: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.3.1 PHT vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.09, 5.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46.4 PHT vs GBP: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.4.1 PHT vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46.5 PHT vs GBP: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.5.1 PHT vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 46.</span> <span class="table-title">PHT vs GBP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0055">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0056"> <div class="table-heading"><span class="table-label">Comparison 47.</span> <span class="table-title">PHT vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47.1 PHT vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1.1 PHT vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.48, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1.2 PHT vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.05, 10.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47.2 PHT vs OXC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.2.1 PHT vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.13, 10.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47.3 PHT vs OXC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.3.1 PHT vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.43, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47.4 PHT vs OXC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.4.1 PHT vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.10, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47.5 PHT vs OXC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.5.1 PHT vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.23, 6.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 47.</span> <span class="table-title">PHT vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0056">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0057"> <div class="table-heading"><span class="table-label">Comparison 48.</span> <span class="table-title">PHT vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.1 PHT vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1.1 PHT vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.57, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1.2 PHT vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.07, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.2 PHT vs PB: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2.1 PHT vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.10, 5.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.3 PHT vs PB: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.3.1 PHT vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.29, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.4 PHT vs PB: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.4.1 PHT vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.07, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.5 PHT vs PB: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.5.1 PHT vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.39, 4.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 48.</span> <span class="table-title">PHT vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0057">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0058"> <div class="table-heading"><span class="table-label">Comparison 49.</span> <span class="table-title">PHT vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.1 PHT vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1.1 PHT vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.39, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1.2 PHT vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.04, 8.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.2 PHT vs PRM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.2.1 PHT vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.3 PHT vs PRM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.3.1 PHT vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.02, 8.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.4 PHT vs PRM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.4.1 PHT vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.5 PHT vs PRM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.5.1 PHT vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.38 [0.14, 79.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 49.</span> <span class="table-title">PHT vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0058">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0059"> <div class="table-heading"><span class="table-label">Comparison 50.</span> <span class="table-title">PHT vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.1 PHT vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1.1 PHT vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.48, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1.2 PHT vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.02, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.2 PHT vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2.1 PHT vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.17, 8.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.3 PHT vs TPM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.3.1 PHT vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.65, 9.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.4 PHT vs TPM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.4.1 PHT vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.10, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.5 PHT vs TPM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.5.1 PHT vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.19, 2.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 50.</span> <span class="table-title">PHT vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0059">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0060"> <div class="table-heading"><span class="table-label">Comparison 51.</span> <span class="table-title">PHT vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.1 PHT vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1.1 PHT vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.42, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.2 PHT vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.2.1 PHT vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.00, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.3 PHT vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.3.1 PHT vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.04, 23.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.4 PHT vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.4.1 PHT vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.04, 23.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.5 PHT vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.5.1 PHT vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 51.</span> <span class="table-title">PHT vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0060">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0061"> <div class="table-heading"><span class="table-label">Comparison 52.</span> <span class="table-title">PB vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.1 PB vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1.1 PB vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.83, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1.2 PB vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.50, 18.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.2 PB vs OXC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2.1 PB vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.06, 37.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.3 PB vs OXC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.3.1 PB vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [0.94, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.4 PB vs OXC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.4.1 PB vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.66 [0.41, 32.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.5 PB vs OXC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.5.1 PB vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.16, 5.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 52.</span> <span class="table-title">PB vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0061">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0062"> <div class="table-heading"><span class="table-label">Comparison 53.</span> <span class="table-title">PB vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.1 PB vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1.1 PB vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.21, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1.2 PB vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.08, 29.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.2 PB vs PRM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2.1 PB vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.3 PB vs PRM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.3.1 PB vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.03, 6.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.4 PB vs PRM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.4.1 PB vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.5 PB vs PRM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.5.1 PB vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.05, 30.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 53.</span> <span class="table-title">PB vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0062">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0063"> <div class="table-heading"><span class="table-label">Comparison 54.</span> <span class="table-title">PB vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54.1 PB vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1.1 PB vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.68, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1.2 PB vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.30, 6.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54.2 PB vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.2.1 PB vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54.3 PB vs TPM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.3.1 PB vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.44 [0.98, 20.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54.4 PB vs TPM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.4.1 PB vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.39, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54.5 PB vs TPM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.5.1 PB vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.06, 2.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 54.</span> <span class="table-title">PB vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0063">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0064"> <div class="table-heading"><span class="table-label">Comparison 55.</span> <span class="table-title">PB vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.1 PB vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1.1 PB vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.46 [0.62, 175.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.2 PB vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2.1 PB vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.3 PB vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3.1 PB vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.4 PB vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.4.1 PB vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.5 PB vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.5.1 PB vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 55.</span> <span class="table-title">PB vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0064">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0065"> <div class="table-heading"><span class="table-label">Comparison 56.</span> <span class="table-title">TPM vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.1 TPM vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1.1 TPM vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.54, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.2 TPM vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2.1 TPM vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.3 TPM vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.3.1 TPM vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [0.28, 129.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.4 TPM vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.4.1 TPM vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.09, 38.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.5 TPM vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.5.1 TPM vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 56.</span> <span class="table-title">TPM vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0065">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0066"> <div class="table-heading"><span class="table-label">Comparison 57.</span> <span class="table-title">TPM vs LAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.1 TPM vs LAC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.1.1 TPM vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.2 TPM vs LAC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2.1 TPM vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.3 TPM vs LAC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.3.1 TPM vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.4 TPM vs LAC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.4.1 TPM vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.5 TPM vs LAC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.5.1 TPM vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 57.</span> <span class="table-title">TPM vs LAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0066">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0067"> <div class="table-heading"><span class="table-label">Comparison 58.</span> <span class="table-title">VPA vs GBP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.1 VPA vs GBP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.1.1 VPA vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.27 [1.60, 11.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.1.2 VPA vs GBP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.74 [0.24, 59.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.2 VPA vs GBP: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2.1 VPA vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.05, 13.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.3 VPA vs GBP: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.3.1 VPA vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.08, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.4 VPA vs GBP: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.4.1 VPA vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.09, 22.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.5 VPA vs GBP: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.5.1 VPA vs GBP (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.04, 12.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 58.</span> <span class="table-title">VPA vs GBP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0067">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0068"> <div class="table-heading"><span class="table-label">Comparison 59.</span> <span class="table-title">VPA vs LAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59.1 VPA vs LAC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.1.1 VPA vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.08, 12.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59.2 VPA vs LAC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.2.1 VPA vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59.3 VPA vs LAC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.3.1 VPA vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59.4 VPA vs LAC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.4.1 VPA vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59.5 VPA vs LAC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.5.1 VPA vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 59.</span> <span class="table-title">VPA vs LAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0068">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0069"> <div class="table-heading"><span class="table-label">Comparison 60.</span> <span class="table-title">VPA vs LEV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.1 VPA vs LEV: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1.1 VPA vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.77 [2.48, 5.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1.2 VPA vs LEV (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [1.51, 7.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.2 VPA vs LEV: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.2.1 VPA vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.76 [1.22, 11.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.3 VPA vs LEV: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.3.1 VPA vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [1.46, 6.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.4 VPA vs LEV: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.4.1 VPA vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [1.19, 11.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.5 VPA vs LEV: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.5.1 VPA vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [0.99, 5.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 60.</span> <span class="table-title">VPA vs LEV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0069">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0070"> <div class="table-heading"><span class="table-label">Comparison 61.</span> <span class="table-title">VPA vs LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.1 VPA vs LTG: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1.1 VPA vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [2.76, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1.2 VPA vs LTG (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.86, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.2 VPA vs LTG: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.2.1 VPA vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.48 [3.27, 17.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.3 VPA vs LTG: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.3.1 VPA vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [2.06, 5.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.4 VPA vs LTG: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.4.1 VPA vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [2.14, 8.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.5 VPA vs LTG: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.5.1 VPA vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.09 [2.91, 12.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 61.</span> <span class="table-title">VPA vs LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0070">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0071"> <div class="table-heading"><span class="table-label">Comparison 62.</span> <span class="table-title">VPA vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.1 VPA vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1.1 VPA vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [1.50, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1.2 VPA vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.36, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.2 VPA vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2.1 VPA vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.73, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.3 VPA vs TPM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.3.1 VPA vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.48 [1.16, 10.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.4 VPA vs TPM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.4.1 VPA vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.37, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.5 VPA vs TPM: Skeletal/Limb Malformation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.5.1 VPA vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.55, 3.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 62.</span> <span class="table-title">VPA vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0071">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0072"> <div class="table-heading"><span class="table-label">Comparison 63.</span> <span class="table-title">VPA vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63.1 VPA vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1.1 VPA vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [1.42, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1.2 VPA vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.11, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63.2 VPA vs OXC: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.2.1 VPA vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.49, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63.3 VPA vs OXC: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.3.1 VPA vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.84, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63.4 VPA vs OXC: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.4.1 VPA vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.76, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63.5 VPA vs OXC: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.5.1 VPA vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.42, 4.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 63.</span> <span class="table-title">VPA vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0072">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0073"> <div class="table-heading"><span class="table-label">Comparison 64.</span> <span class="table-title">VPA vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.1 VPA vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1.1 VPA vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.08, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1.2 VPA vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.26, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.2 VPA vs PB: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.2.1 VPA vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [1.27, 7.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.3 VPA vs PB: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.3.1 VPA vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.50, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.4 VPA vs PB: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.4.1 VPA vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.23, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.5 VPA vs PB: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.5.1 VPA vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.70, 3.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 64.</span> <span class="table-title">VPA vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0073">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0074"> <div class="table-heading"><span class="table-label">Comparison 65.</span> <span class="table-title">VPA vs PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.1 VPA vs PHT: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1.1 VPA vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.44, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1.2 VPA vs PHT (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.64, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.2 VPA vs PHT: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.2.1 VPA vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [1.57, 8.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.3 VPA vs PHT: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3.1 VPA vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.07, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.4 VPA vs PHT: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.4.1 VPA vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.89, 5.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.5 VPA vs PHT: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.5.1 VPA vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.01, 4.45]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 65.</span> <span class="table-title">VPA vs PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0074">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0075"> <div class="table-heading"><span class="table-label">Comparison 66.</span> <span class="table-title">VPA vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.1 VPA vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1.1 VPA vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [0.95, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.2 VPA vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.2.1 VPA vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.3 VPA vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3.1 VPA vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.07, 3.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.4 VPA vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.4.1 VPA vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.06, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.5 VPA vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.5.1 VPA vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.03, 7.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 66.</span> <span class="table-title">VPA vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0075">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0076"> <div class="table-heading"><span class="table-label">Comparison 67.</span> <span class="table-title">CZP vs VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.1 CZP vs VPA: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1.1 CZP vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.09, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1.2 CZP vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.13, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.2 CZP vs VPA: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.2.1 CZP vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.77 [0.58, 165.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.3 CZP vs VPA: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.3.1 CZP vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.12, 23.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.4 CZP vs VPA: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.4.1 CZP vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.60 [0.47, 123.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 67.</span> <span class="table-title">CZP vs VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0076">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0077"> <div class="table-heading"><span class="table-label">Comparison 68.</span> <span class="table-title">CZP vs LEV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68.1 CZP vs LEV: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1.1 CZP vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.32, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1.2 CZP vs LEV (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.15, 7.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 68.</span> <span class="table-title">CZP vs LEV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0077">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0078"> <div class="table-heading"><span class="table-label">Comparison 69.</span> <span class="table-title">OXC vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69.1 OXC vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1.1 OXC vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.08, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1.2 OXC vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 69.</span> <span class="table-title">OXC vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0078">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0079"> <div class="table-heading"><span class="table-label">Comparison 70.</span> <span class="table-title">OXC vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.1 OXC vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1.1 OXC vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.28, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1.2 OXC vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.04, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.2 OXC vs TPM: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.2.1 OXC vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.3 OXC vs PRM: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.3.1 OXC vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.09, 6.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.4 OXC vs PRM: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.4.1 OXC vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.05, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.5 OXC vs PRM: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.5.1 OXC vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.07, 2.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 70.</span> <span class="table-title">OXC vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0079">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0080"> <div class="table-heading"><span class="table-label">Comparison 71.</span> <span class="table-title">OXC vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.1 OXC vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1.1 OXC vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.48 [0.24, 82.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.2 OXC vs ZNS: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.2.1 OXC vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.3 OXC vs ZNS: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.3.1 OXC vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.4 OXC vs ZNS: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.4.1 OXC vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.5 OXC vs ZNS: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.5.1 OXC vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 71.</span> <span class="table-title">OXC vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0080">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0081"> <div class="table-heading"><span class="table-label">Comparison 72.</span> <span class="table-title">PRM vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72.1 PRM vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1.1 PRM vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [0.30, 118.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1.2 PRM vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 72.</span> <span class="table-title">PRM vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0081">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0082"> <div class="table-heading"><span class="table-label">Comparison 73.</span> <span class="table-title">PRM vs VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.1 PRM vs VPA: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1.1 PRM vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.39, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1.2 PRM vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.09, 17.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.2 PRM vs VPA: Neural Tube Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.2.1 PRM vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.3 PRM vs VPA: Cardiac Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3.1 PRM vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [0.16, 89.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.4 PRM vs VPA: Oro‐Facial Cleft/Craniofacial Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.4.1 PRM vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.5 PRM vs VPA: Skeletal/Limb Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.5.1 PRM vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.02, 9.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 73.</span> <span class="table-title">PRM vs VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0082">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0083"> <div class="table-heading"><span class="table-label">Comparison 74.</span> <span class="table-title">LEV vs LAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74.1 LEV vs LAC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1.1 LEV vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 74.</span> <span class="table-title">LEV vs LAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0083">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0084"> <div class="table-heading"><span class="table-label">Comparison 75.</span> <span class="table-title">CBZ vs LAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75.1 CBZ vs LAC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.1.1 CBZ vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 75.</span> <span class="table-title">CBZ vs LAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0084">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0085"> <div class="table-heading"><span class="table-label">Comparison 76.</span> <span class="table-title">OXC vs LAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76.1 OXC vs LAC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.1.1 OXC vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 76.</span> <span class="table-title">OXC vs LAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0085">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0086"> <div class="table-heading"><span class="table-label">Comparison 77.</span> <span class="table-title">PB vs LAC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77.1 PB vs LAC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.1.1 PB vs LAC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 77.</span> <span class="table-title">PB vs LAC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0086">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0087"> <div class="table-heading"><span class="table-label">Comparison 78.</span> <span class="table-title">LAC vs ZNS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78.1 LAC vs ZNS: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.1.1 LAC vs ZNS (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 78.</span> <span class="table-title">LAC vs ZNS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0087">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0088"> <div class="table-heading"><span class="table-label">Comparison 79.</span> <span class="table-title">GBP vs PGB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79.1 GBP vs PGB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.1.1 GBP vs PGB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 79.</span> <span class="table-title">GBP vs PGB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0088">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0089"> <div class="table-heading"><span class="table-label">Comparison 80.</span> <span class="table-title">GBP vs CZP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80.1 GBP vs CZP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.1.1 GBP vs CZP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.03, 10.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 80.</span> <span class="table-title">GBP vs CZP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0089">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0090"> <div class="table-heading"><span class="table-label">Comparison 81.</span> <span class="table-title">VPA vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">81.1 VPA vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>81.1.1 VPA vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.11, 21.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 81.</span> <span class="table-title">VPA vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0090">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0091"> <div class="table-heading"><span class="table-label">Comparison 82.</span> <span class="table-title">LTG vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">82.1 LTG vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.1.1 LTG vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 82.</span> <span class="table-title">LTG vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0091">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0092"> <div class="table-heading"><span class="table-label">Comparison 83.</span> <span class="table-title">LEV vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">83.1 LEV vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.1.1 LEV vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 83.</span> <span class="table-title">LEV vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0092">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0093"> <div class="table-heading"><span class="table-label">Comparison 84.</span> <span class="table-title">CBZ vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">84.1 CBZ vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>84.1.1 CBZ vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.02, 6.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 84.</span> <span class="table-title">CBZ vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0093">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0094"> <div class="table-heading"><span class="table-label">Comparison 85.</span> <span class="table-title">OXC vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">85.1 OXC vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>85.1.1 OXC vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 85.</span> <span class="table-title">OXC vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0094">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0095"> <div class="table-heading"><span class="table-label">Comparison 86.</span> <span class="table-title">PB vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">86.1 PB vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>86.1.1 PB vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 86.</span> <span class="table-title">PB vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0095">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0096"> <div class="table-heading"><span class="table-label">Comparison 87.</span> <span class="table-title">LAC vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">87.1 LAC vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>87.1.1 LAC vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 87.</span> <span class="table-title">LAC vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0096">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0097"> <div class="table-heading"><span class="table-label">Comparison 88.</span> <span class="table-title">ZNS vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">88.1 ZNS vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>88.1.1 ZNS vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 88.</span> <span class="table-title">ZNS vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0097">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0098"> <div class="table-heading"><span class="table-label">Comparison 89.</span> <span class="table-title">CZP vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">89.1 CZP vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>89.1.1 CZP vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.03, 15.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>89.1.2 CZP vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.07, 1.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 89.</span> <span class="table-title">CZP vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0098">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0099"> <div class="table-heading"><span class="table-label">Comparison 90.</span> <span class="table-title">CZP vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">90.1 CZP vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>90.1.1 CZP vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.01, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>90.1.2 CZP vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.13, 5.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 90.</span> <span class="table-title">CZP vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0099">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0100"> <div class="table-heading"><span class="table-label">Comparison 91.</span> <span class="table-title">CZP vs COZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">91.1 CZP vs COZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>91.1.1 CZP vs COZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 91.</span> <span class="table-title">CZP vs COZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0100">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0101"> <div class="table-heading"><span class="table-label">Comparison 92.</span> <span class="table-title">CZP vs ESM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">92.1 CZP vs ESM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>92.1.1 CZP vs ESM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>92.1.2 CZP vs ESM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.05, 17.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 92.</span> <span class="table-title">CZP vs ESM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0101">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0102"> <div class="table-heading"><span class="table-label">Comparison 93.</span> <span class="table-title">CZP vs PRG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">93.1 CZP vs PRG: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>93.1.1 CZP vs PRG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 93.</span> <span class="table-title">CZP vs PRG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0102">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0103"> <div class="table-heading"><span class="table-label">Comparison 94.</span> <span class="table-title">CZP vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">94.1 CZP vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>94.1.1 CZP vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>94.1.2 CZP vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.02, 7.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 94.</span> <span class="table-title">CZP vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0103">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0104"> <div class="table-heading"><span class="table-label">Comparison 95.</span> <span class="table-title">CZP vs VGB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">95.1 CZP vs VGB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>95.1.1 CZP vs VGB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>95.1.2 CZP vs VGB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.02, 7.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 95.</span> <span class="table-title">CZP vs VGB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0104">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0105"> <div class="table-heading"><span class="table-label">Comparison 96.</span> <span class="table-title">TPM vs BNZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">96.1 TPM vs BNZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>96.1.1 TPM vs BNZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 96.</span> <span class="table-title">TPM vs BNZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0105">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0106"> <div class="table-heading"><span class="table-label">Comparison 97.</span> <span class="table-title">ESM vs VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">97.1 ESM vs VPA: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>97.1.1 ESM vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.04, 8.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>97.1.2 ESM vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.04, 8.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 97.</span> <span class="table-title">ESM vs VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0106">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0107"> <div class="table-heading"><span class="table-label">Comparison 98.</span> <span class="table-title">ESM vs CBZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">98.1 ESM vs CBZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>98.1.1 ESM vs CBZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.10, 20.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>98.1.2 ESM vs CBZ (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.09, 20.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 98.</span> <span class="table-title">ESM vs CBZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0107">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0108"> <div class="table-heading"><span class="table-label">Comparison 99.</span> <span class="table-title">ESM vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">99.1 ESM vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>99.1.1 ESM vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>99.1.2 ESM vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 99.</span> <span class="table-title">ESM vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0108">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0109"> <div class="table-heading"><span class="table-label">Comparison 100.</span> <span class="table-title">ESM vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">100.1 ESM vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>100.1.1 ESM vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>100.1.2 ESM vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 6.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 100.</span> <span class="table-title">ESM vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0109">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0110"> <div class="table-heading"><span class="table-label">Comparison 101.</span> <span class="table-title">ESM vs PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">101.1 ESM vs PHT: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>101.1.1 ESM vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.11, 54.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>101.1.2 ESM vs PHT (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.05, 12.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 101.</span> <span class="table-title">ESM vs PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0110">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0111"> <div class="table-heading"><span class="table-label">Comparison 102.</span> <span class="table-title">ESM vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">102.1 ESM vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>102.1.1 ESM vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.05, 23.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>102.1.2 ESM vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 102.</span> <span class="table-title">ESM vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0111">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0112"> <div class="table-heading"><span class="table-label">Comparison 103.</span> <span class="table-title">ESM vs VGB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">103.1 ESM vs VGB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>103.1.1 ESM vs VGB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>103.1.2 ESM vs VGB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 103.</span> <span class="table-title">ESM vs VGB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0112">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0113"> <div class="table-heading"><span class="table-label">Comparison 104.</span> <span class="table-title">ESM vs LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">104.1 ESM vs LTG: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>104.1.1 ESM vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.11, 24.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>104.1.2 ESM vs LTG (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.07, 19.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 104.</span> <span class="table-title">ESM vs LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0113">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0114"> <div class="table-heading"><span class="table-label">Comparison 105.</span> <span class="table-title">ESM vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">105.1 ESM vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>105.1.1 ESM vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>105.1.2 ESM vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 105.</span> <span class="table-title">ESM vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0114">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0115"> <div class="table-heading"><span class="table-label">Comparison 106.</span> <span class="table-title">ESM vs GBP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">106.1 ESM vs GBP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>106.1.1 ESM vs GBP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 106.</span> <span class="table-title">ESM vs GBP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0115">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0116"> <div class="table-heading"><span class="table-label">Comparison 107.</span> <span class="table-title">VGB vs VPA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">107.1 VGB vs VPA: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>107.1.1 VGB vs VPA (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.15, 18.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>107.1.2 VGB vs VPA (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.09, 17.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 107.</span> <span class="table-title">VGB vs VPA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0116">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0117"> <div class="table-heading"><span class="table-label">Comparison 108.</span> <span class="table-title">VGB vs CBZ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">108.1 VGB vs CBZ: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>108.1.1 VGB vs CBZ (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.18 [0.37, 47.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>108.1.2 VGB vs CBZ (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.23, 42.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 108.</span> <span class="table-title">VGB vs CBZ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0117">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0118"> <div class="table-heading"><span class="table-label">Comparison 109.</span> <span class="table-title">VGB vs PRM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">109.1 VGB vs PRM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>109.1.1 VGB vs PRM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>109.1.2 VGB vs PRM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 109.</span> <span class="table-title">VGB vs PRM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0118">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0119"> <div class="table-heading"><span class="table-label">Comparison 110.</span> <span class="table-title">VGB vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">110.1 VGB vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>110.1.1 VGB vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.03, 12.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 110.</span> <span class="table-title">VGB vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0119">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0120"> <div class="table-heading"><span class="table-label">Comparison 111.</span> <span class="table-title">VGB vs PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">111.1 VGB vs PHT: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>111.1.1 VGB vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.50 [0.43, 132.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>111.1.2 VGB vs PHT (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.12, 25.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 111.</span> <span class="table-title">VGB vs PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0120">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0121"> <div class="table-heading"><span class="table-label">Comparison 112.</span> <span class="table-title">VGB vs OXC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">112.1 VGB vs OXC: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>112.1.1 VGB vs OXC (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [0.19, 57.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>112.1.2 VGB vs OXC (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 112.</span> <span class="table-title">VGB vs OXC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0121">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0122"> <div class="table-heading"><span class="table-label">Comparison 113.</span> <span class="table-title">VGB vs LTG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">113.1 VGB vs LTG: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>113.1.1 VGB vs LTG (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.31 [0.25, 43.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>113.1.2 VGB vs LTG (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.16, 39.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 113.</span> <span class="table-title">VGB vs LTG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0122">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0123"> <div class="table-heading"><span class="table-label">Comparison 114.</span> <span class="table-title">VGB vs TPM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">114.1 VGB vs TPM: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>114.1.1 VGB vs TPM (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.51, 159.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>114.1.2 VGB vs TPM (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 114.</span> <span class="table-title">VGB vs TPM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0123">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0124"> <div class="table-heading"><span class="table-label">Comparison 115.</span> <span class="table-title">VGB vs GBP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">115.1 VGB vs GBP: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>115.1.1 VGB vs GBP (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 115.</span> <span class="table-title">VGB vs GBP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0124">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0125"> <div class="table-heading"><span class="table-label">Comparison 116.</span> <span class="table-title">CZP vs PB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">116.1 CZP vs PB: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>116.1.1 CZP vs PB (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.05, 13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>116.1.2 CZP vs PB (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.06, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 116.</span> <span class="table-title">CZP vs PB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0125">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0126"> <div class="table-heading"><span class="table-label">Comparison 117.</span> <span class="table-title">CZP vs PHT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">117.1 CZP vs PHT: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>117.1.1 CZP vs PHT (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.10, 5.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>117.1.2 CZP vs PHT (database studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.13, 2.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 117.</span> <span class="table-title">CZP vs PHT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0126">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0127"> <div class="table-heading"><span class="table-label">Comparison 118.</span> <span class="table-title">ESM vs LEV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">118.1 ESM vs LEV: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>118.1.1 ESM vs LEV (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.13, 34.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 118.</span> <span class="table-title">ESM vs LEV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0127">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0128"> <div class="table-heading"><span class="table-label">Comparison 119.</span> <span class="table-title">ESM vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">119.1 ESM vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>119.1.1 ESM vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.17, 43.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 119.</span> <span class="table-title">ESM vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0128">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010224-tbl-0129"> <div class="table-heading"><span class="table-label">Comparison 120.</span> <span class="table-title">VGB vs Controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">120.1 VGB vs Controls: All Major Malformations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>120.1.1 VGB vs WWE ‐ No Medication (cohort studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.05 [0.64, 101.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 120.</span> <span class="table-title">VGB vs Controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010224.pub3/references#CD010224-tbl-0129">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010224.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010224-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010224-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010224-note-0021">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD010224-note-0022">Magyar</a> </li> <li class="section-language"> <a class="" href="id#CD010224-note-0020">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD010224-note-0018">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD010224-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD010224-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD010224-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010224-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010224-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010224\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010224\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010224\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010224\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010224\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010224.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010224.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010224.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010224.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010224.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716175558"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010224.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716175562"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010224.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9910e8301bf6',t:'MTc0MDcxNjE3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 